

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification: C12N 15/12, A01K 67/027, A61K 31/00, A61K 31/70, A61K 38/17, A61K 38/45, A61K 48/00, C07K 14/705, C12N 5/10, C12N 15/00, C12N 15/11, C12Q 1/68, G01N 33/68	A2	(11) International Publication Number: WO 00/55318 (43) International Publication Date: 21 September 2000 (21.09.2000)
(21) International Application Number: PCT/IB00/00532 (22) International Filing Date: 15 March 2000 (15.03.2000) (30) Priority Data: 60/124,702 15 March 1999 (15.03.1999) US 60/138,048 08 June 1999 (08.06.1999) US 60/139,600 17 June 1999 (17.06.1999) US 60/151,977 01 September 1999 (01.09.1999) US (60) Parent Application or Grant UNIVERSITY OF BRITISH COLUMBIA [/]; O. XENON BIORESEARCH, INC. [/]; O. HAYDEN, Michael, R. [/]; O. WILSON, Angela, R. [/]; O. PIMSTONE, Simon, N. [/]; O.		Published
(54) Title: METHODS AND REAGENTS FOR MODULATING CHOLESTEROL LEVELS (54) Titre: METHODES ET REACTIFS PERMETTANT DE MODULER LES TAUX DE CHOLESTEROL		
(57) Abstract		
<p>The invention features ABC1 nucleic acids and polypeptides for the diagnosis and treatment of abnormal cholesterol regulation. The invention also features methods for identifying compounds for modulating cholesterol levels in an animal (e.g., a human).</p>		
(57) Abrégé <p>L'invention se rapporte à des acides nucléiques et à des polypeptides ABC1 permettant de diagnostiquer et de traiter une régulation anormale du cholestérol. Elle se rapporte également à des méthodes d'identification de composés permettant de moduler les taux de cholestérol chez un animal (par exemple, un humain).</p>		

09/596,

#6

194
~~194~~
~~194~~
~~194~~

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<p>(51) International Patent Classification 7 : C12N 15/12, C07K 14/705, C12N 5/10, A01K 67/027, C12N 15/00, A61K 38/17, 48/00, 38/45, 31/00, 31/70, G01N 33/68, C12Q 1/68, C12N 15/11</p>		<p>A2</p>	<p>(11) International Publication Number: WO 00/55318 (43) International Publication Date: 21 September 2000 (21.09.00)</p>
<p>(21) International Application Number: PCT/IB00/00532 (22) International Filing Date: 15 March 2000 (15.03.00) (30) Priority Data: 60/124,702 15 March 1999 (15.03.99) US 60/138,048 8 June 1999 (08.06.99) US 60/139,600 17 June 1999 (17.06.99) US 60/151,977 1 September 1999 (01.09.99) US</p>		<p>(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).</p>	
<p>(71) Applicants: UNIVERSITY OF BRITISH COLUMBIA [CA/CA]; 2329 West Mall, Vancouver, British Columbia V6T 1Z4 (CA). XENON BIORESEARCH, INC. [CA/CA]; NRC Innovation Centre, 3250 East Mall, Vancouver, British Columbia V6T 1W5 (CA). (72) Inventors: HAYDEN, Michael, R.; 4484 West 7th Avenue, Vancouver, British Columbia V6R 1W9 (CA). WILSON, Angela, R.; 7100 Langton Road, Richmond, British Columbia V7C 4B2 (CA). PIMSTONE, Simon, N.; 4746 West 6th Avenue, Vancouver, British Columbia V6T 1C5 (CA).</p>		<p>Published Without international search report and to be republished upon receipt of that report.</p>	
<p>(54) Title: METHODS AND REAGENTS FOR MODULATING CHOLESTEROL LEVELS</p>			
<p>Mutation Polymorphism</p>			
<p>(57) Abstract The invention features ABC1 nucleic acids and polypeptides for the diagnosis and treatment of abnormal cholesterol regulation. The invention also features methods for identifying compounds for modulating cholesterol levels in an animal (e.g., a human).</p>			

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MR	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

Description

5

10

15

20

25

30

35

40

45

50

55

METHODS AND REAGENTS FOR MODULATING CHOLESTEROL LEVELS

Background of the Invention

Low HDL cholesterol (HDL-C), or hypoalphalipoproteinemia, is a blood lipid abnormality which correlates with a high risk of cardiovascular disease (CVD), in particular coronary artery disease (CAD), but also cerebrovascular disease, coronary restenosis, and peripheral vascular disease. HDL, or 'good cholesterol' levels are influenced by both environmental and genetic factors.

Epidemiological studies have consistently demonstrated that plasma HDL-C concentration is inversely related to the incidence of CAD. HDL-C levels are a strong graded and independent cardiovascular risk factor. Protective effects of an elevated HDL-C persist until 80 years of age. A low HDL-C is associated with an increased CAD risk even with normal (<5.2 mmol/l) total plasma cholesterol levels. Coronary disease risk is increased by 2% in men and 3% in women for every 1 mg/dL (0.026 mmol/l) reduction in HDL-C and in the majority of studies this relationship is statistically significant even after adjustment for other lipid and non-lipid risk factors. Decreased HDL-C levels are the most common lipoprotein abnormality seen in patients with premature CAD. Four percent of patients with premature CAD have an isolated form of decreased HDL-C levels with no other lipoprotein abnormalities while 25% have low HDL levels with accompanying hypertriglyceridemia.

Even in the face of other dyslipidemias or secondary factors, HDL-C levels are important predictors of CAD. In a cohort of diabetics, those with isolated low HDL cholesterol had a 65% increased death rate compared to diabetics with normal HDL cholesterol levels (>0.9 mmol/l). Furthermore, it has been shown that even within high risk populations, such as those with familial hypercholesterolemia, HDL cholesterol level is an important predictor of CAD. Low HDL cholesterol levels thus constitute a major, independent, risk for CAD.

5
10
15
20
25
30
35
40
45
50
55

These findings have led to increased attention to HDL cholesterol levels as a focus for treatment, following the recommendations of the National Cholesterol Education Program. These guidelines suggest that HDL cholesterol values below 0.9 mmol/l confer a significant risk for men and women. As such, nearly half of patients with CAD would have low HDL cholesterol. It is therefore crucial that we obtain a better understanding of factors which contribute to this phenotype. In view of the fact that pharmacological intervention of low HDL cholesterol levels has so far proven unsatisfactory, it is also important to understand the factors that regulate these levels in the circulation as this understanding may reveal new therapeutic targets.

10
15
20
25
30
35
40
45
50
55

Absolute levels of HDL cholesterol may not always predict risk of CAD. In the case of CETP deficiency, individuals display an increased risk of developing CAD, despite increased HDL cholesterol levels. What seems to be important in this case is the functional activity of the reverse cholesterol transport pathway, the process by which intracellular cholesterol is trafficked out of the cell to acceptor proteins such as ApoAI or HDL. Other important genetic determinants of HDL cholesterol levels, and its inverse relation with CAD, may reside in the processes leading to HDL formation and intracellular cholesterol trafficking and efflux. To date, this process is poorly understood, however, and clearly not all of the components of this pathway have been identified. Thus, defects preventing proper HDL-mediated cholesterol efflux may be important predictors of CAD. Therefore it is critical to identify and understand novel genes involved in the intracellular cholesterol trafficking and efflux pathways.

20
25
30
35
40
45
50
55

HDL particles are central to the process of reverse cholesterol transport and thus to the maintenance of tissue cholesterol homeostasis. This process has multiple steps which include the binding of HDL to cell surface components, the acquisition of cholesterol by passive absorption, the esterification of this cholesterol by LCAT and the subsequent transfer of esterified cholesterol by CETP, to VLDL and chylomicron remnants for liver uptake. Each of these steps is known to impact the plasma concentration of HDL.

30
35
40
45
50
55

Changes in genes for ApoAI-CIII, lipoprotein lipase, CETP, hepatic lipase, and LCAT all contribute to determination of HDL-C levels in humans. One rare form of genetic HDL deficiency is Tangier disease (TD), diagnosed in approximately 40

5 patients world-wide, and associated with almost complete absence of HDL cholesterol (HDL-C) levels (listed in OMIM as an autosomal recessive trait (OMIM 205400)).

10 These patients have very low HDL cholesterol and ApoAI levels, which have been ascribed to hypercatabolism of nascent HDL and ApoAI, due to a delayed acquisition
5 of lipid and resulting failure of conversion to mature HDL. TD patients accumulate cholesterol esters in several tissues, resulting in characteristic features, such as
15 enlarged yellow tonsils, hepatosplenomegaly, peripheral neuropathy, and cholesterol ester deposition in the rectal mucosa. Defective removal of cellular cholesterol and phospholipids by ApoAI as well as a marked deficiency in HDL mediated efflux of
20 intracellular cholesterol has been demonstrated in TD fibroblasts. Even though this is a rare disorder, defining its molecular basis could identify pathways relevant for cholesterol regulation in the general population. The decreased availability of free
25 cholesterol for efflux in the surface membranes of cells in Tangier Disease patients appears to be due to a defect in cellular lipid metabolism or trafficking.

15 Approximately 45% of Tangier patients have signs of premature CAD, suggesting a strong link between decreased cholesterol efflux, low HDL cholesterol and CAD. As increased cholesterol is observed in the rectal mucosa of persons with TD, the
30 molecular mechanism responsible for TD may also regulate cholesterol adsorption from the gastrointestinal (GI) tract.

20 A more common form of genetic HDL deficiency occurs in patients who have low plasma HDL cholesterol usually below the 5th percentile for age and sex (OMIM 10768), but an absence of clinical manifestations specific to Tangier disease (Marcil
35 et al., *Arterioscler. Thromb. Vasc. Biol.* 19:159-169, 1999; Marcil et al., *Arterioscler. Thromb. Vasc. Biol.* 15:1015-1024, 1995). These patients have no obvious
40 25 environmental factors associated with this lipid phenotype, and do not have severe hypertriglyceridemia nor have known causes of severe HDL deficiency (mutations in ApoAI, LCAT, or LPL deficiency) and are not diabetic. The pattern of inheritance of
45 this condition is most consistent with a Mendelian dominant trait (OMIM 10768).

30 The development of drugs that regulate cholesterol metabolism has so far progressed slowly. Thus, there is a need for a better understanding of the genetic components of the cholesterol efflux pathway. Newly-discovered components can

5 then serve as targets for drug design.

10 Low HDL levels are likely to be due to multiple genetic factors. The use of pharmacogenomics in the aid of designing treatment tailored to the patient makes it desirable to identify polymorphisms in components of the cholesterol efflux pathway.

5 An understanding of the effect of these polymorphisms on protein function would allow for the design of a therapy that is optimal for the patient.

15 Summary of the Invention

20 In a first aspect, the invention features a substantially pure ABC1 polypeptide having ABC1 biological activity. Preferably, the ABC1 polypeptide is human ABC1 (e.g., one that includes amino acids 1 to 60 or amino acids 61 to 2261 of SEQ ID NO: 1). In one preferred embodiment, the ABC1 polypeptide includes amino acids 1 to 2261 of SEQ ID NO: 1.

25 Specifically excluded from the polypeptides of the invention are the polypeptide having the exact amino acid sequence as GenBank accession number CAA10005.1 and the nucleic acid having the exact sequence as AJ012376.1. Also excluded is protein having the exact amino acid sequence as GenBank accession number X75926.

30 In a related aspect, the invention features a substantially pure ABC1 polypeptide that includes amino acids 1 to 2261 of SEQ ID NO: 1.

35 In another aspect, the invention features a substantially pure nucleic acid molecule encoding an ABC1 polypeptide having ABC1 biological activity (e.g., a nucleic acid molecule that includes nucleotides 75 to 254 or nucleotides 255 to 6858 of SEQ ID NO: 2). In one preferred embodiment, the nucleic acid molecule includes nucleotides 75 to 6858 of SEQ ID NO: 2.

40 In a related aspect, the invention features an expression vector, a cell, or a non-human mammal that includes the nucleic acid molecule of the invention.

45 In yet another aspect, the invention features a substantially pure nucleic acid molecule that includes nucleotides 75 to 254 of SEQ ID NO: 2, nucleotides 255 to 6858 of SEQ ID NO: 2, or nucleotides 75 to 6858 of SEQ ID NO: 2.

5

10

In still another aspect, the invention features a substantially pure nucleic acid molecule that includes at least fifteen nucleotides corresponding to the 5' or 3' untranslated region from a human ABC1 gene. Preferably, the 3' untranslated region includes nucleotides 7015-7860 of SEQ ID NO: 2.

5

15

In a related aspect, the invention features a substantially pure nucleic acid molecule that hybridizes at high stringency to a probe comprising nucleotides 7015-7860 of SEQ ID NO: 2.

20

10

In another aspect, the invention features a method of treating a human having low HDL cholesterol or a cardiovascular disease, including administering to the human an ABC1 polypeptide, or cholesterol-regulating fragment thereof, or a nucleic acid molecule encoding an ABC1 polypeptide, or cholesterol-regulating fragment thereof. In a preferred embodiment, the human has a low HDL cholesterol level relative to normal. Preferably, the ABC1 polypeptide is wild-type ABC1, or has a mutation increases its stability or its biological activity. A preferred biological activity is regulation of cholesterol.

25

15

30

In a related aspect, the invention features a method of preventing or treating cardiovascular disease, including introducing into a human an expression vector comprising an *ABC1* nucleic acid molecule operably linked to a promoter and encoding an ABC1 polypeptide having ABC1 biological activity.

35

20

In another related aspect, the invention features a method of preventing or ameliorating the effects of a disease-causing mutation in an *ABC1* gene, including introducing into a human an expression vector comprising an *ABC1* nucleic acid molecule operably linked to a promoter and encoding an ABC1 polypeptide having ABC1 biological activity.

40

25

In still another aspect, the invention features a method of treating or preventing cardiovascular disease, including administering to an animal (e.g., a human) a compound that mimics the activity of wild-type ABC1 or modulates the biological activity of ABC1.

45

30

One preferred cardiovascular disease that can be treated using the methods of the invention is coronary artery disease. Others include cerebrovascular disease and peripheral vascular disease.

50

55

5
10
15
The discovery that the ABC1 gene and protein are involved in cholesterol transport that affects serum HDL levels allows the ABC1 protein and gene to be used in a variety of diagnostic tests and assays for identification of HDL-increasing or CVD-inhibiting drugs. In one family of such assays, the ability of domains of the ABC1 protein to bind ATP is utilized; compounds that enhance this binding are potential HDL-increasing drugs. Similarly, the anion transport capabilities and membrane pore-forming functions in cell membranes can be used for drug screening.

20
25
15
ABC1 expression can also serve as a diagnostic tool for low HDL or CVD; determination of the genetic subtyping of the *ABC1* gene sequence can be used to subtype low HDL individuals or families to determine whether the low HDL phenotype is related to ABC1 function. This diagnostic process can lead to the tailoring of drug treatments according to patient genotype (referred to as pharmacogenomics), including prediction of the patient's response (e.g., increased or decreased efficacy or undesired side effects upon administration of a compound or drug.

30
35
40
20
Antibodies to an ABC1 polypeptide can be used both as therapeutics and diagnostics. Antibodies are produced by immunologically challenging a B-cell-containing biological system, e.g., an animal such as a mouse, with an ABC1 polypeptide to stimulate production of anti-ABC1 protein by the B-cells, followed by isolation of the antibody from the biological system. Such antibodies can be used to measure ABC1 polypeptide in a biological sample such as serum, by contacting the sample with the antibody and then measuring immune complexes as a measure of the ABC1 polypeptide in the sample. Antibodies to ABC1 can also be used as therapeutics for the modulation of ABC1 biological activity.

25
Thus, in another aspect, the invention features a purified antibody that specifically binds to ABC1.

45
50
55
30
In yet another aspect, the invention features a method for determining whether a candidate compound modulates ABC1 biological activity, comprising: (a) providing an ABC1 polypeptide; (b) contacting the ABC1 polypeptide with the candidate compound; and (c) measuring ABC1 biological activity, wherein altered ABC1 biological activity, relative to an ABC1 polypeptide not contacted with the compound,

5 indicates that the candidate compound modulates ABC1 biological activity.
Preferably, the ABC1 polypeptide is in a cell or is in a cell-free assay system.

10 In still another aspect, the invention features a method for determining whether a candidate compound modulates ABC1 expression. The method includes
5 (a) providing a nucleic acid molecule comprising an ABC1 promoter operably linked to a reporter gene; (b) contacting the nucleic acid molecule with the candidate
15 compound; and (c) measuring reporter gene expression, wherein altered reporter gene expression, relative to a nucleic acid molecule not contacted with the compound, indicates that the candidate compound modulates ABC1 expression.

20 In another aspect, the invention features a method for determining whether candidate compound is useful for modulating cholesterol levels, the method including the steps of: (a) providing an ABC1 polypeptide; (b) contacting the polypeptide with
25 the candidate compound; and (c) measuring binding of the ABC1 polypeptide, wherein binding of the ABC1 polypeptide indicates that the candidate compound is
15 useful for modulating cholesterol levels.

30 In a related aspect, the invention features method for determining whether a candidate compound mimics ABC1 biological activity. The method includes (a) providing a cell that is not expressing an ABC1 polypeptide; (b) contacting the cell with the candidate compound; and (c) measuring ABC1 biological activity of the cell,
20 wherein altered ABC1 biological activity, relative to a cell not contacted with the compound, indicates that the candidate compound modulates ABC1 biological activity. Preferably, the cell has an *ABC1* null mutation. In one preferred
35 embodiment, the cell is in a mouse or a chicken (e.g., a WHAM chicken) in which its *ABC1* gene has been mutated.

40 In still another aspect, the invention features a method for determining whether a candidate compound is useful for the treatment of low HDL cholesterol. The method includes (a) providing an ABC transporter (e.g., ABC1); (b) contacting
45 the transporter with the candidate compound; and (c) measuring ABC transporter biological activity, wherein increased ABC transporter biological activity, relative to a
30 transporter not contacted with the compound, indicates that the candidate compound is useful for the treatment of low HDL cholesterol. Preferably the ABC transporter is

5 in a cell or a cell free assay system.

10 In yet another aspect, the invention features a method for determining whether candidate compound is useful for modulating cholesterol levels. The method includes
5 (a) providing a nucleic acid molecule comprising an ABC transporter promoter operably linked to a reporter gene; (b) contacting the nucleic acid molecule with the candidate compound; and (c) measuring expression of the reporter gene, wherein
15 increased expression of the reporter gene, relative to a nucleic acid molecule not contacted with the compound, indicates that the candidate compound is useful for modulating cholesterol levels.

20 In still another aspect, the invention features a method for determining whether a candidate compound increases the stability or decreases the regulated catabolism of an ABC transporter polypeptide. The method includes (a) providing an ABC transporter polypeptide; (b) contacting the transporter with the candidate
25 compound; and (c) measuring the half-life of the ABC transporter polypeptide, wherein an increase in the half-life, relative to a transporter not contacted with the compound, indicates that the candidate compound increases the stability or decreases the regulated catabolism of an ABC transporter polypeptide. Preferably the ABC
30 transporter is in a cell or a cell free assay system.

35 In a preferred embodiment of the screening methods of the present invention, the cell is in an animal. The preferred ABC transporters are ABC1, ABC2, ABCR, and ABC8, and the preferred biological activity is transport of cholesterol (e.g., HDL cholesterol or LDL cholesterol) or interleukin-1, or is binding or hydrolysis of ATP by the ABC1 polypeptide.

40 Preferably, the ABC1 polypeptide used in the screening methods includes amino acids 1-60 of SEQ ID NO: 1. Alternatively, the ABC1 polypeptide can include
25 a region encoded by a nucleotide sequence that hybridizes under high stringency conditions to nucleotides 75 to 254 of SEQ ID NO: 2.

45 In another aspect, the invention features a method for determining whether a patient has an increased risk for cardiovascular disease. The method includes
30 determining whether an *ABC1* gene of the patient has a mutation, wherein a mutation indicates that the patient has an increased risk for cardiovascular disease.

5
10
5
In related aspect, the invention features a method for determining whether a patient has an increased risk for cardiovascular disease. The method includes determining whether an *ABC1* gene of the patient has a polymorphism, wherein a polymorphism indicates that the patient has an increased risk for cardiovascular disease.

15
10
20
In another aspect, the invention features a method for determining whether a patient has an increased risk for cardiovascular disease. The method includes measuring *ABC1* biological activity in the patient, wherein increased or decreased levels in the *ABC1* biological activity, relative to normal levels, indicates that the patient has an increased risk for cardiovascular disease.

25
15
30
In still another aspect, the invention features a method for determining whether a patient has an increased risk for cardiovascular disease. The method includes measuring *ABC1* expression in the patient, wherein decreased levels in the *ABC1* expression relative to normal levels, indicates that the patient has an increased risk for cardiovascular disease. Preferably, the *ABC1* expression is determined by measuring levels of *ABC1* polypeptide or *ABC1* RNA.

30
20
35
In another aspect, the invention features a non-human mammal having a transgene comprising a nucleic acid molecule encoding a mutated *ABC1* polypeptide. In one embodiment, the mutation is a dominant-negative mutation.

20
35
In a related aspect, the invention features a non-human mammal, having a transgene that includes a nucleic acid molecule encoding an *ABC1* polypeptide having *ABC1* biological activity.

40
25
In another related aspect, the invention features a cell from a non-human mammal having a transgene that includes a nucleic acid molecule encoding an *ABC1* polypeptide having *ABC1* biological activity.

45
30
50
In still another aspect, the invention features a method for determining whether a candidate compound decreases the inhibition of a dominant-negative *ABC1* polypeptide. The method includes (a) providing a cell expressing a dominant-negative *ABC1* polypeptide; (b) contacting the cell with the candidate compound; and (c) measuring *ABC1* biological activity of the cell, wherein an increase in the *ABC1* biological activity, relative to a cell not contacted with the compound, indicates that

the candidate compound decreases the inhibition of a dominant-negative ABC1 polypeptide.

By "polypeptide" is meant any chain of more than two amino acids, regardless of post-translational modification such as glycosylation or phosphorylation.

By "substantially identical" is meant a polypeptide or nucleic acid exhibiting at least 50%, preferably 85%, more preferably 90%, and most preferably 95% identity to a reference amino acid or nucleic acid sequence. For polypeptides, the length of comparison sequences will generally be at least 16 amino acids, preferably at least 20 amino acids, more preferably at least 25 amino acids, and most preferably 35 amino acids. For nucleic acids, the length of comparison sequences will generally be at least 50 nucleotides, preferably at least 60 nucleotides, more preferably at least 75 nucleotides, and most preferably 110 nucleotides.

Sequence identity is typically measured using sequence analysis software with the default parameters specified therein (e.g., Sequence Analysis Software Package of the Genetics Computer Group, University of Wisconsin Biotechnology Center, 1710 University Avenue, Madison, WI 53705). This software program matches similar sequences by assigning degrees of homology to various substitutions, deletions, and other modifications. Conservative substitutions typically include substitutions within the following groups: glycine, alanine, valine, isoleucine, leucine; aspartic acid, glutamic acid, asparagine, glutamine; serine, threonine; lysine, arginine; and phenylalanine, tyrosine.

By "high stringency conditions" is meant hybridization in 2X SSC at 40°C with a DNA probe length of at least 40 nucleotides. For other definitions of high stringency conditions, see F. Ausubel et al., *Current Protocols in Molecular Biology*, pp. 6.3.1-6.3.6, John Wiley & Sons, New York, NY, 1994, hereby incorporated by reference.

By "substantially pure polypeptide" is meant a polypeptide that has been separated from the components that naturally accompany it. Typically, the polypeptide is substantially pure when it is at least 60%, by weight, free from the proteins and naturally-occurring organic molecules with which it is naturally associated. Preferably, the polypeptide is an ABC1 polypeptide that is at least 75%,

5
10
15
20
25
30
35
40
45
50
55

more preferably at least 90%, and most preferably at least 99%, by weight, pure. A substantially pure ABC1 polypeptide may be obtained, for example, by extraction from a natural source (e.g., a pancreatic cell), by expression of a recombinant nucleic acid encoding a ABC1 polypeptide, or by chemically synthesizing the protein. Purity can be measured by any appropriate method, e.g., by column chromatography, polyacrylamide gel electrophoresis, or HPLC analysis.

A polypeptide is substantially free of naturally associated components when it is separated from those contaminants that accompany it in its natural state. Thus, a polypeptide which is chemically synthesized or produced in a cellular system different from the cell from which it naturally originates will be substantially free from its naturally associated components. Accordingly, substantially pure polypeptides include those which naturally occur in eukaryotic organisms but are synthesized in *E. coli* or other prokaryotes.

By "substantially pure nucleic acid" is meant nucleic acid that is free of the genes which, in the naturally-occurring genome of the organism from which the nucleic acid of the invention is derived, flank the nucleic acid. The term therefore includes, for example, a recombinant nucleic acid that is incorporated into a vector; into an autonomously replicating plasmid or virus; into the genomic nucleic acid of a prokaryote or a eukaryote cell; or that exists as a separate molecule (e.g., a cDNA or a genomic or cDNA fragment produced by PCR or restriction endonuclease digestion) independent of other sequences. It also includes a recombinant nucleic acid that is part of a hybrid gene encoding additional polypeptide sequence.

By "modulates" is meant increase or decrease. Preferably, a compound that modulates cholesterol levels (e.g., HDL-cholesterol levels, LDL-cholesterol levels, or total cholesterol levels), or ABC1 biological activity, expression, stability, or degradation does so by at least 10%, more preferably by at least 25%, and most preferably by at least 50%.

By "purified antibody" is meant antibody which is at least 60%, by weight, free from proteins and naturally occurring organic molecules with which it is naturally associated. Preferably, the preparation is at least 75%, more preferably 90%, and most preferably at least 99%, by weight, antibody. A purified antibody may be

5 obtained, for example, by affinity chromatography using recombinantly-produced protein or conserved motif peptides and standard techniques.

10 By "specifically binds" is meant an antibody that recognizes and binds to, for example, a human ABC1 polypeptide but does not substantially recognize and bind to
5 other non-ABC1 molecules in a sample, e.g., a biological sample, that naturally includes protein. A preferred antibody binds to the ABC1 polypeptide sequence of
15 Fig. 9A (SEQ ID NO: 1).

By "polymorphism" is meant that a nucleotide or nucleotide region is characterized as occurring in several different forms. A "mutation" is a form of a
20 polymorphism in which the expression level, stability, function, or biological activity of the encoded protein is substantially altered.

By "ABC transporter" or "ABC polypeptide" is meant any transporter that hydrolyzes ATP and transports a substance across a membrane. Preferably, an ABC
25 transporter polypeptide includes an ATP Binding Cassette and a transmembrane region. Examples of ABC transporters include, but are not limited to, ABC1, ABC2, ABCR, and ABC8.
15

By "ABC1 polypeptide" is meant a polypeptide having substantial identity to an ABC1 polypeptide having the amino acid sequence of SEQ ID NO: 1.
30

By "ABC biological activity" or "ABC1 biological activity" is meant
20 hydrolysis or binding of ATP, transport of a compound (e.g., cholesterol, interleukin-1) or ion across a membrane, or regulation of cholesterol or phospholipid levels (e.g.,
35 either by increasing or decreasing HDL-cholesterol or LDL-cholesterol levels).

The invention provides screening procedures for identifying therapeutic compounds (cholesterol-modulating or anti-CVD pharmaceuticals) which can be used
40 in human patients. Compounds that modulate ABC biological activity (e.g., ABC1 biological activity) are considered useful in the invention, as are compounds that
25 modulate ABC concentration, protein stability, regulated catabolism, or its ability to bind other proteins or factors. In general, the screening methods of the invention
45 involve screening any number of compounds for therapeutically active agents by employing any number of *in vitro* or *in vivo* experimental systems. Exemplary
30 methods useful for the identification of such compounds are detailed below.
50

5 The methods of the invention simplify the evaluation, identification and
development of active agents for the treatment and prevention of low HDL and CVD.
10 In general, the screening methods provide a facile means for selecting natural product
extracts or compounds of interest from a large population which are further evaluated
5 and condensed to a few active and selective materials. Constitutes of this pool are
then purified and evaluated in the methods of the invention to determine their HDL-
15 raising or anti-CVD activities or both.

Other features and advantages of the invention will be apparent from the
following description of the preferred embodiments thereof, and from the claims.

20 Brief Description of the Drawings

Figs. 1A and 1B are schematic illustrations showing two pedigrees with
Tangier Disease, (TD-1 and TD-2). Square and circle symbols represent males and
25 females, respectively. Diagonal lines are placed through the symbols of all deceased
individuals. A shaded symbol on both alleles indicates the probands with Tangier
15 Disease. Individuals with half shaded symbols have HDL-C levels at or below the
10th percentile for age and sex, while those with quarter shaded symbols have HDL-C
30 between the 11th and 20th percentiles.

Each individual's ID number, age at the time of lipid measurement,
20 triglyceride level and HDL cholesterol level followed by their percentile ranking for
age and sex are listed below the pedigree symbol. Markers spanning the 9q31.1
35 region are displayed to the left of the pedigree. The affected allele is represented by
the darkened bars which illustrate the mapping of the limits of the shared haplotype
region as seen in Fig. 3. Parentheses connote inferred marker data, questions marks
40 indicate unknown genotypes, and large arrows show the probands.

Fig. 1C shows ApoAI (10 $\mu\text{g/mL}$) -mediated cellular cholesterol efflux in
control fibroblasts ($n=5$, normalized to 100%) and two subjects with Tangier disease
45 (TD). Cells were ^3H -cholesterol (0.2 $\mu\text{Ci/mL}$) labeled during growth and cholesterol
(20 $\mu\text{g/mL}$) loaded in growth arrest. Cholesterol efflux is determined as ^3H
30 medium/ $(^3\text{H}$ cell + ^3H medium)

Fig. 2A - 2D are schematic illustrations showing four French Canadian pedigrees with FHA (FHA-1 to -4). The notations are as in Fig. 1. Exclamation points on either side of a genotype (as noted in Families FHA-3 and FHA-4) are used when the marker data appears to be inconsistent due to potential microsatellite repeat expansions. A bar that becomes a single thin line suggests that the haplotype is indeterminate at that marker.

Figs. 3A - 3E are a schematic illustration showing a genetic and physical map of 9q31 spanning 35 cM. Fig. 3A: YACs from the region of 9q22-34 were identified and a YAC contig spanning this region was constructed. Fig. 3B: A total of 22 polymorphic CA microsatellite markers were mapped to the contig and used in haplotype analysis in TD-1 and TD-2. Fig 3C: The mutant haplotypes for probands in TD-1 and -2 indicate a significant region of homozygosity in TD-2, while the proband in TD-1 has 2 different mutant haplotypes. The candidate region can be narrowed to the region of homozygosity for CA markers in proband 2. A critical crossover at D9S1690 in TD-1 (A)* also provides a centromeric boundary for the region containing the gene. Three candidate genes in this region (*ABC1*, *LPA-R* and *RGS-3*) are shown. Fig. 3D: Meiotic recombinations in the FHA families (A-H) refine the minimal critical region to 1.2 cM between D9S277 and D9S1866. The heterozygosity of the TD-2 proband at D9S127, which ends a continuous region of homozygosity in TD-2, further refines the region to less than 1 cM. This is the region to which *ABC1* has been mapped. Fig. 3E: Isolated YAC DNA and selected markers from the region were used to probe high-density BAC grid filters, selecting BACs which via STS-content mapping produced an 800 Kb contig. Four BACs containing *ABC1* were sequenced using high-throughput methods.

Fig. 4A shows sequence of one mutation in family TD-1. Patient III-01 is heterozygous for a T to C transition at nucleotide 4503 of the cDNA; the control is homozygous for T at this position. This mutation corresponds to a cysteine to arginine substitution in the *ABC1* protein (C1477R).

Fig 4B shows the amino acid sequence conservation of residue 1477 in mouse and human, but not a related *C. elegans* gene. A change from cysteine to arginine likely has an important effect on the protein secondary and tertiary structure, as noted

by its negative scores in most substitution matrices (Schuler et al., A Practical Guide to the Analysis of Genes and Proteins, eds. Baxevaris, A.D. & Ouellette, B.F.F. 145:171, 1998). The DNA sequences of the normal and mutant genes are shown above and below the amino acid sequences, respectively.

Fig. 4C shows the segregation of the T4503C mutation in TD-1. The presence of the T4503C mutation (+) was assayed by restriction enzyme digestion with *HgaI*, which cuts only the mutant (C) allele (!). Thus, in the absence of the mutation, only the 194 bp PCR product (amplified between - and -) is observed, while in its presence the PCR product is cleaved into fragments of 134 bp and 60 bp. The proband (individual III.01) was observed to be heterozygous for this mutation (as indicated by both the 194 bp and 134 bp bands), as were his daughter, father, and three paternal cousins. A fourth cousin and three of the father's siblings were not carriers of this mutation.

Fig. 4D shows Northern blot analysis with probes spanning the complete ABC1 gene reveal the expected ~8 Kb transcript and, in addition, a ~3.5 kb truncated transcript only seen in the proband TD-1 and not in TD-2 or control. This was detected by probes spanning exons 1-49 (a), 1-41 (b), 1-22 (c), and 23-29 (d), but not with probes spanning exons 30-41 (e) or 42-49 (f).

Fig. 5A shows the sequence of the mutation in family TD-2. Patient IV-10 is homozygous for an A to G transition at nucleotide 1864 of the cDNA (SEQ ID NO: 2); the control is homozygous for A at this position. This mutation corresponds to a glutamine to arginine substitution in the ABC1 protein (Q597R).

Fig. 5B shows that the glutamine amino acid, which is mutated in the TD-2 proband, is conserved in human and mouse ABC1 as well as in an ABC orthologue from *C. elegans*, revealing the specific importance of this residue in the structure/function of this ABC protein in both worms and mammals. The DNA sequences of the normal and mutant proteins are shown above and below the amino acid sequences, respectively.

Fig. 5C shows the segregation of the A1864G mutation in TD-2. The presence of the A1864G mutation (indicated by +) was assayed by restriction enzyme digestion with *AccI*. The 360 bp PCR product has one invariant *AccI* recognition site

(↓), and a second one is created by the A1864G mutation. The wild-type allele is thus cleaved to fragments of 215 bp and 145 bp, while the mutant allele (G-allele) is cleaved to fragments of 185 bp, 145 bp and 30 bp. The proband (individual IV-10), the product of a consanguineous mating, was homozygous for the A1864G mutation (+/+), as evidenced by the presence of only the 185 bp and 145 bp bands, while four other family members for whom DNA was tested are heterozygous carriers of this mutation (both the 215 bp and 185 bp fragments were present). Two unaffected individuals (-/-), with only the 215 bp and 145 bp bands are shown for comparison.

Fig. 6A shows a sequence of the mutation in family FHA-1. Patient III-01 is heterozygous for a deletion of nucleotides 2151-2153 of the cDNA (SEQ ID NO: 2). This deletion was detected as a superimposed sequence starting at the first nucleotide after the deletion. This corresponds to deletion of leucine 693 in the ABC1 protein (SEQ ID NO: 1).

Fig. 6B is an alignment of the human and mouse wild-type amino acid sequences, showing that the human and mouse sequences are identical in the vicinity of ΔL693. L693 is also conserved in *C. elegans*. This highly conserved residue lies within a predicted transmembrane domain. The DNA sequences of the normal and mutant proteins are shown above and below the amino acid sequences, respectively.

Fig. 6C shows segregation of the ΔL693 mutation in FHA-1, as assayed by *EcoRI* restriction digestion. Two invariant *EcoRI* restriction sites (indicated by ↓) are present within the 297 bp PCR product located between the horizontal arrows (--) while a third site is present in the wild-type allele only. The presence of the mutant allele is thus distinguished by the presence of a 210 bp fragment (+), while the normal allele produces a 151 bp fragment (-). The proband of this family (III.01) is heterozygous for this mutation, as indicated by the presence of both the 210 and 151 bp bands.

Fig. 6D shows a sequence of the mutation in family FHA-3. Patient III-01 is heterozygous for a deletion of nucleotides 5752-5757 of the cDNA (SEQ ID NO: 2). This deletion was detected as a superimposed sequence starting at the first nucleotide after the deletion. This corresponds to deletion of glutamic acid 1893 and aspartic acid 1894 in the ABC1 protein (SEQ ID NO: 1).

Fig. 6E is an alignment of the human and mouse wild-type amino acid sequences, showing that the human and mouse sequences are identical in the vicinity of $\Delta 5752-5757$. This region is highly conserved in *C. elegans*. The DNA sequences of the normal and mutant proteins are shown above and below the amino acid sequences, respectively.

Fig. 6F shows a sequence of the mutation in family FHA-2. Patient III-01 is heterozygous for a C to T transition at nucleotide 6504 of the cDNA (SEQ ID NO: 2). This alteration converts an arginine at position 2144 of SEQ ID NO: 1 to a STOP codon, causing truncation of the last 118 amino acids of the ABC1 protein.

Figs. 7A and 7B show cholesterol efflux from human skin fibroblasts treated with ABC1 antisense oligonucleotides. Fibroblasts from a control subject were labeled with ^3H cholesterol (0.2 $\mu\text{Ci/mL}$) during growth for 48 hours and transfected with 500 nM ABC1 antisense AN-1 (5'-GCA GAG GGC ATG GCT TTA TTT G-3'; SEQ ID NO: 3) with 7.5 μg lipofectin for 4 hours. Following transfection, cells were cholesterol loaded (20 $\mu\text{g/mL}$) for 12 hours and allowed to equilibrate for 6 hours. Cells were either then harvested for total RNA and 10 μg was used for Northern blot analysis. Cholesterol efflux experiments were carried out as described herein. Fig. 7A: AN-1 was the oligonucleotide that resulted in a predictable decrease in ABC1 RNA transcript levels. Fig. 7B: A double antisense transfection method was used. In this method, cells were labeled and transfected with AN-1 as above, allowed to recover for 20 hours, cholesterol loaded for 24 hours, and then re-transfected with AN-1. Twenty hours after the second transfection, the cholesterol efflux as measured. A ~50% decrease in ABC1 transcript levels was associated with a significant decrease in cholesterol efflux intermediate between that seen in wild-type and TD fibroblasts.

Fig. 7C shows show cholesterol efflux from human skin fibroblasts treated with antisense oligonucleotides directed to the region encoding the amino-terminal 60 amino acids. Note that the antisense oligonucleotide AN-6, which is directed to the previously unrecognized translation start site, produces a substantial decrease in cellular cholesterol efflux.

Fig. 8 is a schematic illustration showing predicted topology, mutations, and polymorphisms of ABC1 in Tangier disease and FHA. The two transmembrane and

ATP binding domains are indicated. The locations of mutations are indicated by the arrows with the amino acid changes, which are predicted from the human *ABC1* cDNA sequence. These mutations occur in different regions of the ABC1 protein.

Fig. 9A shows the amino acid sequence of the human ABC1 protein (SEQ ID NO: 1).

Figs. 9B - 9E show the nucleotide sequence of the human *ABC1* cDNA (SEQ ID NO: 2).

Fig. 10 shows the 5' and 3' nucleotide sequences suitable for use as 5' and 3' PCR primers, respectively, for the amplification of the indicated ABC1 exon.

Fig. 11 shows a summary of alterations found in ABC1, including sequencing errors, mutations, and polymorphisms.

Fig. 12 shows a series of genomic contigs (SEQ ID NOS. 14-29) containing the ABC1 promoter (SEQ ID NO: 14), as well as exons 1-49 (and flanking intronic sequence) of ABC1. The exons (capitalized letters) are found in the contigs as follows: SEQ ID NO: 14--exon 1; SEQ ID NO: 15--exon 2; SEQ ID NO: 16--exon 3; SEQ ID NO: 17--exon 4; SEQ ID NO: 18--exon 5; SEQ ID NO: 19--exon 6; SEQ ID NO: 20--exons 7 and 8; SEQ ID NO: 21--exons 9 through 22; SEQ ID NO: 22--exons 23 through 28; SEQ ID NO: 23--exon 29; SEQ ID NO: 24--exons 30 and 31; SEQ ID NO: 25--exon 32; SEQ ID NO: 26--exons 33 through 36; SEQ ID NO: 27--exons 37 through 41; SEQ ID NO: 28--exons 42-45; SEQ ID NO: 29--exons 46-49.

Fig. 13 is a series of illustrations showing that the amino-terminal 60 amino acid region of ABC1 is protein-coding. Lysates of normal human fibroblasts were immunoblotted in parallel with a rabbit polyclonal antibody to amino acids 1-20 of human ABC1 (1); a rabbit polyclonal antibody to amino acids 1430-1449 of human ABC1 (2); and a mouse monoclonal antibody to amino acids 2236-2259 of human ABC1. The additional bands detected in lane 2 may be due to a lack of specificity of that antibody or the presence of degradation products of ABC1.

Fig. 14 is a schematic illustration showing that the WHAM chicken contains a non-conservative substitution (G265A) resulting in an amino acid change (E89K).

Fig. 15 is a schematic illustration showing that the mutation in the WHAM chicken is at an amino acid that is conserved among human, mouse, and chicken.

Fig. 16 show a summary of locations of consensus transcription factor binding sites in the human ABC1 promoter (nucleotides 1-8238 of SEQ ID NO: 14). The abbreviations are as follows: PPRE=peroxisome proliferator-activated receptor. SRE=steroid response element-binding protein site. ROR=RAR-related orphan receptor.

Detailed Description

Genes play a significant role influencing HDL levels. Tangier disease (TD) was the first reported genetic HDL deficiency. The molecular basis for TD is unknown, but has been mapped to 9q31 in three families. We have identified two additional probands and their families, and confirmed linkage and refined the locus to a limited genomic region. Mutations in the *ABC1* gene accounting for all four alleles in these two families were detected. A more frequent cause of low HDL levels is a distinct disorder, familial HDL deficiency (FHA). On the basis of independent linkage, meiotic recombinants and disease associated haplotypes, FHA was localized to a small genomic region encompassing the *ABC1* gene. A mutation in a conserved residue in ABC1 segregated with FHA. Antisense reduction of the *ABC1* transcript in fibroblasts was associated with a significant decrease in cholesterol efflux.

Cholesterol is normally assembled with intracellular lipids and secreted, but in TD the process is diverted and cholesterol is degraded in lysosomes. This disturbance in intracellular trafficking of cholesterol results in an increase in intracellular cholesterol ester accumulation associated with morphological changes of lysosomes and the Golgi apparatus and cholesteryl ester storage in histiocytes, Schwann cells, smooth muscle cells, mast cells and fibroblasts.

The clinical and biochemical heterogeneity in patients with TD has led to the possibility that genetic heterogeneity may also underlie this disorder. Considering this, we initially performed linkage analysis on these two families of different ancestries (TD-1 is Dutch, TD-2 is British; Frohlich et al., Clin. Invest. Med. 10:377-382, 1987) and confirmed that the genetic mutations underlying TD in these families were localized to the same 9q31 region, to which a large family with TD had been

5 assigned (Rust et al., Nature Genetics 20:96-98, 1998). Detailed haplotype analysis,
together with the construction of a physical map, refined the localization of this gene.
10 Mutations in the *ABC1* gene were found in TD.

5 *FHA* is much more common than TD, although its precise frequency is not
known. While TD has been described to date in only 40 families, we have identified
15 more than 40 *FHA* families in the Netherlands and Quebec alone. After initial
suggestions of linkage to 9q31, thirteen polymorphic markers spanning approximately
10 cM in this region were typed and demonstrated the highest LOD score at D9S277.
20 Analysis of the homozygosity of markers in the TD-2 proband, who was expected to
be homozygous for markers close to TD due to his parents' consanguinity, placed the
TD gene distal to D9S127. Combined genetic data from TD and *FHA* families
pointed to the same genomic segment spanning approximately 1,000 kb between
25 D9S127 and D9S1866. The *ABC1* transporter gene was contained within the minimal
genomic region. RT-PCR analysis in one family demonstrated a deletion of leucine at
15 residue 693 ($\Delta 693$) in the first transmembrane domain of *ABC1*, which segregated
with the phenotype of HDL deficiency in this family.

30 *ABC1* is part of the ATP-binding cassette (ABC transporter) superfamily,
which is involved in energy-dependent transport of a wide variety of substrates across
membranes (Dean et al., Curr. Opin. Gen. Dev. 5:779-785, 1995). These proteins
20 have characteristic motifs conserved throughout evolution which distinguish this class
of proteins from other ATP binding proteins. In humans these genes essentially
35 encode two ATP binding segments and two transmembrane domains (Dean et al.,
Curr. Opin. Gen. Dev. 5:779-785, 1995). We have now shown that the *ABC1*
transporter is crucial for intracellular cholesterol transport.

40 25 We have demonstrated that reduction of the *ABC1* transcript using
oligonucleotide antisense approaches results in decreased efflux, clearly
demonstrating the link between alterations in this gene and its functional effects. TD
45 and *FHA* now join the growing list of genetic diseases due to defects in the ABC
group of proteins including cystic fibrosis (Zielenski, et al., Annu. Rev. Genet.
30 29:777-807, 1995), adrenoleukodystrophy (Mosser et al., Nature 361: 726-730, 1993),
Zellweger syndrome (Gärtner et al., Nat. Genet. 1:23, 1992), progressive familial

5 intrahepatic cholestasis (Bull et al., Nat. Genet. 18:219-224, 1998), and different eye disorders including Stargardt disease (Allikmets et al., Nat. Genet. 15:236-246, 1997),
10 autosomal recessive retinitis pigmentosa (Allikmets et al., Science 277:1805-1807, 1997), and cone-rod dystrophy (Cremers et al., Hum. Mol. Genet. 7:355-362, 1998).

5 Patients with TD have been distinguished from patients with FHA on the basis that Tangier disease was an autosomal recessive disorder (OMIM 20540) while FHA is inherited as an autosomal dominant trait (OMIM 10768). Furthermore, patients
15 with TD have obvious evidence for intracellular cholesterol accumulation which is not seen in FHA patients. It is now evident that heterozygotes for TD do have reduced
20 HDL levels and that the same mechanisms underlie the HDL deficiency and cholesterol efflux defects seen in heterozygotes for TD as well as FHA. Furthermore, the more severe phenotype in TD represents loss of function from both alleles of the *ABC1* gene.

25 ABC1 is activated by protein kinases, presumably via phosphorylation, which also provides one explanation for the essential role of activation of protein kinase C in
15 promoting cholesterol efflux (Drobnick et al., Arterioscler. Thromb. Vasc. Biol. 15: 1369-1377, 1995). Brefeldin, which inhibits trafficking between the endoplasmic reticulum and the Golgi, significantly inhibits cholesterol efflux, essentially
30 reproducing the effect of mutations in ABC1, presumably through the inhibition of ABC1 biological activity. This finding has significance for the understanding of
20 mechanisms leading to premature atherosclerosis. TD homozygotes develop premature coronary artery disease, as seen in the proband of TD-1 (III-01) who had evidence for coronary artery disease at 38 years. This is particular noteworthy as TD
35 patients, in addition to exhibiting significantly reduced HDL, also have low LDL cholesterol, and yet they develop atherosclerosis despite this. This highlights the importance of HDL intracellular transport as an important mechanism in
40 atherogenesis. There is significant evidence that heterozygotes for TD are also at increased risk for premature vascular disease (Schaefer et al., Ann. Int. Med. 93:261-266, 1980; Serfaty-Lacrosniere et al., Atherosclerosis 107:85-98, 1994). There is also
45 preliminary evidence for premature atherosclerosis in some probands with FHA (Fig. 2B), e.g., the proband in FHA-2 (III-01) had a coronary artery bypass graft at 46 years
50

5 while the proband in FHA-3 (Fig. 2C) had evidence for CAD around 50 years of age. The TD-1 proband had more severe efflux deficiency than the TD-2 proband (Fig. 10 1C). Interestingly, the TD-2 proband had no evidence for CAD by 62 when he died of unrelated causes, providing preliminary evidence for a relationship between the degree of cholesterol efflux (mediated in part by the nature of the mutation) and the likelihood of atherosclerosis.

15 The *ABCI* gene plays a crucial role in cholesterol transport and, in particular, intracellular cholesterol trafficking in monocytes and fibroblasts. It also appears to play a significant role in other tissues such as the nervous system, GI tract, and the 20 10 cornea. Completely defective intracellular cholesterol transport results in peripheral neuropathy, corneal opacities, and deposition of cholesterol esters in the rectal mucosa.

25 HDL deficiency is heterogeneous in nature. The delineation of the genetic basis of TD and FHA underlies the importance of this particular pathway in intracellular cholesterol transport, and its role in the pathogenesis of atherosclerosis. 15 Unraveling of the molecular basis for TD and FHA defines a key step in a poorly defined pathway of cholesterol efflux from cells and could lead to new approaches to treatment of patients with HDL deficiency in the general population.

30 HDL has been implicated in numerous other biological processes, including but not limited to: prevention of lipoprotein oxidation; absorption of endotoxins; 35 20 protection against *Trypanosoma brucei* infection; modulation of endothelial cells; and prevention of platelet aggregation (see Genest et al., J. Invest. Med. 47: 31-42, 1999, hereby incorporated by reference). Any compound that modulates HDL levels may be useful in modulating one or more of the foregoing processes. The present 40 25 discovery that ABC1 functions to regulate HDL levels links, for the first time, ABC1 with the foregoing processes.

45 The following examples are to illustrate the invention. They are not meant to limit the invention in any way.

Analysis of TD Families

Studies of cholesterol efflux

Both probands had evidence of marked deficiency of cholesterol efflux similar to that previously demonstrated in TD patients (Fig. 1C). TD-1 is of Dutch descent while TD-2 is of British descent.

Linkage analysis and establishment of a physical map

Multiple DNA markers were genotyped in the region of 9q31 to which linkage to TD had been described (Rust et al., Nat. Genet. 20, 96-98, 1998). Two point linkage analysis gave a maximal peak LOD score of 6.49 at D9S1832 (Table 1) with significant evidence of linkage to all markers in a ~10 cM interval. Recombination with the most proximal marker, D9S1690 was seen in II-09 in Family TD-1 (A* in Fig. 3D) providing a centromeric boundary for the disease gene. Multipoint linkage analysis of these data did not increase the precision of the positioning of the disease trait locus.

A physical map spanning approximately 10 cM in this region was established with the development of a YAC contig (Fig. 3A). In addition, 22 other polymorphic multi-allelic markers which spanned this particular region were mapped to the contig (Fig. 3B) and a subset of these were used in construction of a haplotype for further analysis (Figs. 1A and 1B; Table 2).

While the family of Dutch decent did not demonstrate any consanguinity, the proband in TD-2 was the offspring of a first-cousin consanguineous marriage (Fig. 1B). We postulated, therefore, that it was most likely that this proband would be homozygous for the mutation while the proband in the Dutch family was likely to be a compound heterozygote. The Dutch proband shows completely different mutation bearing haplotypes, supporting this hypothesis (Fig. 3C).

The TD-2 proband was homozygous for all markers tested (Fig. 1B) distal to D9S127 but was heterozygous at D9S127 and DNA markers centromeric to it (Fig. 3C). This suggested that the gene for TD was likely located to the genomic region telomeric of D9S127 and encompassed by the markers demonstrating homozygosity (Fig. 3B).

TABLE 1

Two Point Linkage Analysis of TD-1 and TD-2

Marker Locus	LOD Score at recombination fraction						
	0	0.01	0.05	0.10	0.20	0.30	0.40
D9S1690	-infini	4.25	4.52	4.26	3.39	2.30	1.07
D9S277	6.22	6.11	5.67	5.10	3.90	2.60	1.17
D9S1866	4.97	4.87	4.49	4.00	2.96	1.85	0.70
D9S1784	5.50	5.40	5.00	4.47	3.36	2.17	0.92
D9S1832	6.49	6.37	5.91	5.31	4.05	2.69	1.21
D9S1677	4.60	4.51	4.18	3.76	2.88	1.93	0.93

Results of pairwise linkage analysis using MLINK. Values correspond to the LOD score for linkage between the disease locus and a marker locus for specified values of the recombination fraction.

TABLE 2. Microsatellite markers used in this study

Genetic Markers	Type	Heterozygosity	Number of alleles	Allele frequency* size, bp (proportion)
D9S283	CA	0.80	10	179(0.04); 181(0.34); 183(0.15); 185(0.20); 189(0.05); 193(0.04); 197(0.07); 199(0.02); 201(0.04); 203(0.04)
D9S176	CA	0.82	9	129(0.03); 131(0.16); 133(0.22); 135(0.12); 137(0.25); 139(0.03); 141(0.01); 143(0.05); 147(0.03)
D9S1690	CA	0.79	8	225(0.38); 227(0.14); 229(0.02); 231(0.12); 233(0.05); 235(0.16); 237(0.05); 239(0.05)
D9S277	CA	0.89	15	167(0.07); 171(0.02); 173(0.12); 175(0.11); 177(0.07); 179(0.04); 181(0.17); 183(0.06); 185(0.02); 187(0.02); 189(0.12); 191(0.13); 193(0.02); 197(0.00); 199(0.00)
D9S127	CA	0.72	6	149(0.11); 151(0.07); 153(0.23); 155(0.03); 157(0.45); 159(0.06)
D9S306	CA	0.87	13	103(0.06); 104(0.01); 110(0.03); 112(0.05); 114(0.16); 116(0.15); 118(0.11); 120(0.23); 122(0.06); 124(0.06); 126(0.03); 134(0.02); 136(0.01)
D9S1866	CA	0.62	11	248(0.06); 252(0.04); 254(0.01); 256(0.58); 258(0.03); 260(0.06); 262(0.02); 264(0.12); 266(0.06); 268(0.03); 270(0.01)
D9S1784	CA	0.86	15	174(0.10); 176(0.02); 178(0.00); 180(0.08); 182(0.11); 184(0.22); 186(0.15); 188(0.06); 190(0.04); 192(0.07); 194(0.02); 196(0.07); 198(0.01); 200(0.01); 202(0.01)
AFMa107x19	CA	n.a.	n.a.	n.a.
D9S2170	CA	n.a.	n.a.	n.a.
D9S2171	CA	n.a.	n.a.	n.a.
D9S2107	CA	0.63	5	n.a.
D9S172	CA	0.54	5	291(0.00); 297(0.05); 299(0.32); 303(0.62); 305(0.02)
D9S2109	CA	0.51	3	1(0.42); 3(0.56); 3(0.02)
D9S1832	CA	0.88	12	161(0.04); 163(0.02); 167(0.02); 169(0.04); 171(0.10); 173(0.09); 175(0.15); 177(0.28); 179(0.19); 181(0.04); 183(0.01); 185(0.01)
D9S1835	CA	0.48	4	110(0.02); 112(0.23); 116(0.58); 118(0.07)
D9S1801	CA	0.77	10	166(0.10); 172(0.04); 174(0.02); 182(0.02); 184(0.19); 186(0.40); 188(0.15); 190(0.04); 192(0.02); 194(0.02)
D9S261	CA	0.65	7	90(0.02); 92(0.32); 94(0.02); 98(0.02); 100(0.29); 102(0.04); 104(0.08)
D9S160	CA	0.62	6	136(0.25); 138(0.53); 140(0.01); 142(0.12); 144(0.00); 146(0.07)
D9S1677	CA	0.81	10	251(0.27); 257(0.27); 259(0.07); 261(0.09); 263(0.27); 265(0.14); 267(0.02); 269(0.02); 271(0.04); 273(0.02)
D9S279	CA	0.78	6	244(0.09); 246(0.18); 248(0.39); 250(0.29); 252(0.07); 254(0.09)
D9S275	CA	0.62	4	190(0.31); 196(0.07); 198(0.52); 200(0.09)

* In a Caucasian population of French Canadian or French descent (J. Weissenbach, Personal Communication 1993).
n.a. = not assessed.

These polymorphic microsatellite markers were used for DNA typing in the region of 9q31 seen in Fig.3. The majority come from the last version of the Génethon human linkage map⁵³. The frequency of heterozygosity, the number of alleles as well as the allele frequency of each marker are presented.

Mutation detection

Based on the defect in intracellular cholesterol transport in patients with TD, we reviewed the EST database for genes in this region which might be relevant to playing a role in this process. One gene that we reviewed as a candidate was the lysophosphatidic acid (LPA) receptor (*EDG2*) which mapped near D9S1801 (Fig. 3C). This receptor binds LPA and stimulates phospholipase-C (PLC), and is expressed in fibroblasts. It has previously been shown that the coordinate regulation of PLC that is necessary for normal HDL3 mediated cholesterol efflux is impaired in TD (Walter et al., J. Clin. Invest. 98:2315-2323, 1996). Therefore this gene represented an excellent candidate for the TD gene. Detailed assessment of this gene, using Northern blot and RT-PCR and sequencing analysis, revealed no changes segregating with the mutant phenotype in this family, in all likelihood excluding this gene as the cause for TD. Polymorphisms were detected, however, in the RT-PCR product, indicating expression of transcripts from both alleles.

The second candidate gene (*RGS3*) encodes a member of a family regulating G protein signaling which could also be involved in influencing cholesterol efflux (Mendez et al., Trans. Assoc. Amer. Phys. 104:48-53, 1991). This gene mapped 0.7 cM telomeric to the LPA-receptor (Fig. 3C), and is expressed in fibroblasts. It was assessed by exon-specific amplification, as its genomic organization was published (Chatterjee et al., Genomics 45:429-433, 1997). No significant sequence changes were detected.

The *ABCI* transporter gene had previously been mapped to 9q31, but its precise physical location had not been determined (Luciani et al., Genomics 21:150-159, 1994). The *ABCI* gene is a member of the ATP binding cassette transporters which represents a super family of highly conserved proteins involved in membrane transport of diverse substrates including amino acids, peptides, vitamins and steroid hormones (Luciani et al., Genomics 21:150-159, 1994; Dean et al., Curr. Opin. Gen. Dev. 5:779-785, 1995). Primers to the 3' UTR of this gene mapped to YACs spanning D9S306 (887-B2 and 930-D3) compatible with it being a strong candidate for TD. We initiated large scale genomic sequencing of BACs spanning approximately 800 kb around marker D9S306 (BACs 269, 274, 279 and 291) (Fig

5
10
3E). The *ABCI* gene was revealed encompassing 49 exons and a minimum of 75 Kb of genomic sequence. In view of the potential function of a gene in this family as a cholesterol transporter, its expression in fibroblasts and localization to the minimal genomic segment underlying TD, we formally assessed ABC1 as a candidate.

5 Patient and control total fibroblast RNA was used in Northern blot analysis and RT-PCR and sequence analyses. RT-PCR and sequence analysis of TD-1
15 revealed a heterozygous T to C substitution (Fig. 4A) in the TD-1 proband, which would result in a substitution of arginine for cysteine at a conserved residue between mouse and man (Fig. 4B). This mutation, confirmed by sequencing exon 30 of the
20 ABC1 gene, exhibited complete segregation with the phenotype on one side of this family (Fig. 4C). This substitution creates a *HgaI* site, allowing for RFLP analysis of amplified genomic DNA and confirmation of the mutation (Fig. 4C). The point
25 mutation in exon 30 was not seen on over 200 normal chromosomes from unaffected persons of Dutch decent, and 250 chromosomes of Western European decent,
15 indicating it is unlikely to be a polymorphism. Northern blot analysis of fibroblast RNA from this patient, using a cDNA encompassing exons 1 to 49 of the gene,
30 revealed a normal sized ~8 Kb transcript and a truncated mutant transcript which was not visible in control RNA or in RNA from other patients with HDL deficiency (Fig. 4D). Additionally, Northern blot analysis using clones encompassing discrete regions
20 of the cDNA revealed that the mutant transcript was detected with a cDNA
35 compassing exons 1 to 49 (a), 1 to 41 (b), 1 to 22 (c), much more faintly with a probe spanning exon 23 to 29 (d) and not seen with probes encompassing exons 30 to 42 (e),
40 but not seen with cDNA fragment spanning exons 30 to 49 (f). This was repeated on multiple filters with control RNA, RNA from other patients with HDL deficiency and
25 the other TD proband, and only in TD-1 was the truncated transcript observed. Sequence analysis of the coding region did not reveal an alteration in sequence that
45 could account for this finding. Furthermore, DNA analysis by Southern blot did not reveal any major rearrangements. Completion of exon sequencing in genomic DNA
30 showed that this mutation was a G to C transversion at position (+1) of intron 24, (Fig. 11) affecting a splice donor site and causing aberrant splicing.

50 RT-PCR analysis of fibroblast RNA encoding the *ABCI* gene from the

proband in TD-2 (Fig. 1B) revealed a homozygous nucleotide change of A to G at nucleotide 1864 of SEQ ID NO: 2 in exon 13 (Fig. 5A), resulting in a substitution of arginine for glutamine at residue 597 of SEQ ID NO: 1 (Fig. 5B), occurring just proximal to the first predicted transmembrane domain of ABC1 (Fig. 8) at a residue conserved in mouse and as well as a *C. elegans* homolog. This mutation creates a second *AclI* site within exon 13. Segregation analysis of the mutation in this family revealed complete concordance between the mutation and the low HDL phenotype as predicted (Fig 5C). The proband in TD-2 is homozygous for this mutation, consistent with our expectation of a disease causing mutation in this consanguineous family.

Analysis of FHA families

Linkage analysis and refinement of the minimal genomic region containing the gene for FHA

Data from microsatellite typing of individual family members from the four pedigrees of French Canadian origin were analyzed (Fig. 2). A maximum LOD score of 9.67 at a recombination fraction of 0.0 was detected at D9S277 on chromosome 9q31 (Fig. 3; Table 3). Thereafter, 22 markers were typed in a region spanning 10 cM around this locus in these families (Figs. 2 and 3). The frequency for these markers were estimated from a sample of unrelated and unaffected subjects of French ancestry (Table 2).

TD and FHA have thus far been deemed distinct with separate clinical and biochemical characteristics. Even though the genes for these disorders mapped to the same region, it was uncertain whether FHA and TD were due to mutations in the same gene or, alternatively, due to mutations in genes in a similar region. Refinement of the region containing the gene for FHA was possible by examining haplotype sharing and identification of critical recombination events (Fig. 2). Seven separate meiotic recombination events were seen in these families ("A" through "G" in Figs. 2 and 3), clearly indicating that the minimal genomic region containing the potential disease gene was a region of approximately 4.4 cM genomic DNA spanned by marker D9S1690 and D9S1866 (Figs. 2 and 3). This region is consistent with the results of two point linkage analysis which revealed maximal LOD scores with markers

TABLE 3
Two Point Linkage Analysis in FHA

Marker Locus	LOD Score at recombination fraction						
	0	0.01	0.05	0.10	0.20	0.30	0.40
D9S253	-infini	-2.57	0.51	1.48	1.84	1.48	0.76
D9S176	-infini	1.42	3.07	3.39	3.05	2.22	1.12
D9S1690	-infini	3.11	4.04	4.04	3.33	2.24	0.96
D9S277	9.67	9.51	8.89	8.06	6.29	4.30	2.10
D9S306	5.60	5.51	5.13	4.62	3.55	2.36	1.11
D9S1666	-infini	7.24	7.35	6.87	5.50	3.82	1.91
D9S1784	-infini	9.85	9.76	9.03	7.09	4.78	2.25
D9S172	-infini	2.63	3.00	2.87	2.26	1.50	0.67
D9S1632	-infini	5.20	5.97	5.75	4.59	3.02	1.30
D9S1801	0.14	0.13	0.11	0.09	0.06	0.03	0.01
D9S1677	-infini	7.83	7.90	7.38	5.90	4.08	2.01
D9S279	-infini	3.43	3.80	3.66	3.01	2.12	1.05
D9S275	-infini	2.57	2.98	2.91	2.41	1.69	0.81

Results of pairwise linkage analysis using MLINK. Values correspond to the LOD score for linkage between the disease locus and a marker locus for specified values of the recombination fraction.

5
10 D9S277 and D9S306 and essentially excluded the region centromeric to D9S1690 or telomeric to D9S1866. An 8th meiotic recombination event ("H" in Fig. 3) further refined the FHA region to distal to D9S277.

5 As described herein, the *ABCI* gene mapped within this interval. The overlapping genetic data strongly suggested that FHA may in fact be allelic to TD. Utilization of sets of genetic data from FHA and TD provided a telomeric boundary at D9S1866 (meiotic recombinant) (Fig. 3D) and a centromeric marker at D9S127 based on the homozygosity data of TD-2. This refined the locus to approximately 1 Mb between D9S127 and D9S1866. The *ABCI* gene mapped within this minimal region (Fig. 3E).

Mutation detection in FHA

25 Mutation assessment of the *ABCI* gene was undertaken in FHA-1 (Fig. 2A). Using primers that spanned overlapping segments of the mRNA we performed RT-PCR analysis and subjected these fragments to mutational analysis. A deletion of 15 three nucleotides is evident in the RT-PCR sequence of FHA-1 III.01 (Fig. 6A), resulting in a loss of nucleotides 2151-2153 of SEQ ID NO: 2 and deletion of a 30 leucine (Δ L693) at amino acid position 693 of SEQ ID NO: 1 (Fig. 6A). This leucine is conserved in mouse and *C. elegans* (Fig. 6B). The alteration was detected in the 20 RT-PCR products as well as in genomic sequence from exon 14 specific amplification. This mutation results in a loss of an *Eco*RI restriction site. Analysis of 35 genomic DNA from the family indicated that the mutation segregated completely with the phenotype of HDL deficiency. The loss of the *Eco*RI site results in a larger fragment being remaining in persons heterozygous for this mutation (Fig. 6C). This 40 mutation maps to the first putative transmembrane domain of ABC1 (Fig. 8) and was not seen in 130 chromosomes from persons of French Canadian descent nor seen in over 400 chromosomes from persons of other Western European ancestry.

45 A mutation has also been found in patient genomic DNA in pedigree FHA-3 from Quebec. The alteration, a 6 bp deletion of nucleotides 5752-5757 of SEQ ID 30 NO: 2 within exon 41, results in a deletion of amino acids 1893 (Glu) and 1894 (Asp) of SEQ ID NO: 1. The deletion was detected as a double, superimposed, sequence 50

starting from the point of the deletion (Fig. 6D), and was detected in sequence reads in both directions. The deletion can be detected on 3% agarose or 10% polyacrylamide gels, and segregates with disease in FHA-3. It was not seen in 128 normal chromosomes of French-Canadian origin or in 434 other control chromosomes.

Amino acids 1893 and 1894 are in a region of the ABC1 protein that is conserved between human, mouse, and *C. elegans* (Fig. 6E), implying that it is of functional importance.

An additional mutation has been found in patient genomic DNA in pedigree FHA-2 from Quebec (Fig. 6F). The alteration, a C to T transition at position 6504 of SEQ ID NO: 2, converts an arginine at position 2144 of SEQ ID NO: 1 to a STOP codon, causing truncation of the last 118 amino acids of the ABC1 protein. This alteration segregates with disease in family FHA-2.

A summary of all mutations and polymorphisms found in ABC1 is shown in Fig. 11. Each variant indicated as a mutation segregates with low HDL in its family, and was not seen in several hundred control chromosomes.

Functional relationship between changes in ABC1 transcript levels and cholesterol efflux

Antisense approaches were undertaken to decrease the ABC1 transcript and assess the effect of alteration of the transcript on intracellular cholesterol transport. The use of antisense primers to the 5' end of ABC1 clearly resulted in a decrease to approximately 50% of normal RNA levels (Fig. 7A). This would be expected to mimic in part the loss of function due to mutations on one allele, similar to that seen in heterozygotes for TD and patients with FHA. Importantly, reduction in the mRNA for the ABC1 gene resulted in a significant reduction in cellular cholesterol efflux (Fig. 7B), further establishing the role of this protein in reverse cholesterol transport and providing evidence that the mutations detected are likely to constitute loss of function mutations. Furthermore, these data support the functional importance of the first 60 amino acids of the protein. Antisense oligonucleotide AN-6 is directed to the novel start codon 5' to the one indicated in AJ012376.1; this antisense oligonucleotide effectively suppresses efflux.

The above-described results were obtained using the following materials and methods.

Patient selection

The probands in TD families had previously been diagnosed as suffering from TD based on clinical and biochemical data. Study subjects with FHA were selected from the Cardiology Clinic of the Clinical Research Institute of Montréal. The main criterion was an HDL-C level <5th percentile for age and gender, with a plasma concentration of triglycerides <95th percentile in the proband and a first-degree relative with the same lipid abnormality. In addition, the patients did not have diabetes.

Biochemical studies

Blood was withdrawn in EDTA-containing tubes for plasma lipid, lipoprotein cholesterol, ApoAI, and triglyceride analyses, as well as storage at -80°C. Leukocytes were isolated from the buffy coat for DNA extraction.

Lipoprotein measurement was performed on fresh plasma as described elsewhere (Rogler et al., *Arterioscler. Thromb. Vasc. Biol.* 15:683-690, 1995). The laboratory participates and meets the criteria of the Lipid Research Program Standardization Program. Lipids, cholesterol and triglyceride levels were determined in total plasma and plasma at density $d < 1.006$ g/mL (obtained after preparative ultracentrifugation) before and after precipitation with dextran manganese. Apolipoprotein measurement was performed by nephelometry for ApoB and ApoAI.

Linkage analysis

Linkage between the trait locus and microsatellite loci was analyzed using the FASTLINK version (4.0 P). FASTLINK/MLINK was used for two-point linkage analysis assuming an autosomal dominant trait with complete penetrance. In FHA and TD heterozygotes, the phenotype was HDL deficiency <5th percentile for age and sex. The disease allele frequency was estimated to be 0.005. Marker allele frequencies were estimated from the genotypes of the founders in the pedigrees using

NEWPREP. Multipoint linkage analysis was carried out using FASTLINK/LINKMAP.

Genomic clone assembly and physical map construction of the 9q31 region

Using the Whitehead Institute/MIT Center for Genome Research map as a reference, the genetic markers of interest at 9q31 were identified within YAC contigs. Additional markers that mapped to the approximate 9q31 interval from public databases and the literature were then assayed against the YAC clones by PCR and hybridization analysis. The order of markers was based on their presence or absence in the anchored YAC contigs and later in the BAC contig. Based on the haplotype analysis, the region between D9S277 and D9S306 was targeted for higher resolution physical mapping studies using bacterial artificial chromosomes (BACs). BACs within the region of interest were isolated by hybridization of DNA marker probes and whole YACs to high-density filters containing clones from the RPCI-11 human BAC library (Fig. 3).

Sequence retrieval and alignment

The human *ABC1* mRNA sequence was retrieved from GenBank using the Entrez nucleotide query (Baxeavanis et al., A Practical Guide to the Analysis of Genes and Proteins, eds. Baxeavanis, A.D. & Ouellette, B.F.F. 98:120, 1998) as GenBank accession number AJ012376.1. The version of the protein sequence we used as wild-type (normal) was CAA10005.1.

We identified an additional 60 amino acids in-frame with the previously-believed start methionine (Fig. 9A). Bioinformatic analysis of the additional amino acids indicates the presence of a short stretch of basic amino acid residues, followed by a hydrophobic stretch, then several polar residues. This may represent a leader sequence, or another transmembrane or membrane-associated region of the *ABC1* protein. In order to differentiate among the foregoing possibilities, antibodies directed to the region of amino acids 1-60 are raised against and used to determine the physical relationship of amino acids 1-60 in relation to the cell membrane. Other standard methods can also be employed, including, for example, expression of fusion

5 proteins and cell fractionation.

10 We also identified six errors in the previously-reported nucleotide sequence (at positions 839, 4738, 5017, 5995, 6557, and 6899 of SEQ ID NO: 2; Fig. 11). Hence, the sequence of the ABC1 polypeptide of Fig. 9A differs from CAA10005.1 as follows: Thr⇒Ile at position 1554; Pro⇒Leu at position 1642; Arg⇒Lys at position 1973; and Pro⇒Leu at position 2167. We also identified 5' and 3' UTR sequence (Figs. 9B - 9E).

15 The mouse *ABC1* sequence used has accession number X75926. It is very likely that this mouse sequence is incomplete, as it lacks the additional 60 amino acids described herein for human ABC1.

20 Version 1.7 of ClustalW was used for multiple sequence alignments with BOXSHADE for graphical enhancement (http://www.isrec.isb-sib.ch:8080/software/BOX_form.html) with the default parameter. A *Caenorhabditis elegans* ABC1 orthologue was identified with BLAST (version 2.08) using CAA1005.1 (see above) as a query, with the default parameter except for doing an organism filter for *C. elegans*. The selected protein sequence has accession version number AAC69223.1 with a score of 375, and an E value of 103.

25 Genomic DNA sequencing

30 BAC DNA was extracted from bacterial cultures using NucleoBond Plasmid Maxi Kits (Clontech, Palo Alto, CA). For DNA sequencing, a sublibrary was first constructed from each of the BAC DNAs (Rowen et al., Automated DNA Sequencing and Analysis, eds. Adams, M.D., Fields, C. & Venter, J.C., 1994). In brief, the BAC DNA was isolated and randomly sheared by nebulization. The sheared DNA was then size fractionated by agarose gel electrophoresis and fragments above 2 kb were collected, treated with Mung Bean nuclease followed by T4 DNA polymerase and klenow enzyme to ensure blunt-ends, and cloned into *Sma*I-cut M13mp19. Random clones were sequenced with an ABI373 or 377 sequencer and fluorescently labeled primers (Applied BioSystems, Foster City, CA). DNASTar software was used for gel trace analysis and contig assembly. All DNA sequences were examined against available public databases primarily using BLASTn with RepeatMasker (University

of Washington).

Reverse transcription (RT)-PCR amplification and sequence analysis

Total RNA was isolated from the cultured fibroblasts of TD and FHA patients, and reverse transcribed with a CDS primer containing oligo d(T)18 using 250 units of SuperScript II reverse transcriptase (Life Technologies, Inc., Rockville, MD) as described (Zhang et al., J. Biol. Chem. 27:1776-1783, 1996). cDNA was amplified with Taq DNA polymerase using primers derived from the published human *ABCI* cDNA sequence (Luciani et al., Genomics 21:150-159, 1994). Six sets of primer pairs were designed to amplify each cDNA sample, generating six DNA fragments which are sequentially overlapped covering 135 to 7014 bp of the full-length human *ABCI* cDNA. The nucleotides are numbered according to the order of the published human cDNA sequence (AJ012376.1). Primer pairs (1): 135-158 (f) and 1183-1199 (r); (2): 1080-1107 (f) and 2247-2273 (r); (3): 2171-2197 (f) and 3376-3404 (r); (4): 3323-3353 (f) and 4587-4617 (r); (5) 4515-4539 (f) and 5782-5811 (r); (6): 5742-5769 (f) and 6985-7014 (r). RT-PCR products were purified by Qiagen spin columns. Sequencing was carried out in a Model 373A Automated DNA sequencer (Applied Biosystems) using Taq di-deoxy terminator cycle sequencing and Big Dye Kits according to the manufacturer's protocol.

Northern blot analysis

Northern transfer and hybridizations were performed essentially as described (Zhang et al., J. Biol. Chem. 27:1776-1783, 1996). Briefly, 20 µg of total fibroblast RNA samples were resolved by electrophoresis in a denaturing agarose (1.2%; w/v) gel in the presence of 7% formaldehyde, and transferred to nylon membranes. The filters were probed with ³²P-labeled human *ABC1* cDNA as indicated. Pre-hybridization and hybridizations were carried out in an ExpressHyb solution (ClonTech) at 68°C according to the manufacturer's protocol.

Detection of the mutations in TD

Genotyping for the T4503C and A1864G variants was performed by PCR

5
10
15
20
25
30
35
40
45
50
55

amplification of exon 30 followed by restriction digestion with *HgaI* and amplification of exon 13 followed by digestion with *AciI*, respectively. PCR was carried out in a total volume of 50 μ L with 1.5 mM $MgCl_2$, 187.5 nM of each dNTP, 2.5U Taq polymerase and 15 pmol of each primer (forward primer in exon 30: 5'-CTG CCA GGC AGG GGA GGA AGA GTG-3' (SEQ ID NO: 4); reverse primer spanning the junction of exon 30 and intron 30: 5'-GAA AGT GAC TCA CTT GTG GAG GA-3' (SEQ ID NO: 5); forward primer in intron 12: 5'-AAA GGG GCT TGG TAA GGG TA-3' (SEQ ID NO: 6); reverse in intron 13: 5'-CAT GCA CAT GCA CAC ACA TA -3' (SEQ ID NO: 7)). Following an initial denaturation of 3 minutes at 95°C, 35 cycles consisting of 95°C 10 seconds, 58°C 30 seconds, 72°C 30 seconds were performed, with a final extension of 10 minutes at 72°C. For detection of the T4503C mutation, 15 μ L of exon 30 PCR product was incubated with 4 U *HgaI* in a total volume of 25 μ L, for 2 hours at 37°C, and the resulting fragments were separated on a 1.5% agarose gel. The presence of the T4503C mutation creates a restriction site for *HgaI*, and thus the 194 bp PCR product will be cut into fragments of 134 and 60 bp in the presence of the T4503C variant, but not in its absence. For detection of the A1864G mutation, 15 μ L of exon 13 PCR products were digested with 8 U *AciI* for three hours at 37°C. Products were separated on 2% agarose gels. The presence of the A1864G mutation creates a second *AciI* site within the PCR product. Thus, the 360 bp PCR product is cleaved into fragments of 215 bp and 145 bp on the wild-type allele, but 185 bp, 145 bp and 30 bp on the mutant allele.

Detection of mutation in FHA

Genotyping for the $\Delta 693$ variant was performed by PCR amplification of exon 14 followed by restriction enzyme digestion with *EaeI*. PCR was carried out in a total volume of 80 μ L with 1.5 mM $MgCl_2$, 187.5 nM of each dNTP, 2.5 U Taq polymerase and 20 pmol of each primer (forward primer in exon 14: 5'-CTT TCT GCG GGT GAT GAG CCG GTC AAT-3' (SEQ ID NO: 8); reverse primer in intron 14: 5'-CCT TAG CCC GTG TTG AGC TA-3' (SEQ ID NO: 9)). Following an initial denaturation of 3 minutes at 95°C, 35 cycles consisting of 95°C 10 seconds, 55°C 30 seconds, 72°C 30 seconds were performed, with a final extension of 10

minutes at 72°C. Twenty microliters of PCR product was incubated with 4 U *EaeI* in a total volume of 25 µL, for two hours at 37°C, and the fragments were separated on a 2 % agarose gel. The presence of the Δ693 mutation destroys a restriction site for *EaeI*, and thus the 297 bp PCR product will be cut into fragments of 151 bp, 59 bp, 48 bp and 39 bp in the presence of a wild-type allele, but only fragments of 210 bp, 48 bp and 39 bp in the presence of the deletion.

A 6 bp deletion encompassing nucleotides 5752-5757 (inclusive), was detected in exon 41 in the proband of family FHA-3 by genomic sequencing using primers located within the introns flanking this exon. Genotyping of this mutation in family FHA-3 and controls was carried out by PCR with forward (5'-CCT GTA AAT GCA AAG CTA TCT CCT CT- 3' (SEQ ID NO: 10)) and reverse primers (5'-CGT CAA CTC CTT GAT TTC TAA GAT GT (SEQ ID NO: 11)) located near the 5' and 3' ends of exon 41, respectively. Each PCR was carried out as for the genotyping of the 693 variant, but with annealing temperature of 58°C. Twenty microliters of PCR product was resolved on 3% agarose or 10% acrylamide gels. The wild type allele was detected as a 117 bp band and the mutant allele as a 111 bp band upon staining with ethidium bromide.

A C to T transition was detected at nucleotide 6504 in genomic DNA of the proband of family FHA-2. It was detectable as a double C and T peak in the genomic sequence of exon 48 of this individual, who is heterozygous for the alteration. This mutation, which creates a STOP codon that results in truncation of the last 118 amino acids of the ABC1 protein, also destroys an *RsaI* restriction site that is present in the wild type sequence. Genotyping of this mutation in family FHA-2 and controls was carried out by PCR with forward (5'-GGG TTC CCA GGG TTC AGT AT-3') (SEQ ID NO: 12)) and reverse (5'-GAT CAG GAA TTC AAG CAC CAA-3') (SEQ ID NO: 13)) primers directed to the intronic sequences flanking exon 48. PCR was done as for the 693 variant. Fifteen microliters of PCR product was digested with 5 Units of *RsaI* at 37°C for two hours and the digestion products resolved on 1.5% agarose gels. The mutant allele is detected as an uncut 436 bp band. The normal sequence is cut by *RsaI* to produce 332 and 104 bp bands.

Cell culture

Skin fibroblast cultures were established from 3.0 mm punch biopsies of the forearm of FHD patients and healthy control subjects as described (Marcil et al., Arterioscler. Thromb. Vasc. Biol. 19:159-169, 1999).

Cellular cholesterol labeling and loading

The protocol for cellular cholesterol efflux experiments was described in detail elsewhere (Marcil et al., Arterioscler. Thromb. Vasc. Biol. 19:159-169, 1999). The cells were ³H-cholesterol labeled during growth and free cholesterol loaded in growth arrest.

Cholesterol efflux studies

Efflux studies were carried out from 0 to 24 hours in the presence of purified ApoAI (10 µg protein/mL medium). Efflux was determined as a percent of free cholesterol in the medium after the cells were incubated for specified periods of time. All experiments were performed in triplicate, in the presence of cells from one control subject and the cells from the study subjects to be examined. All results showing an efflux defect were confirmed at least three times.

Oligonucleotide synthesis

Eight phosphorothioate deoxyoligonucleotides complementary to various regions of the human *ABCI* cDNA sequence were obtained from GIBCO BRL. The oligonucleotides were purified by HPLC. The sequences of the antisense oligonucleotides and their location are listed. One skilled in the art will recognize that other *ABCI* antisense sequences can also be produced and tested for their ability to decrease ABC1-mediated cholesterol regulation.

Name	Sequence (5'-3')	mRNA target	% control
AN-1	GCAGAGGGCATGGCTTTATTG (SEQ ID NO: 3)	AUG codon	46
AN-2	GTGTTCTTCGAGAGGGCATG (SEQ ID NO: 30)	AUG codon	50
AN-3	CACTTCCAGTAACAGCTGAC (SEQ ID NO: 31)	5'-Untranslated	79
AN-4	CTTTGCGCATGTCCTTCATGC (SEQ ID NO: 32)	Coding	80

AN-5	GACATCAGCCCTCAGCATCTT (SEQ ID NO: 33)	Coding	120
AN-6:	CAACAAGCCATGTTCCCTC (SEQ ID NO: 34)	Coding	
AN-7:	CATGTTCCCTCAGCCAGC (SEQ ID NO: 35)	Coding	
AN-8:	CAGAGCTCACAGCAGGGA C (SEQ ID NO: 36)	Coding	

Cell transfection with antisense oligonucleotides

Cells were grown in 35 mm culture dishes until 80 % confluent, then washed once with DMEM medium (serum and antibiotics free). One milliliter of DMEM (serum and antibiotics free) containing 500 nM antisense oligonucleotides and 5 µg/ml or 7.5 µg/ml of lipofectin (GIBCO BRL) were added to each well according to the manufacturer's protocol. The cells were incubated at 37°C for 4 hours, and then the medium was replaced by DMEM containing 10% FCS. Twenty-four hours after the transfection, the total cell RNA was isolated. Ten micrograms of total RNA was resolved on a 1% of agarose-formaldehyde gel and transferred to nylon membrane. The blot was hybridized with α -³²P dCTP labeled human *ABCI* cDNA overnight at 68°C. The membrane was subsequently exposed to x-ray film. The hybridizing bands were scanned by optical densitometry and standard to 28S ribosome RNA.

Cholesterol efflux with anti-ABCI oligonucleotides

Human skin fibroblasts were plated in 6-well plates. The cells were labeled with ³H-cholesterol (0.2 µCi /ml) in DMEM with 10% FBS for two days when the cell reached 50% confluence. The cells were then transfected with the antisense *ABCI* oligonucleotides at 500nM in DMEM (serum and antibiotic free) with 7.5 µg/ml Lipofectin (GIBCO BRL) according to the manufacturer's protocol. Following the transfection, and the cells were loaded with nonlipoprotein (20 µg/ml) for 12 hours in DMEM containing 2 mg/ml BSA without serum. The cellular cholesterol pools were then allowed to equilibrate for 6 hours in DMEM-BSA. The cholesterol efflux mediated by ApoAI (10µg /ml, in DMEM-BSA) were then carried out which is 48 hours after transfection.

Radiolabeled cholesterol released into the medium is expressed as a percentage of total ³H-cholesterol per well (medium + cell). Results are the mean +/-

SD of triplicate dishes.

Determination of genomic structure of the ABC1 gene

Most splice junction sequences were determined from genomic sequence generated from BAC clones spanning the ABC1 gene. More than 160 kb of genomic sequence were generated. Genomic sequences were aligned with cDNA sequences to identify intron/exon boundaries. In some cases, long distance PCR between adjacent exons was used to amplify intron/exon boundary sequences using amplification primers designed according to the cDNA sequence.

Functionality of the newly-discovered 60 amino acids at the N-terminus

Antisense experiments

Phosphorothioate antisense oligonucleotides were designed to be complementary to the regions of the cDNA near newly discovered translation start site. AN-6 and AN-7 both overlap the initiator methionine codon; this site is in the middle of oligonucleotide AN-6. AN-8 is complementary to the very 5' end of the ABC1 cDNA. Antisense oligonucleotide AN-1 is complementary to the region of the ABC1 cDNA corresponding to the site identified as the ABC1 initiator methionine in AJ012376. Fig. 7C shows that antisense oligonucleotide AN-6 interferes with cellular cholesterol efflux in normal fibroblasts to the same extent as does antisense oligonucleotide AN-1. Transfection with either of these antisense oligonucleotides results in a decrease in cellular cholesterol efflux almost as severe as that seen in FHA cells. In general, antisense oligonucleotides complementary to coding sequences, especially near the 5' end of a gene's coding sequence, are expected to be more effective in decreasing the effective amount of transcript than are oligonucleotides directed to more 3' sequences or to non-coding sequences. The observation that AN-6 depresses cellular cholesterol efflux as effectively as AN-1 implies that both of these oligonucleotides are complementary to ABC1 coding sequences, and that the amino terminal 60 amino acids are likely to be contained in ABC1 protein. In contrast, the ineffectiveness of AN-8 shows that it is likely to be outside the protein coding region of the transcript, as predicted by presence of an in-frame stop codon

between the initiator methionine and the region targeted by AN-8.

Antibody experiments

Polyclonal and monoclonal antibodies have been generated using peptides corresponding to discrete portions of the ABC1 amino acid sequence. One of these, 20-amino acid peptide #2 (Pep2: CSVRLSYPPYEQHECHFPNKA (SEQ ID NO: 37), in which the N-terminal cysteine was added to facilitate conjugation of the peptide) corresponds to a protein sequence within the 60 amino-terminal amino acids of the newly-discovered ABC1 protein sequence. The peptide was coupled to the KLH carrier protein and 300 µg injected at three intervals into two Balb/c mice over a four week period. The spleen was harvested from the mouse with the highest ELISA-determined immune response to free peptide, and the cells fused to NS-1 myeloma cells by standard monoclonal antibody generation methods. Positive hybridomas were selected first by ELISA and then further characterized by western blotting using cultured primary human fibroblasts. Monoclonal cell lines producing a high antibody titre and specifically recognizing the 245 kD human ABC1 protein were saved. The same size ABC1 protein product was detected by antibodies directed to four other discrete regions of the same protein. The 245 kD band could be eliminated in competition experiments with appropriate free peptide, indicating that it represents ABC1 protein (Fig. 13).

The foregoing experiments indicate that ABC1 protein is detected not only by antibodies corresponding to amino acid sequences within the previously-described ABC1 amino acid sequence, but also by the Pep2 monoclonal antibody that recognizes an epitope within the newly-discovered N-terminal 60 amino acids. The N-terminal 60 amino acid region is therefore coding, and is part of the ABC1 protein.

The epitope recognized by the Pep2 monoclonal antibody is also conserved among human, mouse, and chicken. Liver tissues from these three species employed in a Western blot produced an ABC1 band of 245 kD when probed with the Pep2 monoclonal antibody. This indicates that the 60 amino acid N-terminal sequence is part of the ABC1 coding sequence in humans, mice, and chickens. Presence of this region is therefore evolutionarily conserved and likely to be of important functional

significance for the ABC1 protein.

Bioinformatic analyses of ABC1 protein sequences

Transmembrane prediction programs indicate 13 transmembrane (TM) regions, the first one being between amino acids 26 and 42 (<http://psort.nibb.ac.jp:8800/psort/helpwww2.html#ealom>). The tentative number of TM regions for the threshold 0.5 is 13. (INTEGRAL Likelihood = -7.75 Transmembrane 26-42). The other 12 TM range in value between -0.64 and -12 (full results below). It is therefore very likely that the newly-discovered 60 amino acids contain a TM domain, and that the amino end of ABC1 may be on the opposite side of the membrane than originally thought.

ALOM: TM region allocation

Init position for calculation: 1

Tentative number of TMs for the threshold 0.5: 13

INTEGRAL	Likelihood = -7.75	Transmembrane 26 - 42
INTEGRAL	Likelihood = -3.98	Transmembrane 640 - 656
INTEGRAL	Likelihood = -8.70	Transmembrane 690 - 706
INTEGRAL	Likelihood = -9.61	Transmembrane 717 - 733
INTEGRAL	Likelihood = -1.44	Transmembrane 749 - 765
INTEGRAL	Likelihood = -0.64	Transmembrane 771 - 787
INTEGRAL	Likelihood = -1.28	Transmembrane 1041 - 1057
INTEGRAL	Likelihood = -12.79	Transmembrane 1351 - 1367
INTEGRAL	Likelihood = -8.60	Transmembrane 1661 - 1677
INTEGRAL	Likelihood = -6.79	Transmembrane 1708 - 1724
INTEGRAL	Likelihood = -3.40	Transmembrane 1737 - 1753
INTEGRAL	Likelihood = -1.49	Transmembrane 1775 - 1791
INTEGRAL	Likelihood = -8.39	Transmembrane 1854 - 1870
PERIPHERAL	Likelihood = 0.69 (at 1643)	
ALOM score:	-12.79 (number of TMSs: 13)	

There does not appear to be an obvious cleaved peptide, so this first 60 amino acid residues are not likely to be cleaved, and are therefore not specifically a signal/targeting sequence. No other signals (e.g., for targeting to specific organelles) are apparent.

Agonists and Antagonists

Useful therapeutic compounds include those which modulate the expression, activity, or stability of ABC1. To isolate such compounds, ABC1 expression,

5 biological activity, or regulated catabolism is measured following the addition of
candidate compounds to a culture medium of ABC1-expressing cells. Alternatively,
10 the candidate compounds may be directly administered to animals (for example mice,
pigs, or chickens) and used to screen for their effects on ABC1 expression.

5 In addition its role in the regulation of cholesterol, ABC1 also participates in
other biological processes for which the development of ABC1 modulators would be
15 useful. In one example, ABC1 transports interleukin-1 β (IL-1 β) across the cell
membrane and out of cells. IL-1 β is a precursor of the inflammatory response and, as
such, inhibitors or antagonists of ABC1 expression or biological activity may be
20 useful in the treatment of any inflammatory disorders, including but not limited to
rheumatoid arthritis, systemic lupus erythematosus (SLE), hypo- or hyper- thyroidism,
inflammatory bowel disease, and diabetes mellitus. In another example, ABC1
expressed in macrophages has been shown to be engaged in the engulfment and
25 clearance of dead cells. The ability of macrophages to ingest these apoptotic bodies is
impaired after antibody-mediated blockade of ABC1. Accordingly, compounds that
15 modulate ABC1 expression, stability, or biological activity would be useful for the
treatment of these disorders.

30 ABC1 expression is measured, for example, by standard Northern blot
analysis using an ABC1 nucleic acid sequence (or fragment thereof) as a hybridization
20 probe, or by Western blot using an anti-ABC1 antibody and standard techniques. The
level of ABC1 expression in the presence of the candidate molecule is compared to
35 the level measured for the same cells, in the same culture medium, or in a parallel set
of test animals, but in the absence of the candidate molecule. ABC1 activity can also
be measured using the cholesterol efflux assay.

25 Transcriptional Regulation of ABC1 Expression

45 ABC1 mRNA is increased approximately 8-fold upon cholesterol loading.
This increase is likely controlled at the transcriptional level. Using the promoter
sequence described herein, one can identify transcription factors that bind to the
30 promoter by performing, for example, gel shift assays, DNase protection assays, or *in*
vitro or *in vivo* reporter gene-based assays. The identified transcription factors are

5 themselves drug targets. In the case of ABC1, drug compounds that act through
modulation of transcription of ABC1 could be used for HDL modulation,
10 atherosclerosis prevention, and the treatment of cardiovascular disease. For example,
using a compound to inhibit a transcription factor that represses ABC1 would be
5 expected to result in up-regulation of ABC1 and, therefore, HDL levels. In another
example, a compound that increases transcription factor expression or activity would
15 also increase ABC1 expression and HDL levels.

Transcription factors known to regulate other genes in the regulation of
apolipoprotein genes or other cholesterol- or lipid-regulating genes are of particular
20 10 relevance. Such factors include, but are not limited to, the steroid response element
binding proteins (SREBP-1 and SREBP-2), the PPAR (peroxisomal
proliferation-activated receptor) transcription factors. Several consensus sites for
certain elements are present in the sequenced region 5' to the ABC1 gene (Fig. 16)
25 and are likely to modulate ABC1 expression. For example, PPARs may alter
15 transcription of ABC1 by mechanisms including heterodimerization with retinoid X
receptors (RXRs) and then binding to specific proliferator response elements
(PPREs). Examples of such PPARs include PPAR α , β , γ and δ . These distinct
30 PPARs have been shown to have transcriptional regulatory effects on different genes.
PPAR α is expressed mainly in liver, whereas PPAR γ is expressed in predominantly in
20 adipocytes. Both PPAR α and PPAR γ are found in coronary and carotid artery
atherosclerotic plaques and in endothelial cells, smooth muscle cells, monocytes and
35 monocyte-derived macrophages. Activation of PPAR α results in altered lipoprotein
metabolism through PPAR α 's effect on genes such as lipoprotein lipase (LPL),
apolipoprotein CIII (apo CIII) and apolipoprotein AI (apo AI) and AII (apo AII).
40 25 PPAR α activation results in overexpression of LPL and apoA-I and apoA-II, but
inhibits the expression of apo CIII. PPAR α activation also inhibits inflammation,
stimulates lipid oxidation and increases the hepatic uptake and esterification of free
45 fatty acids (FFA's). PPAR α and PPAR γ activation may inhibit nitric oxide (NO)
synthase in macrophages and prevent interleukin-1 (IL-1) induced expression of IL-6
30 and cyclo-oxygenase-2 (COX-2) and thrombin induced endothelin-1 expression
secondary to negative transcriptional regulation of NF-KB and activation of protein-1

5
10 signaling pathway. It has also been shown that PPAR α induces apoptosis in monocyte-derived macrophages through the inhibition of NF-KB activity.

10 Activation of PPAR α can be achieved by compounds such as fibrates, β -estradiol, arachidonic acid derivatives, WY-14,643 and LTB₄ or 8(s)HETE.

5 PPAR γ activation can be achieved through compounds such as thiozolidinedione antidiabetic drugs, 9-HODE and 13-HODE. Additional compounds such as nicotinic
15 acid or HMG CoA reductase inhibitors may also alter the activity of PPARs.

Compounds which alter activity of any of the PPARs (e.g., PPAR α or PPAR γ)
may have an effect on ABC1 expression and thereby could affect HDL levels,
20 atherosclerosis and risk of CAD. PPARs are also regulated by fatty acids (including modified fatty acids such as 3 thia fatty acids), leukotrienes such as leukotriene B₄ and prostaglandin J₂, which is a natural activator/ligand for PPAR γ . Drugs that
25 modulate PPARs may therefore have an important effect on modulating lipid levels (including HDL and triglyceride levels) and altering CAD risk. This effect could be
15 achieved through the modulation of ABC1 gene expression. Drugs may also effect ABC1 gene expression and thereby HDL levels, by an indirect effect on PPARs via
30 other transcriptional factors such as adipocyte differentiation and determination factor-1 (ADD-1) and sterol regulatory element binding protein-1 and 2 (SREBP-1 and 2). Drugs with combined PPAR α and PPAR γ agonist activity or PPAR α and
20 PPAR γ agonists given in combination for example, may increase HDL levels even
35 more.

A PPAR binding site (PPRE element) is found 5' to the ABC1 gene
(nucleotides 2150 to 2169 of SEQ ID NO: 14). Like the PPRE elements found in the
40 C-ACS, HD, CYP4A6 and ApoA-I genes, this PPRE site is a trimer related to the
25 PPRE consensus sequence. Partly because of its similarity in the number and arrangement of repeats in this PPAR binding site, this element in particular is very
likely to be of physiological relevance to the regulation of the ABC1 gene.

45 Additional transcription factors which may also have an effect in modulating ABC1 gene expression and thereby HDL levels, atherosclerosis and CAD risk
30 include; REV-ERB α , SREBP-1 & 2, ADD-1, EBP α , CREB binding protein, P300, HNF 4, RAR, LXR, and ROR α . Additional degenerate binding sites for these factors
50

5
can be found through examination of the sequence in SEQ ID NO: 14.

10 Additional utility of ABC1 polypeptides, nucleic acids, and modulators

5 ABC1 may act as a transporter of toxic proteins or protein fragments (*e.g.*, APP) out of cells. Thus, ABC1 agonists/upregulators may be useful in the treatment of other disease areas, including Alzheimer's disease, Niemann-Pick disease, and
15 Huntington's disease.

ABC transporters have been shown to increase the uptake of long chain fatty acids from the cytosol to peroxisomes and, moreover, to play a role in β -oxidation of
20 10 very long chain fatty acids. Importantly, in x-linked adrenoleukodystrophy (ALD), fatty acid metabolism is abnormal, due to defects in the peroxisomal ABC transporter. Any agent that upregulates ABC transporter expression or biological activity may therefor be useful for the treatment of ALD or any other lipid disorder.

25 ABC1 is expressed in macrophages and is required for engulfment of cells
15 undergoing programmed cell death. The apoptotic process itself, and its regulation, have important implications for disorders such as cancer, one mechanism of which is failure of cells to undergo cell death appropriately. ABC1 may facilitate apoptosis, and as such may represent an intervention point for cancer treatment. Increasing
30 ABC1 expression or activity or otherwise up-regulating ABC1 by any method may constitute a treatment for cancer by increasing apoptosis and thus potentially
35 decreasing the aberrant cellular proliferation characterized by this disease. Conversely, down-regulation of ABC1 by any method may provide opportunity for decreasing apoptosis and allowing increased proliferation of cells in conditions where cell growth is limited. Such disorders include but are not limited to neurodeficiencies
40 25 and neurodegeneration, and growth disorders. ABC1 could, therefore, potentially be used as a method for identification of compounds for use in the treatment of cancer, or in the treatment of degenerative disorders.

45 Agents that have been shown to inhibit ABC1 include, for example, the anti-diabetic agents glibenclamide and glyburide, flufenamic acid, diphenylamine-2-
30 carbonic acid, sulfobromophthalein, and DIDS.

50 Agents that upregulate ABC1 expression or biological activity include but are

not limited to protein kinase A, protein kinase C, vanadate, okadaic acid, and IBMX1.

Those in the art will recognize that other compounds can also modulate ABC1 biological activity, and these compounds are also in the spirit of the invention.

Drug screens based on the ABC1 gene or protein

The ABC1 protein and gene can be used in screening assays for identification of compounds which modulate its activity and may be potential drugs to regulate cholesterol levels. Useful ABC1 proteins include wild-type and mutant ABC1 proteins or protein fragments, in a recombinant form or endogenously expressed.

Drug screens to identify compounds acting on the ABC1 expression product may employ any functional feature of the protein. In one example, the phosphorylation state or other post-translational modification is monitored as a measure of ABC1 biological activity. ABC1 has ATP binding sites, and thus assays may wholly or in part test the ability of ABC1 to bind ATP or to exhibit ATPase activity. ABC1, by analogy to similar proteins, is thought to be able to form a channel-like structure; drug screening assays could be based upon assaying for the ability of the protein to form a channel, or upon the ability to transport cholesterol or another molecule, or based upon the ability of other proteins bound by or regulated by ABC1 to form a channel. Alternatively, phospholipid or lipid transport can also be used as measures of ABC1 biological activity.

There is evidence that, in addition to its role as a regulator of cholesterol levels, ABC1 also transports anions. Functional assays could be based upon this property, and could employ drug screening technology such as (but not limited to) the ability of various dyes to change color in response to changes in specific ion concentrations in such assays can be performed in vesicles such as liposomes, or adapted to use whole cells.

Drug screening assays can also be based upon the ability of ABC1 or other ABC transporters to interact with other proteins. Such interacting proteins can be identified by a variety of methods known in the art, including, for example, radioimmunoprecipitation, co-immunoprecipitation, co-purification, and yeast two-hybrid screening. Such interactions can be further assayed by means including but

5
10
15
20
25
30
35
40
45
50
55

not limited to fluorescence polarization or scintillation proximity methods. Drug screens can also be based upon functions of the ABC1 protein deduced upon X-ray crystallography of the protein and comparison of its 3-D structure to that of proteins with known functions. Such a crystal structure has been determined for the prokaryotic ABC family member HisP, histidine permease. Drug screens can be based upon a function or feature apparent upon creation of a transgenic or knockout mouse, or upon overexpression of the protein or protein fragment in mammalian cells *in vitro*. Moreover, expression of mammalian (e.g., human) ABC1 in yeast or *C. elegans* allows for screening of candidate compounds in wild-type and mutant backgrounds, as well as screens for mutations that enhance or suppress an ABC1-dependent phenotype. Modifier screens can also be performed in ABC1 transgenic or knock-out mice.

Additionally, drug screening assays can also be based upon ABC1 functions deduced upon antisense interference with the gene function. Intracellular localization of ABC1, or effects which occur upon a change in intracellular localization of the protein, can also be used as an assay for drug screening. Immunocytochemical methods will be used to determine the exact location of the ABC1 protein.

Human and rodent ABC1 protein can be used as an antigen to raise antibodies, including monoclonal antibodies. Such antibodies will be useful for a wide variety of purposes, including but not limited to functional studies and the development of drug screening assays and diagnostics. Monitoring the influence of agents (e.g., drugs, compounds) on the expression or biological activity of ABC1 can be applied not only in basic drug screening, but also in clinical trials. For example, the effectiveness of an agent determined by a screening assay as described herein to increase ABC1 gene expression, protein levels, or biological activity can be monitored in clinical trials of subjects exhibiting altered ABC1 gene expression, protein levels, or biological activity. Alternatively, the effectiveness of an agent determined by a screening assay to modulate ABC1 gene expression, protein levels, or biological activity can be monitored in clinical trials of subjects exhibiting decreased altered gene expression, protein levels, or biological activity. In such clinical trials, the expression or activity of ABC1 and, preferably, other genes that have been implicated in, for example,

cardiovascular disease can be used to ascertain the effectiveness of a particular drug.

For example, and not by way of limitation, genes, including ABC1, that are modulated in cells by treatment with an agent (e.g., compound, drug or small molecule) that modulates ABC1 biological activity (e.g., identified in a screening assay as described herein) can be identified. Thus, to study the effect of agents on cholesterol levels or cardiovascular disease, for example, in a clinical trial, cells can be isolated and RNA prepared and analyzed for the levels of expression of ABC1 and other genes implicated in the disorder. The levels of gene expression can be quantified by Northern blot analysis or RT-PCR, or, alternatively, by measuring the amount of protein produced, by one of a number of methods known in the art, or by measuring the levels of biological activity of ABC1 or other genes. In this way, the gene expression can serve as a marker, indicative of the physiological response of the cells to the agent. Accordingly, this response state may be determined before, and at various points during, treatment of the individual with the agent.

In a preferred embodiment, the present invention provides a method for monitoring the effectiveness of treatment of a subject with an agent (e.g., an agonist, antagonist, peptidomimetic, protein, peptide, nucleic acid, small molecule, or other drug candidate identified by the screening assays described herein) including the steps of (i) obtaining a pre-administration sample from a subject prior to administration of the agent; (ii) detecting the level of expression of an ABC1 protein, mRNA, or genomic DNA in the preadministration sample; (iii) obtaining one or more post-administration samples from the subject; (iv) detecting the level of expression or activity of the ABC1 protein, mRNA, or genomic DNA in the post-administration samples; (v) comparing the level of expression or activity of the ABC1 protein, mRNA, or genomic DNA in the pre-administration sample with the ABC1 protein, mRNA, or genomic DNA in the post administration sample or samples; and (vi) altering the administration of the agent to the subject accordingly. For example, increased administration of the agent may be desirable to increase the expression or activity of ABC1 to higher levels than detected, i.e., to increase the effectiveness of the agent. Alternatively, decreased administration of the agent may be desirable to decrease expression or activity of ABC1 to lower levels than detected.

5

10

15

5

20

10

25

15

30

20

35

40

25

45

30

50

55

The *ABC1* gene or a fragment thereof can be used as a tool to express the protein in an appropriate cell *in vitro* or *in vivo* (gene therapy), or can be cloned into expression vectors which can be used to produce large enough amounts of ABC1 protein to use in *in vitro* assays for drug screening. Expression systems which may be employed include baculovirus, herpes virus, adenovirus, adeno-associated virus, bacterial systems, and eucaryotic systems such as CHO cells. Naked DNA and DNA-liposome complexes can also be used.

Assays of ABC1 activity includes binding to intracellular interacting proteins; interaction with a protein that up-regulates ABC1 activity; interaction with HDL particles or constituents; interaction with other proteins which facilitate interaction with HDL or its constituents; and measurement of cholesterol efflux. Furthermore, assays may be based upon the molecular dynamics of macromolecules, metabolites and ions by means of fluorescent-protein biosensors. Alternatively, the effect of candidate modulators on expression or activity may be measured at the level of ABC1 protein production using the same general approach in combination with standard immunological detection techniques, such as Western blotting or immunoprecipitation with an ABC1-specific antibody. Again, useful cholesterol-regulating or anti-CVD therapeutic modulators are identified as those which produce an change in ABC1 polypeptide production. Agonists may also affect ABC1 activity without any effect on expression level.

Candidate modulators may be purified (or substantially purified) molecules or may be one component of a mixture of compounds (*e.g.*, an extract or supernatant obtained from cells). In a mixed compound assay, ABC1 expression is tested against progressively smaller subsets of the candidate compound pool (*e.g.*, produced by standard purification techniques, *e.g.*, HPLC or FPLC; Ausubel et al.) until a single compound or minimal compound mixture is demonstrated to modulate ABC1 expression.

Agonists, antagonists, or mimetics found to be effective at modulating the level of cellular ABC1 expression or activity may be confirmed as useful in animal models (for example, mice, pigs, rabbits, or chickens). For example, the compound may ameliorate the low HDL levels of mouse or chicken hypoalphalipoproteinemias.

5

10

A compound that promotes an increase in ABC1 expression or activity is considered particularly useful in the invention; such a molecule may be used, for example, as a therapeutic to increase the level or activity of native, cellular ABC1 and thereby treat a low HDL condition in an animal (for example, a human).

5

15

One method for increasing ABC biological activity is to increase the stabilization of the ABC protein or to prevent its degradation. Thus, it would be useful to identify mutations in an ABC polypeptide (e.g., ABC1) that lead to increased protein stability. These mutations can be incorporated into any protein therapy or gene therapy undertaken for the treatment of low HDL-C or any other condition resulting from loss of ABC1 biological activity. Similarly, compounds that increase the stability of a wild-type ABC polypeptide or decrease its catabolism may also be useful for the treatment of low HDL-C or any other condition resulting from loss of ABC1 biological activity. Such mutations and compounds can be identified using the methods described herein.

20

10

25

15

In one example, cells expressing an ABC polypeptide having a mutation are transiently metabolically labeled during translation and the half-life of the ABC polypeptide is determined using standard techniques. Mutations that increase the half-life of an ABC polypeptide are ones that increase ABC protein stability. These mutations can then be assessed for ABC biological activity. They can also be used to identify proteins that affect the stability of ABC1 mRNA or protein. One can then assay for compounds that act on these factors or on the ability of these factors to bind ABC1.

30

20

35

40

25

In another example, cells expressing wild-type ABC polypeptide are transiently metabolically labeled during translation, contacted with a candidate compounds, and the half-life of the ABC polypeptide is determined using standard techniques. Compounds that increase the half-life of an ABC polypeptide are useful compounds in the present invention.

45

If desired, treatment with an agonist of the invention may be combined with any other HDL-raising or anti-CVD therapies.

30

It is understood that, while ABC1 is the preferred ABC transporter for the drug screens described herein, other ABC transporters can also be used. The

50

55

5 replacement of ABC1 with another ABC transporter is possible because it is likely
that ABC transporter family members, such as ABC2, ABCR, or ABC8 will have a
10 similar mechanism of regulation.

Exemplary assays are described in greater detail below.

5 Protein-based assays

15 ABC1 polypeptide (purified or unpurified) can be used in an assay to
determine its ability to bind another protein (including, but not limited to, proteins
found to specifically interact with ABC1). The effect of a compound on that binding
20 is then determined.

Protein Interaction Assays

25 ABC1 protein (or a polypeptide fragment thereof or an epitope-tagged form or
fragment thereof) is harvested from a suitable source (e.g., from a prokaryotic
15 expression system, eukaryotic cells, a cell-free system, or by immunoprecipitation
from ABC1-expressing cells). The ABC1 polypeptide is then bound to a suitable
support (e.g., nitrocellulose or an antibody or a metal agarose column in the case of,
30 for example, a his-tagged form of ABC1). Binding to the support is preferably done
under conditions that allow proteins associated with ABC1 polypeptide to remain
20 associated with it. Such conditions may include use of buffers that minimize
interference with protein-protein interactions. The binding step can be done in the
35 presence and absence of compounds being tested for their ability to interfere with
interactions between ABC1 and other molecules. If desired, other proteins (e.g., a cell
lysate) are added, and allowed time to associate with the ABC polypeptide. The
40 25 immobilized ABC1 polypeptide is then washed to remove proteins or other cell
constituents that may be non-specifically associated with it the polypeptide or the
support. The immobilized ABC1 polypeptide is then dissociated from its support, and
45 so that proteins bound to it are released (for example, by heating), or, alternatively,
associated proteins are released from ABC1 without releasing the ABC1 polypeptide
30 from the support. The released proteins and other cell constituents can be analyzed,
for example, by SDS-PAGE gel electrophoresis, Western blotting and detection with

specific antibodies, phosphoamino acid analysis, protease digestion, protein sequencing, or isoelectric focusing. Normal and mutant forms of ABC1 can be employed in these assays to gain additional information about which part of ABC1 a given factor is binding to. In addition, when incompletely purified polypeptide is employed, comparison of the normal and mutant forms of the protein can be used to help distinguish true binding proteins.

The foregoing assay can be performed using a purified or semipurified protein or other molecule that is known to interact with ABC1. This assay may include the following steps.

1. Harvest ABC1 protein and couple a suitable fluorescent label to it;
2. Label an interacting protein (or other molecule) with a second, different fluorescent label. Use dyes that will produce different quenching patterns when they are in close proximity to each other vs. when they are physically separate (i.e., dyes that quench each other when they are close together but fluoresce when they are not in close proximity);
3. Expose the interacting molecule to the immobilized ABC1 in the presence or absence of a compound being tested for its ability to interfere with an interaction between the two; and
4. Collect fluorescent readout data.

Another assay is includes Fluorescent Resonance Energy Transfer (FRET) assay. This assay can be performed as follows.

1. Provide ABC1 protein or a suitable polypeptide fragment thereof and couple a suitable FRET donor (e.g., nitro-benzoxadiazole (NBD)) to it;
2. Label an interacting protein (or other molecule) with a FRET acceptor (e.g., rhodamine);
3. Expose the acceptor-labeled interacting molecule to the donor-labeled ABC1 in the presence or absence of a compound being tested for its ability to interfere with an interaction between the two; and
4. Measure fluorescence resonance energy transfer.

Quenching and FRET assays are related. Either one can be applied in a given case, depending on which pair of fluorophores is used in the assay.

Membrane permeability assay

The ABC1 protein can also be tested for its effects on membrane permeability. For example, beyond its putative ability to translocate lipids, ABC1 might affect the permeability of membranes to ions. Other related membrane proteins, most notably the cystic fibrosis transmembrane conductance regulator and the sulfonylurea receptor, are associated with and regulate ion channels.

ABC1 or a fragment of ABC1 is incorporated into a synthetic vesicle, or, alternatively, is expressed in a cell and vesicles or other cell sub-structures containing ABC1 are isolated. The ABC1-containing vesicles or cells are loaded with a reporter molecule (such as a fluorescent ion indicator whose fluorescent properties change when it binds a particular ion) that can detect ions (to observe outward movement), or alternatively, the external medium is loaded with such a molecule (to observe inward movement). A molecule which exhibits differential properties when it is inside the vesicle compared to when it is outside the vesicle is preferred. For example, a molecule that has quenching properties when it is at high concentration but not when it is at another low concentration would be suitable. The movement of the charged molecule (either its ability to move or the kinetics of its movement) in the presence or absence of a compound being tested for its ability to affect this process can be determined.

In another assay, membrane permeability is determined electrophysiologically by measuring ionic influx or efflux mediated by or modulated by ABC1 by standard electrophysiological techniques. A suitable control (e.g., TD cells or a cell line with very low endogenous ABC1 expression) can be used as a control in the assay to determine if the effect observed is specific to cells expressing ABC1.

In still another assay, uptake of radioactive isotopes into or out of a vesicle can be measured. The vesicles are separated from the extravesicular medium and the radioactivity in the vesicles and in the medium is quantitated and compared.

5

Nucleic acid-based assays

10

5

15

ABC1 nucleic acid may be used in an assay based on the binding of factors necessary for ABC1 gene transcription. The association between the *ABC1* DNA and the binding factor may be assessed by means of any system that discriminates between protein-bound and non-protein-bound DNA (e.g., a gel retardation assay). The effect of a compound on the binding of a factor to *ABC1* DNA is assessed by means of such an assay. In addition to *in vitro* binding assays, *in vivo* assays in which the regulatory regions of the *ABC1* gene are linked to reporter genes can also be performed.

20

10

Assays measuring ABC1 stability

25

15

A cell-based or cell-free system can be used to screen for compounds based on their effect on the half-life of *ABC1* mRNA or ABC1 protein. The assay may employ labeled mRNA or protein. Alternatively, *ABC1* mRNA may be detected by means of specifically hybridizing probes or a quantitative PCR assay. Protein can be quantitated, for example, by fluorescent antibody-based methods.

30

In vitro mRNA stability assay

35

20

1. Isolate or produce, by *in vitro* transcription, a suitable quantity of ABC1 mRNA;
2. Label the ABC1 mRNA;
3. Expose aliquots of the mRNA to a cell lysate in the presence or absence of a compound being tested for its ability to modulate *ABC1* mRNA stability;
4. Assess intactness of the remaining mRNA at suitable time points.

40

25

In vitro protein stability assay

45

30

1. Express a suitable amount of ABC1 protein;
2. Label the protein;
3. Expose aliquots of the labeled protein to a cell lysate in the presence or absence of a compound being tested for its ability to modulate ABC1 protein stability;
4. Assess intactness of the remaining protein at suitable time points

50

55

5

In vivo mRNA or protein stability assay

10

1. Incubate cells expressing ABC1 mRNA or protein with a tracer (radiolabeled ribonucleotide or radiolabeled amino acid, respectively) for a very brief time period (e.g., five minutes) in the presence or absence of a compound being tested for its effect on mRNA or protein stability;

5

15

2. Incubate with unlabeled ribonucleotide or amino acid; and

20

10

3. Quantitate the ABC1 mRNA or protein radioactivity at time intervals beginning with the start of step 2 and extending to the time when the radioactivity in ABC1 mRNA or protein has declined by approximately 80%. It is preferable to separate the intact or mostly intact mRNA or protein from its radioactive breakdown products by a means such as gel electrophoresis in order to quantitate the mRNA or protein.

25

Assays measuring inhibition of dominant negative activity

15

30

Mutant ABC1 polypeptides are likely to have dominant negative activity (i.e., activity that interferes with wild-type ABC1 function). An assay for a compound that can interfere with such a mutant may be based on any method of quantitating normal ABC1 activity in the presence of the mutant. For example, normal ABC1 facilitates cholesterol efflux, and a dominant negative mutant would interfere with this effect.

20

35

The ability of a compound to counteract the effect of a dominant negative mutant may be based on cellular cholesterol efflux, or on any other normal activity of the wild-type ABC1 that was inhibitable by the mutant.

40

Assays measuring phosphorylation

25

45

The effect of a compound on ABC1 phosphorylation can be assayed by methods that quantitate phosphates on proteins or that assess the phosphorylation state of a specific residue of a ABC1. Such methods include but are not limited to ³²P labelling and immunoprecipitation, detection with antiphosphoamino acid antibodies (e.g., antiphosphoserine antibodies), phosphoamino acid analysis on 2-dimensional TLC plates, and protease digestion fingerprinting of proteins followed by detection of ³²P-labeled fragments.

30

50

55

Assays measuring other post-translational modifications

The effect of a compound on the post-translational modification of ABC1 is based on any method capable of quantitating that particular modification. For example, effects of compounds on glycosylation may be assayed by treating ABC1 with glycosylase and quantitating the amount and nature of carbohydrate released.

Assays measuring ATP binding

The ability of ABC1 to bind ATP provides another assay to screen for compounds that affect ABC1. ATP binding can be quantitated as follows.

1. Provide ABC1 protein at an appropriate level of purity and reconstitute it in a lipid vesicle;

2. Expose the vesicle to a labeled but non-hydrolyzable ATP analog (such as gamma ³⁵S-ATP) in the presence or absence of compounds being tested for their effect on ATP binding. Note that azido-ATP analogs can be used to allow covalent attachment of the azido-ATP to protein (by means of U.V. light), and permit easier quantitation of the amount of ATP bound to the protein.

3. Quantitate the amount of ATP analog associated with ABC1

Assays measuring ATPase activity

Quantitation of the ATPase activity of ABC1 can also be assayed for the effect of compounds on ABC1. This is preferably performed in a cell-free assay so as to separate ABC1 from the many other ATPases in the cell. An ATPase assay may be performed in the presence or absence of membranes, and with or without integration of ABC1 protein into a membrane. If performed in a vesicle-based assay, the ATP hydrolysis products produced or the ATP hydrolyzed may be measured within or outside of the vesicles, or both. Such an assay may be based on disappearance of ATP or appearance of ATP hydrolysis products.

For high-throughput screening, a coupled ATPase assay is preferable. For example, a reaction mixture containing pyruvate kinase and lactate dehydrogenase can be used. The mixture includes phosphoenolpyruvate (PEP), nicotinamide adenine dinucleotide (NAD⁺), and ATP. The ATPase activity of ABC1 generates ADP from

5
10
15
20
25
30
35
40
45
50
55

ATP. The ADP is then converted back to ATP as part of the pyruvate kinase reaction. The product, pyruvate, is then converted to lactate. The latter reaction generates a colored quinone (NADH) from a colorless substrate (NAD⁺), and the entire reaction can be monitored by detection of the color change upon formation of NADH. Since ADP is limiting for the pyruvate kinase reaction, this coupled system precisely monitors the ATPase activity of ABC1.

Assays measuring cholesterol efflux

A transport-based assay can be performed *in vivo* or *in vitro*. For example, the assay may be based on any part of the reverse cholesterol transport process that is readily re-created in culture, such as cholesterol or phospholipid efflux. Alternatively, the assay may be based on net cholesterol transport in a whole organism, as assessed by means of a labeled substance (such as cholesterol).

For high throughput, fluorescent lipids can be used to measure ABC1-catalyzed lipid efflux. For phospholipids, a fluorescent precursor, C6-NBD-phosphatidic acid, can be used. This lipid is taken up by cells and dephosphorylated by phosphatidic acid phosphohydrolase. The product, NBD-diglyceride, is then a precursor for synthesis of glycerophospholipids like phosphatidylcholine. The efflux of NBD-phosphatidylcholine can be monitored by detecting fluorescence resonance energy transfer (FRET) of the NBD to a suitable acceptor in the cell culture medium. This acceptor can be rhodamine-labeled phosphatidylethanolamine, a phospholipid that is not readily taken up by cells. The use of short-chain precursors obviates the requirement for the phospholipid transfer protein in the media. For cholesterol, NBD-cholesterol ester can be reconstituted into LDL. The LDL can efficiently deliver this lipid to cells via the LDL receptor pathway. The NBD-cholesterol esters are hydrolyzed in the lysosomes, resulting in NBD-cholesterol that can now be transported back to the plasma membrane and efflux from the cell. The efflux can be monitored by the aforementioned FRET assay in which NBD transfers its fluorescence resonance energy to the rhodamine-phosphatidylethanolamine acceptor.

Animal Model Systems

Compounds identified as having activity in any of the above-described assays are subsequently screened in any available animal model system, including, but not limited to, pigs, rabbits, and WHAM chickens. Test compounds are administered to these animals according to standard methods. Test compounds may also be tested in mice bearing mutations in the *ABC1* gene. Additionally, compounds may be screened for their ability to enhance an interaction between ABC1 and any HDL particle constituent such as ApoAI, ApoAII, or ApoE.

The cholesterol efflux assay as a drug screen

The cholesterol efflux assay measures the ability of cells to transfer cholesterol to an extracellular acceptor molecule and is dependent on ABC1 function. In this procedure, cells are loaded with radiolabeled cholesterol by any of several biochemical pathways (Marcil et al., *Arterioscler. Thromb. Vasc. Biol.* 19:159-169, 1999). Cholesterol efflux is then measured after incubation for various times (typically 0 to 24 hours) in the presence of HDL3 or purified ApoAI. Cholesterol efflux is determined as the percentage of total cholesterol in the culture medium after various times of incubation. ABC1 expression levels and/or biological activity are associated with increased efflux while decreased levels of ABC1 are associated with decreased cholesterol efflux.

This assay can be readily adapted to the format used for drug screening, which may consist of a multi-well (e.g., 96-well) format. Modification of the assay to optimize it for drug screening would include scaling down and streamlining the procedure, modifying the labeling method, using a different cholesterol acceptor, altering the incubation time, and changing the method of calculating cholesterol efflux. In all these cases, the cholesterol efflux assay remains conceptually the same, though experimental modifications may be made. A transgenic mouse overexpressing ABC1 would be expected to have higher than normal HDL levels.

Knock-out mouse model

An animal, such as a mouse, that has had one or both ABC1 alleles inactivated

(e.g., by homologous recombination) is likely to have low HDL-C levels, and thus is a preferred animal model for screening for compounds that raise HDL-C levels. Such an animal can be produced using standard techniques. In addition to the initial screening of test compounds, the animals having mutant ABC1 genes are useful for further testing of efficacy and safety of drugs or agents first identified using one of the other screening methods described herein. Cells taken from the animal and placed in culture can also be exposed to test compounds. HDL-C levels can be measured using standard techniques, such as those described herein.

WHAM chickens: an animal model for low HDL cholesterol

Wisconsin Hypo-Alpha Mutant (WHAM) chickens arose by spontaneous mutation in a closed flock. Mutant chickens came to attention through their a Z-linked white shank and white beak phenotype referred to as 'recessive white skin' (McGibbon, 1981) and were subsequently found to have a profound deficiency of HDL (Poernama *et al.*, 1990).

This chicken low HDL locus (Y) is Z-linked, or sex-linked. (In birds, females are ZW and males are ZZ). Genetic mapping placed the Y locus on the long arm of the Z chromosome (Bitgood, 1985), proximal to the ID locus (Bitgood, 1988). Examination of current public mapping data for the chicken genome mapping project, ChickMap (maintained by the Roslin Institute; <http://www.ri.bbsrc.ac.uk/chickmap/ChickMapHomePage.html>) showed that a region of synteny with human chromosome 9 lies on the long arm of the chicken Z chromosome (Zq) proximal to the ID locus. Evidence for this region of synteny is the location of the chicken aldolase B locus (ALDOB) within this region. The human ALDOB locus maps to chromosome 9q22.3 (The Genome Database, <http://gdbwww.gdb.org/>), not far from the location of human ABC1. This comparison of maps showed that the chicken Zq region near chicken ALDOB and the human 9q region near human ALDOB represent a region of synteny between human and chicken.

Since a low HDL locus maps to the 9q location in humans and to the Zq region in chickens, these low HDL loci are most probably located within the syntenic region. Thus we predicted that ABC1 is mutated in WHAM chickens. In support of

5
10
this, we have identified an E→K mutation at a position that corresponds to amino acid 89 of human ABC1 (Figs. 14 and 15). This non-conservative substitution is at a position that is conserved among human, mouse, and chicken, indicating that it is in a region of the protein likely to be of functional importance.

5
15
20
Discovery of the WHAM mutation in the amino-terminal portion of the ABC1 protein also establishes the importance of the amino-terminal region. This region may be critical because of association with other proteins required to carry out cholesterol efflux or related tasks. It may be an important regulatory region (there is a phosphorylation site for casein kinase near the mutated residue), or it may help to dictate a precise topological relationship with cellular membranes (the N-terminal 60 amino acid region contains a putative membrane-spanning or membrane-associated segment).

25
15
30
The amino-terminal region of the protein (up to the first 6-TM region at approximately amino acid 639) is an ideal tool for screening factors that affect ABC1 activity. It can be expressed as a truncated protein in ABC1 wild type cells in order to test for interference of the normal ABC1 function by the truncated protein. If the fragment acts in a dominant negative way, it could be used in immunoprecipitations to identify proteins that it may be competing away from the normal endogenous protein.

35
20
The C-terminus also lends itself to such experiments, as do the intracellular portions of the molecule, expressed as fragments or tagged or fusion proteins, in the absence of transmembrane regions.

40
25
45
Since it is possible that there are several genes in the human genome which affect cholesterol efflux, it is important to establish that any animal model to be used for a human genetic disease represents the homologous locus in that animal, and not a different locus with a similar function. The evidence above establishes that the chicken Y locus and the human chromosome 9 low HDL locus are homologous. WHAM chickens are therefore an important animal model for the identification of drugs that modulate cholesterol efflux.

50
30
The WHAM chickens' HDL deficiency syndrome is not, however, associated with an increased susceptibility to atherosclerosis in chickens. This probably reflects the shorter lifespan of the chicken rather than an inherent difference in the function of

5 the chicken ABC1 gene compared to the human gene. We propose the WHAM
chicken as a model for human low HDL for the development and testing of drugs to
10 raise HDL in humans. Such a model could be employed in several forms, through the
use of cells or other derivatives of these chickens, or by the use of the chickens
5 themselves in tests of drug effectiveness, toxicity, and other drug development
purposes.

15 Therapy

Compounds of the invention, including but not limited to, ABC1 polypeptides,
20 ABC1 nucleic acids, other ABC transporters, and any therapeutic agent that modulates
biological activity or expression of ABC1 identified using any of the methods
disclosed herein, may be administered with a pharmaceutically-acceptable diluent,
carrier, or excipient, in unit dosage form. Conventional pharmaceutical practice may
25 be employed to provide suitable formulations or compositions to administer such
compositions to patients. Although intravenous administration is preferred, any
15 appropriate route of administration may be employed, for example, perenteral,
subcutaneous, intramuscular, intracranial, intraorbital, ophthalmic, intraventricular,
30 intracapsular, intraspinal, intracisternal, intraperitoneal, intranasal, aerosol, or oral
administration. Therapeutic formulations may be in the form of liquid solutions or
20 suspension; for oral administration, formulations may be in the form of tablets or
capsules; and for intranasal formulations, in the form of powders, nasal drops, or
35 aerosols.

Methods well known in the art for making formulations are found in, for
example, Remington: The Science and Practice of Pharmacy, (19th ed.) ed. A.R.
40 Gennaro AR., 1995, Mack Publishing Company, Easton, PA. Formulations for
parenteral administration may, for example, contain excipients, sterile water, or saline,
polyalkylene glycols such as polyethylene glycol, oils of vegetable origin, or
45 hydrogenated naphthalenes. Biocompatible, biodegradable lactide polymer,
lactide/glycolide copolymer, or polyoxyethylene-polyoxypropylene copolymers may
30 be used to control the release of the compounds. Other potentially useful parenteral
delivery systems for agonists of the invention include ethylenevinyl acetate

5
10
15
20
25
30
35
40
45
50
55

copolymer particles, osmotic pumps, implantable infusion systems, and liposomes. Formulations for inhalation may contain excipients, or example, lactose, or may be aqueous solutions containing, for example, polyoxyethylene-9-lauryl ether, glycocholate and deoxycholate, or may be oily solutions for administration in the form of nasal drops, or as a gel.

Compounds

In general, novel drugs for the treatment of aberrant cholesterol levels and/or CVD are identified from large libraries of both natural product or synthetic (or semi-synthetic) extracts or chemical libraries according to methods known in the art. Those skilled in the field or drug discovery and development will understand that the precise source of test extracts or compounds is not critical to the screening procedure(s) of the invention. Accordingly, virtually any number of chemical extracts or compounds can be screened using the exemplary methods described herein. Examples of such extracts or compounds include, but are not limited to, plant-, fungal-, prokaryotic- or animal-based extracts, fermentation broths, and synthetic compounds, as well as modification of existing compounds. Numerous methods are also available for generating random or directed synthesis (*e.g.*, semi-synthesis or total synthesis) of any number of chemical compounds, including, but not limited to, saccharide-, lipid-, peptide-, and nucleic acid-based compounds. Synthetic compound libraries are commercially available from Brandon Associates (Merrimack, NH) and Aldrich Chemical (Milwaukee, WI). Alternatively, libraries of natural compounds in the form of bacterial, fungal, plant, and animal extracts are commercially available from a number of sources, including Biotics (Sussex, UK), Xenova (Slough, UK), Harbor Branch Oceanographics Institute (Ft. Pierce, FL), and PharmaMar, U.S.A. (Cambridge, MA). In addition, natural and synthetically produced libraries are produced, if desired, according to methods known in the art, *e.g.*, by standard extraction and fractionation methods. Furthermore, if desired, any library or compound is readily modified using standard chemical, physical, or biochemical methods.

In addition, those skilled in the art of drug discovery and development readily understand that methods for dereplication (*e.g.*, taxonomic dereplication, biological

dereplication, and chemical dereplication, or any combination thereof) or the elimination of replicates or repeats of materials already known for their HDL-raising and anti-CVD activities should be employed whenever possible.

When a crude extract is found to have cholesterol-modulating or anti-CVD activities or both, further fractionation of the positive lead extract is necessary to isolate chemical constituent responsible for the observed effect. Thus, the goal of the extraction, fractionation, and purification process is the careful characterization and identification of a chemical entity within the crude extract having cholesterol-modulating or anti-CVD activities. The same *in vivo* and *in vitro* assays described herein for the detection of activities in mixtures of compounds can be used to purify the active component and to test derivatives thereof. Methods of fractionation and purification of such heterogeneous extracts are known in the art. If desired, compounds shown to be useful agents for the treatment of pathogenicity are chemically modified according to methods known in the art. Compounds identified as being of therapeutic value are subsequently analyzed using any standard animal model of diabetes or obesity known in the art.

It is understood that compounds that modulate activity of proteins that modulate or are modulated by ABC1 are useful compounds for modulating cholesterol levels. Exemplary compounds are provided herein; others are known in the art.

Compounds that are structurally related to cholesterol, or that mimic ApoAI or a related apolipoprotein, and increase ABC1 biological activity are particularly useful compounds in the invention. Other compounds, known to act on the MDR protein, can also be used or derivatized and assayed for their ability to increase ABC1 biological activity. Exemplary MDR modulators are PSC833, bromocriptine, and cyclosporin A.

Screening patients having low HDL-C

ABC1 expression, biological activity, and mutational analysis can each serve as a diagnostic tool for low HDL; thus determination of the genetic subtyping of the *ABC1* gene sequence can be used to subtype low HDL individuals or families to

5
10
15
20
25
30
35
40
45
50
55

determine whether the low HDL phenotype is related to ABC1 function. This diagnostic process can lead to the tailoring of drug treatments according to patient genotype, including prediction of side effects upon administration of HDL increasing drugs (referred to herein as pharmacogenomics). Pharmacogenomics allows for the selection of agents (e.g., drugs) for therapeutic or prophylactic treatment of an individual based on the genotype of the individual (e.g., the genotype of the individual is examined to determine the ability of the individual to respond to a particular agent).

Agents, or modulators which have a stimulatory or inhibitory effect on ABC1 biological activity or gene expression can be administered to individuals to treat disorders (e.g., cardiovascular disease or low HDL cholesterol) associated with aberrant ABC1 activity. In conjunction with such treatment, the pharmacogenomics (i.e., the study of the relationship between an individual's genotype and that individual's response to a foreign compound or drug) of the individual may be considered. Differences in efficacy of therapeutics can lead to severe toxicity or therapeutic failure by altering the relation between dose and blood concentration of the pharmacologically active drug. Thus, the pharmacogenomics of the individual permits the selection of effective agents (e.g., drugs) for prophylactic or therapeutic treatments based on a consideration of the individual's genotype. Such pharmacogenomics can further be used to determine appropriate dosages and therapeutic regimens. Accordingly, the activity of ABC1 protein, expression of ABC1 nucleic acid, or mutation content of ABC1 genes in an individual can be determined to thereby select appropriate agent(s) for therapeutic or prophylactic treatment of the individual.

Pharmacogenomics deals with clinically significant hereditary variations in the response to drugs due to altered drug disposition and abnormal action in affected persons (Eichelbaum, M., Clin. Exp. Pharmacol. Physiol., 23:983-985, 1996; Linder, M. W., Clin. Chem., 43:254-266, 1997). In general, two types of pharmacogenetic conditions can be differentiated. Genetic conditions transmitted as a single factor altering the way drugs act on the body (altered drug action) or genetic conditions transmitted as single factors altering the way the body acts on drugs (altered drug metabolism). Altered drug action may occur in a patient having a polymorphism

(e.g., an single nucleotide polymorphism or SNP) in promoter, intronic, or exonic sequences of ABC1. Thus by determining the presence and prevalence of polymorphisms allow for prediction of a patient's response to a particular therapeutic agent. In particular, polymorphisms in the promoter region may be critical in determining the risk of HDL deficiency and CVD.

In addition to the mutations in the *ABC1* gene described herein, we have detected polymorphisms in the human *ABC1* gene (Fig. 11). These polymorphisms are located in promoter, intronic, and exonic sequence of ABC1. Using standard methods, such as direct sequencing, PCR, SSCP, or any other polymorphism-detection system, one could easily ascertain whether these polymorphisms are present in a patient prior to the establishment of a drug treatment regimen for a patient having low HDL, cardiovascular disease, or any other ABC1-mediated condition. It is possible that some these polymorphisms are, in fact, weak mutations. Individuals harboring such mutations may have an increased risk for cardiovascular disease; thus, these polymorphisms may also be useful in diagnostic assays.

Association Studies of ABC1 Gene Variants and HDL Levels or Cardiovascular Disease

The following polymorphisms have been examined for their effect on cholesterol regulation and the predisposition for the development of cardiovascular disease.

Substitution of G for A at nucleotide -1045 [G(-1045)A]. This variant is in complete linkage disequilibrium with the variant at -738 in the individuals we have sequenced, and thus any potential phenotypic effects currently attributed to the variant at -738 may at least in part be due to changes at this site.

Substitution of G for A at nucleotide -738 [G(-738)A]. This variant has been found at very high frequencies in populations selected for low HDL cholesterol or premature coronary artery disease.

Insertion of a G nucleotide at position -4 [G ins (-4)]. This variant has been associated with less coronary artery disease in its carriers than in non-carriers.

Substitution of a C for G at nucleotide -57 [G(-57)C]. This variant is in

complete linkage disequilibrium with the variant at -4 in the individuals we have sequenced, and thus the phenotypic effects currently attributed to the variant at -4 may at least in part be due to changes at this site.

Substitution of A for G at nucleotide 730 (R219K). We have found carriers to have significantly less cardiovascular disease.

Substitution of C for T at nucleotide 1270 (V399A). Within the French Canadian population, this variant has only been found in individuals from the low HDL population. It has also been seen in individuals with low HDL or premature coronary artery disease in individuals of Dutch ancestry.

Substitution of A for G at nucleotide 2385 (V771M). This variant has been found at an increased frequency in a Dutch population selected for low HDL and at an increased frequency in a population selected for premature coronary artery disease compared to a control Dutch population, indicating carriers of this variant may have reduced HDL and an increased susceptibility to coronary artery disease.

Substitution of C for A at nucleotide 2394 (T774P). This variant has been seen at lower frequencies in populations with coronary artery disease or low HDL than in individuals without.

Substitution of C for G at nucleotide 2402 (K776N). This variant has been found at a significantly lower frequency (0.56% vs. 2.91%, $p=0.02$) in a coronary artery disease population vs. a control population of similar Dutch background.

Substitution of C for G at nucleotide 3590 (E1172D). This variant is seen at lower frequencies in individuals with low HDL and in some populations with premature coronary artery disease.

Substitution of A for G at nucleotide 4384 (R1587K). This variant has been found at decreased frequencies in the 1/3 of individuals with the highest HDL levels in our large Dutch coronary artery disease population ($p=0.036$), at increased frequencies in those with HDL cholesterol <0.9 mmol/L ($p<0.0001$) and at decreased frequencies in the cohorts with HDL cholesterol >1.4 mmol/L in both this population ($p=0.02$) and the Dutch control population ($p=0.003$).

Substitution of G for C at nucleotide 5266 (S1731C). Two FHA individuals who have this variant on the other allele have much lower HDL cholesterol

(0.155±0.025) than the FHA individuals in the family who do not have this variant on the other allele (0.64±0.14, p=0.0009). This variant has also been found in one general population French Canadian control with HDL at the 8th percentile (0.92) and one French Canadian individual from a population selected for low HDL and coronary disease (0.72).

Substitution of G for A at nucleotide -1113 [A(-1113)G]. This variant has been seen at varying frequencies in populations distinguished by their HDL levels.

Additional polymorphisms that may be associated with altered risk for cardiovascular disease or altered cholesterol levels are as follows:

Substitution of G for A at nucleotide 2723 (I883M). This variant has been seen at a much higher frequency in individuals of Dutch ancestry with premature coronary artery disease.

Insertion of 4 nucleotides (CCCT) at position -1181.

Substitution of C for A at nucleotide -479 (linkage disequilibrium with -518).

Substitution of G for A at nucleotide -380.

Other Embodiments

All publications mentioned in this specification are herein incorporated by reference to the same extent as if each independent publication was specifically and individually indicated to be incorporated by reference.

While the invention has been described in connection with specific embodiments thereof, it will be understood that it is capable of further modifications. This application is intended to cover any variations, uses, or adaptations following, in general, the principles of the invention and including such departures from the present disclosure within known or customary practice within the art to which the invention pertains and may be applied to the essential features hereinbefore set forth.

Claims

5

10

15

20

25

30

35

40

45

50

55

5

What we claim is:

10

1. A substantially pure ABC1 polypeptide having ABC1 biological activity.

5

2. The substantially pure ABC1 polypeptide of claim 1, wherein said ABC1 polypeptide is human ABC1.

15

3. The substantially pure ABC1 polypeptide of claim 1, wherein said polypeptide comprises amino acids 1 to 60 of SEQ ID NO: 1.

20

10

4. The substantially pure ABC1 polypeptide of claim 1, wherein said polypeptide comprises amino acids 61 to 2261 of SEQ ID NO: 1.

25

15

5. The substantially pure ABC1 polypeptide of claim 1, wherein said polypeptide comprises amino acids 1 to 2261 of SEQ ID NO: 1.

30

6. A substantially pure ABC1 polypeptide comprising amino acids 1 to 60 of SEQ ID NO: 1.

20

7. A substantially pure ABC1 polypeptide comprising amino acids 61 to 2261 of SEQ ID NO: 1.

35

8. A substantially pure ABC1 polypeptide comprising amino acids 1 to 2261 of SEQ ID NO: 1.

40

25

9. A substantially pure nucleic acid molecule that hybridizes at high stringency conditions to nucleotides 75 to 254 of SEQ ID NO: 2 and encodes a polypeptide having ABC1 biological activity.

45

30

10. A substantially pure nucleic acid molecule encoding an ABC1 polypeptide having ABC1 biological activity.

50

55

5

11. The substantially pure nucleic acid molecule of claim 9 or 10, wherein said nucleic acid molecule comprises nucleotides 75 to 254 of SEQ ID NO: 2.

10

12. The substantially pure nucleic acid molecule of claim 9 or 10, wherein said nucleic acid molecule comprises nucleotides 255 to 6857 of SEQ ID NO: 2.

15

13. The substantially pure nucleic acid molecule of claim 9 or 10, wherein said nucleic acid molecule comprises nucleotides 75 to 6857 of SEQ ID NO: 2.

20

14. An expression vector comprising the nucleic acid molecule of claim 9.

15. A cell expressing the nucleic acid molecule of claim 9.

25

16. A non-human mammal expressing the nucleic acid molecule of claim 9.

15

17. A substantially pure nucleic acid molecule comprising nucleotides 75 to 254 of SEQ ID NO: 2.

30

18. A substantially pure nucleic acid molecule comprising nucleotides 255 to 6857 of SEQ ID NO: 2.

20

35

19. A substantially pure nucleic acid molecule comprising nucleotides 75 to 6857 of SEQ ID NO: 2.

40

20. A substantially pure nucleic acid molecule comprising at least thirty consecutive nucleotides corresponding to nucleotides 7015-7860 of SEQ ID NO: 2.

45

21. The substantially pure nucleic acid molecule of claim 20, wherein said nucleic acid molecule comprises nucleotides 7015-7860 of SEQ ID NO: 2.

30

50

55

5

22. A substantially pure nucleic acid molecule that hybridizes at high stringency to a probe comprising nucleotides 7015-7860 of SEQ ID NO: 2.

10

23. A method of treating a human having low HDL cholesterol or cardiovascular disease, said method comprising administering to said human an ABC1 polypeptide, or cholesterol-regulating fragment thereof.

15

24. The method of claim 23, wherein said ABC1 polypeptide has the sequence of SEQ ID NO: 1.

20

10

25. The method of claim 23, wherein said ABC1 polypeptide comprises a mutation that increases its stability.

25

15

26. The method of claim 23, wherein said ABC1 polypeptide comprises a mutation that increases its biological activity.

30

20

27. A method of treating a human having low HDL cholesterol or cardiovascular disease, said method comprising administering to said human a nucleic acid molecule encoding an ABC1 polypeptide or a cholesterol-regulating fragment thereof.

35

28. The method of claim 27, wherein said ABC1 polypeptide has the amino acid sequence of SEQ ID NO: 1.

40

25

29. The method of claim 27, wherein said ABC1 polypeptide comprises a mutation that increases its stability.

45

30

30. The method of claim 27, wherein said ABC1 polypeptide comprises a mutation that increases its biological activity.

50

55

5

31. The method of claim 30, wherein said biological activity is regulation of cholesterol.

10

32. The method of claim 27, wherein said human has low HDL cholesterol levels relative to normal.

5

15

33. A method of increasing ABC1 biological activity in a human, said method comprising administering to said human a nucleic acid molecule that hybridizes at high stringency conditions to nucleotides 75 to 254 of SEQ ID NO: 2 and encodes a polypeptide having ABC1 biological activity.

20

10

25

34. The method of claim 33, wherein said human has a disease selected from the group consisting of Alzheimer's disease, Niemann-Pick disease, Huntington's disease, x-linked adrenoleukodystrophy, and cancer.

15

30

35. A method of increasing ABC1 biological activity in a human, said method comprising administering to said human a compound that increases ABC1 biological activity.

35

20

36. The method of claim 35, wherein said human has a disease selected from the group consisting of Alzheimer's disease, Niemann-Pick disease, Huntington's disease, x-linked adrenoleukodystrophy, and cancer.

40

25

37. A method of preventing cardiovascular disease in a human, said method comprising administering to said human an expression vector comprising an *ABC1* nucleic acid molecule operably linked to a promoter, said *ABC1* nucleic acid molecule encoding an ABC1 polypeptide having ABC1 biological activity.

45

50

55

5
10
15
20
25
30
35
40
45
50
55

38. A method of preventing or ameliorating the effects of a disease-causing mutation in an *ABC1* gene in a human, said method comprising introducing into said human an expression vector comprising a promoter operably linked to an *ABC1* nucleic acid molecule encoding an ABC1 polypeptide having ABC1 biological activity.

39. A method of treating or preventing cardiovascular disease in an animal, said method comprising administering to said animal a compound that mimics the activity of wild-type ABC1.

40. The method of claim 39, wherein said animal is a human.

41. A method of treating or preventing cardiovascular disease in an animal, said method comprising administering to said animal a compound that modulates the biological activity of ABC1.

42. The method of claim 41, wherein said animal is a human.

43. The method of claim 41, wherein said compound is selected from a group consisting of protein kinase A, protein kinase C, vanadate, okadaic acid, IBMX1, fibrates, β -estradiol, arachidonic acid derivatives, WY-14,643, LTB4, 8(s)HETE, thiozolidinedione antidiabetic drugs, 9-HODE, 13-HODE, nicotinic acid, HMG CoA reductase inhibitors, and compounds that increase PPAR-mediated ABC1 expression.

44. The method of claim 23, 27, 39, or 41, wherein said cardiovascular disease is coronary artery disease, cerebrovascular disease, coronary restenosis, or peripheral vascular disease.

5

45. A method for determining whether a candidate compound is useful for modulating cholesterol levels, said method comprising the steps of:

10

(a) providing a chicken comprising a mutation in an *ABC1* gene;

(b) administering said candidate compound to said chicken; and

5

(c) measuring ABC1 biological activity in said chicken,

15

wherein altered ABC1 biological activity, relative to a WHAM chicken not contacted with said compound, indicates that said candidate compound modulates cholesterol levels.

20

10

46. The method of claim 45, wherein said ABC1 biological activity is transport of cholesterol.

25

47. A method for determining whether a candidate compound modulates ABC1 biological activity, said method comprising the steps of:

15

(a) providing a cell expressing an ABC1 polypeptide comprising amino acids 1 to 60 of SEQ ID NO: 1;

30

(b) contacting said cell with said candidate compound; and

(c) measuring ABC1 biological activity of said cell,

20

wherein altered ABC1 biological activity, relative to a cell not contacted with said compound, indicates that said candidate compound modulates ABC1 biological activity.

35

48. A method for determining whether a candidate compound modulates ABC1 expression, said method comprising the steps of:

40

25

(a) providing a cell expressing an *ABC1* gene comprising nucleotides 75 to 254 of SEQ ID NO: 2;

45

(b) contacting said cell with said candidate compound; and

(c) measuring ABC1 expression of said cell,

30

wherein altered ABC1 expression, relative to a cell not contacted with said compound, indicates that said candidate compound modulates ABC1 expression.

50

55

5

49. A method for determining whether a candidate compound modulates ABC1 expression, said method comprising the steps of:

10

(a) providing a nucleic acid molecule comprising an ABC1 promoter operably linked to a reporter gene;

5

(b) contacting said nucleic acid molecule with said candidate compound; and

15

(c) measuring expression of said reporter gene,

wherein altered reporter gene expression, relative to a control not contacted with said compound, indicates that said candidate compound modulates ABC1 expression.

20

10

50. The method of claim 49, wherein said promoter comprises 50 consecutive nucleotides selected from nucleotides 1 to 8238 of SEQ ID NO: 14.

25

15

51. The method of claim 50, wherein said promoter comprises a binding site for a transcription factor selected from a group consisting of steroid response element binding proteins, peroxisomal proliferation-activated receptors, retinoid X receptors, and RAR-related orphan receptors.

30

52. A method for determining whether a candidate compound modulates ABC1 biological activity, said method comprising the steps of:

20

35

(a) providing an ABC1 polypeptide comprising amino acids 1 to 60 of SEQ ID NO: 1;

(b) contacting said polypeptide with said candidate compound; and

(c) measuring ABC1 biological activity,

40

25

wherein a change in ABC1 biological activity, relative to a control not contacted with said compound, indicates that said candidate compound modulates ABC1 biological activity.

45

50

55

53. A method for determining whether a candidate compound modulates ABC1 expression, said method comprising the steps of:

(a) providing an ABC1 polypeptide comprising amino acids 1 to 60 of SEQ ID NO: 1;

(b) contacting said polypeptide with said candidate compound; and

(c) measuring expression of said ABC1 polypeptide,

wherein a change in expression of said ABC1 polypeptide, relative to a control not contacted with said compound, indicates that said candidate compound modulates ABC1 expression.

54. A method for determining whether candidate compound modulates ABC1 biological activity, said method comprising the steps of:

(a) providing an ABC1 polypeptide comprising amino acids 1 to 60 of SEQ ID NO: 1;

(b) contacting said polypeptide with said candidate compound; and

(c) measuring binding of said ABC1 polypeptide to said candidate compound, wherein binding of said ABC1 polypeptide to said compound indicates that said candidate compound modulates ABC1 biological activity.

55. A method for determining whether candidate compound modulates ABC1 biological activity, said method comprising the steps of:

(a) providing (i) an ABC1 polypeptide comprising amino acids 1 to 60 of SEQ ID NO: 1, and (ii) a second polypeptide that interacts with said ABC1 polypeptide;

(b) contacting said polypeptides with said candidate compound; and

(c) measuring interaction of said ABC1 polypeptide with said second polypeptide, wherein an alteration in the interaction of said ABC1 polypeptide with said second polypeptide indicates that said candidate compound modulates ABC1 biological activity.

5

56. A method for determining whether a candidate compound increases the stability or decreases the regulated catabolism of an ABC1 polypeptide, said method comprising the steps of:

10

(a) providing a cell comprising an ABC1 polypeptide comprising amino acids 1 to 60 of SEQ ID NO: 1;

5

(b) contacting said cell with said candidate compound; and

15

(c) measuring the half-life of said ABC1 polypeptide,

wherein an increase in said half-life, relative to a control not contacted with said compound, indicates that said candidate compound increases the stability or decreases the regulated catabolism of an ABC1 polypeptide.

20

10

57. A method for determining whether a candidate compound modulates ABC1 biological activity, said method comprising the steps of:

25

(a) providing an ABC1 polypeptide in a lipid membrane;

15

(b) contacting said polypeptide with said candidate compound; and

(c) measuring ABC1-mediated lipid transport across said lipid membrane,

30

wherein a change in lipid transport, relative to a control not contacted with said compound, indicates that said candidate compound modulates ABC1 biological activity.

20

35

58. The method of claim 49, 52, 53, 54, 55, or 57, wherein said ABC1 polypeptide is in a cell-free system.

40

25

59. The method of claim 49, 52, 53, 54, 55, or 57, wherein said ABC1 polypeptide is in a cell.

45

60. The method of claim 59, wherein said cell is from a WHAM chicken.

30

61. The method of claim 59, wherein said cell is in a human or in a non-human mammal.

50

55

5

62. The method of claim 61, wherein said animal is a WHAM chicken.

10

63. The method of claim 52, wherein said biological activity is transport of lipid or interleukin-1.

5

15

64. The method of claim 62, wherein said lipid is cholesterol.

65. The method of claim 64, wherein said cholesterol is HDL-cholesterol.

20

10

66. The method of claim 52, wherein said biological activity is binding or hydrolysis of ATP by the ABC1 polypeptide.

25

15

67. A method for determining whether a patient has an increased risk for cardiovascular disease, said method comprising determining whether an *ABC1* gene of said patient has a mutation, wherein a mutation indicates that said patient has an increased risk for cardiovascular disease.

30

20

35

68. A method for determining whether a patient has an increased risk for cardiovascular disease, said method comprising measuring ABC1 biological activity in said patient or in a cell from said patient, wherein increased or decreased levels in said ABC1 biological activity, relative to normal levels, indicates that said patient has an increased risk for cardiovascular disease.

40

25

45

69. A method for determining whether a patient has an increased risk for cardiovascular disease, said method comprising measuring ABC1 expression in said patient or in a cell from said patient, wherein decreased levels in said ABC1 expression relative to normal levels, indicates that said patient has an increased risk for cardiovascular disease.

30

50

55

5
10
70. The method of claim 69, wherein said ABC1 expression is determined by measuring levels of ABC1 polypeptide.

15
5
71. The method of claim 69, wherein said ABC1 expression is determined by measuring levels of ABC1 RNA.

20
15
72. A non-human mammal comprising a transgene comprising a nucleic acid molecule encoding a dominant-negative ABC1 polypeptide.

25
10
73. A cell isolated from a non-human mammal comprising a transgene comprising a nucleic acid molecule encoding an ABC1 polypeptide having biological activity.

30
15
74. A method for determining whether a candidate compound decreases the inhibition of a dominant-negative ABC1 polypeptide, said method comprising the steps of:

- 35
20
(a) providing a cell expressing a dominant-negative ABC1 polypeptide;
(b) contacting said cell with said candidate compound; and
(c) measuring ABC1 biological activity of said cell,

40
35
wherein an increase in said ABC1 biological activity, relative to a cell not contacted with said compound, indicates that said candidate compound decreases the inhibition of a dominant-negative ABC1 polypeptide.

45
25
75. A method for determining whether a person has an altered risk for developing cardiovascular disease, comprising examining the person's ABC1 gene for polymorphisms, wherein the presence of a polymorphism associated with cardiovascular disease indicates the person has an altered risk for developing cardiovascular disease.

50
30

5

76. A method for predicting a person's response to a drug, comprising determining whether the person has a polymorphism in an ABC1 gene that alters the person's response to said drug.

10

5 77. A method for predicting a person's response to a drug, comprising determining whether the person has a polymorphism in an ABC1 promoter that alters the person's response to said drug.

15

78. A method for altering ABC1 expression in a cell, said method comprising contacting said cell with a compound selected from a group consisting of fibrates, β -estradiol, arachidonic acid derivatives, WY-14,643, LTB₄, 8(s)HETE, thiozolidinedione antidiabetic drugs, 9-HODE, 13-HODE, nicotinic acid, HMG CoA reductase inhibitors, and compounds that increase PPAR-mediated ABC1 expression.

20

25

15 79. A pharmaceutical composition comprising (i) a nucleic acid molecule that hybridizes under high stringency conditions to nucleotides 75 to 254 of SEQ ID NO: 2 and encodes a polypeptide having ABC1 biological activity; and (ii) a pharmaceutically acceptable carrier.

30

20 80. A nucleic acid that hybridizes under high stringency conditions to nucleotides 1 to 8236 of SEQ ID NO: 14.

35

81. A nucleic acid comprising a region that is 80% identical to at least thirty contiguous nucleotides of nucleotides 1 to 8236 of SEQ ID NO: 14.

40

25

45

50

55

5

82. A method for determining whether candidate compound modulates ABC1 biological activity, said method comprising the steps of:

10

(a) providing an ABC1 polypeptide;

(b) contacting said polypeptide with cholesterol and said candidate compound;

5 and

15

(c) measuring binding of said cholesterol to said ABC1 polypeptide, wherein binding of said cholesterol to said ABC1 polypeptide indicates that said candidate compound modulates ABC1 biological activity.

20

10 83. The method of claim 82, wherein said cholesterol is HDL cholesterol.

25

84. The method of claim 82, wherein said method is performed in a cell free assay.

15

85. The method of claim 82, wherein said ABC1 polypeptide comprises amino acids 1 to 60 of SEQ ID NO: 1.

30

86. the method of claim 82, wherein said cholesterol or said ABC1 polypeptide is detectably labeled.

35

40

45

50

55

Family TD - 1





Fig. 1A







Fig. 1C

Fig. 2B

Family FIA - 2



Family RIA - J





Fig. 2C

Fig. 2D

Family FHA - 4






Fig. 3

Exon 30 mutation:




Fig. 4A




Fig. 4B




Fig. 4C




Fig. 4D




Fig. 5A




Fig. 5B




Fig. 5C

Exon 14: FHA - I, patient III:01




Fig. 6A




Fig. 6B




Fig. 6C

Exon 41
FHA-J

wt sequence
HUMAN_AEC1
MCUSE_AEC1
Patient (Δ E1893, D1894)
CAISL_AEC

Δ 5752-5757




Fig. 6E

Exon 48 mutation:




Fig. 6F





Fig. 1A







Fig. 7C

002



Mutation
Polymorphism

Fig. 8

SEQ ID NO: 1

MACWPQLRLLLWKNLTFRRRQTCQLLEVAWPLFIFLILISVRLSYPPYEQHECHFPNKAMPSAGTLPWVQ
GIICNANNPFCFRYPTPGAPGVVGNFNKSIVARLFSDARRLLLYSQKDTSMKDMRKVLRLTQIQKSSSNL
KLQDFLVDNETFSGFLYHNLSPKSTVDKMLRADVILHKVFLQGYQLHLTSLCNGSHSEEMIQLDQDEVSE
LCGLPREKLAARVLRNMDILKPIRLTLNSTSPFPKELAEATKTLHSLGLTACELFSMRSDMRQE
VMFLTNVNSSSTQIYQAVSRIVCGHPGGGLKIKSLNWYEDNNYKALFGGNGTEEDAETFYDNSTTPYC
NDLMKNLESSPLSRIIWKALKPLLVGKILYTPDTPATROVMAEVNKTFOELAVFHDLEGMWHEELSPKIWTF
MENSOEMDLVRMLLDSRDNDHFWEQQLDGLDWTADQDIVAFLAKHPEDVQSSNGSVYTWREAFNETNQAIR
ISRFMECVNLAKLEPIATEVWLINKSMELDERKFWAGIVFTGITPGSIELPHHVYKIRMDIDNVERTNK
IKDQWDPGPRADPFEDMRVWGGFAYLQDVVEQAIIRVLTGTGKTKGVYMQMPYPCYVDDIFLVRMSRS
MPLFMTLAWIYSVAVIIGIVYEKEARLKETMRIMGLDINSILWFSWFISSLIPLLSAGLLVILKGNLL
PYSDDPSVVFVFLSVFAVVITLQCFLLISTLFSRANLAAACGGIITYFTLYLPYVLCVAKQDYVGFTLKIFASL
LSFVAFGFGCEYFALFEEQIGVQWDLNLFESPVEEDGFNLITTSVMMLFDITFLYGVMTWYIEAVFPQGYGI
PRPWYFPCTKSYWFGESDEKSHPGSNQKRISIEICMEEPTHKLGVSIQNLVKVYRDGMKVAVDGLALNF
YEGQITSLFGLHNGAGKTTMSILTGLFPPTSGTAYILGKDIRSEMSTIRQNLGVCPQHNVLFDMLTVEEHI
WYFARLKLGLSEKHVKAEMEQAALDVLGPPSSKLKSKTSQLSGGMQRKLSSVALAFVGGSKVVLDEPTAGVDP
YSRRGIWELLKRYRQRTIILSTHMDADVLGDRIAIISHGKLCCVGSFLPKNLQGTGYLTLVKKDVE
SSLSSCRNSSSTVSYLKEDSVSQSSDAGLSDHESDITLIDVSAISNLIRKHVSZARLVEDIGHELTYV
LPYEAKEGAFVELFHEIDRLSDLGISSYGISSETTLEEFLKVAEESGVDAETSDGTLPARRNRRAFGDK
QSCLRPFTEDDAADPNDSIDPESRETDLLSGMDGKGSYQVKGWKLQQQFVALLWKRLLIARRSRKGGFA
QIVLPAVFVCIALVFSLVPPFGKPSLELQPMWYNEQYTFVSNDAPEDTGTLELLNALTQDPGFGTRCME
GNPPIPDTPCQAGEEWTAPVPQTIMDLFQNGNWTMONPSPACQCSSDKIKMLPVCPPGAGGLPPPQRKQ
NTADILQDLTGRNISDYLVKTYVQIIAKSLKNKIWNNEFRYGGFSLGVSNTOALPPSQEVNDAIKOMKHL
KLAKSSADRFLNLSLGRFMTGLDTRNNVWVFNKGWHAISSFLNVINNAILRANLQKGENPSHYGITAFN
HPLNLTQQLSEVALMTTSVDVLVSI CVIFAMSFVPASFVFLIQERVS KAKHLQF:SGVKPVIYWLNSFV
WDMCNVYVPATLVIIIFICFQKSYVSSTNLPVLALLLLYGWSITPLMPASVFKIPSTAYVVLTSVNL
FIGINGSVATFVLELFTDNKLNINDILKSVFLIPPHFCLGRGLIDMVKNQAMADALERFGENRFVSPLSW
DLVGRNLFAMAVEGVVFLITVLIQYRFFIRPRPVNAKLSPLNDEDEDVRRERQRIIDGGGQNDILEIKEL
TKIYRAKRPKPAVDRI CVGIFPGECFGLLGVNGAGKSSTFKMLTGDITVTRGDAFLNKNLSLSNIHEVHQN
GYCPOFDAITELLTGREHVEFFALLRGVPEKEVGKVGEWAIRKGLVKYGEKYAGNYSGGNKRKLSTAMAL
IGGPPVVFLDEPTTGMDPKARRFLWNCALSVVKEGRSVVLTSHSMEECEALCTRMAIMVNGRFRCLGSVQH
LKNRFGDGYTIVVRIAGSNPDLKPVQDFGLAFPGSVLKEKHRNMLQYQLPSSLSSLARIFSI LSQSKKRL
HIEDYSVSQTTLDQVFVNFADQSDDDHLKDLSLHKNQTVVDVAULTSFLQDEKVKESYV*

Fig. 9A

SEQ ID NO: 2

GTCCCTGCTGTGAGCTCTGGCCGCTGCCCTCCAGGGCTCCCGAGCCACACGCTGGGGGTG
CTGGCTGAGGGAACATGGCTTGTGGCCCTCAGCTGAGGTTGCTGCTGTGGAAGAACCTCA
CTTTCAGAAGAAGACAAACATGTCAGCTGTTACTGGAAGTGGCCTGGCCTCTATTATCT
TCCTGATCCTGATCTCTGTTCCGGCTGAGCTACCCACCCTATGAACAACATGAATGCCATT
TTCCAAATAAAGCCATGCCCTCTGCAGGAACACTTCCTTGGGTTGAGGGGATTATCTGTA
ATGCCAACAACCCCTGTTTCCGTTACCCGACTCCTGGGGAGGCTCCCGGAGTTGTTGGAA
ACTTTAACAATCCATTGTGGCTCGCCTGTTCTCAGATGCTCGGAGGCTTCCTTTATACA
GCCAGAAAGACACCAGCATGAAGGACATGCGCAAAGTTCTGAGAACATTACAGCAGATCA
AGAAATCCAGCTCAAACCTGAAGCTTCAAGATTTCTGGTGGACAATGAAACCTTCTCTG
GGTTCCTGTATCACAACCTCTCTCTCCCAAAGTCTACTGTGGACAAGATGCTGAGGGCTG
ATGTCATTCTCCACAAGGTATTTTGCAGGCTACCAGTTACATTGACAAAGTCTGTGCA
ATGGATCAAATCAGAAGAGATGATTCAACTTGGTGACCAAGAGTTTCTGAGCTTTGTG
GCCTACCAAGGGAGAACTGGCTGCAGCAGAGCGAGTACTTCGTTCCAACATGGACATCC
TGAAGCCAAATCCTGAGAACACTAACTCTACATCTCCCTTCCCGAGCAAGGAGCTGGCTG
AAGCCACAAAACATTGCTGCATAGTCTTGGGACTCTGGCCAGGAGCTGTTGAGCATGA
GAAGCTGGAGTGACATGCGCAGGAGGTGATGTTTCTGACCAATGTGAACAGCTCCAGCT
CCTCCACCCAAATCTACAGGCTGTGTCTCGTATTGTCTGCGGGCATCCCGAGGGAGGGG
GGCTGAAGATCAAGTCTCTCAACTGGTATGAGGACAACAATACAAAGCCCTCTTTGGAG
GCAATGGCACTGAGGAGATGCTGAACCTTCTATGACAACTCTACAACTCCTTACTGCA
ATGATTTGATGAAGAAATTGGAGTCTAGTCTCTTTCCCGCATTTATCTGAAAGCTCTGA
AGCCGCTGCTCGTTGGAAGATCCTGTATACACCTGACACTCCAGCCCAAGGCAGGTCA
TGGCTGAGGTGAACAAGACCTTCCAGGAACCTGGCTGTGTTCCATGATCTGGAAGGCATGT
GGGAGGAACCTCAGCCCAAGATCTGGACCTTCATGGAGAACAGCCAAGAAATGGACCTTG
TCCGGATGCTGTTGGAAGCAGGAGCAATGACCACCTTTTGGGAACAGCAGTTGGATGGCT
TAGATTGGACAGCCCAAGACATCGTGGCGTTTTTGGCCAAGCAGCCAGAGGATGTCCAGT
CCAGTAATGGTTCTGTCTACACCTGGAGAGAAGCTTCAACGAGACTAACCAGGCAATCC
GGACCATATCTCGCTTCATGGAGTGTGTCAACCTGAACAAGCTAGAACCCATAGCAACAG
AAGTCTGGCTCATCAACAAGTCCATGGAGCTGCTGGATGAGAGGAAGTTCTGGGCTGGTA
TTGTGTTCACTGGAATTACTCCAGSCAGCATTGAGCTGCCCCATCATGTCAAGTACAAGA
TCCGAATGGACATTGACAATGTGGAGAGGACAAATAAAATCAAGGATGGGTACTGGGACC
CTGGTCTCTGAGCTGACCCCTTTGAGGACATGCGGTACGCTGCGGGGGCTTCGCCTACT
TGAGGATSTGGTGGAGCAGGCAATCATCAGGGTGTGACGGGCACCGAGAAAGAAACTG

Fig. 9B

GTGTCATATGCAACAGATGCCCTATCCCTGTACGTTGATGACATCTTTCTGCGGGTGA
TGAGCCSGTCAATGCCCTCTTCATGACGCTGGCTGGATTACTCAGTGGCTGTGATCA
TCAAGGGCATCGTGTATGAGAAGGAGGCACGGCTGAAAGAGACCATGCCGATCATGGGCC
TGGACACAGCATCCTCTGGTTTAGCTGGTTCATTAGTAGCCTCATTCTCTTGTGA
GGGCTGCGCTGTAGTGGTCATCCTGAAGTTAGGAAACCTGCTGCCCTACAGTGATCCCA
GCGTGSTGTTTGTCTTCTGTGCTCGTGTGCTGTGGTGACAACTCTGCAGTGTCTCTGA
TTAGCACACTCTTCTCCAGAGCCAACCTGGCAGCAGCCTGTGGGGCATCATCTACTTCA
CGCTGTACCTGCCCTACGTCTGTGTGTGGCATGGCAGGACTACGTGGGCTTCACACTCA
AGATCTTCGCTAGCCTGTGTCTCTGTGGCTTTTGGGTTTGGCTGTGAGTACTTTGCCC
TTTTTGAGGAGCAGGGCATTGAGTSCAGTGGGACAACCTGTTTGAGAGTCTGTGGAGG
AAGATGGCTTCAATCTCACCACTTCGGTCTCCATGATGCTGTTTGACACCTTCTCTATG
GGGTGATGACCTGGTACATTGAGGCTGTCTTCCAGGCCAGTACGGAATCCAGGCCCT
GGTATTTCTCTGCACCAAGTCTACTGGTTTGGCGAGGAAAGTATGAGAAGAGCCACC
CTGGTTCCAAACCAGAAGAGAATATCAGAAATCTGCATGGAGGAGGAACCCACCCACTTGA
AGCTGGGCGTGTCCATTGAGAACCTGGTAAAAGTCTACCGAGATGGGATGAAGGTGGCTG
TCGATGGCCTGGCACTGAATTTTATGAGGGCCAGATCACCTCTCTCTGGGCCACAATG
GAGCGGGGAAGACGACCACCATGTCAATCCTGACCGGGTGTGTTCCCCCGACCTCGGGCA
CCGCCCTACATCTCGGGAAGACATTCTGCTCTGAGATGAGCACCATCCGGCAGAACCTGG
GGGTCTGTCTCCAGCATAACGTGCTGTTTGACATGCTGACTGTGGAAGAACACATCTGGT
TCTATGCCCCCTTGAAGGGCTCTCTGAGAAGCAGTGAAGGCGGAGATGGAGCAGATGG
CCCTGGATGTGGTTTGGCATCAAGCAAGCTGAAAGCAAAACAGCCAGCTGTGAGGTG
GAATGCAGAGAAAGCTATCTGTGGCCTTGGCCTTGTGCGGGGATCTAAGGTTGTCTATC
TGGATGAACCCACAGCTGGTGTGGACCTTACTCCCGCAGGGGAATATGGGAGCTGCTGC
TGAAATACCGACAAGGCCGACCATTTATCTCTCTACACACCACATGGATGAAGCGGACG
TCCTGGGGACAGGATTGCCATCATCTCCCATGGGAAGCTGTGCTGTGTGGGCTCCTCCC
TGTTTCTGAAGAACCAGCTGGGAACAGGCTACTACCTGACCTTGGTCAAGAAAGATGTGG
AATCCTCCCTCAGTCTCTGCAGAAACAGTAGTAGCACTGTGTACATCTGAAAAAGGAGG
ACAGTGTCTCTCAGAGCAGTCTGATGCTGSCCTGGGCAGCGACCATGAGAGTGACACGC
TGACCATCGATGTCTCTGCTATCTCAACCTCATCAGGAAGCATGTGTCTGAAGCCCGGC
TGGTGAAGACATAGGGCATGAGCTGACCTATGTGCTGCCATATGAAGCTGCTAAGGAGG
GAGCCTTTGTGGAACCTTTTCATGAGATTGATGACCGGCTCTCAGACCTGGGCATTTCTA
GTTATGGCATCTCAGAGACGACCCCTGGAAGAAATATTCCTCAAGGTGGCCGAAGAGAGTG
GGGTGGATGCTGAGACCTCAGATGGTACCTTGCCAGCAAGACGAACAGGCGGGCCTTCG
GGGACAAGCAGAGCTGTCTTCGCCCTTCACTGAAGATGATGCTGTGATCCAAATGATT

Fig. 9C

CTGACATAGACCCAGAATCCAGAGAGACAGACTTGCTCAGTGGGATGGATGSCAAAGGGT
CCTACCAGGTGAAAGGCTGGAACTTACACAGCAACAGTTTGTGGCCCTTTTGTGGAAGA
GACTGCTAATTGCCAGACGGAGTCGGAAAGGATTTTTGTCTCAGATTGCTTGGCAGCTG
TGTTTTCTGCATTGCCCTTGTGTTTCCGCTGATCGTGCCACCCCTTTGGCAAGTACCCCA
GCCTGGAATTCAGCCCTGGATGTACACGAACAGTACACATTGTGAGCAATGATGCTC
CTGAGGACACGGGAACCTGGAACTCTTAAACGCCCTCACCAAGACCCCTGCTTCGGGA
CCCGCTGTATGGAAGGAAACCAATCCAGACACGCCCTGCCAGGAGGGGAGGAAGAGT
GGACCACTGCCCCAGTTCCCCAGACCATCATGGACCTCTCCAGAATGGGAAGTGGACAA
TGCAGAACCCCTTACCTGCATGCCAGTGTAGCAGCGACAAAATCAAGAAGATGCTGCCTG
TGTGTCCCCAGGGGAGGGGGCTGCCTCCTCCACAAAGAAAACAAACACTGCAGATA
TCCTTCAGGACCTGACAGGAAGAAACATTTCCGATTATCTGGTGAAGACGTATGTGCAGA
TCATAGCCAAAAGCTTAAAGAACAAAGATCTGGGTGAATGAGTTTAGGTATGGCGGCTTTT
CCCTGGGTGTCACTAATACTCAAGCACTTCCCTCCGAGTCAAGAAGTTAATGATGCCATCA
AACAAATGAAGAAACACCTAAAGCTGGCCAAAGGACAGTTCTGCAGATCGATTTCACAACA
GCTTGGGAAGATTTATGACAGGACTGACACACAGAAATAATGTCAAGCTGTGGTTCAATA
ACAAGGGCTGGCATGCAATCAGCTCTTCCCTGAATGTCAACAATGCCATTCTCCGGG
CCAACCTGCAAAAGGAGAGAACCTAGCCATTATGGAATTACTGCTTCAATCATCCCC
TGAATCTCACCAAGCAGCAGCTCTCAGAGGTGGCTCTGATGACCACATCAGTGGATGTCC
TTGTGTCCATCTGTGTCTTTGCAATGTCTTCCGTCCAGCCAGCTTTGTGCTATTCC
TGATCCAGGAGCGGGTCAAGCAAGCAAAACACCTGCAGTTTATCAGTGGAGTGAAGCCTG
TCATCTACTGGCTCTTAATTTTGTCTGGATATGTGCAATTACGTTGTCCCTGCCACAC
TGGTCATTATCATCTTCATCTGCTTCCAGCAGAAGTCTATGTGCTCCACCAATCTGC
CTGTGCTAGCCCTTCTACTTTTGTCTGTATGGGTGGTCAATCACACCTCTCATGTACCCAG
CCTCCTTTGTGTTCAAGATCCCAGCACAACCTATGTGGTGTCTCACCAGCGTGAACCTCT
TCATTGGCATTAAATGCGAGCGTGGCCACCTTTGTGCTGGAGCTGTTACCCGACAATAAGC
TGAATAATATCAATGATATCCTGAAGTCCGTGTTCTTGATCTTCCACATTTTTCCTGG
GACGAGGGCTCATCGACATGGTGAAAAACAGGCAATGGCTGATGCCCTGGAAAGGTTTG
GGGAGAAATCGCTTTGTGTACCATTTATCTTGGGACTTGGTGGGACGAAACCTCTTCGCCA
TGGCCGTGGAAGGGGTGGTGTCTTCTCTTACTGTCTGTATCCAGTACAGATTCTTCA
TCAGGCCAGACCTGTAAATGCAAGCTATCTCCTCTGAATGATGAAGATGAAGATGTGA
GGCGGGAAGACAGAGAAATTTCTGTATGGTGGAGGCCAGAAATGACATCTTAGAAATCAAGG
AGTTGACGAAGATATATAGAAGGAAGCGGAAGCCTGCTGTTGACAGGATTTGCGTGGGCA
TTCCTCCTGCTGAGTGTCTTGGGCTCCTGGGAGTTAATGGGCTGGAAAATCATCAACTT
TCAAGATGTTAACAGAGATACCACTGTACCAGAGGAGATGCTTCTTAAACAAAATA

Fig. 9D

GTATCTTATCAAACATCCATGAAGTACATCAGAACATGGGCTACTGCCCTCACTTTGATG
CCATCACAGAGCTGTTGACTGGGAGAGAACACGTGGAGTTCTTTGCCCTTTTGAGAGGAG
TCCCAGAGAAAGAACTTGGCAAGGTTGGTGAGTGGGCGATTCCGAAACTGGGCTCTCGTGA
AGTATGGAGAAAAATATGCTGGTAACTATAGTGGAGGCAACAAACGCAAGCTTCTTACAG
CCATGGCTTTGATCGGCGGGCTCCTGTGGTGTCTTGGATGAACCCACCAAGGCATGG
ATCCCAAAGCCCGCGGTTCTTGTGAATTTGTGCCCTAAGTGTGTCAAGGAJGGGAGAT
CAGTAGTGTCTTACATCTCATAGTATGGAAGAATGTGAAGCTCTTTGCACTAAGATGGCAA
TCATGCTCAATGGAAGTTTCAAGTGCCTTGGCAGTGTCCAGCATCTAAAAATAGGTTTG
GAGATGCTTATACAATAGTTGTACGAATAGCAGGGTCCAACCCGACCTGAAGCCTGTCC
AGGATTTCTTTGGACTTGCAATTCCTGGAAGTGTCTTAAAGAGAAACACCCGAAACATGC
TACAATACCAGCTTCCATCTTCATTATCTTCTCTGGCCAGGATATTGAGCATCCTCTCCC
AGAGCAAAAAGCGACTCCACATAGAAGACTACTCTGTTTCTCAGACAACACTTGACCAAG
TATTTGTGAACCTTGCCAAGGACCAAGTGATGATGACCACTTAAAGACCTCTCATTAC
ACAAAACCCAGACAGTAGTGGACGTTGCAGTTCTCAGATCTTTTCTACAGGATGAGAAAG
TGAAAGAAAGCTATGTATGAAGAATCTGTTTATACGGGGTGGCTGAAAGTAAAGAGGAA
CTAGACTTTCTTTGCACCATGTGAAGTGTGTGGAGAAAAGAGCCAGAAAGTTGATGTGG
GAAGAAGTAAACTGGTACTGTACTGATCTATTCAATGCAATGCAATTCAATGCAATGA
AAACAAAATTCATTACAGGGGCGAGTGCCTTTGTAGCCTATGTCTTGTATGGCTCTCAAG
TGAAGACTTGAATTTAGTTTTTACCTATACCTATGTGAAACTCTATTATGGAACCCAA
TGGACATATGGGTTTGAACACACATTTTCTTTTCTTTTGTCTCTGTATTTCTCATT
GGGGTTGACACAATAATTCATCAAGTAATCATGGCCAGCGATTATTGATCAAAATCAAAA
GGTAATGCACATCCTCATTCACTAAGCCATGCCATGCCAGGAGACTGGTTTCCCGGTGA
CACATCCATTGCTGGCAATGAGTGTGCCAGAGTTATTAGTGCCAAAGTTTTTCAGAAAGTT
TGAAGCACCATGGTGTCTCATGCTCACTTTTGTGAAGCTGCTCTGCTCAGAGTCTATCA
ACATTGAATATCACTTACAGAAATGGTGCCATGCCGTGGCTAACATCCTGCTTTGATTCCC
TCTGATAAGCTGTTCTGTTGGCAGTACATGCAACAAAATGTGGTGTCTCCAGGCACG
GGAAACTTGGTTCCATTGTTATATTGCTTATGCTTCGAGCCATGGGTCTACAGGTCAT
CCTTATGAGACTCTTAATATATACTTAACTCCTGGTAAGAGGCAAGAAATCAACAGCCAAA
CTGCTGGGGCTGCAACTGCTGAAGCCAGGGCATGGGATTAAAGAGATTGTGCGTTCAAAC
CTAGGGAAGCCTGTGCCATTGTCTGACTGTCTGCTAACATGGTACACTGCATCTCAA
GATGTTTATCTGACACAAGTGATTATTTCTGGCTTTTGAATTAATCTAGAAAATGAAA

Fig. 9E

Exon	Forward Primer	SEQ ID No.	Reverse Primer	SEQ ID No.	Exon (kb)	Intron (kb)
exon 1	140 GGCCTGATTTAAAGATGCTG	70	ATCCGACCTTCAAAAGCTG	119	intron 1	0.413
exon 2	94 GATTTCCAGAGCCAGCTG	71	AGCTGATTTAGGCGAGTT	120	intron 2	0.413
exon 3	142 GACAGCTGGATGAGCA	72	CGCCATTAATTTCTG	121	intron 3	0.413
exon 4	119 GACAGCTGGATGAGCA	73	CGCCATTAATTTCTG	122	intron 4	0.413
exon 5	112 GATTTCCAGAGCCAGCTG	74	CGCCATTAATTTCTG	123	intron 5	0.413
exon 6	117 TCTGAGGAGCTGCTG	75	CGCCATTAATTTCTG	124	intron 6	0.413
exon 7	93 TCGGTTCTGTTGTTAACTCA	76	AGGACCTTCTGAGCTCA	125	intron 7	0.413
exon 8	244 TCCAGAGCTTGAATGAC	77	AGGACCTTCTGAGCTCA	126	intron 8	0.413
exon 9	140 GGCCTGATTTAAAGATGCTG	78	AGGACCTTCTGAGCTCA	127	intron 9	0.413
exon 10	117 GTCCTGATTTAAAGATGCTG	79	AGGACCTTCTGAGCTCA	128	intron 10	0.413
exon 11	198 TTTGAAATTTGATGCTGCTCA	80	AGGACCTTCTGAGCTCA	129	intron 11	0.413
exon 12	205 TATGAGGCTTTGATGCTGCTCA	81	AGGACCTTCTGAGCTCA	130	intron 12	0.413
exon 13	177 TATGAGGCTTTGATGCTGCTCA	82	AGGACCTTCTGAGCTCA	131	intron 13	0.413
exon 14	223 GATGAGGCTTTGATGCTGCTCA	83	AGGACCTTCTGAGCTCA	132	intron 14	0.413
exon 15	172 TATGAGGCTTTGATGCTGCTCA	84	AGGACCTTCTGAGCTCA	133	intron 15	0.413
exon 16	202 GATGAGGCTTTGATGCTGCTCA	85	AGGACCTTCTGAGCTCA	134	intron 16	0.413
exon 17	114 TATGAGGCTTTGATGCTGCTCA	86	AGGACCTTCTGAGCTCA	135	intron 17	0.413
exon 18	172 TATGAGGCTTTGATGCTGCTCA	87	AGGACCTTCTGAGCTCA	136	intron 18	0.413
exon 19	132 TATGAGGCTTTGATGCTGCTCA	88	AGGACCTTCTGAGCTCA	137	intron 19	0.413
exon 20	143 GATGAGGCTTTGATGCTGCTCA	89	AGGACCTTCTGAGCTCA	138	intron 20	0.413
exon 21	138 GATGAGGCTTTGATGCTGCTCA	90	AGGACCTTCTGAGCTCA	139	intron 21	0.413
exon 22	221 GATGAGGCTTTGATGCTGCTCA	91	AGGACCTTCTGAGCTCA	140	intron 22	0.413
exon 23	172 TATGAGGCTTTGATGCTGCTCA	92	AGGACCTTCTGAGCTCA	141	intron 23	0.413
exon 24	202 GATGAGGCTTTGATGCTGCTCA	93	AGGACCTTCTGAGCTCA	142	intron 24	0.413
exon 25	114 TATGAGGCTTTGATGCTGCTCA	94	AGGACCTTCTGAGCTCA	143	intron 25	0.413
exon 26	172 TATGAGGCTTTGATGCTGCTCA	95	AGGACCTTCTGAGCTCA	144	intron 26	0.413
exon 27	143 GATGAGGCTTTGATGCTGCTCA	96	AGGACCTTCTGAGCTCA	145	intron 27	0.413
exon 28	125 TATGAGGCTTTGATGCTGCTCA	97	AGGACCTTCTGAGCTCA	146	intron 28	0.413
exon 29	93 GATGAGGCTTTGATGCTGCTCA	98	AGGACCTTCTGAGCTCA	147	intron 29	0.413
exon 30	180 TATGAGGCTTTGATGCTGCTCA	99	AGGACCTTCTGAGCTCA	148	intron 30	0.413
exon 31	93 GATGAGGCTTTGATGCTGCTCA	100	AGGACCTTCTGAGCTCA	149	intron 31	0.413
exon 32	172 TATGAGGCTTTGATGCTGCTCA	101	AGGACCTTCTGAGCTCA	150	intron 32	0.413
exon 33	102 GATGAGGCTTTGATGCTGCTCA	102	AGGACCTTCTGAGCTCA	151	intron 33	0.413
exon 34	75 TATGAGGCTTTGATGCTGCTCA	103	AGGACCTTCTGAGCTCA	152	intron 34	0.413
exon 35	170 TATGAGGCTTTGATGCTGCTCA	104	AGGACCTTCTGAGCTCA	153	intron 35	0.413
exon 36	176 TATGAGGCTTTGATGCTGCTCA	105	AGGACCTTCTGAGCTCA	154	intron 36	0.413
exon 37	116 TATGAGGCTTTGATGCTGCTCA	106	AGGACCTTCTGAGCTCA	155	intron 37	0.413
exon 38	115 TATGAGGCTTTGATGCTGCTCA	107	AGGACCTTCTGAGCTCA	156	intron 38	0.413
exon 39	124 TATGAGGCTTTGATGCTGCTCA	108	AGGACCTTCTGAGCTCA	157	intron 39	0.413
exon 40	172 TATGAGGCTTTGATGCTGCTCA	109	AGGACCTTCTGAGCTCA	158	intron 40	0.413
exon 41	172 TATGAGGCTTTGATGCTGCTCA	110	AGGACCTTCTGAGCTCA	159	intron 41	0.413
exon 42	107 TATGAGGCTTTGATGCTGCTCA	111	AGGACCTTCTGAGCTCA	160	intron 42	0.413
exon 43	107 TATGAGGCTTTGATGCTGCTCA	112	AGGACCTTCTGAGCTCA	161	intron 43	0.413
exon 44	142 TATGAGGCTTTGATGCTGCTCA	113	AGGACCTTCTGAGCTCA	162	intron 44	0.413
exon 45	135 TATGAGGCTTTGATGCTGCTCA	114	AGGACCTTCTGAGCTCA	163	intron 45	0.413
exon 46	104 TATGAGGCTTTGATGCTGCTCA	115	AGGACCTTCTGAGCTCA	164	intron 46	0.413
exon 47	93 TATGAGGCTTTGATGCTGCTCA	116	AGGACCTTCTGAGCTCA	165	intron 47	0.413
exon 48	245 TATGAGGCTTTGATGCTGCTCA	117	AGGACCTTCTGAGCTCA	166	intron 48	0.413
exon 49	245 TATGAGGCTTTGATGCTGCTCA	118	AGGACCTTCTGAGCTCA	167	intron 49	0.413

Fig. 10

[illegible]

Fig. 11

[illegible]

Fig. 11

underline = putative promoter element

Fig. 12
Page 1 of 30

Fig. 12
Page 2 of 30

cttgttttatttctgcagaggggttctaagccattccacttcccagatggggccaataatgctttagtaaatctggagatca
tctttaatgcgcagggtgaatggaaactcttccacagagggatgtgagggctgtagagcagagtgaactccctgaaactca
gacgtcagctcttctgtctcttatctctgaacaccccttcccttagagatcccatctctaggatgcatttctctgtagtta
gttcttaagctctctgtctctgtctgtcttatttttttctctggattctaaagccagtatccccacttgggtgtctt
aatgtagcttaacatgtctgttaataaaatgatcatcttcttgagattcaagggctataagggactttggagagaatt
tcattcagtttccctcaaaactagaataatgcttgcactgtctgtaaaagaaacaaagtgtcaaagcatccttttcttca
ctaaatttcccttttctattatagtggttactttaaattattaggaagttaaaagttaggtataaacttcttataggctgttat
tatacaactatatagcccatatatttacaataaagtgagcccaaaattgcaaaatcaataccattcaaatataac
cttaaatgtggtgagggcagctgttcttcaactgaacccaaattataagtgcatggcagtaaatgctatcatgctgac
attttgagtttggccagcttatattatcatgtgctaatgattgaatttccacccatttcttacttgtatgaccttaa
tttgatggcactgttccatcctcatgagtttgcctacaattatactggtgccaacacaaatcataaacacaaatataaac
ttgggcttgaatcttctgtgccagaacttggctttaaagtaagcatttaaaaaatccatatgtgtttattagacttctgt
ctagatgactgttgaatgaacaaagtgtttaaataccctcttagagaacttaaatataatccctcagcaatatgtat
acagatcttcccttgagaaaaactgattgtgttccagcctctcatgttacaatggggaacctgaattctgaggtctcta
gtgagagaaacagggactgggaactctgtggatcctatctgttttaataataattgtaagataatagataatattatatt
aaaaagagagannnnnacacttagaatgagcttccatgtgtgagggcactaaactgatttaggcatttataactagatttat
tccctttaaggccccgcgatgtactgttatttccacatgtgttagctggggaacgtgctactcagagaggttaagtaac
ttgtctgaggtccacaccactaaacaggagcacaggtagggttcaaaatccagataatctgactttggagctggcactct
aactcaatgtgcctaatgcttctcagtggtgtcattattttgctatttccatctgagaatattgaagtcttctgact
ccttcccttgccttctccctgcctccctgtgttatccccagggtcttgggtgttccagtcctctatgtccgtcccttactct
tattcccttgcctacagtggtatccagggtcctcctccttcttatcttggtagagggggccacttgcctgggaaattgtc
ccgcatggtttatccatgttctgtgtccattagtgagtagtggaagaatcatatcatgttggcaatgaaagggggg
ctatggctctggggtagtctagtctgaactcttatttt

Genomic contig containing ABC1 exon 2:

[illegible]

Fig. 12
Page 4 of 30

ccaggcaattaacgtgggctaattggacttttccaaagatgctgtctttgggaaacatcacacatgctttggatcagaa
aacctaggcttctaatttgttgataaggcatgaactcaggagactgttttcagtcctagtgaatgggtgataattgtaatt
ataacagttagacaacatctcttttacacattttaaatcatgaaaatagaataaccttactgataatttagaaaagtggg
attaaaagcacattttaagataatgccttaacacctagtctttcccatatgcacgatgtcttaatcacacattgcaaatca
tggaacacagaatttt

Genomic contig containing ABC1 exon 3:

a c t t a c a a t c a c a g t c t t t c t t a g g g c t g g g c t c a g t g g g t g g a t g a c a c t g c a g a a a t g g c c a g a t c t a a a g g a t
 a a c c t t t a c c g a g c t g g g a a a t g t a g t c g g g a c t t g t t c a c t c c c t a t g a : a t t t c c t a c c a c t a a g c a g c t a g
 g c c a t a c c c c t a c a g a c c a a c c a g a t t c t a g a t a c t g t t t c b c a g g a a a g a g c t g g g c c g g g c c c a t t t a a t
 t g t g t t t t c g g c c t g g c c c a t t t t t c a c a a t t a t a g c a a c a g t a t t a c t t c t g t g a t t t t t a t g c a c a t c a c
 a s t a g t a t t a t a a a c a c a c a c a c a c a c a c a c a c a c a c c c t c a a g a a a c t t t c t g a g a c t a t t c c
 t g a t t c t c a a a a a a g a a a d a g c g g g c a g g c a c a g : g g s a a t c a a g g t g g g t g s a t c a c t t g a g g t c a g s a g t t g
 a a a c c a g c t g c c c a a c a g g t g g a a c t c g t c t c a t c a a a a t a c a a a a t t a g c c a g g c t g g t g g c g c a c a c t g
 a a t c c a c c t a c t g g g g a g c t g a g g c a g g a a a t g e t t c a a c c t c a g g g t c a g g t t g c a g t g a g c c a g a t t g c g c
 a t t g c a c t c a g c c t g g g c a c a g a t g a g a t c t g t c t c a a a a a a a a a a a a a a a a g c a t a a a c t g a a a t t a t
 t a g c a a t t a t a c t c g t t g a g a t a a t t c t g t t t c t t c t t t g g a a c c c c a a g a g a t t t t t g a t t a g t a g c a a a
 a c a t t t t c a g a t t t t a t t a g a c t t g c c a a g c a c c a c t a g a g t a t a a g t t c a a g g g c a a a c t c a g t t t t c a c t a
 t a g a c a a g a t g a t t t t c t g g a a t g a t t a c a a g c a g g c a a g a t g g t g a g t g a a a t g t c t t c g g c a c t a g a c a
 a g t t g g g g t t g t t g t a c c c g c c t c t g c c t c a c c a g g g t g a a t t t g g g c a g a t t g t a g t t t a a c c t a g a t
 t c c t c t g a c t c c a g a t c a t a a a t t t c a g a a g t t c g a a a t t c t g t a t a t a c : a g t g a a a t t g a g a c t t t c c t a t
 a c a t a t g a t t c a a t t t t g t t g t t g t t t g a g t g g t c t g t c t t g c c a a g t g g a g t g a g t a g t a a t c c g
 c c c a c t a c a a t g t c t g c t c c a g g t t c c a g t a g c c t c t c c t a c c t c c c a a t a g t c a g a c t a c a g g a t a t t g g
 c c a c c a c c t c c g g t a a t t t t t g a t t t t a g t a g a c a g g g t t t g c a t g t t g a c a c a c t g g t c t g a a c t c t g g
 c c t c a g g t g a t t g c c g c c c t c a g c c t c c c a a a g t g c t g g g a t t a c a g g c a t a g c c a g c a t g c c c g g c c a t a t c c a t g
 a c t c t t t g c a c c c t a c c t t c t t t t c c t a c c c t c a c g g g c a c t a g t g g a a g a c a g a g t t a a a a g t a a a g g t g a a a
 c t g g a g a g g t c t t g t c c t a g g a a a a a g g c a t t g t t g a a t t c t g c t g a a a t t c c c c a g t t c a a a c a g a g t t
 a l c a a g g t c t a a a a a a c t c c t g g g t c c t g a g g c c c a t a t a t t a t c a t t g c t t c t t c t g a c a c c a c t g c c t a g t
 c c t g a t c c a c t t t t g t t g c a a a t a g a t a g g g c a c a a g t c a a g a a g g c c t t g c c a c c c t c t a a g g a t a a a c
 t g a a a a c c t t a c a t c a c t c a g t c c c t g t c g t c t t t c a c c t a t g c a g t t g t c t c a a g t g c a a g t g t c t c t g g c a t
 t g a a a c g g g a a t c t t t t g g t t g a g t a t t g g t t g g g t a c a t a a a c t c c c t g a t t g a a g a a g a g c a g c t a g
 g c a a g g g g c c t g t t g g g t t t c c t t g a a c t a t t a a c a g g a a g a t a g g g a g a t t a a c t g t g a a a t g t t c a a t a g g c a g
 a g t c c c c g a a g a g g t g g c c a c a g t a g a t c a g a t t a t c a c a c t c t g c t t g g g g t t g c c c t c t c t g t t g g a g t a t g g
 a t a g a a a a a a g a a a g c c c t a t t g a a a t g a a a g t g a a g a c a a g t c t a g a t t t g g a t t a a c t t a a c t a g c c c a t t g
 c t g a a a a t a a a a a g a t a a a a a c a g g t c c c a c t t t g g g a g g a g g t g a g t g t g a g a t g a a g a a g a g t t t c c t g
 c t g g a a a c a g a g a g t a a g t c t c a g g t l a g a t t a c t c c c a c a g t c c t g g a a a t c t c t a g g c a t t t g t g a g t
 c t t g t c t a c c a c c a g g a c c t t c g a a a a g a c c t t g c t c t c a g a g t t c t a g c a g t c c a c c a a g c t c t g a a g t
 a a t t g t a c t t t a t c a c c a t t t c a a g a t g a a a a t g a g g t a t g g g g t c a a t a g t t g g t c a a g t c a g t c t g t t a g c
 a a g c t c a g g a g t c g a t g t g a a t t c c a a t t g c t t t g a c t c c a a a g c c t g t g a a c t a c t t g t t c t t a c a c c a t t a g c c
 t g t g g t c t g a t a a c t g t g a a c t t t t g g g g t c a a a a t a g c c t g a a a t a t a g a t a g a a c a g g a g g a c t t g g c c t t
 c t g t c t a c a t t g a a c a g g t c t t t g g g t t a g a g c c c t c g t c a g g g c c t a t a a b t t t g a t c t c a t a a g c a g a t c c
 a t g t a t c a g g c g c a a a c c a a c t t g t c c a g a c a g a a t c t a g g a c a a g c c a a a t a t g t c c c a t c c t t t t g g t a
 a g a a g c t a t t g a a a a g a a a g a g g a g a g a a g a a g a t a g a c t a g t g t a c a g g g c c a a t t g t g t t t a a a t a g t a g a a
 a c a a c a t a t a a a a a a a a c c c c a a g c c t t c a g a t g a c a t a c a g c a c a a g g c c t g b t g t t t c a g g t g c c c t
 t a g a g g a c t t t g t a g t c g g a g a g g g t g a a a c t g a a a a t g t t g g c a g t g a g a a g a g a t a c c a a g g a g t t g a g a
 t g a g c a a a t t c a a t c t a a c c g c a g t t g t g a g s a a g a g s c t g g a t t g g g a c c t g g a g a t g g g g g t c t a c t c c a g t
 c a c g c c a g c a g t t t g c g a g g t t c t t t g t a g t c a c t t a c t t a t t t a t t t t t t t t t t t t t g a a a t g g a g t
 t g c t c t t g t c c c a g g a g t g g a g t g a a t t g g c g a a t t g g c t c a t g c a a c c c c c c c t c a g t c a a g c a g a t c
 t c t c t g c t a c a g t c c a g a g t a c c t g g g a t t a a a g c c c t a g a g c c t c a a a c t c g t t a g t t a g t t a g a g a
 c a g g g t t t g c c a t g t t g t c c a g g g g g t c t : a a a c t c t g a c c t c a g g t a c g c c c a c c t t g c c t c c c a a g t g c t
 g g g a t t a c a g g c g c a g c a c t g t c c c a g c a c a t t a c t t a c c g t a g t a c c t c t a a g a t t a g a a a a a a g g c t
 t a g g c a t t c c c a a a c c c c c t a t g t c g a g c t g a g g c t g g c t t g c a a a g a a a c t a a g a t g c a a g g a c t t c t
 g c t a g g a c c c c t c t a c a c t t t c c a a c c t t g g t a t a t g a c c c a t t c t a c a g a t a g t c c a c t a g a t t a a g a a t
 g g c a t g a g g a g c a g t t c c a c t a g a g t a g t t a t c a g a a g a c a g g t c t t g g g a t g g g g a a t g g g a a t
 a a t t g g g g t t t g g g g t a c c a t c a c c t c a g a t t a t t a t t c t g t a t t g t t g t g a a c a t t c a a g c c t g t c g c t
 a g c a t t t t g g a a t a t a c t a t g t t g t t a a g a t a a t c a c a g a c a g c t a g a t t g a a t t g g g c t g c t a g g a g a t a
 g a g c t a g g g g t c g c a a a a g t g a c t g a t c g t g a a g g g t c t t g c c a t a a g a a g t c a c a g c a a g g t a g g g a g t a

Fig. 12
Page 6 of 30

tgtcttctctgcatcagggtcacctctctcacctctgtcactgccccatcagactacaatgtcttcagggtcttctccccct
gagtgtgagctccctgagcaaaagcaggatgctgccccctccctttgcatctcttgctccttgcttcagtgccctgtacata
agtaagggcataataagtggtcccccaaatgagacattgaggattcttcaaatgcacaggaccgtgatgtgagttaggacg
gagtaaggacgatgggatgtggctcatgacaatcctgaggaagctgcagctgcggcacgcaggggccacactgtcatgttc
atggaccctagactggctttgtagcctccatgggccccctccatacac

SEQ ID NO: 17

Genomic contig containing ABC1 exon 4:

```
ccatgactgccattgggtataaagatgaatataatccagaccagattcatgattattcatacatttttagtgtattcaactt
ctaatcttgcctttaaaataaatataaacattctaatatgcccttaagagtatcccagcccaggccactgagccctactgt
ggttcatggataagtttgccttgggggcatgtgtgtgcatgcatgtgtgtgcacatgcatgatgagccgggcttgaag
gggtgtaagatttgggtgtgtgtagaccaatggagaaaaggcatttggggcagtgatgatgggtgggggagggaaacatgggtga
tgaatggagctgggtgtggggagccatggggagtggttagggccagcctgtggaggacctggggagccaggctgagttcta
tgcacttggcagtcacttctgtaaagcagcagaggcagttggcctagctaaagcctttgccttttcttgccacctttac
agtgtggctcgcttctcagatgctcggaggcttcttttatagccagaaagacacacagcatgaaggacatgcgcacaa
agttctgagAACATTACAGCAGATCAAGAAATCCAGCTCAAgttaagtaaaaccttctctgcattccgtttataattggaa
attgacctgcaccagggaagagagtagcccggtgtctggggcttgttccattagatcttcccaagggttttctc
cttgggtggctggcctgtgggggccccctctccaggaggcattgggtgaagaaactaggggagctgggttggcacagacagtgtat
gtactaatcttctctggaagacagaaagaaagtcctccagggaagaatactacagacttggccttagggacagctagggg
tgagatttgcctgcaactgcatttttctgaagtggccatatgggttgagtgaaatggatttatagacagagatattctctg
tgcatataaagagcaattacagttgtaagttgatatggataaagtgaagtttaagcacttctttctaaaaagagaatgcaat
tcattttccctaatcatttcaattagtctgatgggcatttgaacttgttgcctttaaaaagtgaatctttacctctga
tcggtaagtataccaggcaatttcttgtgtgccacccaggagggtatctggggagtgggcattttctgactgaggcatttg
ctgccatagcatcagagcagccttccaggcagtgccctggcaagggaagcagaggctgggtgggagcagctggctgagtgca
gccagtaatggcatgt
```

Genomic contig containing ABC1 exon 5:

[illegible]

SEQ ID NO: 19

Genomic contig containing ABC1 exon 6:

agtaaaatggagaattccaaattctgaaattgttagaacatagttctgtgtcttagttaaatatcgacacttacagataa
atagcataaattgctttctccccatatttcagcccagtcctacttaagacaacataaattgcataatagtgaggatgttg
ttcatctaaataaaagtgggtccaggaattcagactctggattcctgtttgccaaatcatgtgtccactcttaagaaaac
gagttggactntggattttctttgcaagagggacaaagagtggtggagatactgagttaatgcaacttgccaggttttaag
tgctctgtcattgtgcttggcttggatgatactctgagtttcagtaagagagacctgagcattggactgttgcaatgga
acctgttttaagatcttcaagctgtattgatatgaagttctccaaagacttcaaggacccagcttccaatcttcataa
tctctctgtgtctgtctctcttgcattgaaatgcttccagctatTTTTGCAAGGCTACCAGTTACATTGACAAAGTCTGT
GCAATGGATCAAAATCAGAAAGAGATGATTCAACTTGGTGACCAAGAAAGTTTCTGAGCTTTGTGGCCTACCAAGGGAGAAA
CTGGCTGCAGCAGAGCGACTTCTGTTCCAAACATGGACATCCTGAAGCCAAATCCTGgtgagtagacttgcctcactggag
aaacttcaagcactaatgctttcggaatgtgaggcttttcttggacagcatgactttgtttttagaaaaagtacggctg
gctgggagtttgtgataataatttagttcagtggtattctaaagtgtctttagtgttcttccagacttttgggcatctccc
aaagggtgaatgggaagaataagctgggtgtggctgagtttaagccaaaagcttttgytctgtttcaatcagagaaga
cctgctttttcatgtttttactattataataactaagcaagagctcatttgaaaacagagttcttcatatttaaaaaaaa
aagtcttgaaccattgtatgggaagatggatattctattatgttcaaaaaccatcatgaagatgacattgtgggtgtc
acagttggaaggccctggaattagatgagaccacactatttagcttacttagtaataacattg

SEQ ID NO: 20

Genomic exon containing ABC1 exon 7 and 8:

tcgtttggcgaatgctcagtaaaagaaaaggggttagaaggggagaaagcattttatcccaagccttcaggaaatcaggat
gaggaatgctttcccttgggtggggagtaattatacaattagagacagcacattggagtggtgctgatgctgtgtga
tagatgcttcagctctctgctcagcagaggaagacatttcaatagaagaaaagtttaagaccttgccgagaaacagag
aaaggaatgctttgcttttaagaagttgaaaccctgttgcagacaaaagccctccagttttggcagtaaaactttcatg
caagggaaagaaaagggcaggggatgacattgttgacaattgtgaggaattacatgtgcccagcagctgtgaggggggtt
tgtacatctcctctagtttttagtgcttataaaaaactctgtgatgtgacacagca:tttaaaactttgctgcatagtcgag
aaaatggaaaggaatggggaatttgagtcattttgcccaggggttctatagctaccccaggttcccatgactgggaatgggg
cacaggggtgggggggagagtgagtgacaagaatccttaacaaactcttattccattgagtccttataaaagaaagtggaat
actaccacgttttaagtttttcttaaatcttaggttatgtggatctggcgtttctgttttggctgggtttgtttgtt
ttgtctatgctgtcttgaaacatctgtcatcttgcaggcctaaacacaaaaacactttaccccttatagctttca
attaaagatctctcagtttgtgtttgtaaatgtttccaggcaagttctccctaggttcggcttctagctgtgttaacct
agttataaagatgaacccaaagagagaaagtagaacaacacacccctcacctgttttggctcatgaattactctctatggaa
ggaaacacatgaacacccctctgcttatcacagagccctctctgagcttgacgttttaaggagaccccgtaggtccctttg
aggacttgaaatgtgggagtcctgggactctgtggaagaacccgttccagaagagatgaatgagctggacaagctctctt
atagaacctttaggcaggtttttctagaatgacatctgaggtattatgctggatattgtgatgacagaatgatactca
atccctttctcagtttggaattctctttgaaagaaaacatcccagggcagctatttctcagagatagtgagtcccagccact
cttagacatctcttctgtgtagtctacattataatctcacagcagctctctgatatgacaaatgtcaaaatagcccaact
ctctaaactctagagatgtctgatatgatatgaataaaacatgctctagaacatcaagaagagtggaattttccctg
gatactttttctgcttgacaaataacagtgaaagaaactgacttccacagctctgtaaatattgttctttttctcttagctta
aacccaaacttgaggctcctcagctatagcaattctgacttccacagctctgtaaatattgttctttttctcttagctta
tgctttctgcccataattatcttttccctgtttctaatgaattattgtcctatattctgctgtgagtgagtgctacattaa
cagcaattaaatataatgaattgtgacataaaagatttgactaaaactcgatgtaaaaaataagtggttctacattcaatt
ccagtgtagaacaacagtgctgacttgacacagagtgacagaaatccatcttccctatttttgacagctttaaactttata
ttttcttccctttctgtgagccgtctattaacttttctcaagccattcccgattaccctcttgccagacggagacag
atttgggaaatttgccgtcagagcttgataggacatccccccagccacatgagatccttttaattctattgcatattaa
ctagcttttaagtacaattatcttacttcaattaaaccattaatcaagaatgagtttgaataatgaacaaaatgcaaac
tcagcttagaataatgttagtgcttttagttttgggttaggagtcgggtttctgttttaactcaagattgtgaaacag
tttaaatctactgtttatttccaatagagattcaggtttacatttgaattcagaacaaagttttctttctcattaca
GAGAACAACATAACTCTACATCTCCCTTCCCGAGCAAGGAGCTGGCCGAGCCACAAAAACATTGCTGCATAGCTTGGGA
CTCTGGCCAGGAGgttaagtgtgtctttccagtaaccaggaagcggatcatccactgtatcagatattttcattcctgag
ctggcagaggttcccttttgagttgaatattcacatgggatgtaatatcaattttcaagatataagtgatgtaaacataat
gttttgatttccctatttttagaaatgaagaaactcaaaactcatagatgtctcagagctaatgtgttagtggttaacagc
tggaattctgatttagaaccttctccatttttcttttggccctcaggttaattcccaatgttgaagaggagaatttatct
ctgcaactgcccattgcaactgctttgtctgacacagcaatttctccatattgttcttctcagtagcaaggccaatcttta
ccacacacatgcttgcataacaggaataacagtggttaccctaatcagccctttcccttgaaagcatctggcctct
gaggttcaactatgggaaataggttctcttaattgaacattaaagttgagtttgccttttaggttccacatgttgacaaatgta
tcagagtaactctgtctcaggaatcagagggcttgtaggcacttgcaaaagcagttagctctgactccagcagcagtgac
actccacctttctgactccagccttgtctcaaaattaggttggaaagcaggaactgtctgggttccccagcagcataggaa
gcttagccagggggcagtgctccacaaacatcagactttaacgtgtaggatattggaaaaataaatttggggggaat
tgtctcagacttggtccacccctatttttagtgcttctctaatccgtttttcttttttgggtgcttgtatctaacctac
ccatttttgggtgcttgcatcattttttcaaaatcaaaaaacgaacttcatgttttctcaacaaatgaagatttgcatgtt
catttgggaaaaatgctgaagacttggaataacaaaaatgctgagatcaaacactattgatacgttagtgtattttctcc
tgtctgttctactttcttttttgaaattctgcccagtgctttctgactgagaggtctgacttttgggttcccttttcca
gaggagaagcctttctttcagcttgccatttttaccctgggttatgaaggctggtaacctttttactaggtagagaagct
ggacaaactgggggttcttccaggggggaaatgagaaagagaaactgttttgcaagtcctgtagctattttcttagggccct
gttagctgacattgacatgcttgcttgcttgcttgcttgcttgcttgcttgcttgcttgcttgcttgcttgcttgcttgct
agaaagcaaaagcaggggtctgttaacaggggaggtgctctaaactcaggggtttgggttacagctgttttccattacatcac
tggtctgtgttt
aaactctcaagtgaaacataacgttt
gacctctgctcttttcaatagaacacccctcagatcccttttgatcaaaagttactcatgtctgacttgctattttctgtg
agataaattgggagaagatcaataaatgacactgttttgctcagtcagctgttggaaggttgataattttgaccaaagcaca
accttgaaaggaagaaagaaagggagtgaa:gtcttctgagaagctgcttaggttcagacagtgctcaccattttccctgt
atgctccacatgacaaacccagtggtgtctcatgttccattttgcagatggcaccaggtctcagaaggttagggcaac
ttttccagtcacccaatgagtttaattgacaaaactgggatt:aaacccagaaactgttggaattccaaagcctgtgtgtg
cctgcttctgtaaaaaactccagtagcagctggaa:tagaaagagaaccttccaaagaaagaaatacgcactagcagaacc

Fig. 12

gcaactttaattaaatcccatctctctctctctctctctcagcttgcaagtgacccaaggaagccttcatttccatgacagac
ttaattgtgagggcatctca

SEQ ID NO: 21

genomic contig containing ABC1 exons 9 through 22:

[illegible]

Fig. 12
Page 14 of 30

Fig. 12
Page 15 of 30

...tggagagaatgagttgtttttttgttttgggttttttagtactttaacataatctaccttttagtttaagtatctgtcac
agttaccttagttactgaagcaagcccccaagaattttgttttggcaacactttgttagcctcgtttttctctctacatt
gcatctcgttgagcatctggatcatatcgtacattttagaggtcttagagggcctcgtctctctgtggccagatgtgtgtgt
cctcttagcatgcaggctcagagggccttggcccaacacccctggctcagctgtgtctcttcttctccctctgtctctctct
ggggcctccagcttttctgCGGGGTGATGAGCGGGTCAATGCCCTCTTCATGACGCTGGCCTGGATTACTCAGTGGCTGT
SATCATCAAGGCGATCGGTATGAGAAAGGAGGACCGGCTGAAAGAGACCATGCGCATCATGGGCTGGACAAACAGCATCC
TCTGGTTAGCTGGTTCATTAGTAGCCTCATTCTCTCTTCTGTGAGCGCTGGCCTGCTAGTGGTTCATCTGAAGGTaagg
cagcctcactcgtctcttccctgccaggaactccgaaatagctcaacacgggctaaaggagggagaagaagaaaaaatc
caagcctctggtagagaagggggtcatacctgtctcttccctgcaaattcatccatttatagttgggggaaagttagggccag
agagggggcagtgacttgcctcaaggtcaacccagcgggtagcagctaaagtaggatgagagtgaggggttcagcttcca
gatataacacatgctcactgtgcatgtct
gatataattgggtggcgattctcctcaagtttcttaagaacaaatcagaaggatataatattgttgaggttagactgtct
ggagggcagaggtgaaatagagtttgatgtatgggtatttataggggctcaatcctatggagagataggaagatgca
gattggggcagagggaggttgaactgtgatataggggccaaacccctggggcactctagagaatatgagcgttgttggga
gttgtctctctcagagc-gaaacatccagcctttgtgtctcccccaaggcctcctcctgacacccacacctcagcct
ctcaatcaatcactggt
cagagtttctgtatgacctgagggcgtctactgacagctgggcaacaaaggcttccctgaatggggactctggggcagtgca
ttttgtgtctgaacatacatataatatttatctcgaattttctctctctctctcgaagcatctcataaagacacatcag
gtataaaataatgtttttgaagcaaaaggagtagtaaaagagataaagaactaaactaatataactagttagcctctgttac
aaatagttctctactgattgccaaggactgtttaaacacacatcacagggtctctctctctctctctctctctctctct
agacaaaggaaatgagggctcaggaaggctcaaggactttatgaggttccacagtaggatacagttcttgctaaaggcaac
cctccctcatgctctgttatctaaactgcaagggaaggctcagtgagagggtagtggtcccatgggttggtgcatagagag
tgctctgagacaactgcactgctgggt
atcacagtgagtgcttgggattgttgaggcagcacatttgatgtgtctctctctctctctctctctctctctctctctct
CAGTGAATCCAGCGTGGTGTGTTGCTTCTCTGTCCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT
TCTTCTCCAGAGCCAACTGGCAGCAGCCTGTGGGGGATCATCTACTTCAAGCTGTACCTGCCCTACCTGCTGCTGCTG
GCATGGCAGGACTACGTGGGCTTCACTCAAGATCTTCGCTGtagtacctctcgtgcttctctcagtggtctgttagcatt
ttgaccttctcttggagtcctcgaataaaagcagcaagtgagaaacagaagatgattgtcttctccaatgggacatgaac
cttagctctagattctaaagctctttaagggttaagggaagcatgtgttttattaaattgtttaccttttagctctctcag
tgaatctctgttgaattgaattgaattgaattgaattgaattgaattgaattgaattgaattgaattgaattgaattgaatt
ttgaggaatggcttcaggcaacagatgcatctctgct
accagggccacaaatagaactgaaaactctctgctcagagatgacctctctctctctctctctctctctctctctctct
tgctctgagtaattgtttctgaaactaagcacaaactgaggagcaggtgctctcaccacaaatctctgacttggacacttcc
tccctctgacagagcagggggaatctcttggagaggtgtgagcctctacaagtgcaagttgtcagatgtccccaggttca
cttaccaggaaggctaaagagtgactcataggaatgctctctgttgcctcagcttggggcttcataggcatcagcagccccaaa
cagggcactctgactcctgagccatcttggctgagcagggagcctcagaagactgtgggtatggcgatgtgtgtggggga
acaggactgtgagccttggggcatcttctgaaacataaaagtcttaaaagtcttatgcttccactgtatagcatctctga
aatgtttgtatataatgagtggttacaattggaatct
ttaggttaatactactctctgacacttatgattgact
agagatagaaaaatgagactgaccaggaatggataggggtgacttgcctgttctcagagAGCCTGCTGCTCTCTGCTGGC
TTTTGGGTTTTGGCTGTGAGTACTTTGCCCTTTTCAGGAGCAGGGCATTTGGAGTGCAGTGGGACAACTGTTTGAAGATC
CTGTGGAGGAAGATGGCTTCAATCTCACCACCTTCGGGTCTCCATGATGCTGTTTGAACCTTCTCTATGGGGGTGATGACC
TGGTACTTGAGGCTGTCTTTCCAGgtaca--gcttggggcatgtttggaaatagacttctagctgatgtctctctct
tttctgttagaatctctgacgtgcatgggcttccctgggaagtggtttgggctatagatctatagtaaacagatagctcca
aggagggcagctgagctgaaagtcacaa--gtcactactgtacagcactgtttcttgaaaaactgtgtgcccagggcagc
atgcaaaaatgttttatcacactgtcttca--taactctcacaggctactctgaagtagttactataaataaccagcaatt
tccaaatgagagaactgtgactcaaaagcgttaagttaacagccttctgtcacacaactgtttaaattgttggtacgttgagg
tgaaatccactctgggttacaactgggtcaataagcccagggcgaatcctcccaatgctcaccacaaatctgtatttctgtgtcc
tcagagggggtacaactaggagaggttctgttctcctgagtagaggttgttaataataataataactagctctcaaggcctg
cttg--gatttaattagcatcaataaaaa--catgttgaa--tttctcttagtactctctctcttaataataataactctct
tgaccaagctcaagaggaactcgtgtgagcagtttcaatgagatcaaatctcgagagagcaagatttaacccctctct
ggtcacctctctgactccctccctaaaggaggtacatgaaatatttactcctcgtcagactctctctctctctctctct

Fig. 12
Page 16 of 30

tttgaagttgtaactgctggtgcatggtggccaggcctgctggaacagggttggagcgatctgtcacctttcaccttt
gatttccctgagcagctcatgtggttgctcactgttggttctaccttgaatcttgaagattattttcagaaattgataaag
ttatttttaaaagcacggggagagaaaaatatgcccattctcatctgttctgggcccaggggacactgtattctgggggat
ccagtagggcccgagctgacctgcttccctgctccacagctgactgttgaagaacacatctgggttctatgcccgccttga
aagggtctctctgagaagcacgtgaaggcggagatggagcagatggccctggatgttgggttggccatcaagcaagctgaaa
agcaaaacaaagccagctgtcaggtgcgcccgagagctacattccctatcccttccctccctccctcccggtacacacatg
ggagggaaaaacagcactgcccagggttccaggtgggtgcggttggtaacagaaacttgcctctggctgtgcccctag
gtctctgcttccactcactgtctggggtggtctggagtttgccttgcctctgtttttttaggtggaatgcagagaa
agctatctgtggccttggccttggcggggatctaaaggttgcattctggatgaacccacagctggtggtgaccccttac
tcccgcaagggaatattgggagctgctgctgaaataccgacaagctgctgatgtgtatttctgagtaaatggagctga
gagagagcgggggcttttgagaagtgtggtgtatctcatggctaggcttctgtgaagccatgggatactcttctgtta
xcacagaagagataaaagggtctgagactgagattccctgagaggagatgctgtgtctttattcatctttttgtccccaac
atggtgcaataaatttatggttagttgaaagggtggatgcttaaatgaatggagcggagagggggcaggaagacgattgg
gctctctggttagagatctgatgtgtgtacagtatgagcagcacagggaggttggagccaaactctggcttggccctgaga
cattgggaaagtcaaaacttgctcacccttcttggcgaataataatagtggtgctgtacctcatagaggattaaattaaa
tgagaaatgcacacaaaccacctagcaccaatgcttggcgaatagcaagttcccaaaataaaatgcgtactgttcttacctt
gtgaggatgtgggtacctatataacaaagcttggcatttctagggttcatagccatacagggtgaaagggtggcttccagg
tctcttccagtgcttacccttgcataatctctctagctccctgctgctgtgacaaatcagaactgagaggctcaccctgt
cccacatctctgtgttgtgtcctggcagccgcacacatttctctctacacacacacatggatgaagcggacgtctggg
ggacaggaattgccatcatctcccatgggaagctgtgctgtggtggtcctccctgttctgaagaacacagctgggaacag
gctactacctgaccttggctcaagaaagatgtggaaatcctccctcagttcctgcagaaacagtagtagcactgtgtcatatc
ctgaaaaaggtgagctgcagctcttggagctggcctgggtgtgggtctgggcagccaggacttgctgggtgtgaatgattt
ctccatctccaccccttttgccatgttgaaccacacatctccctgctgttggcccttggaaatcatatcatatcttaag
gcatggaaaagctaaggggccctctgctcccatgttggctagttctgttgaatcccggttttcttcttctatgagggcacana
gagtgatggagaaggtccttagaggacatttatgttgaagaaaagagactgtcaagaggttaagagccttggctacaa
atgacccgggtcgttccctgctcattacttttcaatctcattgaccttaacttttaaaactataaaacagccaattttattta
ggcactgatttcatgcccagagacactctgggcatggaagaaagtaatgataatagtttaattttatataagcgttgttaac
atttcaaccttttttttttttaacctctatctctcaactaaag

SEQ ID NO: 22

Genomic contig containing ABC1 exons 23 to 28:

[illegible]

Fig. 12
Page 20 of 30

Genomic contig containing ABC1 exon 29:

[illegible]

Fig. 12
Page 21 of 30

Genomic contig containing ABC1 exons 30 and 31:

[illegible]

Fig. 12
Page 22 of 30

SEQ ID NO: 25

Genomic contig containing ABC1 exon 12: _

gcacgtcggagtgatagtgaccatgagtttctaagaagaagcataatttctccatctgtcatccacaattgaaatatta
ttgttaattgaaaaagcttctagggccaggcaggtggctcatgcctgtaatcccagcacttttaggagccaaggcgggtgg
atcacttgaggtcaggagtttgagaccagcctggccaacatggggaaacctgtctctactaaaaatacaaaataagctg
ggcgtgggtgggtgcgtgcctgtaatcccagctacttgggaggctgaggcaggagaactgcttgaatctgggagggcggaggt
tgcagtgagctgagttcatgccattgcattccagcctgggcaacaagagcgaacctctcccaaaagaaaaaaaaga
aagaaaaagcttctagtttggtttacatcttgggtctataagggtggtttgtaaattgggttaacccaaggcctggttctccat
ataagtaatagggtatttatgatggagagaaggctggagaggcctgaaacacagggttcttttctctagcacaaccttac
aaggccagctgattctagggttatttctgtccgttcccttatatccctcagggtggatatttactccttttgcatcattagga
ataggctcagtgctttcttgaactgatttttcttcttctgtctctcagCTAAAGAACAAGATCTGGGTGAATGAGT
TTAGgttaagttgctgtctttctggccagcttagctcagggggaggatgggtctgttaggtgtgcttggattgaagaagcc
ttggggattgtttgtcactcacacacttgtgggtgccatctcactgtgagga

[illegible]

Fig. 12
Page 24 of 30

Fig. 12
Page 25 of 30

Genomic contig containing ABC1 exons 17 to 21:

[illegible]

Fig. 12
Page 26 of 30

SEQ ID NO: 43

Genomic contig containing exons 42 through 45:

ttttaaaatcacctgcaatcacatatatgttgaaatagatgaaaaattatgtagatgataatgaatgatacgggtcttcaaaa
 agacagggttaaaaagtaagttcacttttattttgagcttcagaatcattcagaagccagtgccacaaacgcagaccgaag
 gctcttggcacatcaaatatgcctatggcttaggggttattgacaagtcttattgtgcagtgatgtgggtttatagtccttg
 cctccacagttgcttgggagagctgtgagtcactgaggtctacgaatgtttacattttgtttgttcgagatATATAGAA
 GGAAGCGGAGCCTGCTGTGACAGGATTGCGTGGGCAATTCCTCTGCTGAGGcaaaagacactttgtctatatgtcggtt
 tgtccctattagttcagactatctctaccctcaatcaagcaacgatgctcgttaagaggtaaaagtgggattttaaaggcttc
 tgtattttatgccaggatggagcaattagtcactcagagaagagagggaccctgtatgtcagagaatgatttcagagaatcc
 aatacaatttaagaaaaagcatggggctggggcagtgattcactcctgcaatcccagcactttgggaggccgaggtggg
 cggactcacgaggtcaggagattgagaccatcctggccaacatggtgaaaccccatctctactataaatacaaaaatttag
 ctgggcatagtagtcattcctgttagtccacagctcactcgggaggttgaggcaggagaattgcttgaacctaggaggggga
 ggttgccagatttgctgtgctgcactccagcctgggtgacagagtgagactcatgtcaacacaaaaacagaaaaagcacg
 cacatctaaacatgcttttctgtagcattttgggaatgggtgagcattcaaatagtttttaaaaaatagattttctcctt
 tctgggttccgtttgttcttttatgccccttttggcagagtaggtgggtgcaatttggctagctggctttcattactgtt
 tttcacacattaaacttggcctcaacttgacaactcaaaataatattataaatacagccacacttaaaatgggtcccat
 tgaaatcacattttaaatattctatcagatgtgttaaaaccaaagaaaaatatttgattctctcttgatatttaagaatttga
 ggtttgagtagtttaggtttaggggcatttatattcaagtttttagaggtttgcttatcaacttaatttcttcttca
 ggtcttgggctcctgggaggttaattgggctgggaaatcatcaactttcaagatgttaacagagagataccactgttacc
 GAGGAGATGCTTCTTAACAAAAATAGgtgacaaaaagagtggttattttgtctgcaagactttgttttaattt
 ttttaagaaataggttgttattttttagattacagtggttatttttagagttcataaaaaatgttgaatatagtaagggtcaa
 agaagcacataaaatcatcctgtatttcaatatctagagataatcacaaattacatttcccttccagttcctctctctt
 ttttaacagctttatccaggtataaattacatacaaatataatttgccttggcttttaagagtataaatttagtgatttttgg
 aatttgagagttttgcaacacatcacacaaatcagttttagaacttttccatcacccacacatctgctcttatatacacata
 taaatgttccatcaaattgagatcatcactgtatgtagaatttaaaatagtttttattgttaatgagtgatttatgaata
 tttccagtggtgtacatttccatagatgtggaattttacatttgcatacaaaatccccctatgtacatgtacattat
 ttatttaataaatttccctataaattgttggaacacattagtttccatttttccattatgtaaatatgtccctgtatacatt
 ttattatttccctcaggaaacaattccctacaaagttaaatggcctctctaaagagcatataaattgactgagccacgcttag
 gccatttcttgagactgcacaggtcacaagcaatctgactcttgggaaacagactacattttataggtctcttagataa
 tgttactcttaagtactttaaatatgtggggcttctctgggctttttttttttttagagcggaggtttcactcttactgcccc
 ggctggagagcaatggcggagccttggctcactgcaacccctccgctccaggttcaagcgatctctctgctcagcctcc
 tgagtagctgagattacaggtgcccggccacaatgctctgctcaattttttgtattttcagtagagatggggtttcaccat
 gttggccagactgggtctcagctcctgaccttgggagatccacctgctcagcctcccaaggttctgggattacacgcat
 gagccactgcccgggcttctctggacttattttagtgagagatagttacaggcagtggttttccagagttttttgacct
 gacggttgggaaatcacattttatattctcaacctagtagtgcacacagacatgtagacacatgtataacctaaagt
 cataaagcagttactactgttactaattttagtgccactctgctatttcttcttcccttatactgctcattaaaaaag
 tgctgggtcatgacccactaaatttatttcccaaacactaatgaacaaatgactcacaatttgaacacacatgggagggg
 atagcaataaaattgaaaagagcaaggaaatttaattgtattcatgatctcctctcctgtctcttactattttgcagtagc
 aatgtaaggaaatccctaaagagaacagacatttctgggaaatagcaggcctagcgtgcacaaactgcttctcaggttgcct
 ctagtaccagactcctgacgcataatagcagtgagcagtaataaccagcccatagtaagggtttgtcacagggaactgggtgta
 agaactgatttgrttgggtatagctgtgagggcctggcagcgtgtccacgtgtgctcctcaatccttctgaaaaaggctg
 accctgggggtgcttaattagatcacacagagaggaatgaatgctgcccagaaggccaaagtccatggcaatgcccgtggtggt
 gaggtgagtcattcagtcctggaacgtgaacactgaactctctcacatgtgattcttccacttgactggcttcatagaacc
 ccaagccaccccccaccacacataaattgtgtcttaggttctgtgtgctcacactcaaaatttctgggcttctctat
 tgggtgcatgtgaatgggtgcatatgagtgaaagtctaggaatggggccttagcgttaaaagcctggggtagtgtagctgagat
 tgttgggttaagaattgtgcagtggttggcatgacctcagaaaattctgaaatgggagctgcacctgcagactgaagtgttcag
 agagccagggaggtgcaaggactggggagggtagaggcaggaaacccctgctgcccagggaagagctagcattcctggggcag
 aaaggctgtgcttcaagtagcagcagatgtattgggtattttgttaattggagaagcatactttacaggaaacttagccca
 gattgtctaacagagttatctctacctgcttaaaatctaaagttagttttctgtcctttgcagTATCTTATCAAAATCCCA
 TGAAGTATCATCAGAACATGGGCTACTGCCCCAGTTTGGATGCCATCACAGAGCTGTTGACTGGGAGAGAACACCTGGAGT
 TCTTTGCCCCTTTGGAGAGAGTCCCAGAGAAAGAGTTGGCAAGgtactgtgggacacctgaagccagcctgttctctt
 ggcatcctgacaatatataccttatggctttccacacgcattgacttcaggtgtttttcctcatgaatgcagcagcac
 aaaaatgctgggttcttctgtatctgctttcaggggtggaaacctgtacaggtgggtggggcagggctgggtgggcagagagga
 gtgctgctcccccacacagagtcctctctctgcttgggctctcaccagttgtcaggttatgattatagaattctagtc
 ctactcagtgaaagaactttcatatcgtatgttaggacagcatgataaaattcccaagccagaccaaagtccaaggtgc
 tcttttaactgttaggttgggtgagtgagctgatttggaaactgggctctggaagtatggagaaaaaatatgctggtaacta
 TAGTGGAGGCAACAAACGCAAGCTCTCTACAGCCATGGCTTTGATCGGGGGGCTTCTGTGGTGTCTCTGgttagtataa

Fig. 12
Page 27 of 30

ctgtggatggaaaactgttgttctggcctgagtggaacaatgactgttcaaaagtccatatgtccagggctgtgtat.
gattggcttgtcttccccagggacagcagagcaaccttggaaaagcagaggaagcttccccctggcacacactgggg
tggtgttaccatgcctgcagatgctcccaaatagaggcactccaagcacttgtttcttagcgtgattgaggctggatat
gtgatttgatcttctctggaacattcttctaatcatcttctgtgttcattccctgaaaatgaagagtgtggacacagct
ttaaatacccaaggtagcaactaggctcatagtctcttacacacggatagatgaaaaacagatcagactgggaagtggcc
cttgacctttttctctgtagataagagcattgatgtattacgggaagaagccttgaggcttttatgtattccacct
cggctctggaattgtttctgtaaggctaacagctgcaatatactagggttaactctgagtgagctggaattaaaaaaaaa
ggaatttcacccaatcttatactgacttcaatagaggcttcagacaaaagtgttttgat

Genomic contig containing ABC1 exons 46 to 49:

nccnngttnaaaaangaaaaatctnnnnnaaattnaannttanngngnnnttcccccagaaaaaaacnaaaangattctcnc
ccnngggggggcccccnaatcaaaaagcccctcttcttggngngggggaaagntctcttttggaatttttaattctcttgg
tcccccaaaaacctattatcggaatttaattatcaaaaaagactcagaattatgttgattctctgcatacaataagacat
ttataaataatgaccttggtttcaaaatgaatttgaagttaattcaattcttgattctcaagaataaactcagtaagtggca
aggttaaaatttaagctgtttcaagaagtctcttcgcatttaaaaaaacaatttatcttgattctttttcccccagcaaat
aagacttatattttatesaatcacaggttgaacccaccacagccatggatccccaaagccggcggttcttgtggaattgtg
cccttaagtgtttgtcaaggaggggagatcagtagtgccttacctctatctatagtccttgtagtaaaagctctgggttctctacctg
gggtatcttttaacctttccaagttagaattctgcattcattctgttaaaaatagaaaaacagaaaagcaataaaca
cttatctctgaaattatcatatgcatactttcaaaaaatcgaaagccagtaataaactgcctcttttctctcaatatat
tgtaaaacattatccaagtcagtgcaatttaggtgtctcttcttatagctggatagttatccattaggatatactctta
taacctattccccctttttagagactattggattatcttccaaacttgcttcacaaatggttaaacaccactcactgaacagacac
atccctatactccactgactctgtgaacagaaatacaaatctcttcaggaagctggaagtctggaagtcattgggtcagttctca
tggttcagagaaattctcttaaaactaaaacctctctctgttaaccgcagttatggaaagatttggaaagctttgtcacta
ggatgggcaactcattggtcaatgggaaggttcaggtgcctctggcagactgcagagattcaaaaaatagtaataaagataaatt
ctttgggaagtgcgttagtggaaggtcttgattattctcttctgtagatataaaagtgtgcctctcaaaataaaggsgaa
ataaaactcgagcaaaacagttatagtggaagaagttagggggtttgaagttcgcaagtcgattcaaaattctgtctttaccat
tactggtctctgtagctcttggggaagttacttaactctgttaaggttagttctcttggaagattctacctcttagctctg
tgcttatagatcgaaatgaaaaaaatttacaattccagacttggtgagagcgcaagctctggagtcacaaacacaaagsggt
tgcaactctggccctaccaattatgagctctgaagctgggaacagtgtaactccccctgggtccactggttctcttgtaaat
ctgtcagactctcaagggtccaggtagaggaattcaaggagatcatgtaatttcagacacatggcattcagttcttcaataaaaat
aagattttagtaaaatgataaactggttctctctcagaaaactctttctgggctgcaggggccgccccttttctatggc
acaagttgggttccagggttcaagtatttttaaaagattttctggagatctctccattcgggttatctttctctgctct
aggttttggagatggttatcaaatagtttgtacaaatagcagggtccaacccggagctgaagctctgcagacattctttgg
acttgcctctcttggaagtcttcyaaaagagaaacacgggaacatgctacataccagcttccattctcattatcttctc
tggccagagattatcacgactctctccagagaaaacacggcactccacatagaagaactactctgatttctcagacacact
gaccacagtaagctttgagtggtcaaaacagatattactctccaggttggtgattctctgcgccagacactccccccataggtc
caagagcagttgtgactctgaattgggtgctgaattctctgatactactatctcagatactgcttttactaaacctctctg
aacctgaaaaggagatgactgctatgtaactcttaggattatgtgaaatttactctgtaataaaccaacataaaactac
catttagtgagcactaccatggggcaggcattctacttgggtccattccatttaaatagataaaaagtaaccaaat
aggtcctgagcatttaagaagtaactcagtaaaattatcttctctctcttcccttaaatcaagacagattatgtgccaaagttaa
tggaactgagcagcttggtgatgtagggtggggggcgatagaaaagctagttcttggccggggcttggtggtctatgc
ctgttaattccagacacttctggggaggtcgaggccaggcagatcatbaggtcaggagattccagataatctctggccacacagg
tgaaaaccccgctctctactaaaaatcgaaaatttagctgggctaggtggtgcgcactgtgattcgccagcttctggcaggc
tgaggcaggagaattgctctgaacccaggaggtggagggttcacagtcagccaaaggtctgcgcactgactccagctctgggg
cagagcaagaccccatctcaagggggggaaaaaaagctatcttaagtctgttatgctttttcaagattctctctctctc
ttcacacacagcttttctagttaatccattatgtaattctgtactctcactgacctaattcaacactctggaaaact
agaactagaataaagaatgatcgaagttgagtggtcttataaaaggtccatcttaattcttaaacaggtatttgggaact
tgccaaagaccaaagtgatgatgacaccttaaaaagcctctctattacacaaaacacagacagtagtggaagcttgacagttc
tcacatcttttctacaggaatgagaaagtgaagaaagactatgtatgaagaactctgttctcatagcgggttggtctgaaagt
aaggaactagacttcttcttgacatttgaaagttgttgagaaagaaagccaggaattgagctgggaaagaaagttaact
ggatctgactgatactattcttgacatgcaatgcaattcaatgggaataaacaacaaattccatcacaggggcagtgctcttg
tagctctatgtcttgattggtctcaagtgaaagacttgaatttagtttttacctataacctatgtgaaactctatactg
aacccaactggacattatgggtctgaactcacaactctcttttttttttctgtctgtgattctctatgggttggaacaa
taattctatcaagtaactatggccagcgattatgtatcaaaatcaaaagggaatgcacatctctactaagccatgcc
atccccaggaggaactggtttcccggtgacacatccattctgtggcaatagtgctgcagagttattagtggcaagttctca
gaaagttgaagcaactggtgtgtctgcttacttcttgcaagcgctgctgctcagagttctatcaacattgaaattca
gtgtcagagaattgggtgcattcgtggtccaaactctctctgttctccctgataagctgtctgggtggcagtaacatgca
acaaaaattggtgggtcttcacagcagcggaataacttggtctcattgttctatgtctatgctctgcagacatgggttaca
gggtctatctctttagagactctaaataactattagatctgttgtaagggcaagaatacaacagcaaacctgctggggctgc
aacgtctgaagccagggtcggattaaagagatgtggtctcaaacactagggaagctctgtgccatttctgctgaagtg
ctgctaacatggtaactgctctcaagaatttatctctcagacaggtgataattctccggctcttttgaaatttaactagaa
aatgaaaagatggagtgtaattctgacaaaaatgttctgacttttttaagtgtttatgggaattttaagttcttactaggt
tctgaaactctagaattggctctttgttagaccttggttagaggaatggccagctgccacttttactttct
tatgtaagtttgcatcagtcagctagtctgttggaagaaagcaatgtgaaggtcaggtctatgacatctattatgtgt
tcttctcagatcattaggaactctctaaactcaactcaactcaacatacaaatatttttagtctgtatgcttagctgaaagat

Fig. 12
Page 29 of 30




Fig. 13




Fig. 14




Fig. 15

No.	Name	Location in SEQ ID No. 14	Sequence	Sequence Strand
			Length	
1	PPRE	58-69	AGGTAAGATCA	12 Complement
2	PPRE	1997-2009	AGAGTAGAGGCGCA	13 Lead
3	PPRE	2150-2161	ATGTCAAGTTCA	12 Lead
4	PPRE	2156-2169	AGTTCAAAAGGGCA	14 Lead
5	PPRE	4128-4139	AGGCCAGCAGGGCC	14 Complement
6	PPRE	5075-5087	AGGGCAGAGTGA	13 Lead
7	PPRE	5604-5615	ATGCCAAGGTCA	12 Complement
8	PPRE	5731-5743	GGGGCAAGGGTA	13 Complement
9	PPRE	7220-7233	AGGTAATGAGGACA	14 Complement
10	PPRE	7554-7568	GGATCAGGAGGTCA	15 Complement
1	SRE	159-166	CAGCCCAT	8 Lead
2	SRE	1133-1140	CAGCTCAC	8 Complement
3	SRE	1145-1152	CACACCAC	8 Lead
4	SRE	1809-1816	CAGCCCTC	8 Complement
5	SRE	1894-1901	CAGCCCAT	8 Lead
6	SRE	2553-2570	CAAGCCAC	8 Lead
7	SRE	3303-3310	CAGCTCAC	8 Lead
8	SRE	3475-3477	CGGCCAC	8 Lead
9	SRE	4794-4791	CTGCCAC	8 Complement
10	SRE	4802-4809	GAGCCTAC	8 Complement
11	SRE	4975-4977	CAGCTCAC	8 Complement
12	SRE	6437-6454	CAGCCTAC	8 Complement
13	SRE	6555-6572	CACCCAAC	8 Complement
14	SRE	6727-6734	CAGCCTAC	8 Lead
15	SRE	7041-7048	CACCCAAC	8 Lead
16	SRE	8059-8066	CAGCCCTC	8 Complement
1	ROR(resinoid acid receptor related)	156-172	AGGGTCA	7 Complement
2	ROR(resinoid acid receptor related)	156-173	AAGGGTCA	8 Complement
3	ROR(resinoid acid receptor related)	353-370	ATGGGTCA	8 Lead
4	ROR(resinoid acid receptor related)	354-370	TGGGTCA	7 Lead
5	ROR(resinoid acid receptor related)	22-5-2225	TAGGGTCA	8 Lead
6	ROR(resinoid acid receptor related)	22-5-2225	AGGGTCA	7 Lead
7	ROR(resinoid acid receptor related)	3543-3649	TGGGTCA	7 Lead
8	ROR(resinoid acid receptor related)	6624-6610	AAGGTCA	7 Complement
1	SREBP-1 or "E box"	473-478	ACAGCTG	7 Complement
2	SREBP-1 or "E box"	138-541	ACACATG	7 Lead
3	SREBP-1 or "E box"	537-543	TCATGTG	7 Complement
4	SREBP-1 or "E box"	555-561	TCATGTG	7 Complement
5	SREBP-1 or "E box"	925-931	ACAGTGT	7 Lead
6	SREBP-1 or "E box"	937-973	TCAGTGT	7 Lead
7	SREBP-1 or "E box"	938-974	TCAGTGT	7 Complement
8	SREBP-1 or "E box"	1063-1069	ACAGGTG	7 Complement
9	SREBP-1 or "E box"	1124-1110	TCAGTGT	7 Lead
10	SREBP-1 or "E box"	1125-1111	TCAGTGT	7 Complement
11	SREBP-1 or "E box"	1531-1537	TCAGTGT	7 Lead
12	SREBP-1 or "E box"	1570-1575	TCAGTGT	7 Lead
13	SREBP-1 or "E box"	1748-1754	ACAAGTG	7 Complement
14	SREBP-1 or "E box"	1749-1755	ACAAGTG	7 Complement
15	SREBP-1 or "E box"	1852-1858	TCAGTGT	7 Lead
16	SREBP-1 or "E box"	1853-1859	ACACATG	7 Complement
17	SREBP-1 or "E box"	1899-1905	ACAAGTG	7 Complement
18	SREBP-1 or "E box"	2199-2205	ACAGGTG	7 Lead
19	SREBP-1 or "E box"	2293-2299	ACAGGTG	7 Complement
20	SREBP-1 or "E box"	2559-27005	ACAGGTG	7 Lead
21	SREBP-1 or "E box"	2977-2983	TCAGTGT	7 Complement
22	SREBP-1 or "E box"	2740-2746	ACAAGTG	7 Complement
23	SREBP-1 or "E box"	2959-2975	ACAAGTG	7 Lead
24	SREBP-1 or "E box"	2979-2985	ACACATG	7 Lead
25	SREBP-1 or "E box"	2981-2987	ACATGTG	7 Lead
26	SREBP-1 or "E box"	2980-2986	ACATGTG	7 Complement
27	SREBP-1 or "E box"	2982-2988	ACAGTGT	7 Complement
28	SREBP-1 or "E box"	3451-3457	TCAGGTG	7 Lead
29	SREBP-1 or "E box"	3452-3458	TCAGGTG	7 Complement
30	SREBP-1 or "E box"	3547-3553	TCAGGTG	7 Complement
31	SREBP-1 or "E box"	3752-3758	ACAGTGT	7 Lead
32	SREBP-1 or "E box"	4235-4232	TCAGGTG	7 Lead
33	SREBP-1 or "E box"	4532-4538	ACAGGTG	7 Complement
34	SREBP-1 or "E box"	4539-4545	TCAGGTG	7 Lead
35	SREBP-1 or "E box"	4581-4587	TCAGGTG	7 Lead
36	SREBP-1 or "E box"	4591-4597	ACAAGTG	7 Lead
37	SREBP-1 or "E box"	5065-5102	TCAGGTG	7 Complement
38	SREBP-1 or "E box"	5913-5919	ACAAGTG	7 Lead
39	SREBP-1 or "E box"	5913-5919	TCAGGTG	7 Complement
40	SREBP-1 or "E box"	6245-6251	ACACATG	7 Complement
41	SREBP-1 or "E box"	6256-6262	ACAAGTG	7 Complement
42	SREBP-1 or "E box"	6413-6419	TCAGGTG	7 Lead
43	SREBP-1 or "E box"	6836-6842	TCAGGTG	7 Lead
44	SREBP-1 or "E box"	6837-6843	ACAGGTG	7 Complement
45	SREBP-1 or "E box"	7032-7038	ACAGGTG	7 Complement

Fig. 16

46 SREBP-1 or "E box"	7085-7075	TCAGGTG	7 Lead
47 SREBP-1 or "E box"	7101-7107	ACATATG	7 Complement
48 SREBP-1 or "E box"	7139-7144	ACAGTTG	7 Lead
49 SREBP-1 or "E box"	7139-7145	TCAACTG	7 Complement
50 SREBP-1 or "E box"	7240-7248	ACACCTG	7 Complement
51 SREBP-1 or "E box"	7487-7479	ACAGGTG	7 Lead
52 SREBP-1 or "E box"	7640-7648	TCATTTC	7 Lead
53 SREBP-1 or "E box"	7641-7647	TCAAAATG	7 Complement
54 SREBP-1 or "E box"	7653-7659	TCAGTTG	7 Lead
55 SREBP-1 or "E box"	7654-7660	ACAACTG	7 Complement
56 SREBP-1 or "E box"	7735-7741	ACAAATG	7 Lead
57 SREBP-1 or "E box"	7835-7844	TCAGCTG	7 Complement
58 SREBP-1 or "E box"	7880-7888	TCATCTG	7 Complement
59 SREBP-1 or "E box"	8051-8057	TCAGCTG	7 Lead
60 SREBP-1 or "E box"	8052-8058	TCAGCTG	7 Complement

Fig. 16

SEQUENCE LISTING

<110> University of British Columbia
Xenon Bioresearch, Inc.

<120> METHODS AND REAGENTS FOR MODULATING
CHOLESTEROL LEVELS

<130> 50110/002W05

<150> 60/124,702

<151> 1999-03-15

<150> 60/138,048

<151> 1999-06-08

<150> 60/139,600

<151> 1999-06-17

<150> 60/151,977

<151> 1999-09-01

<160> 287

<170> FastSEQ for Windows Version 4.0

<210> 1

<211> 2261

<212> PRT

<213> Homo sapiens

<400> 1

Met	Ala	Cys	Trp	Pro	Gln	Leu	Arg	Leu	Leu	Leu	Trp	Lys	Asn	Leu	Thr
1				5					10					15	
Phe	Arg	Arg	Arg	Gln	Thr	Cys	Gln	Leu	Leu	Glu	Val	Ala	Trp	Pro	
			20					25					30		
Leu	Phe	Ile	Phe	Leu	Ile	Leu	Ile	Ser	Val	Arg	Leu	Ser	Tyr	Pro	Pro
			35				40					45			
Tyr	Glu	Gln	His	Glu	Cys	His	Phe	Pro	Asn	Lys	Ala	Met	Pro	Ser	Ala
			50			55					60				
Gly	Thr	Leu	Pro	Trp	Val	Gln	Gly	Ile	Ile	Cys	Asn	Ala	Asn	Asn	Pro
					70					75				80	
Cys	Phe	Arg	Tyr	Pro	Thr	Pro	Gly	Glu	Ala	Pro	Gly	Val	Val	Gly	Asn
				85					90					95	
Phe	Asn	Lys	Ser	Ile	Val	Ala	Arg	Leu	Phe	Ser	Asp	Ala	Arg	Arg	Leu
			100					105					110		
Leu	Leu	Tyr	Ser	Gln	Lys	Asp	Thr	Ser	Met	Lys	Asp	Met	Arg	Lys	Val
			115				120					125			
Leu	Arg	Thr	Leu	Gln	Gln	Ile	Lys	Lys	Ser	Ser	Ser	Asn	Leu	Lys	Leu
			130				135					140			
Gln	Asp	Phe	Leu	Val	Asp	Asn	Glu	Thr	Phe	Ser	Gly	Phe	Leu	Tyr	His
					150					155				160	
Asn	Leu	Ser	Leu	Pro	Lys	Ser	Thr	Val	Asp	Lys	Met	Leu	Arg	Ala	Asp
				165					170					175	

Val Ile Leu His Lys Val Phe Leu Gln Gly Tyr Gln Leu His Leu Thr
 180 185 190
 Ser Leu Cys Asn Gly Ser Lys Ser Glu Glu Met Ile Gln Leu Gly Asp
 195 200 205
 Gln Glu Val Ser Glu Leu Cys Gly Leu Pro Arg Glu Lys Leu Ala Ala
 210 215 220
 Ala Glu Arg Val Leu Arg Ser Asn Met Asp Ile Leu Lys Pro Ile Leu
 225 230 235 240
 Arg Thr Leu Asn Ser Thr Ser Pro Phe Pro Ser Lys Glu Leu Ala Glu
 245 250 255
 Ala Thr Lys Thr Leu Leu His Ser Leu Gly Thr Leu Ala Gln Glu Leu
 260 265 270
 Phe Ser Met Arg Ser Trp Ser Asp Met Arg Gln Glu Val Met Phe Leu
 275 280 285
 Thr Asn Val Asn Ser Ser Ser Ser Ser Thr Gln Ile Tyr Gln Ala Val
 290 295 300
 Ser Arg Ile Val Cys Gly His Pro Glu Gly Gly Glu Lys Ile Lys
 305 310 315 320
 Ser Leu Asn Trp Tyr Glu Asp Asn Asn Tyr Lys Ala Leu Phe Gly Gly
 325 330 335
 Asn Gly Thr Glu Glu Asp Ala Glu Thr Phe Tyr Asp Asn Ser Thr Thr
 340 345 350
 Pro Tyr Cys Asn Asp Leu Met Lys Asn Leu Glu Ser Ser Pro Leu Ser
 355 360 365
 Arg Ile Ile Trp Lys Ala Leu Lys Pro Leu Leu Val Gly Lys Ile Leu
 370 375 380
 Tyr Thr Pro Asp Thr Pro Ala Thr Arg Gln Val Met Ala Glu Val Asn
 385 390 395 400
 Lys Thr Phe Gln Glu Leu Ala Val Phe His Asp Leu Glu Gly Met Trp
 405 410 415
 Glu Glu Leu Ser Pro Lys Ile Trp Thr Phe Met Glu Asn Ser Gln Glu
 420 425 430
 Met Asp Leu Val Arg Met Leu Leu Asp Ser Arg Asp Asn Asp His Phe
 435 440 445
 Trp Glu Gln Gln Leu Asp Gly Leu Asp Trp Thr Ala Gln Asp Ile Val
 450 455 460
 Ala Phe Leu Ala Lys His Pro Glu Asp Val Gln Ser Ser Asn Gly Ser
 465 470 475 480
 Val Tyr Thr Trp Arg Glu Ala Phe Asn Glu Thr Asn Gln Ala Ile Arg
 485 490 495
 Thr Ile Ser Arg Phe Met Glu Cys Val Asn Leu Asn Lys Leu Glu Pro
 500 505 510
 Ile Ala Thr Glu Val Trp Leu Ile Asn Lys Ser Met Glu Leu Leu Asp
 515 520 525
 Glu Arg Lys Phe Trp Ala Gly Ile Val Phe Thr Gly Ile Thr Pro Gly
 530 535 540
 Ser Ile Glu Leu Pro His His Val Lys Tyr Lys Ile Arg Met Asp Ile
 545 550 555 560
 Asp Asn Val Glu Arg Thr Asn Lys Ile Lys Asp Gly Tyr Trp Asp Pro
 565 570 575
 Gly Pro Arg Ala Asp Pro Phe Glu Asp Met Arg Tyr Val Trp Gly Gly
 580 585 590
 Phe Ala Tyr Leu Gln Asp Val Val Glu Gln Ala Ile Ile Arg Val Leu
 595 600 605
 Thr Gly Thr Glu Lys Lys Thr Gly Val Tyr Met Gln Gln Met Pro Tyr

610	615	620
Pro Cys Tyr Val Asp Asp Ile Phe Leu Arg Val Met Ser Arg Ser Met		
625	630	635
Pro Leu Phe Met Thr Leu Ala Trp Ile Tyr Ser Val Ala Val Ile Ile		
645	650	655
Lys Gly Ile Val Tyr Glu Lys Glu Ala Arg Leu Lys Glu Thr Met Arg		
660	665	670
Ile Met Gly Leu Asp Asn Ser Ile Leu Trp Phe Ser Trp Phe Ile Ser		
675	680	685
Ser Leu Ile Pro Leu Leu Val Ser Ala Gly Leu Leu Val Val Ile Leu		
690	695	700
Lys Leu Gly Asn Leu Leu Pro Tyr Ser Asp Pro Ser Val Val Phe Val		
705	710	715
Phe Leu Ser Val Phe Ala Val Val Thr Ile Leu Gln Cys Phe Leu Ile		
725	730	735
Ser Thr Leu Phe Ser Arg Ala Asn Leu Ala Ala Ala Cys Gly Gly Ile		
740	745	750
Ile Tyr Phe Thr Leu Tyr Leu Pro Tyr Val Leu Cys Val Ala p Gln		
755	760	765
Asp Tyr Val Gly Phe Thr Leu Lys Ile Phe Ala Ser Leu Leu Ser Pro		
770	775	780
Val Ala Phe Gly Phe Gly Cys Glu Tyr Phe Ala Leu Phe Glu Glu Glu		
785	790	795
Gly Ile Gly Val Gln Trp Asp Asn Leu Phe Glu Ser Pro Val Glu Glu		
805	810	815
Asp Gly Phe Asn Leu Thr Thr Ser Val Ser Met Met Leu Phe Asp Thr		
820	825	830
Phe Leu Tyr Gly Val Met Thr Trp Tyr Ile Glu Ala Val Phe Pro Gly		
835	840	845
Gln Tyr Gly Ile Pro Arg Pro Trp Tyr Phe Pro Cys Thr Lys Ser Tyr		
850	855	860
Trp Phe Gly Glu Glu Ser Asp Glu Lys Ser His Pro Gly Ser Asn Gln		
865	870	875
Lys Arg Ile Ser Glu Ile Cys Met Glu Glu Glu Pro Thr His Leu Lys		
885	890	895
Leu Gly Val Ser Ile Gln Asn Leu Val Lys Val Tyr Arg Asp Gly Met		
900	905	910
Lys Val Ala Val Asp Gly Leu Ala Leu Asn Phe Tyr Glu Gly Gln Ile		
915	920	925
Thr Ser Phe Leu Gly His Asn Gly Ala Gly Lys Thr Thr Thr Met Ser		
930	935	940
Ile Leu Thr Gly Leu Phe Pro Pro Thr Ser Gly Thr Ala Tyr Ile Leu		
945	950	955
Gly Lys Asp Ile Arg Ser Glu Met Ser Thr Ile Arg Gln Asn Lys Gly		
965	970	975
Val Cys Pro Gln His Asn Val Leu Phe Asp Met Leu Thr Val Glu Glu		
980	985	990
His Ile Trp Phe Tyr Ala Arg Leu Lys Gly Leu Ser Glu Lys His Val		
995	1000	1005
Lys Ala Glu Met Glu Gln Met Ala Leu Asp Val Gly Leu Pro Ser Ser		
1010	1015	1020
Lys Leu Lys Ser Lys Thr Ser Gln Leu Ser Gly Gly Met Gln Arg Lys		
1025	1030	1035
Leu Ser Val Ala Leu Ala Phe Val Gly Gly Ser Lys Val Val Ile Leu		
1045	1050	1055

Asp Glu Pro Thr Ala Gly Val Asp Pro Tyr Ser Arg Arg Gly Ile Trp
 1060 1065 1070
 Glu Leu Leu Leu Lys Tyr Arg Gln Gly Arg Thr Ile Ile Leu Ser Thr
 1075 1080 1085
 His His Met Asp Glu Ala Asp Val Leu Gly Asp Arg Ile Ala Ile Ile
 1090 1095 1100
 Ser His Gly Lys Leu Cys Cys Val Gly Ser Ser Leu Phe Leu Lys Asn
 1105 1110 1115 1120
 Gln Leu Gly Thr Gly Tyr Tyr Leu Thr Leu Val Lys Lys Asp Val Glu
 1125 1130 1135
 Ser Ser Leu Ser Ser Cys Arg Asn Ser Ser Ser Thr Val Ser Tyr Leu
 1140 1145 1150
 Lys Lys Glu Asp Ser Val Ser Gln Ser Ser Ser Asp Ala Gly Leu Gly
 1155 1160 1165
 Ser Asp His Glu Ser Asp Thr Leu Thr Ile Asp Val Ser Ala Ile Ser
 1170 1175 1180
 Asn Leu Ile Arg Lys His Val Ser Glu Ala Arg Leu Val Glu Asp Ile
 1185 1190 1195 1200
 Gly His Glu Leu Thr Tyr Val Leu Pro Tyr Glu Ala Ala Lys Glu Gly
 1205 1210 1215
 Ala Phe Val Glu Leu Phe His Glu Ile Asp Asp Arg Leu Ser Asp Leu
 1220 1225 1230
 Gly Ile Ser Ser Tyr Gly Ile Ser Glu Thr Thr Leu Glu Glu Ile Phe
 1235 1240 1245
 Leu Lys Val Ala Glu Glu Ser Gly Val Asp Ala Glu Thr Ser Asp Gly
 1250 1255 1260
 Thr Leu Pro Ala Arg Arg Asn Arg Arg Ala Phe Gly Asp Lys Gln Ser
 1265 1270 1275 1280
 Cys Leu Arg Pro Phe Thr Glu Asp Asp Ala Ala Asp Pro Asn Asp Ser
 1285 1290 1295
 Asp Ile Asp Pro Glu Ser Arg Glu Thr Asp Leu Leu Ser Gly Met Asp
 1300 1305 1310
 Gly Lys Gly Ser Tyr Gln Val Lys Gly Trp Lys Leu Thr Gln Gln Gln
 1315 1320 1325
 Phe Val Ala Leu Leu Trp Lys Arg Leu Leu Ile Ala Arg Arg Ser Arg
 1330 1335 1340
 Lys Gly Phe Phe Ala Gln Ile Val Leu Pro Ala Val Phe Val Cys Ile
 1345 1350 1355 1360
 Ala Leu Val Phe Ser Leu Ile Val Pro Pro Phe Gly Lys Tyr Pro Ser
 1365 1370 1375
 Leu Glu Leu Gln Pro Trp Met Tyr Asn Glu Gln Tyr Thr Phe Val Ser
 1380 1385 1390
 Asn Asp Ala Pro Glu Asp Thr Gly Thr Leu Glu Leu Leu Asn Ala Leu
 1395 1400 1405
 Thr Lys Asp Pro Gly Phe Gly Thr Arg Cys Met Glu Gly Asn Pro Ile
 1410 1415 1420
 Pro Asp Thr Pro Cys Gln Ala Gly Glu Glu Glu Trp Thr Thr Ala Pro
 1425 1430 1435 1440
 Val Pro Gln Thr Ile Met Asp Leu Phe Gln Asn Gly Asn Trp Thr Met
 1445 1450 1455
 Gln Asn Pro Ser Pro Ala Cys Gln Cys Ser Ser Asp Lys Ile Lys Lys
 1460 1465 1470
 Met Leu Pro Val Cys Pro Pro Gly Ala Gly Gly Leu Pro Pro Pro Gln
 1475 1480 1485
 Arg Lys Gln Asn Thr Ala Asp Ile Leu Gln Asp Leu Thr Gly Arg Asn

1490	1495	1500
Ile Ser Asp Tyr Leu Val Lys Thr Tyr Val Gln Ile Ile Ala Lys Ser		
1505	1510	1515
Leu Lys Asn Lys Ile Trp Val Asn Glu Phe Arg Tyr Gly Gly Phe Ser		1520
	1525	1530
Leu Gly Val Ser Asn Thr Gln Ala Leu Pro Ser Gln Glu Val Asn		1535
	1540	1545
Asp Ala Ile Lys Gln Met Lys Lys His Leu Lys Leu Ala Lys Asp Ser		1550
	1555	1560
Ser Ala Asp Arg Phe Leu Asn Ser Leu Gly Arg Phe Met Thr Gly Leu		1565
	1570	1575
Asp Thr Arg Asn Asn Val Lys Val Trp Phe Asn Asn Lys Gly Trp His		1580
1585	1590	1595
Ala Ile Ser Ser Phe Leu Asn Val Ile Asn Asn Ala Ile Leu Arg Ala		1600
	1605	1610
Asn Leu Gln Lys Gly Glu Asn Pro Ser His Tyr Gly Ile Thr Ala Phe		1615
	1620	1625
Asn His Pro Leu Asn Leu Thr Lys Gln Gln Leu Ser Glu Val Ala Leu		1630
	1635	1640
Met Thr Thr Ser Val Asp Val Leu Val Ser Ile Cys Val Ile Phe Ala		1645
	1650	1655
Met Ser Phe Val Pro Ala Ser Phe Val Val Phe Leu Ile Gln Glu Arg		1660
1665	1670	1675
Val Ser Lys Ala Lys His Leu Gln Phe Ile Ser Gly Val Lys Pro Val		1680
	1685	1690
Ile Tyr Trp Leu Ser Asn Phe Val Trp Asp Met Cys Asn Tyr Val Val		1695
	1700	1705
Pro Ala Thr Leu Val Ile Ile Ile Phe Ile Cys Phe Gln Gln Lys Ser		1710
	1715	1720
Tyr Val Ser Ser Thr Asn Leu Pro Val Leu Ala Leu Leu Leu Leu		1725
	1730	1735
Tyr Gly Trp Ser Ile Thr Pro Leu Met Tyr Pro Ala Ser Phe Val Phe		1740
1745	1750	1755
Lys Ile Pro Ser Thr Ala Tyr Val Val Leu Thr Ser Val Asn Leu Phe		1760
	1765	1770
Ile Gly Ile Asn Gly Ser Val Ala Thr Phe Val Leu Glu Leu Phe Thr		1775
	1780	1785
Asp Asn Lys Leu Asn Asn Ile Asn Asp Ile Leu Lys Ser Val Phe Leu		1790
	1795	1800
Ile Phe Pro His Phe Cys Leu Gly Arg Gly Leu Ile Asp Met Val Lys		1805
	1810	1815
Asn Gln Ala Met Ala Asp Ala Leu Glu Arg Phe Gly Glu Asn Arg Phe		1820
1825	1830	1835
Val Ser Pro Leu Ser Trp Asp Leu Val Gly Arg Asn Leu Phe Ala Met		1840
	1845	1850
Ala Val Glu Gly Val Val Phe Phe Leu Ile Thr Val Leu Ile Gln Tyr		1855
	1860	1865
Arg Phe Phe Ile Arg Pro Arg Pro Val Asn Ala Lys Leu Ser Pro Leu		1870
	1875	1880
Asn Asp Glu Asp Glu Asp Val Arg Arg Glu Arg Gln Arg Ile Leu Asp		1885
	1890	1895
Gly Gly Gly Gln Asn Asp Ile Leu Glu Ile Lys Glu Leu Thr Lys Ile		1900
1905	1910	1915
Tyr Arg Arg Lys Arg Lys Pro Ala Val Asp Arg Ile Cys Val Gly Ile		1920
	1925	1930
		1935

Pro Pro Gly Glu Cys Phe Gly Leu Leu Gly Val Asn Gly Ala Gly Lys
 1940 1945 1950
 Ser Ser Thr Phe Lys Met Leu Thr Gly Asp Thr Thr Val Thr Arg Gly
 1955 1960 1965
 Asp Ala Phe Leu Asn Lys Asn Ser Ile Leu Ser Asn Ile His Glu Val
 1970 1975 1980
 His Gln Asn Met Gly Tyr Cys Pro Gln Phe Asp Ala Ile Thr Glu Leu
 1985 1990 1995 2000
 Leu Thr Gly Arg Glu His Val Glu Phe Phe Ala Leu Leu Arg Gly Val
 2005 2010 2015
 Pro Glu Lys Glu Val Gly Lys Val Gly Glu Trp Ala Ile Arg Lys Leu
 2020 2025 2030
 Gly Leu Val Lys Tyr Gly Glu Lys Tyr Ala Gly Asn Tyr Ser Gly Gly
 2035 2040 2045
 Asn Lys Arg Lys Leu Ser Thr Ala Met Ala Leu Ile Gly Gly Pro Pro
 2050 2055 2060
 Val Val Phe Leu Asp Glu Pro Thr Thr Gly Met Asp Pro Lys Ala Arg
 2065 2070 2075 2080
 Arg Phe Leu Trp Asn Cys Ala Leu Ser Val Val Lys Glu Gly Arg Ser
 2085 2090 2095
 Val Val Leu Thr Ser His Ser Met Glu Glu Cys Glu Ala Leu Cys Thr
 2100 2105 2110
 Arg Met Ala Ile Met Val Asn Gly Arg Phe Arg Cys Leu Gly Ser Val
 2115 2120 2125
 Gln His Leu Lys Asn Arg Phe Gly Asp Gly Tyr Thr Ile Val Val Arg
 2130 2135 2140
 Ile Ala Gly Ser Asn Pro Asp Leu Lys Pro Val Gln Asp Phe Phe Gly
 2145 2150 2155 2160
 Leu Ala Phe Pro Gly Ser Val Leu Lys Glu Lys His Arg Asn Met Leu
 2165 2170 2175
 Gln Tyr Gln Leu Pro Ser Ser Leu Ser Ser Leu Ala Arg Ile Phe Ser
 2180 2185 2190
 Ile Leu Ser Gln Ser Lys Lys Arg Leu His Ile Glu Asp Tyr Ser Val
 2195 2200 2205
 Ser Gln Thr Thr Leu Asp Gln Val Phe Val Asn Phe Ala Lys Asp Gln
 2210 2215 2220
 Ser Asp Asp Asp His Leu Lys Asp Leu Ser Leu His Lys Asn Gln Thr
 2225 2230 2235 2240
 Val Val Asp Val Ala Val Leu Thr Ser Phe Leu Gln Asp Glu Lys Val
 2245 2250 2255
 Lys Glu Ser Tyr Val
 2260

<210> 2

<211> 7864

<212> DNA

<213> Homo sapiens

<400> 2

gtccctgctg	tgagctctgg	ccgctgcctt	ccagggctcc	cgagccacac	gctgggggtg	60
ctgggctgagg	gaacatggct	tggtggcctc	agctgaggtt	gctgctgtgg	aagaacctca	120
ctttcagaag	aagacaaaca	tgctagctgt	tactggaagt	ggcctggcct	ctatttatct	180
tcctgaccc	gatctctgtt	cggtgagct	acccacccta	tgaacaacat	gaatgccatt	240
ttccaaataa	agccatgcc	tctgcaggaa	cacttccttg	gggttcagggg	attatctgta	300
atgccaaaca	cccctgtttc	cggtacccca	ctcctgggga	gggtcccgga	gttggtggaa	360

actttaacaa	atccattgtg	gctcgcctgt	tctcagatgc	tcggaggctt	cttttataca	420
gccagaaaga	caccagcatg	aaggacatgc	gcaaagttct	gagaacatta	cagcagatca	480
agaaatccag	ctcaaacttg	aagcttcaag	atttctctgt	ggacaatgaa	accttctctg	540
ggttcctgta	tcacaacctc	tctctcccaa	agctactgtg	ggacaagatg	ctgagggctg	600
atgtcattct	ccacaaggta	tttttgcaag	gctaccagtt	acatttgaca	agtctgtgca	660
atggatcaaa	atcagaagag	atgattcaac	ttggtgacca	agaagtttct	gagctttgtg	720
gcctaccaag	ggagaaactg	gctgcagcag	agcgagtact	tcgttccaac	atggacatcc	780
tgaagccaat	cctgagaaca	ctaaactcta	catctccctt	cccgagcaag	gagctggctg	840
aagccacaaa	aacattgctg	catagtcttg	ggactctggc	ccaggagctg	ttcagcatga	900
gaagctggag	tgacatgcga	caggaggtga	tgtttctgac	caatgtgaac	agctccagct	960
cctccaccca	aatctaccag	gctgtgtctc	gtattgtctg	cgggcatccc	gagggagggg	1020
ggctgaagat	caagtctctc	aactgggtatg	aggacaacaa	ctacaaagcc	ctctttggag	1080
gcaatggcac	tgaggaagat	gctgaaacct	tctatgacaa	ctctacaact	ccttactgca	1140
atgatttgat	gaagaatttg	gagttctagt	ctctttcccg	cattatctgg	aaagcttga	1200
agccgctgct	cgttgggaa	atcctgtata	cacctgacac	tcagccaca	agggaggtca	1260
tggtctgaggt	gaacaagacc	ttccaggaac	tggtctgtgt	ccatgatctg	gaaggcatgt	1320
gggaggaact	cagccccaag	atctggacct	tcattggagaa	cagccaagaa	atggaccttg	1380
tcgggatgct	gttggaacag	agggacaatg	accacttttg	ggaacagcag	ttggatggct	1440
tagattggac	agcccaagac	atcgtggcgt	ttttggccaa	gcacccagag	gatgtccagt	1500
ccagtaatgg	ttctgtgtac	acctggagag	aagctttcaa	cgagactaac	caggcaatcc	1560
ggaccatate	tcgcttcatg	gagtgtgtca	acctgaacaa	gctagaaccc	atagcaacag	1620
aagttctggct	catcaacaag	tccatggagc	tgctggatga	gaggaagtgc	tgggctggta	1680
ttgtgttcac	tggaattact	ccaggcagca	ttgagctgcc	ccatcatgtc	aagtacaaga	1740
tcggaatgga	cattgacaat	gtggagagga	caaataaaat	caaggatggg	tactgggacc	1800
ctggctcctcg	agctgacccc	tttggagaca	tgcggtacgt	ctgggggggc	ttcgctact	1860
tgaggatgt	gggtggagcag	gcaatcatca	gggtgctgac	gggcaccgag	aagaaaactg	1920
gdgtgtctat	atgcaacaga	tgccctatcc	ctgttacgtt	gatgacatct	ttctgcgggt	1980
gatgagccgg	tcaatgcccc	tcttcatgac	gctggcctgg	atttactcag	tggtctgtgat	2040
catcaagggc	atcgtgtatg	agaaggaggc	acggctgaaa	gagaccatgc	ggatcatggg	2100
cctggacaac	agcatcctct	ggtttagctg	gttcattagt	agcctcatto	ctcttcttgt	2160
gagcgctggc	ctgctagtgg	tcacccctgaa	gttaggaaac	ctgctgccct	acagtgatcc	2220
cagcggtgtg	tttgtcttcc	tgctcgtgtt	tgctgtgtgt	acaatcctgc	agtgtctect	2280
gattagcaca	ctcttctoca	gagccaacct	ggcagcagcc	tggtggggca	tcacttactt	2340
cacgctgtac	ctgcctacg	tcctgtgtgt	ggcatggcag	gactacgtgg	gcttcacact	2400
caagatcttc	gctagcctgc	tgctcctctg	ggcttttggg	tttggctgtg	agtactttgc	2460
cctttttgag	gagcagggca	ttggagtga	gtgggacaac	ctgtttgaga	gtcctgtgga	2520
ggaagatggc	ttcaatctca	ccacttcggt	ctccatgatg	ctgtttgaca	ccttccctca	2580
tggtgtgatg	acctggtaca	ttgaggtgtg	ctttccaggc	cagtacggaa	ttcccaggcc	2640
ctgttatctt	ccttgaccca	agtcctactg	gtttggcgag	gaaagtgtat	agaagagcoa	2700
ccctgggtcc	aaccagaaga	gaatatacga	aatctgcctg	gaggaggaac	ccacccactt	2760
gaagctgggc	gtgtccattc	agaacctggt	aaaagtctac	cgagatggga	tgaaggtggc	2820
tgctcgatggc	ctggcactga	atttttatga	gggcccagatc	acctccttcc	tgggccacaa	2880
tgagcggggg	aagacgacca	ccatgtcaat	cctgacccgg	ttgttccccc	cgacctcggg	2940
caccgcctac	atcctgggaa	aagacattcg	ctctgagatg	agcaccatcc	ggcagaacct	3000
gggggtctgt	ccccagcata	acgtgctgtt	tgacatgctg	actgtcgaag	aacacatctg	3060
gttctatgoc	cgcttgaaag	ggctctctga	gaagcacgtg	aaggcggaga	tgagagcagat	3120
ggccctggat	gttggtttgc	catcaagcaa	gctgaaaagc	aaaacaagcc	agctgtcagg	3180
tggaatgcag	agaaaagctat	ctgtggcctt	ggcctttgtc	gggggatcta	aggttgtcat	3240
tctggatgaa	cccacagctg	gtgtggaccc	ttactcccg	aggggaatat	gggagctgct	3300
gctgaaatac	cgacaaggcc	gcaccattat	tctctctaca	caccacatgg	atgaagcgga	3360
cgtcctgggg	gacaggattg	ccatcatctc	ccatgggaag	ctgtgctgtg	tggtgctctc	3420
cctgtttctg	aagaaccagc	tggaacagg	ctactacctg	accttggtca	agaaagatgt	3480
ggaaatcctcc	ctcagttcct	cgagaaacag	tagtagcact	gtgtcatacc	tgaaaagga	3540
ggacagtgtt	tctcagagca	gttctgatgc	tggtcctggg	agcgaccatg	agagtgcac	3600
gctgaccatc	gatgtctctg	ctatctccaa	cctcatcagg	aagcatgtgt	ctgaagcccg	3660

gctgggtggaa	gacatagggc	atgagctgac	ctatgtgctg	ccatatgaag	ctgctaagga	3720
gggagccctt	gtggaactct	ttcatgagat	tgatgaccgg	ctctcagacc	tgggcatttc	3780
tagttatggc	atctcagaga	cgaccctgga	agaaatattc	ctcaagggtg	ccgaagagag	3840
tgggggtggat	gctgagacct	cagatggtac	cttgccagca	agacgaaaca	ggcgggcctt	3900
cggggacaag	cagagctgtc	ttcgcccggt	cactgaagat	gatgctgctg	atccaaatga	3960
ttgctgacat	agaccagaa	tccagagaga	cagacttgct	cagtgggatg	gatggcaaa	4020
ggtcctacca	ggtgaaaggc	tggaaactta	cacagcaaca	gtttgtggcc	cttttgtgga	4080
agagactgct	aattggccaga	cggagtcgga	aaggattttt	tgctcagatt	gtcttgccag	4140
ctgtgtttgt	ctgcattgcc	cttgtgttca	gcctgatcgt	gccacccttt	ggcaagtacc	4200
ccagccctgga	acttcagccc	tggatgtaca	acgaacagta	cacatttgct	agcaatgatg	4260
ctcctgagga	cacgggaacc	ctggaactct	taaacgacct	caccaaagac	cctggccttc	4320
ggaccgcgtg	tatggaagga	aacccaatcc	cagacacgcc	ctgccaggca	ggggaggaag	4380
agtggaccac	tgcccagttt	ccccagacca	tcatggacct	cttcagaat	gggaactgga	4440
caatgcagaa	cccttcacct	gcatgccagt	gtagcagcga	caaaatcaag	aagatgctgc	4500
ctgtgtgtcc	cccaggggca	ggggggctgc	ctcctccaca	aagaaaacaa	aacactgcag	4560
atatacttca	ggacctgaca	ggaagaaaca	tttcggatta	tctggtgaag	acgtatgtgc	4620
agatcatagc	caaaagctta	aagaacaaga	tctgggtgaa	tgagtttagg	tatggcggct	4680
tttccctggg	tgctcagta	actcaagcac	ttcctccag	tcaagaagtt	aatgatgcc	4740
tcaacaacaa	gaagaaacac	ctaaagctgg	ccaaggacag	ttctgcagat	cgatttctca	4800
acagcttggg	aagattttatg	acaggactgg	acaccagaaa	taatgtcaag	gtgtggttca	4860
ataacaaggc	ctggcatgca	atcagctctt	tcctgaatgt	catcaacaat	gccattctcc	4920
gggccaacct	gcaaaaggga	gagaacccta	gccattatgg	aattactgct	ttcaatcatc	4980
ccctgaatct	caccaagcag	cagctctcag	aggtggctct	gatgaccaca	tcagtggatg	5040
tccttgtgtc	catctgtgtc	atctttgcaa	tgctcttcgt	cccagccagc	tttgtcgtat	5100
tcctgatcca	ggagcgggtc	agcaaaagcaa	aacacctgca	gttcacagat	ggagtgaagc	5160
ctgtcatcta	ctggctctct	aattttgtct	gggatattgt	caattacgtt	gtccctgcca	5220
cactggatcat	tatcatcttc	atctgtctcc	agcagaaagc	ctatgtgtcc	tcacccaatc	5280
tgctgtgtct	agcccttcta	cttttgtgt	atgggtgggc	aatcacacct	ctcatgtacc	5340
cagctctctt	tggttcaag	atccccagca	cagcctatgt	gggtgctcacc	agcgtgaacc	5400
tcctcatgtg	cattaatggc	agcgtggcca	cctttgtgtc	ggagctgttc	accgacaata	5460
agctgaataa	tatcaatgat	atcctgaagt	cctgtgtctt	gatcttccca	catttttgcc	5520
tgggacgagg	gctcatcgac	atgggtgaaa	accaggcaat	ggctgatgcc	ctggaaagggt	5580
ttggggagaa	tcgctttgtg	tcaccattat	cttgggacct	gggtgggacga	aacctcttcg	5640
ccatggccgt	ggaaggggtg	gtgttcttcc	tcattactgt	tctgatccag	tacagattct	5700
tcacagggcc	cagacctgta	aatgcaaaagc	tatctctctt	gaatgatgaa	gatgaagatg	5760
tgaggcgagg	aagacagaga	attccttgatg	gtggaggcca	gaatgacatc	ttagaatca	5820
aggagttgac	gaagatatat	agaagggaagc	ggaagccctgc	tggtgacagg	atthtgcgtg	5880
gcattcctcc	tggtgagtg	tttgggctcc	tgggagttaa	tggggctgga	aaatcatcaa	5940
ctttcaagat	gttaacagga	gataccactg	ttaccagagg	agatgctttc	cttaacaaaa	6000
ataggatatc	tatcaaacat	ccatgaagta	catcagaaca	tgggctactg	ccctcagttt	6060
gatgccatca	cagagctgtt	gactgggaga	gaacacgtgg	agttctttgc	ccttttgaga	6120
ggagtcccag	agaaagaagt	tggcaagggt	ggtgagtggt	cgattcggaa	actgggcctc	6180
gtgaagtatg	gagaaaaata	tgctggtaac	tatagtgag	gcaacaaacg	caagctctct	6240
acagccatgg	ctttgatcgg	cgggcctcct	gtggtgtttc	tggatgaacc	caccacaggc	6300
atggatccca	aagcccggtg	gttcttgggt	aattgtgccc	taagtgttgt	caaggagggg	6360
agatcagtag	tgcttacatc	tcatagtag	gaagaatgtg	aagctctttg	cactaggatg	6420
gcaatcatgg	tcaatggaag	gttcagggtc	cttggcagtg	tccagcatct	aaaaaatagg	6480
tttggagatg	gttatacaat	agttgtacga	atagcagggt	ccaaccggga	cctgaagcct	6540
gtccaggatt	cttttggact	tgcatttcct	ggaagtgttc	taaaagagaa	acaccggaac	6600
atgctacaat	accagcttcc	atcttcatta	tcttctctgg	ccaggatatt	cagcatcctc	6660
tcccagagca	aaaagcgact	ccacatagaa	gactactctg	tttctcagac	aacacttgac	6720
caagtatttg	tgaaactttgc	caaggaccaa	agtgatgatg	accacttaaa	agactctoca	6780
ttacacaaaa	accagacagt	agtggacgtt	gcagttctca	catcttttct	acaggatgag	6840
aaagtgaag	aaagctatgt	atgaagaatc	ctgttcatac	gggggtggctg	aaagtaaaga	6900
ggaactagac	tttcttttgc	accatgtgaa	gtgttgtgga	gaaaagagcc	agaagttgat	6960

gtgggaagaa	gtaaactgga	tactgtactg	atactattca	atgcaatgca	attcaatgca	7020
atgaaaacaa	aattccatta	caggggcagt	gcctttgtag	cctatgtctt	gtatggctct	7080
caagtgaag	acttgaattt	agttttttac	ctatacctat	gtgaaactct	attatgggaac	7140
ccaatggaca	tatgggtttg	aactcacact	tttttttttt	tttttgttcc	tgtgtattct	7200
cattgggggt	gcaacaataa	ttcatcaagt	aatcatggcc	agcgattatt	gatcaaaatc	7260
aaaaggtaat	gcacatcctc	attcactaag	ccatgccatg	cccaggagac	tggtttcccg	7320
gtgacacatc	cattgctggc	aatgagtgtg	ccagagtatt	tagtgccaag	tttttcagaa	7380
agtttgaagc	accatgggtg	gtcatgctca	cttttgtgaa	agctgctctg	ctcagagtct	7440
atcaacattg	aatatcagtt	gacagaatgg	tgccatgcgt	ggctaacatc	ctgctttgat	7500
tcctctctgat	aagctgttct	ggtggcagta	acatgcaaca	aaaatgtggg	tgtctccagg	7560
caagggaaac	ttggttccat	tgttatattg	tcctatgctt	cgagccatgg	gtctacaggg	7620
tcatccttat	gagactctta	aatatactta	gatcctggta	agaggcaaag	aatcaacagc	7680
caaacctgtg	gggctgcaac	tgctgaagcc	agggcatggg	attaaagaga	ttgtgcgttc	7740
aaacctaggg	aagcctgtgc	ccatttgtcc	tgactgtctg	ctaacatggt	acactgcatc	7800
tcaagatggt	tatctgacac	aagtgtatta	ttctctgctt	tttgaattaa	tctagaaaat	7860
gaaa						7864

<210> 3

<211> 22

<212> DNA

<213> Homo sapiens

<400> 3

gcagagggca tggctttatt tg

22

<210> 4

<211> 24

<212> DNA

<213> Homo sapiens

<400> 4

ctgccaggca ggggaggaag agtg

24

<210> 5

<211> 23

<212> DNA

<213> Homo sapiens

<400> 5

gaaagtgact cacttgtgga gga

23

<210> 6

<211> 20

<212> DNA

<213> Homo sapiens

<400> 6

aaaggggctt ggtaagggtg

20

<210> 7

<211> 20

<212> DNA

<213> Homo sapiens

<400> 7
catgcacatg cacacacata 20

<210> 8
<211> 27
<212> DNA
<213> Homo sapiens

<400> 8
ctttctgagg gtgatgagcc ggtcaat 27

<210> 9
<211> 20
<212> DNA
<213> Homo sapiens

<400> 9
ccttagcccg tggtaggcta 20

<210> 10
<211> 26
<212> DNA
<213> Homo sapiens

<400> 10
cctgtaaagc caaagctatc tcctct 26

<210> 11
<211> 26
<212> DNA
<213> Homo sapiens

<400> 11
cgtcaactcc ttgatttcta agatgt 26

<210> 12
<211> 20
<212> DNA
<213> Homo sapiens

<400> 12
gggttcccag ggttcagtat 20

<210> 13
<211> 21
<212> DNA
<213> Homo sapiens

<400> 13
gatcaggaat tcaagcacca a 21

<210> 14
<211> 10545
<212> DNA
<213> Homo sapiens

<220>
<221> misc_feature
<222> (1)...(10545)
<223> n = a, t, c, or g

<400> 14
acctcttata gaatgataga attcctcttg aatgattgga taacttcatt tcatccttga 60
cttttacctt ggaggatttc ttaccctctt tggcttctca aatttgacta ttaaaatggt 120
gcctttaaaa ataggaacac agtttcaggg gggagtacca gcccatgacc ctctcgcaag 180
gccccctaac tcaaggtagt ttccctggaa ctgtgggtta tggaaatgtt caggagtggtg 240
aggagggtata atttaaggct gtccatgcaa ggataccctt aaggatagag gggccagtag 300
catctggagg ccagaaaagt taaactgagg cagtcagatt agcttcaggc tcaattaagc 360
tgatgggtca gcctgggaga aattgcagga tgactctcaa tatccctoc cacccccaca 420
gcagccacga tctgtctgtc tttaatcatg ggtgcagtga acctgttctt tccagggtgtc 480
ttggccttca gtaacctgtt taggcttgtc cctgaacgtg gctaccgatc caaagacaca 540
tgatcagaga ggcatttaga gaacagacct ttccaaagc aagcatgttc tgttgggctt 600
agaagtttca tgtcctaata ttataggacc ctgtgcattc ctctggagat gaggcacatg 660
agtcatatct gtgattcttg cttttgtgtc aacatctcat gaataggcaa tcagagcttt 720
ggcaccatg tattttcagt tcatatctga tgtagttaaa tccacctcct gctttgtagt 780
ttactggcaa gctgtttttg atataagaca tctagaacac tgtaaatata taacattttt 840
atttgcctat tatacctcaa ttacgaaaaa gacatctaga agcaacctca tcaagagaga 900
tactgaggcc gggcatggta gctcacactt gcaatcccat tactttggga ggctgaggca 960
ggtagatcac ttgaggtcaa gaggttgaaa ccagcctggc caacatgttg aaacctgtc 1020
tctattaaaa atacaaaaaa gttagctggg cttgggtggg ggcacctgta atcccagcta 1080
ctccggaggc tgaggcagga gaatcacttg aacctgggag gcagagggtg cagtgtgctg 1140
agatcacacc actgcactcc aacctgggca ccagagttag attacatcta aaaaataaaa 1200
taaaagtaata aaaaagagag atattgatag ctgttgttgg aaatttcaac ttccatctca 1260
cttctggtaa ctttttggaa gtttgttgaa caaagtggaa tacacgcaca tacacacaca 1320
cacatactct cttgtttgtt taaggtttaa tgaaatagct gtcataataat cactgtttt 1380
gaaagaggag aattagttgc tatctgtaca ttttgggtat gtgaactatt tggatagaac 1440
tctgagaaat gcattcagaa caacaaacaa aatcatagga gaaatagcta agtgggaagg 1500
ggcatataag agttgttgaa aaagtattt cttgagaaac cagctctaag gctaggcaag 1560
tcacttgctt tgggggaggc ctcagcttct ctgtctataa gattgcagca ggggtgtagt 1620
gggaatgagt cttcaacatt ccaagagatt ttatctacta atcgcagct caaatggagc 1680
atgactttgt ggaagcctct cctcttccac ccagaggggc caatttctct gtcccagtga 1740
gatgttgaca cttgtatgat ccctgcttgg agacttccct cttctggaac ctgocctggc 1800
tcaggcatga gggctgactg tcacocctcg ataggagccc agcactaaag ctcagtgtgt 1860
ggcagtgctt ttgctgggaag gaaaagacc agccagccca tttgttactg cacaagcaa 1920
cagcttcttg tagctgtaca gatacatgca ctttctttcc tcaactgtgt tccatagaca 1980
gatttagtgc tgtagaagag tagagggcag tcacgggaag gaggttcctgt ttttctttg 2040
gctatgccaa atggggaaaa atcctcctat cttgtctttt tagtgtcatc ctctctcccc 2100
ttttcttctt ctttataatt ctcactctct atctctcctg gaaatgtgca tgtcaagttc 2160
aaaagggcac aatgttttgg tgaggaagag gtgggagaac acgtgccagg tgctaactag 2220
gggtcatcatt tcccccttca cagccagctt cctgtgaatg tgtgtgtgtg tgtgtgtgtg 2280
tgtgtgtgtg tgtgtgtgtg tgtgtatttc ttttggcagc atcactgaat ctgtctgtctg 2340
tctgttatcc caggttttgg tttagggaag agtaaaagta attttataat ccagctgtc 2400
atttaagcca ccccttttgt ggtagcatat ggtccactct ctcagttcat tgtcctaaag 2460
atgcttcacg agaaaggaa aacttccacc ccgttactct ctgtccctt actctgtctt 2520
atttttcttc gtcaatccta ccaccaccac ccactgtttg aacaaccac tattatttgt 2580
ctgtttccca tccctggtag aataggagcc ccattgaatga aggaactttg cttctgttgt 2640
tcaccactga atctctaagg tatggaacac acctggcatg tgataggcac tcgataaata 2700
ttgttgtgtg ctcatgggca ccttcagag ttaaggctgc agttgtttgt ggaatttata 2760
agtggtaaat aatattttat tactattcct cttccaaggc gatcacacaa taatcaggct 2820
ttacactatc cagttcttag gtcttccaag ttatgacttg tgagggtatgt taattatgat 2880
aatagaaggc agtttatttg gttcagattt attgatgtgt aatttaccac agtaagacct 2940

ccccctttaca	aaagtatgat	gagtttttgac	aaatggatac	acatgtgtat	ctaccaactgc	3000
catgctcctt	ttcagtcctgt	cgtcccccctcc	acccatgacc	actgggcacc	actgcagtgga	3060
tttctgtccc	cttcattttca	cctttttccag	aatgtcatat	aaatggaatc	atgcagtatg	3120
tagtttttttg	tgtctggcctt	attttttctta	gcattaggtc	tttgggattc	atccagggttg	3180
tcgcatgtaa	cagtagctta	ttcctttttta	tggtctagta	agtgtcccag	ttttatttat	3240
atattttattt	atgaggagggt	gtctcactct	gtcaccagg	ctggagtgcg	gtagcgcat	3300
ctcagctcac	tgcaacctcc	gcctcccagg	ttcaagcaat	tctcctgcct	cctgagtagc	3360
tgggattaca	ggcaccacc	gccacgccc	actaattttt	atatttttag	tagagatggg	3420
gtttccaccat	gttggccagg	ctgatctcaa	actcttgacc	tcagggtgatc	cgccccacctc	3480
tccacagctaa	agtgcctagga	ttacaggcat	gagccactgt	gcccagcccc	agttttatatt	3540
attcaccagt	tgatggctctt	ttcgacaact	aattgtttcc	agtttttggc	tattctgtat	3600
aaggcttcta	taaatattca	caaataccta	ggatgggatg	actgggtcat	ataatagtac	3660
tgtataacct	tagcagaaac	tgtaaaacta	ttttccaaag	tggtctcttc	attttacaat	3720
tcacagctgt	attgagtcct	agtgtctcca	tacacatgct	agcactttta	atatttaatt	3780
tagtgggtat	gtaatgatat	ctcattgttg	ttttaatttg	catttctctg	cagctaataga	3840
tgagtgtttc	tgcttatttg	ggaagggttt	aatttagcag	tctgtgttat	tctgtagata	3900
taataaactt	caaaaatca	gtggcatttg	cagttaaaat	ttccttaaaa	aattggccaa	3960
aggtttccag	cagtcacttc	tgccatgccc	aaactgtatg	aaacaaggct	gaggtgtgga	4020
gattgtcaca	ttttggcaag	gagtgatcca	cttgggtgac	tgatgagacc	cagagagcgt	4080
acgctcggg	cttgagggtg	aggacggcg	ggaagtcgac	tgcatggccc	tgctggcctt	4140
gggaggctgc	ccagtcctta	gctaaagctg	gcagttatgg	gaaacagact	tagattctat	4200
tacgtttttc	aggatgtccc	aggagtacc	tggaagctc	agcagtcctt	tgtactttc	4260
aagcatatgg	tagaagctgc	tgaacacaga	gctccctctt	tggggataat	ttgccc aaat	4320
catttaatac	ggcttgagaa	atgagttacc	acaggctccag	gagtgctgcc	acccctgaat	4380
tctgacaccc	tatttctcct	atcgtctct	taattaatta	agcagacatc	cccaagtgtc	4440
tacgacaagc	caggaccctt	ttgcatacta	aggaaaacag	ggatgaagga	aacagaaatg	4500
gtctctgctc	tgactcagaa	ggtagaaatc	ctctttccca	gccaagtctt	cctaggggagc	4560
acgtaggaag	ggctctgaac	ccacgtgtca	gttgccagg	aggatatcag	gaaaggacat	4620
tgaagaagtg	gagacctaag	tttgagacct	aggcatttag	caggctagca	gtgcttgaaa	4680
aagtgtctta	ggacaagaga	actcaccagt	gaagtccag	tggtaggaga	gcgtgcagca	4740
tattctgagc	ctgtatacac	atctccagg	cattgcttag	cagggtggga	gtggcaagag	4800
agtaggctgg	agtcacagaa	gggaggccag	gtagaccttg	gtgagcactg	gactctatgt	4860
tcaggtgctg	aggagctggc	aaaagggttt	aagtccggga	gaggcatgtt	cagatatttg	4920
gtctagctga	gtaactttgg	gtgctctgtg	acaaatggtt	gggagaccag	tgagggtggca	4980
gttgccggta	tctaggagca	ggatcagagt	ggcctattga	ctgggatgac	tgtgaagtgg	5040
gatcctttcc	agccagtaac	tggaaatgtg	tatgagggca	gaagtgagtg	tactgcattt	5100
gaaacattga	gaaatctagt	acatagtact	gtctctttta	tatctttttt	tttttttttt	5160
ttgatttttg	tttgtttgtt	cactaacttg	gaaaactgat	gtggaaatgt	ccctttggct	5220
tcagttacct	gagcagaagg	ggccgggcat	tgccaaaactc	tcctcttagg	acagaattgc	5280
ttccagttat	gatcattgtg	ttctgagttg	ggggagcaaa	ttgtgcagga	ggccagggtca	5340
gtgccaaggt	gggtgggagg	aattggagca	ggaagcttgc	ctaagtgtgc	ccagcaaagc	5400
cacggtagaa	ctttctactg	tggtctctatg	ctacttctta	gcaaccttct	ccatgtgctt	5460
cctggagagt	ccttggaagt	agaacctttt	tcttgaaaac	cagacacttt	acttccaaga	5520
aaatgctgtc	caagaaaact	catccttccc	ttcttctcat	gaacgttgtg	tagagggtgtg	5580
tcttctcttc	ctttgagctt	ttccactcag	ggtttagggg	aggatgattt	ctatatttgg	5640
gtttggctct	gggtactgca	acactaggct	attaagattt	catccttact	gctttgcccc	5700
tcctatcttt	ccagaaaccc	acaatggatt	tgctagaaat	aatggaaact	cctgtttgga	5760
caggatataa	ccattttctca	gctagaggat	attgttgga	tgaagaaaga	taaatgggga	5820
gaagggaact	cacattgctt	tggaacttaa	attaagccat	gtactgtgtt	gggaaattat	5880
ttatattatc	tcgttgaaac	cacagtagaa	cacagttgaa	caccatacaa	ggtaagtatt	5940
gtcatcctta	ttttaccatg	aggaaattga	tgcttagaga	gcataaaagcc	ttggccagg	6000
gcacatagtt	gggaagccgg	ggctaattca	tgctgggct	ctttctgata	gttttctctt	6060
tttaattgtc	ccctcctcat	tgtaaccttg	gggatttcaa	gagattcatg	tagcttctaa	6120
atcaacgaac	tgattcctgg	agagcagctt	ctgtatgaga	aaaatctagc	taattattta	6180
tttcagtgct	tctggaatgc	aagctctgtc	ctgagccact	tagaaaacaa	tttgggatga	6240

caagcatgtg	tctcacaatg	ctgctctggt	tgccagtgct	gtgctgccag	ttgtcatctt	6300
tgaacaaact	gatgcagtgc	tggtttaact	cttctctctt	ttggagtaag	aaactttgga	6360
ggcctgtgtc	cttctagaag	tttgctgagc	aatgggtaag	gaaaagaaat	aggtcctaag	6420
gcttgactat	ttcagagaat	ttcttgattt	attggactgt	caatgaatga	attggaatac	6480
atagtggtag	gctgtctttt	cttctcagac	actgcaattt	cctccaatct	cttgactttt	6540
ctagaagttt	taatccaagt	ccttggtggg	tggtagataa	aagggtattg	ttctactaga	6600
gactgacctt	ggcatggaga	tctcatttgg	actcacagat	ttctagtcta	gcgcttggtt	6660
ttgtatccat	acctcgctac	tgcattctta	gttctctctg	ctccttgctt	ctcatgccca	6720
gtgtcccaac	ctacccttgc	ccctactcct	ctagaggcca	cagtgaatca	ctgagccatt	6780
tcataagcac	agctaggaga	gttcatgggt	accaagtgcc	agcaggggcg	aattttcacc	6840
tggtgtctct	cccttccatt	tttcatcttc	tgccccctcc	ccagctttaa	ctttaatata	6900
actacttggg	actattccag	cattaaataa	gggtaactgc	tggatgggtg	gctgggatac	6960
acagaatgta	gtatcccttg	ttcacagaaa	gacctctctg	ccctagcatg	gcaaacagtc	7020
ctccaaggag	gcacctgtga	cacccaacgg	agtagggggg	cgggtgtgtt	aggtgcaggt	7080
ggaacaaggc	cagaagtgtg	catatgtgct	gacctgggga	gcttgtttgt	cgggttccaca	7140
gttgatgccc	tgagcctgcc	atagcagact	tgtttctcca	tgggatgctg	ttttctttcc	7200
agagacacag	cgttaggggt	gtcctcatta	cctgagagcc	aggtgtcggg	agcattttct	7260
tggtgtttac	tcacactcat	ctaaggcacg	ttgtggtttt	ccagattagg	aaactgcttt	7320
attgatgggt	cttttttttt	ttttttttga	gacagagtct	cgctctgtcg	ccatgctgga	7380
gtgtagtggc	acaatcttgg	ctcactgcac	ctccgcctgc	caggttcagc	gattctcctg	7440
cctcagcctc	ccaagtagct	gggactacag	gtgcctgcca	ccatgcccag	ctaatttttt	7500
tattttttagt	agagacgggg	tttcaacgta	ttggctagga	tgggtctcgat	ttcttgacct	7560
cgtgatccgc	ctgcctcggc	ctcccaaagt	gctgggatta	taggcttgag	ccaccacgcc	7620
tggccgatgg	tgctttttat	catttgaaag	actcagttgt	ataaccact	gaaaattagt	7680
atgtaaggaa	gttcagggaa	tagtataagt	cactccaggc	ttgaggcaaa	atttacaat	7740
gctgtgact	ttgtatgtaa	ggggaggcat	tttcttagaa	aagagaggta	ggctctctgg	7800
attccagtat	gccatttcca	tcctcagtgt	ttttggccac	ctgagagagg	tctattttca	7860
gaaatgcatt	cttcattccc	agatgataac	atctatagaa	ctaaaatgat	taggaccata	7920
acacgtagct	cctagcctgc	tgtcggaaca	cctcccaggt	ccctctttgt	gggtgaacct	7980
agaggctggg	agctgggtgac	tcatgatcca	ttgagaagca	gtcatgatgc	agagctgtgt	8040
gttggaggte	tcagctgaga	gggctggatt	agcagtcctc	attggtgtat	ggctttgcag	8100
caataactga	tggctgttte	ccctcctgct	ttatctttca	gttaattgacc	agccacggcg	8160
tcctctgtgt	gagctctggc	cgctgccttc	cagggtctcc	gagccacacg	ctgggggtgc	8220
tggctgaggg	aacatggctt	gttggcctca	gctgaggttg	ctgctgtgga	agaacctcac	8280
tttcagaaga	agacaaacag	taagcttggg	tttttcagca	goggggggtt	ctctcatttt	8340
ttctttgtgg	ttttgagttg	gggattggag	gagggaggga	gggaagggaag	ctgtgttggt	8400
tttcacacag	ggattgatgg	aatctggctc	ttatggacac	agaactgtgt	ggctccggata	8460
tggcatgtgg	cttatcatag	agggcagatt	tgcagccagg	tagaaatagt	agctttgggt	8520
tgtgctactg	cccaggcatg	agttctgatc	cctaggacct	ggctccgaat	cgccctgtag	8580
caccccatctt	tttctctttg	ctgcagccct	gggaccacct	ggctctccaa	aagcccttaa	8640
tgggcccctg	tatttctgga	agctgtgggt	gaagttagtt	agtggcccca	ctcttagaga	8700
tcaataactgg	gtatcttggg	gtcaatctgg	attctttcct	tcaggccttg	aggaatataa	8760
taactgagac	ttgttttatt	tctgcagagg	gttctaagcc	attcacttcc	cagatgggcc	8820
aataatgctt	tgagtaatct	ggagatcacc	tttaatgcgc	aggtgaatgg	aactcttcca	8880
cagagggatg	tgagggctgt	agagcagagt	gaactccctg	aaactcagac	gtcagctctt	8940
tgtctctcta	tctctgaaca	cccttcctta	gagatcccat	ctctaggatg	catttctctg	9000
tagtttagttt	ctaagtctct	tgttcctgtt	ctgcctttat	ttttttttcc	tggattctaa	9060
gccagtatcc	ccacttggct	gtcttaatgt	agcttaacat	gtctgtaatc	aaaatgatca	9120
tcctttctgag	attcaagggt	ctataaggga	ctttggagag	aatttcattc	agttttcttc	9180
aaactagaat	aatgcttgca	ctgtctgtaa	aagaacaaaa	gtgtcaaagc	atccttttgt	9240
tcactaaatt	tcctttttta	ttatagtgtt	acttaaatat	taggaagtta	aaagtaggta	9300
taaaacttctt	ataggctgtt	attatacaac	tatatgacct	atacatattt	acaaattaaag	9360
tgagcccaaa	attgcacaaat	caataccatt	caaattaata	ccttaaatgt	ggtgaggcag	9420
ctgtgttcca	actgaaacca	aattataagt	tgcattggcg	taaatgctat	catgctgac	9480
attttgagtt	tggccagctc	atattatcat	gtgctaataga	ttgaattctc	cacctatttt	9540

tctacttgta	tgaccttaat	ttgatggcac	ctgttccatc	ctcatgagtt	tgctacaatt	9600
atactgggtgc	caacacaatc	ataaacacaa	atataaaactt	gggctttgaa	atcttgtgccc	9660
agaacttggc	tttaaagtaa	gcattttaaaa	aatccatag	tgtttattag	actttgttta	9720
gatgactggt	gaaatgaaaa	caaagtgttt	aaaatccctc	tagagaactt	aaatataatc	9780
cctcagcaat	atgtatacag	atcttccctt	gagaaaaact	gattgtgttc	agcctctcat	9840
gttacaaatg	gggaacctga	attctgaggt	ctctagttag	agaacaggga	ctggaatctg	9900
tggtatcctat	ctgttttaat	aataattgta	aagtataata	gataatatta	tattaaaaag	9960
agagnnnnnn	acacttagaa	tgagcttcca	tgtgtgaggg	actaactgat	taggcattat	10020
taactagatt	tattcccttt	aaggccccc	gatgtactgt	tatttccaca	tgttgttagct	10080
ggggaacgtg	ctactcagag	agggttaagta	acttgtctga	gggtccacacc	actaacaagg	10140
agcacaggta	gggttcaaat	ccagataatc	tgactttgga	gctggcactc	taactcaatg	10200
tgccataatcg	cttttcagtg	gtgtcattat	tttgcctatt	ctccatctga	gaattattgaa	10260
gtttctgact	ccttcccttg	ctttctccct	gcctcccggtg	gttatcccca	gggtctgtgtg	10320
ttccagtcct	ctatgtccgt	ccttactcct	attcctttgc	tacagtgtga	tccagggctc	10380
ctgcccttct	tatcctggta	gagggggccc	acttgcctggg	aaattgtctc	cgccatgggt	10440
tatccatggt	gtgtgtccat	tagtgagtag	tgggaagaat	catatcatgt	tggcaatgaa	10500
aggggggcta	tggtctctggg	gtagtctagt	ctgaactcct	atctt		10545

<210> 15
 <211> 4736
 <212> DNA
 <213> Homo sapiens

<400> 15						
cttttttttt	tttttttttt	tttttttttt	tgaggtgaag	tctcactctg	ttgccaggcc	60
tgagagtgc	tgagcgatc	ttgggtcacc	ccaacctctg	tctcctgggt	tcaaacagtt	120
ctcctgcctc	agcctccga	gtagctggga	ttacaggctc	ccgccaccat	gccagctat	180
ttttttgtat	tttcagtaga	gatgggggtt	cacctttttg	accaggctgg	tcttgaactc	240
ctgacctcat	gatcaaccca	cctcagcctc	ccaaagtgtc	gggattacag	gtgtgagcca	300
ccacgccggg	cctcataagt	attttctaaa	tttatttaca	gtcatgccat	ttaaaaggaa	360
agttgtattc	ctgtctttgt	taatatattt	aagtgttttt	attcagctac	aagcttggaa	420
tggtatataa	ttttgtattc	tgcttttttc	acttaataat	acatggctaa	tgatttctgt	480
gtttcataaa	cattattctg	atgatggcat	gatataattg	tgagtacatg	taccataatt	540
gaatcatttc	cctattgcta	tgcaattaa	ttgtttccaa	tattttgcaa	ttataatgtt	600
tcaatgaatg	aataacttta	tgcatatagc	tttttgatat	cttaagttca	gtttcctagg	660
atgaatttcc	aggaatagta	attggggcaa	tggtgataaac	atgactcctg	aatacgtatt	720
gttaacattg	ctttcccaaa	gggtccaact	gatttatatt	tccgtgttca	ttatctttta	780
aaccagctca	tttactcacc	aaacattttt	aaagccatta	tcattgtggt	ggcttagtaa	840
gaagaaagtg	accctaaggg	agaagcttat	atataaatag	gggtccctgg	gtaccaagtg	900
ctgatacaga	cacaaagtac	ctgggggaaat	tgagatgagg	gagtcctggc	tcagctggga	960
gaaaagttca	ttttcataga	gtcatgggtt	tggtcttttg	cagaaagaaa	attgtcttct	1020
tccccacccc	caccccagc	tttattgagg	tataattgac	aaataaaaaat	tgtatatcct	1080
taagatatgc	aatgtgatat	atatgtatat	ctcaacttaa	aaaataagct	acagaataaa	1140
aaggtgtttg	ctattaaaaa	aaaagaaaag	gctgaatgtc	attcccaagc	ttggaaattt	1200
gagtattgtg	cctctttggg	attattttaca	gaaatattag	caagaccagc	cccatctttg	1260
gtcttgagta	ctccactgtc	agcatgcttt	cttccagaga	gggatccatt	tgcccttatt	1320
tttcattctg	ttgtgcccgt	tatgcaaaact	attcttgata	gtttttatgg	aacagtgttt	1380
ttttgttcca	tgagataaat	ttatacatgc	tcattgtgga	aaattttagaa	aagacaggaa	1440
agtattaaaa	acatcmcytt	tttttttttt	tttttttttt	ttttttttamg	cagacagagt	1500
cttgctctgt	cgccaggcc	ggagtgcagt	ggcgtgatct	cagctcacag	caacctccgc	1560
ttccagggtt	taagtgtatc	tcttgcctca	gcctcccaag	tagctgggag	tacaggcatg	1620
caccaccacg	ccgggcta	tttgtatttt	tagtagagat	gggggtttcac	catgttggcc	1680
aggctggtct	caaactcctg	acctcagggtg	atccgcctgc	cttggcctcg	caaagtctg	1740

ggattatagg	caggagccac	tgcgccagcc	acacctacgt	tcttatcatc	ctagtagatc	1800
cactgtcatt	atcttgctgt	atttccttct	gccagtcctc	actctgatca	tgcagtggcg	1860
tgatcatgca	gtgatctcgg	ctcactgcaa	cctaggcctt	ctgggttcga	gtgattctcc	1920
tgccttagcc	tcctgggttc	aagtgattct	cttgcccttg	cctcccaagt	agctgggatt	1980
acaggcatac	accccatg	ccatctaatt	tttgattttt	tagtagacac	agcgtttcac	2040
taaaattttg	tatttttagt	agagatgggg	tttcaccatg	ttggccaggc	tggtctccaa	2100
ctcctgacct	caggtgatcc	gcctgccttg	gcctcacaaa	gtgattacag	gcattgagcca	2160
ctgcattccat	cgccaaaaag	attttttaaa	agagtttaat	gtagaacctt	atcaaaaggtc	2220
tttgggaaata	aaaaacagtt	ttttaaaaaat	atcagaaaata	aaacaacaaa	taataaaata	2280
aataaaaaaca	cccaaaacaa	tctgaagcac	gagcacctag	cagaaaggtt	caattatgat	2340
ctattcatag	agtggaaatat	caagtagaca	ttacaggaca	tgttttaaga	ttatatttta	2400
tgtctggga	aatgctctcc	cagtagatg	ttaaatgaaa	aaacagaata	caaaagtata	2460
tatgctgcat	agtctcaata	ttgtagagaa	aaaatattat	ttatgtatgc	atgaaaaaag	2520
acaaaagatg	ttaacagaga	tccattgtta	cttcagttta	ctagggattg	tctctgggag	2580
gtaggattaa	gggtgatttat	atttaccttt	ttaaactttt	ctgtattttt	ttattttcaa	2640
attttccata	aaaatataag	gacttgaaga	tcaagaaaaa	atttctgctt	tggtcagtg	2700
cagtcgtcac	gcctgtaatc	ccagcagttt	gggagcccta	ggggagagga	tcacttgaa	2760
ccaagagttt	gacgttcocg	tgagctatga	tctccggatc	gtaccgcctg	gacgatggag	2820
caagaccctg	tctcaaaaaa	aaaaatcttt	gctttttttt	ttgtttgttt	tttgagacgg	2880
agtctctctc	tggttgccta	gctggagtag	agtggcacaa	tctcagctca	ccgcaacctc	2940
tgctctctgg	gttcaagcga	ttctcttgcc	tcagcctccc	aagtacctgg	gattccatgc	3000
accaccact	atgccagct	acttttttgt	attttcagta	gagacagggt	ttcaccatgt	3060
tggtccaggct	ggtctcgaat	tccctgacct	agctgatcca	ccggccttgg	cctcccaaag	3120
tgctgggatt	acaggcatga	gccactgtgc	ccagcccaat	cttttgcttt	ttttaaaaaa	3180
agaagacaaa	aagggatttt	ataccagtat	tatcttggct	gtgtgactct	gaagccacag	3240
ttgtaagtta	taattactct	gaaacacaag	gccctgtgac	tcttttgggc	tctttggtgt	3300
ttatcttgat	tacaacgttg	gaatatagaa	atgaaaggaa	tggtgagagt	gatagacttc	3360
aggcagtgtg	actagtgtgc	tgaacactac	tggtctcaatt	atattgtgtc	tagtgatttc	3420
catcttgtcc	gtctgtctaat	ttatcgcttg	gtaactcact	gaggtcagggt	tttcttttgg	3480
agaaacctca	ttgttttaac	cagtgatcca	tgcttggtta	gaagttcaat	gatcttttta	3540
actcatcgga	gaagatgatg	accagacctg	gacagatggg	gaaggacttt	gcactctctc	3600
tttacagctc	tgagtgcaca	caggtcaata	tggaactatg	tgtgaatttt	cattgtcttt	3660
gagagccctc	ttctctgccc	catagggagc	agctttgtgt	gcaattagag	gagcaagggt	3720
tggtgtgatt	tagcacagca	gggtggcctg	gtcctctcct	ctcaacatag	tcaccacata	3780
cctggcacta	tgctaaggct	gggaatgcag	acagatgggt	gcctgctttc	agagtgtcca	3840
atgtgctgag	gaagccagca	acagaaacag	atgatttcag	gagctccagg	aaaatgctac	3900
aggaggagtg	tgcttgggtt	actggagtag	cacaggagga	gggtctctag	ctcaggctga	3960
gatttttagta	aaggaaatta	tgccacgatg	aatctgaag	aatgaataga	agtgaaccag	4020
ataaagcag	ataggaagca	tcttccctta	cctaaggga	gacacagagg	tatatggaat	4080
ggtagtgtaa	aagggtggga	ctccaaacag	ttctgtttaa	gcttagagag	tggtgggaga	4140
gactggagaa	gttgattaat	tagtaaatga	agttgtctgt	ggatttccca	gatccagtg	4200
gcattggata	tccatattat	ttttaaattt	acagtgctct	atcttatttc	ccactcagtg	4260
tcagctgctg	ctggaagtg	cctggcctct	atttatcttc	ctgatcctga	tctctgttcg	4320
gctgagctac	ccacctatg	aacaacatga	atgtaagtaa	ctgtggatgt	tgcttgagac	4380
tcaccaatgg	cagggaaaat	ccaggcaatt	aacgtgggct	aaattggact	tttccaaaga	4440
tgctgtcttt	gggaaacatc	acacatgctt	tggtacagaa	aacctaggct	tctaatttgt	4500
tgataaggca	tgaactcagg	agactgtttt	cagtcctagt	gaatgggtat	aattgtaatt	4560
ataacagtag	acaacatctc	ttttacacat	tttaaatcat	gaaaatagaa	taaccttact	4620
gataatttta	gaaagtgggtg	attaaaagca	catttaagat	aatgccttaa	cacctagtct	4680
tttccatag	catgatgtct	taatcacaca	ttgcaaatca	tggaacacag	aattttt	4736

<210> 16

<211> 4768

<212> DNA

<213> Homo sapiens

<400> 16

atcttacaa	cacagtcctt	ctcttagggc	tgggctcagt	gggtggattg	acactgcaga	60
aattggccaga	tctaaaggat	caacattttac	gtagctggga	aattgtagctg	ggacttcagt	120
ttcactgccc	tagtgatttt	tcctaccact	aagcagctca	gtccataccc	ctacgagacc	180
cacaagctta	tgagatactg	ttcttccagg	aaagcagtg	ggccaggggc	accttttaat	240
tgtgtttctt	ggcctgggtc	catctttctc	acaatatata	gcaacagtta	tttacttgct	300
gatttttctaa	tgacatcac	acatagtcac	attaaacaca	cacacacaca	cacacacaca	360
cacacacccc	tcaagaaaca	ttttctgaga	cgtgatttcc	tgatttcatc	aaaaaagaaa	420
agagcggggc	aggcacagt	ggaagtcaag	gtgggtggat	cacttgaggt	caggagtttg	480
aaaccagcct	ggccaacacg	gtggaacctc	gtctctacta	aaaatacaaa	aattagccag	540
gcgtgggtggc	gcacacctgt	aatcccagct	actggggagg	ctgaggcagg	agaattgctt	600
caacctgcga	ggctgaggtt	gcagtgcagc	gagattgctc	cattgcactc	cagcctgggc	660
aacagagtga	gactctgtct	caaaaaaaaa	aaaaaaaaaa	aaagcataaa	ctgaaattta	720
tatgcaattt	atatgcctgt	gagataattc	tgttttctct	tttggaaacc	caaagagatt	780
tttttgattg	atgagcaaat	acatttttaga	ttttatttaa	gcattatgcc	aagcaccact	840
gaagtataag	tttcaagggt	aaactcagtt	ttttcatcta	ctagacgaat	gattttctgg	900
aattgattaca	agcaggcaag	atgggtgtagt	ggaaatagca	aattgtcttcg	gcacagacac	960
agttgggggt	tgtttgatc	ctgcctctgc	ccttcaccga	ggttgtgac	ttgggcagat	1020
tggtgagttt	taacctagat	tcctctgact	ccagatcata	aattttcaga	aaagtctcga	1080
aattcttgta	tatactgatg	gtaaatgaga	cttttccctta	catctatgca	cttcttttgt	1140
tggttggttt	gagatggtct	tgctctgttg	cccagactgg	agtgcagtag	tgcaatctcc	1200
gctcactaca	atgtctgcct	cccaggttcc	agtgagcctc	ctgcctcagc	ctcccaata	1260
gctgagacta	caggcatgtg	ccaccacgtc	cggctaattt	ttgtattttt	agtagagaca	1320
gggttttgcc	atgttgacca	cactggtctc	gaactcctgg	cctcaggtga	ttcgcccgcc	1380
tcagcctccc	aaagtgtctg	gattacaggc	atgagccacc	atgcccgcc	atatccatgc	1440
acttcttgca	accttacctt	cttttctcat	cacctccag	ggacctagtt	ggaagagcag	1500
agttaaaagt	taagggtgaa	cttgagagg	tgctctgtcc	ctaggaacaa	aggactgggt	1560
tgaaattctc	tgtaaatctt	ccccagttca	aaccagagtt	atcaaggctc	taaaaaactc	1620
cctgggtcct	gagagcccat	tattattatt	acttgctctc	ctgtacaccc	actgcctagt	1680
cctgaccta	cttttggttg	caaataggat	ggggcacac	gtacaaggaa	gggcctttgc	1740
ccccctgct	aagggataac	ctgaaatacc	ttcacatca	ctgcctgtg	ctgcttttca	1800
ccatgcccag	tctgtctaca	gtgccagtgt	ctcctggcat	tgaaagggga	gaatcttttg	1860
gtcctttgag	tatttggttg	ggttacataa	atctccctga	atgaagagca	gctgacttag	1920
gcaaggggcc	ttgtttggtt	ttccttgaac	tattaacagg	aagataggga	gattaactgt	1980
gtaaatgttc	aataggccag	agtccctgca	gagggtggcc	acagtgtatca	gatcttatca	2040
catccttgct	ttgggtgttg	cctctctggt	tggagtattg	atagaaaaga	aagaaagacc	2100
ctatattgaa	atgcaaaagt	cagcaagtc	tgactttgga	ttactttctc	agccatttg	2160
catgaaaata	aaaagatgaa	taaaacaagg	ttcccacttt	ggaggggagg	ggtagctgtg	2220
agatggaagg	agtgttctct	ctgggcaaca	gcagagtaag	tgctggggta	gattcactcc	2280
cacagtgcct	ggaaaatcct	cataggctca	ttgtttgagt	ctttgtccta	caccaggcac	2340
tctgcaaaaa	cgctttgcct	gcaaggctc	atgcgatgct	caccacagct	ctgtgaagtt	2400
aattgtactt	ttatcccat	tttacagatg	agaaaactga	gggtatgggg	tcaatgactt	2460
ggctaaagtc	actgcttagc	aagctgcagg	gactggatgt	gaattccaat	tggtttgact	2520
ccaaagcctg	tgaagctact	tgctcttcac	cacctagagc	tggtgttctt	gataactgtg	2580
aactcttttg	gggtcacaaa	tagccctgag	aatatgatag	aagcaggagc	tctggccttt	2640
ctgtccatc	ctgaacagggt	ccttgggtta	agagccccctc	gtccaggggc	tattaatctt	2700
gatccctcata	agcagcatcc	atgtattacg	gccgcaaac	aaactgtgcc	agaccgaatc	2760
ctaggaccaa	gccccaaat	gtcccatcat	ccttttggtta	agaagctcat	tgtaagaaag	2820
aaagaggaga	gcaagaggat	gacctagtc	atggggcctc	attgttttaa	ttagtacaaa	2880
aacaacaata	ataacaacaa	aacccccgaa	gcttcacaga	tgacatcaga	ccccaggcct	2940
gtgtgttttt	caggtgccc	tgaggagctt	tgtagctggc	agaggagggtg	aaactgacaa	3000
atgttttgca	gatggaggag	agtaccagag	gggtttgaga	tgagctaaat	tccaatctaa	3060
ccgcagtggt	gaggaagagg	cttggtattg	gacctggag	atgggggttc	tactccaggt	3120
cagccagct	gactttgcga	gtgttctttg	tcagtcactt	tattcttattt	tattttattt	3180
tatttttttg	aaatggagtt	tcgctcttgt	cgcccaggct	ggagtgaat	ggcgcgatct	3240

tggtctcactg	caacctcccc	ctcctgagtt	caagcgattc	tcctgcctca	gcctccagag	3300
tacctgggat	tacaggcgcc	tgccaccaag	cccatcgat	ttttgtatgc	ttagtagaga	3360
cagggtttcg	ccatgttggc	cagggtgggc	ttgaactcct	gacctcaggt	gatccgcccc	3420
ccttggcctc	ccaaagtgc	gggattacag	gcgcgagcca	ctgtgcccag	cccacttcat	3480
cttaccgtag	ttacctcctt	agagtatgaa	aaaataggct	tagggcatcc	ccaagtcccc	3540
tctatgtctg	agagctgagg	ctggctgtca	aagaggaact	aaggatgcca	gggactttct	3600
gcttaggacc	cctctcatca	cttctccaac	gctggtatca	tgaaccccat	tctacagatg	3660
atgtccacta	gattaagaat	ggcatgtgag	gccaagtttc	caactgagag	tcagttttat	3720
tcagaagaga	caggtctctg	ggatgtgggg	aatgggacgg	acagacttgg	catgaagcat	3780
tgtataaatg	gagcctcaaa	atcgcttcag	ggaattaatg	tttctccctg	tgtttttcta	3840
ctcctcgatt	tcaacaggcc	attttccaaa	taaagccatg	ccctctgcag	gaacacttcc	3900
ttgggttcag	gggattatct	gtaatgccaa	caacccctgt	ttccgttacc	cgactcctgg	3960
ggaggctccc	ggagtgtttg	gaaactttta	caaatccatg	taagtatcag	atcaggtttt	4020
ctttccaaac	ttgtcagtta	atccttttcc	ttccttttct	gtcctctgga	gaattttgaa	4080
tggtcggatt	taagtgaagt	tgtttttgta	aatgcttggt	tgatagagtc	tcgagaatga	4140
gggaagggag	aattttggag	aattttgggt	atttggggta	tcctcacctc	cgagtattta	4200
tcatttctgt	atgttgtgaa	catttcaagt	cctgtctgct	agctattttg	gaatatacta	4260
tatgttgtta	atgatatcat	gcagcagacg	tgcatctgaa	tggtctggct	ctaggagcta	4320
gagggttaggg	gctggcacaa	agatgcacgc	tggaagggtc	cttgcccata	agaagcttac	4380
agccaaggct	aggggagttc	tgtcttctct	gcacacagtc	acctctctca	cctctgtcac	4440
tgccccatca	gactacaatg	tctgcaggtc	tttctccctc	gagtgtagag	tccttgagca	4500
aagcaggatg	ctgccccctc	cctttgtatt	ccttgctcct	tgcttcagtg	cctgtacata	4560
agtatgggca	taataagtg	cccccaaatg	agacattgag	gattcttcaa	atgcacagga	4620
ccgtgatgtg	agttaggacg	gagtaaggac	gatgggatgt	ggctcatgac	aatcctgagg	4680
aagctgcagc	tgccgcacgc	agggccacac	tgcatgttcc	atggacccta	gactggcttt	4740
gtagcctcca	tggtgcccc	ccatacac				4768

<210> 17

<211> 1295

<212> DNA

<213> Homo sapiens

<400> 17

tcattgactgc	cattggtata	aagatgaata	taatccagac	cagattcatg	attattcata	60
catttttagt	gtattaactt	ttaattctgc	ttttaaaata	aattaaaaca	ttctaataatg	120
cccttaagag	tatcccagcc	caggccactg	agcctactgt	ggttcatgga	taagtttgcc	180
cctgggggca	tgtgtgtgca	tgcatgtgtg	tgcatatgca	tgatgagccg	ggccttgaag	240
gggtgtaaga	tttgggtgtg	tagaccaatg	gagaaaggca	tttggggcag	tgatgatggg	300
tggtgggagg	aacatgggtg	tgaatggagc	tggtgtgtgg	gagccatggg	agtggtttag	360
ggccagcctg	tggaggacct	gggagccagg	ctgagttcta	tgcaacttgc	agtcacttct	420
gtaaagcagc	agaggcagtt	ggcctagcta	aagcctttcg	ccttttcttg	caccttttac	480
agtgtggctc	gcctgttctc	agatgctcgg	aggcttcttt	tatacagcca	gaaagacacc	540
agcatgaagg	acatgcgcaa	agttctgaga	acattacagc	agatcaagaa	atccagctca	600
agtaagtata	aaccttctct	gcacccgttt	ataattggaa	attgacctgc	accagggaat	660
agagttagcc	aggtgtctgg	ggcttggtcc	cattagatct	ttcccaaggg	gtttttctcc	720
ttggtggctg	gcctgtgggg	ccccctccca	ggaggcattg	gtgaagaaac	tagggggagct	780
gggtgcccaca	gacagtgatg	tactaatctt	ctctgggaag	acagaagaaa	agtccccagg	840
gaagaataact	acagacttgg	ccttagggac	agctaggggt	gcagattgct	gccaactgca	900
ttttttctga	agttggccat	atgggtgcag	tgaatggatt	tatagacaga	gtattttctgt	960
gcatataaga	gcaattacag	ttgtaagttg	atatggataa	gtgaaagtta	agcacttctt	1020
tctaaaaaga	gaatgcaatt	cattttcccc	taatcatttc	aattagtctg	atggggcattt	1080
gaacttggtg	cttttaaaaa	gtgaaatctt	tacctctgat	ctggttaagta	tcagggaat	1140
ttcttggtgtg	ccaccagga	ggatatctggg	gagtgggcat	tttctgactg	aggcattggc	1200
tgccatagca	tcagagcagc	cttccaggca	gtggcctggc	aaggggacag	aggctggtgg	1260
gagcagctgg	ctgagtgtag	ccagtaatgg	catgt			1295

<210> 18
<211> 2188
<212> DNA
<213> Homo sapiens

<400> 18
agctctccag gtgattctga tgcatactta agtttgagaa ccattgcttg ttttgcatta 60
aacaggagat tagtctctgc agcttgtggg aataaagctt taaatctctc caatttttagc 120
tctgtgaaaa ggcagtgggg agacaggaaat gaacggacta gtgccacaaa gctcagggtgg 180
ggtaggggtgag atcattttaga agagaaagac cgggcatggg ggctcacgcc tgtactgtca 240
gcacttttggg agggccaaggc aggttggatc acaaggtcag gagtttgaga ccagcctgcc 300
tatcatgggtg aaaccctgtc tgtactaaag ataaaaaaaa aaaaatttgc cagtcattggg 360
gatgcatacc tghtaatccca gctactcggg aggctgaggc aggagaatct cttgaaccgc 420
ggaggcgggg gttgcagtga gctgagattc caccattgca ctccaacctt ggtgacaggg 480
tgagactccg tctcaaaata aaaaaaaaaa aagaaaagga aaggctgtgt gtgtgtgtat 540
gtgtgtgtgt gtgtgtgtgt gtgtgtgtta cagcaccatc acactgtttg agttgaggag 600
cacatgctga gtgtggctca acatgtttacc agaaagcaat attttcatgc ctctcctgat 660
atggcgatgc tcccctatct cattcctgtg tgtgttttagc caggcaactg ttgatcatca 720
atattatgat aacgtttctc cactgtccca ttgtgcccac tttttttttt tttttgagtt 780
acttactaaa taaaaataaa acactatttc tcaatagact tgaagcttca agatttccctg 840
gtggacaatg aaaccttctc tgggttcctg tatcacaacc tctctctccc aaagtctact 900
gtggacaaga tgctgagggc tgatgtcatt ctccacaagg taagctgatg cctccagctt 960
cctcagtagg gctgatggca attacgttgt gcagctactg gaaagaaatg aataaaccct 1020
tgtccttgta atggtgggtga aggggaggga ggtagtgtga atacaacttc acttaatttt 1080
acttccctat tcaggcagga attgccaaac catccaggag tggaaatagc aacctggcgt 1140
catgggccag ctggttaaaa taaaattgat ttctgggtta tcacttggca tttgtgatga 1200
tttctctcta caagggatac attttaagtt gagttaaact taaaaaatat tcacagttct 1260
gaggcaataa ccgtgggttaa gggttattga tctggaggag ctctgtctaa aaaattgagg 1320
acaggagact ttagacaagg gtgtatttgg agacttttaa gaattttata aataaagggc 1380
tggacgcagt ggcactgagt tgagaactgt tgcttgcttt gcattaaata ggagatcagt 1440
ccctgcagct tgtgggaata aggcctttaa tctctccaat ttttagctctg tgagatggca 1500
ctggggaaac agaaatgaac ggactagtgt cacaaagctc aggtgggatg gacgagatca 1560
cttcaaaggc ctgtaatccc acgtctataa tcccagcact ttgggaggcc aaggcgggaa 1620
aatcacttga ggtcaggagt tgcagaccat cctggccaac aatgcaaagc ctgtctctac 1680
taaaaaatat aaaattagct cagcgtgtgt gcatgtcctt gtagtcccag ctactcgtga 1740
ggctgagaca ggagaatcgt ttgaacctgg gaggcggagg ttgcagttag ccaatatcac 1800
gccattgcac tccagcctgg ctgacagagt gagactccat ctcaaaaaaa aaaaaaaa 1860
aagaatttta taaaatcagg aaataatatt agtgtttatg ttgaatttta actttagaat 1920
catagaaaaa ttcctctggc atcattatta gacagctctt gtgcagtggg tagcaccaga 1980
cccagcttgc atggttattg atttttcaga gacacttttt gagcttattc tctggcagaa 2040
aggggaactg cttcctcccc tatctcgtgt ctgcatacta gcttgtcttt acaagaagca 2100
gaagtagtgg aaatgtttat tcttgaaaat aagctttttg cttcacatga tctagaattt 2160
ttaaatttag aaaaatgtgc ttactgcg 2188

<210> 19
<211> 1183
<212> DNA
<213> Homo sapiens

<220>
<221> misc_feature
<222> (1)...(1183)
<223> n = a, t, c, or g

<400> 19

agtaaaatgg	agaattccaa	attctgaaat	tgtagaaca	tagttctgtg	tcttagttaa	60
atatcgacac	ttacagataa	atagcataaa	tgctttctcc	ccataattca	gcccagtcct	120
acttaaagac	aacataaatt	gcaaaatagt	gaggatgttg	ttcatctaata	aaaagtgggt	180
ccaggaattc	agactctgga	ttctgtttg	ccaaatcatg	tgtccactc	ttaagaaaac	240
gagttggact	ntggattttt	ctttgcaaga	gggacaagag	tgtgggagat	actgagttaa	300
tgcaacttgc	agggttttaag	tgctctgtca	ttgtgccttg	tgctttgata	cattctgagt	360
ttcagtaaaag	agacctgatg	cattggactg	ttgcaatgga	acctgtttta	agatcttcaa	420
agctgtattg	atatgaagtt	ctccaaaaga	cttcaaggac	ccagcttcca	atcttcataa	480
tctctctgtg	cttgtctctc	tttgcatgaa	atgcttccag	gtatttttgc	aaggctacca	540
gttacatttg	acaagtctgt	gcaatggatc	aaaatcagaa	gagatgattc	aacttggtga	600
ccaagaagtt	tctgagcttt	gtggcctacc	aagggagaaa	ctggctgcag	cagagcgagt	660
acttcgttcc	aacatggaca	tctgaagcc	aatcctggtg	agtagacttg	ctcactggag	720
aaacttcaag	cactaatgct	ttcggaatgt	gaggcttttc	cttgacagc	atgactttgt	780
tttgtagaaa	agtacggctg	gctgggagtt	tgtgatataa	tttagttcag	tggtattcta	840
agtgttctta	gtgttctttc	agacttttgg	gccatctccc	aaaggtgtaa	tggaagaat	900
aaacttcaag	cactaatgct	ttcggaatgt	gaggcttttc	cttgacagc	atgactttgt	960
cttgcctttc	catgttttta	ctattataat	actaagcaag	agctcatttg	aaaacagagt	1020
tcttcataatt	taaaaaaaaaa	aagtcttgaa	accattgatg	ggaagatgga	tatctattta	1080
tgtttaaaaa	cccatcataa	agatgacatt	gtgggctgtc	acagttggaa	ggccttgtaa	1140
ttagatgaga	ccacactatt	tagcttactt	agtaataaca	ttg		1183

<210> 20

<211> 8981

<212> DNA

<213> Homo sapiens

<400> 20

ccgtttggca	aatgctcagt	aaaagaaaag	ggtagaagg	ggagaaaggc	attttatccc	60
agccttcag	gaatcaggat	gaggatgtct	tcaccttgtg	gtggggagta	attatacaat	120
tagagacagc	acattggagt	gtggctgata	tgctgtgtga	tgatagctct	agctctctgc	180
ctagcagagg	aaggacattt	caatagaaga	aaaagttaa	gaccttgccg	agaaacagag	240
aaaggatgtt	tgtcttttta	agaagttgaa	aacctgttt	gcagacaaaa	gccctccagt	300
tttggcagta	aactttcatg	caaggggaaga	aaaaggcagg	ggatgacatt	gttgacaatt	360
gtgaggaatt	accatgtgcc	aggcactgtg	cgaggggctt	tgtacatata	ctctagtttt	420
agtgcctata	aaaactctgt	gatagtgtca	cagcatttta	aactttgctg	catagtccag	480
aaaatggaag	gatggggaat	ttgagtcatt	tgcccagggt	tctatagcta	ccccagggtc	540
ccatgactgg	agaattgggg	cacagggtgg	cgggggagag	tgagtgcaca	gaatcctaac	600
aatcttattt	ccattgagtc	cttataaaaag	aagtggatta	actaccacgt	ttttaagttt	660
ttcttaaat	taggttatgt	ggatctggcg	ttctctgttt	tgtcctgggt	ttgttttgtt	720
tttgcctatg	tgtcttgaac	atctgtcctc	ttgtaggcct	aacggtaaac	acaaaaaac	780
tttacctcct	atagctttca	attaagatct	ctcagtttgt	gtttgtaata	gtttccagg	840
caagttctcc	ctaggttcgg	cttctagtgt	gttaaccttt	agttataaag	tgaacccaaa	900
gagagaaagt	agaaacaaaa	cacctcacct	gtttttgtct	atgaattact	ctctatggaa	960
ggaacaatca	tgaacacctc	tgcttatcac	agaggcctat	ctgagtctga	cgtttaaggg	1020
agaccgcgta	ggtccctttg	aggactgtga	atgtgggagt	cctgggactc	tggtgaagaa	1080
cccgttccag	aagagatgaa	tgagctggac	aagtctcttc	atagaacctt	taggcagggt	1140
ttcttagaaa	tgacacattg	ggattatgct	tgatatttgt	gatgatcaga	atgatactca	1200
atcccttctg	cattttggaat	tctctttgaa	agaaaacatc	ccaggcagct	atttctcaga	1260
gatagttagt	cccagccact	tctagacatt	ttcttgtgta	gtotacatta	taatttcaca	1320
gcagtctctg	atatgacaaa	tgtaaaaata	gcccacactt	ctctaaactt	cagagatgtc	1380
tgatatgata	ttgaataaaa	caatgctcat	agaaacatca	agaaagggtg	attttccctg	1440
gatacttttt	tctgtcttga	caaataacag	tgaagaaact	gatctcacgt	ctttttctct	1500
ttggaagcct	gaacactcag	aacccaactt	gaggctcctc	agctatagca	attctgactt	1560
cacagtctgt	aaattattgt	tctttttttt	cttttagctta	tgctttctgc	cctaatttat	1620
cttttccctg	ttctaataaa	ttattgtcct	atatctgctg	tgagtttagg	tgacatataa	1680

cagcaattaa	atatatgaat	tggtacatat	aaagatttga	ctaaaaactcg	atgtaaaaat	1740
aagtgttcta	cattcaattt	ccagtgttag	aaacagtgtc	gacttgaaca	gagtgacaga	1800
attccatctt	tccttatttt	tgacagcttt	aaactttata	ttttcttcc	ttcttgtgag	1860
ccgtcaattaa	cttgtttctc	aaagccatto	ccgtattacc	catcttgcag	acgcagacag	1920
atgtgggaat	ttgcgggtcag	agttgtattg	gacacatccc	cccagcccac	atgagatcct	1980
tttaattctat	tgcatattaa	ctagttttaa	gtacaatatt	cctacttcat	ttaaaaccat	2040
taatcaaga	atgagtttga	aatgaacaa	aatgcaaa	tacagttaga	aataattgta	2100
gtgtctttta	ttttgggttag	gagtcgggtt	cttgtttgtt	aaactcaaga	ttgtgaacag	2160
ttttaattca	cttgtttatt	tccaatagag	atttcagggt	tacatttgaa	ttcagaacaa	2220
aagttttctt	tctcattaca	gagaacacta	aactctacat	ctcccttccc	gagcaaggag	2280
ctggccgaag	ccacaaaaac	attgctgcat	agtcttggga	ctctggccca	ggaggttaagt	2340
tggtcttttc	cagtaccagg	aagcggatca	tccactgtat	cagtattttc	attcctgagt	2400
ctggcaagag	gtccttttga	gttgaatata	acatgggag	taatatcaat	tttcaagta	2460
taagtgtagt	aaacaataat	gttttgattt	ccttatttta	gaaatgaaga	aacctaaaac	2520
tcatagatgt	ctcagagcta	attgggttagt	ggctaacagc	tggatatcta	gtttagaacc	2580
ttctccattt	tttctttttg	cccctaggta	atcatacatt	tgtaaaggag	agaattatct	2640
ctggccactgc	ccatgcactg	ctttgtctg	accagcaatt	tctccatatt	gcttcttcag	2700
tagcaaggcc	aatcatttta	ccaacacaca	tgcttgctaa	ctaacaggaa	taacgtggta	2760
ccccaaattc	agcccttttc	cttgaaagca	tctggcttct	gaggttcaac	tatgggaata	2820
tggtctctta	atgaacatta	agttgagttt	gccttttagg	tccacatggt	gacaaatgta	2880
tcagagtaat	ctctgtccta	ggatcagagg	gcctgtaggc	acttgcaaaa	gcagttagct	2940
ctgactccca	gccagtgcac	actccacctt	tctgactccc	agccttgtct	caaattaggc	3000
ttggaagcga	ggaactgtct	ggtgtcccc	agcataggaa	gctgagccag	ggggcagtg	3060
tcacaaacaa	tacagacttt	aacgtgtagg	atattggaaa	ataataattt	gtggggaaat	3120
tgctctcagac	ttggtccacc	cttattttta	gctgcttctc	taatccgttt	ttcttttttt	3180
gggtccttga	tctaacctac	ccattttttg	gtgcttgcat	cattttttca	aatatcaaaa	3240
acgaacttta	tgtttttcta	caatgaaagt	attgcatggt	cattgtggaa	aatgctgaag	3300
acttgaaaaa	tacaaaaatg	ctgagatcaa	acactattga	tacgttagtg	tattttcttc	3360
tgctcgttcc	tactttcttt	ctttgaattc	tgctcacgtg	ttctgactg	atgaggtctg	3420
acttttgggt	tcctttttca	gaggagaagc	cttctttcag	cttgccattt	gttaccctgg	3480
ttatgaaggc	tggtaacctt	ttttactagg	tagagaagct	ggaccaactg	gggttcttcc	3540
agggggagaa	tgagaagag	aaactgtttt	gcaagtccgt	agctatttct	ctagggccct	3600
ggttagctgac	attgacatgc	cttgcatgct	tctgcagatc	ccctgcagc	ccctgttccc	3660
ttgttcattt	ctggccttag	agaaagcaaa	gcagggtctg	taacagggga	ggctgcctct	3720
aaactcaggg	tttggttaca	gctgttttca	cttacatcac	tgccctgggt	tttttttttt	3780
tttctggcat	taaaaaaaaa	aattggaagc	aggtgatggt	ccatttgctg	atgtggtgga	3840
aactctccaa	gtgaacaata	tacgtttttc	ttggcagctg	tttcttgtgc	cctgcttgct	3900
cctggtccag	gacaagcaag	gaccatctgc	ctctttcaat	agaacacctc	cagatccctt	3960
tgatcaaaa	ttactcattg	tctgacttgc	tatttctgtg	agataaatgg	gagaagatca	4020
ataaatgcac	ttgtttgtcc	agtcagcgtg	tggaagttg	ataattttga	ccaaagcaca	4080
accctgaaag	gaaaagaaaa	agggagtga	tgcttcttga	gaagctgcct	aggttcagac	4140
agtgtcaccc	atttccttgt	atgtccacac	tgacaaacct	gagtggtctc	catcatgtcc	4200
attttgcaga	tggcaccaag	gctcagaaa	ggttaggcaac	ttttccagtc	acccaatgag	4260
tttaattgaca	aaactgggat	tcaaacccag	aactgttggg	ttccaaagcc	tgtgttgttg	4320
cctgcttcgt	gaaaaactcc	agtagcgact	ggaatagaaa	ggagaacctt	ccaagaaaga	4380
aaatacgcac	tagcagaacc	tggaatttgg	gaggaaatga	ggacttgagg	aataagatga	4440
atgaaagctg	acctgagttt	cacatctggg	tgatgggaag	ggaggacagg	gaggcagcat	4500
ctcagatgtc	caccagcac	cgaccagctg	cctggcattg	ctaggtgttg	aggactcagc	4560
agtgaacacg	ctaacttctc	tgctttcttg	gggcacgtat	agggtgagag	acagaaacaa	4620
acaggtcagt	gtacaatgcc	acaggaggga	tatatgcagt	gaagaaaaag	cagggtaagg	4680
ggcatagagc	atgagaaggt	gcttttttta	aaggggktga	ttaggaaagc	tctctctaag	4740
gtgacagttg	gacctgaagg	agatgatagc	atgtctgtgg	tgagggaaag	aaactccgaa	4800
cagggaagaat	ggcagatata	aagacattga	tgctagagca	tgccaaagga	atgtgtttta	4860
ggaccagggg	aagttagcaa	gtggtggggg	gaggagagga	gctcagagca	ggaggaggtg	4920
agtgccatata	aggcctggca	agactttgga	ttcctgctgg	gtgagatgag	aatccagcgg	4980

agggcttgag	ggaggggaca	tgatgtgac	tagagtttag	actgtttaca	ctctgggtgt	5040
ggggttgaga	agagactggg	atgggggaaa	gggaggacaa	aggacattgt	gctggattga	5100
gaaagcagta	agtcagtttc	attcattcac	tcaaccgatg	atgttcaa	accaccatca	5160
tccgtgggct	aaaggatgaa	gagccatccc	tccctgagag	tcaggaagca	cttcccagat	5220
aaagtgttga	gtgtgagctg	agggttagga	gaaagagtaa	gagtttacc	ctgaaacggg	5280
tgctgggaag	agtcaatagt	ttggaataac	tcaataat	atggtgcttc	tttagaaaga	5340
tttgctggct	ttatgtggga	agaaat	ttttttgatt	ggggagtggt	gggttggtgg	5400
tgaggctgcc	tgtggaaaga	gaagtgaagt	ttttgactca	ctgttattta	aaaatctcta	5460
gggctgttcc	aataagcaac	aaaaggcaaa	atggcctggg	tctctgtccc	ctttctgtct	5520
ggtatgctcg	tacaggttat	gaaaagaaaa	agttgggaaa	agctgtccac	ctcaccta	5580
tgtgttcttg	tggagtgtgc	tagatgcccc	ctctctggag	aaaaaaatc	cttgtggcct	5640
ctgaccacc	tctggagagc	ctagttoctt	tctggaggca	gaaggcaaa	cttaggacct	5700
agagagtgtc	ggaccacgcc	actcacagga	accagcaggc	tgtgaggttg	aaagctaggc	5760
atatggagct	ttccaggctg	gggtgcaggc	ctcgtggccc	ttccctccc	ctctgtgctc	5820
tatagctcag	tcttcccagg	cggtgtgaac	acgcagtgac	atttccagga	atcacaggat	5880
ttattaatga	tttcttgtga	aatgttttga	aatacaaa	actctataaa	tatttcataa	5940
tagcatgtgg	gctgagaact	ccacaaagt	ccggaataca	tttgcatgta	agacagaacg	6000
ctgctgggt	cattgatgcc	tggtgagtg	cagtcacaga	cactgcctag	ggtttctgac	6060
tcacgctgtt	gggactgttc	tatgcagggc	accctcttgt	gtggcatagg	atgtgtgcct	6120
caccacacac	tggtgtagct	ttgctgtctt	gatgatgagt	agagggcagt	gtccaggcca	6180
tggtataaag	atctactgcc	ccccagggtt	accaaaacca	agccaagtgt	tgtctcagcg	6240
agctccgtga	agcatggaga	agttgagtac	tcagagacat	gacgtgactt	ttcaaaggct	6300
gtaagctgac	gagggacata	gctagggttc	agacttgagt	ttttcttttt	cttttctctt	6360
ttcttttttt	tttaagactg	agctctgtct	ttgtcgccca	ggctggattg	cagtgggtgt	6420
tggtctactg	caacctctgc	ctcccgggtt	caagcaattc	tcctgcctca	gcctcccacg	6480
tagctgggat	tacaggcacc	tgccaccatg	cctggccaac	atttttgtat	tttttttagta	6540
gagatgggg	ttocaccatgt	tggtccaggct	gggtctgaac	tcctgacctc	aggtgatcca	6600
ccgcctcoga	cctcccaaag	tactgggatt	acaggtgtga	gccactgcac	ccggcccaga	6660
agctagtttt	tcactctaat	gctttttcat	tgcttgacac	tttactgaga	ccaagatagg	6720
gaacttcaca	tacagtacct	tttctcccaa	ggcgggaag	ggctgttcaa	tttctacact	6780
agagttcggg	gagttttaga	aatgagtcag	ttatcgagga	tgagagcagt	tcctgatagg	6840
ctcaaccaca	atgagatgta	gctgttcaga	gaaagcattc	ttttatctat	aaactgggaag	6900
ataatcccg	tgaaacgaag	cccagcccca	ggggcttcac	taactccagg	ctgtgcttct	6960
caaactttag	tgagcatagg	aatcacctgg	gcattcttgt	aaagctgtaga	tttgaattct	7020
gcaggtcggc	agaggggtct	cagaatccgc	atttccaaca	atgtctccag	taagtctgat	7080
gctgctcgtc	cctggaccac	agattgggta	gccaggttct	ggcaagctca	tcccaggct	7140
ttgagatgac	atcagacaaa	atatgttctg	ggacatggct	tttgagaggt	caagaaaata	7200
agatgtttct	ttctcttctc	atccccaa	cttgcaactgc	ccttttctcc	cttcccctac	7260
cctcctttct	gtccccatcc	ctgacgccag	ctgttcagca	tgagaagctg	gagtgacatg	7320
cgacaggagg	tgatgtttct	gaccaatgtg	aacagctcca	gctcctccac	ccaaatctac	7380
caggctgtgt	ctcgtattgt	ctgcgggcat	cccaggggag	gggggctgaa	gatcaagtct	7440
ctcaactgg	atgaggacaa	caactacaaa	gccctctttg	gaggcaatgg	cactgaggaa	7500
gatgctgaaa	ccttctatga	caactctaca	agtgagtgtc	catgcagacc	ccagccctgt	7560
ccccaaaccc	atccctccct	tagttctggc	cttggcctgt	gtcatctcct	ccctctgtag	7620
cagcgttaga	tgtctacatg	cccatttgcc	caccagactg	agctcttctc	agaggagaga	7680
ggcttctctt	gaatagctac	ctgtccccag	ttctctgaat	gcagcctggc	acatctcagg	7740
tgcacagtag	tgtttatcaa	tggaaatgaat	gattgacagc	caaccttctg	gttttctggg	7800
ggatgtggaa	gggtggcttc	caggggtgatc	aagaatgaga	taatggcaga	aggacaaatc	7860
ctgcaagatc	tcacttatat	atggaatata	tgtaaggtag	aaagtgtcag	tttcacatga	7920
tgaataagtt	cctgggatct	tgatgtacat	cgtgatgact	atagttagta	acactgtata	7980
gtatacttga	aatttgctaa	gagagttagt	ccgaagtgtt	cacactacac	aaaaaggcca	8040
actatgaggt	gatggattta	ttaacagctt	gattgtgggt	atccttttac	aaagtataca	8100
tatatataaa	catcacattg	tataccttaa	atatatacaa	tttttatattg	tcagttgtaa	8160
ctcaaaaaag	ctagaaaagc	attttttaaa	aggatgatgt	actggtctta	atattaccat	8220
tgagataaag	tttataataa	cataaaaaa	aataacagta	atgataatag	caacaacaac	8280

aacaacaaag	aactaacatt	taagtagaat	ttcttgtgca	ctgtgcattc	tgtttaagtt	8340
atctcatttt	accctcatga	taacctgcag	ggaagattct	ttaaaccac	atttcatagg	8400
ctcagagagg	ttaagtgcct	tgggttagagc	cacatcagag	ttaatccaca	agagccagga	8460
ttcaagccca	aatctgcctg	gatctgtgct	ctctaagata	actgttagtg	gtggcgtgtg	8520
tgttctcaca	ctcagacatt	tgatctgccc	tttgtttccc	attcttagct	gcaaggcagt	8580
gttaaagaac	cctgtgtctc	catatccact	ccccacactt	aagcactttt	gtgggcccgt	8640
gtgccttatg	cctcgtggca	gcagggatcc	aatgtcacag	ttttaggcag	tggcatcctt	8700
ttocctgaaa	acttgatgca	ggggaacctt	tctccatttc	caaccacagg	tgtgtctttc	8760
agacactgag	tgaggcaggt	tttgtacttt	attgtaaac	aagaaccttt	tcttctctgg	8820
agtaaaagcac	tccagacatt	cgcaagtgtc	tttacaagcc	ttaaaaggat	ggattttag	8880
gcaactttta	ttaaatccca	tctcctcctc	tccccagct	tgcaagttga	cccaagggaag	8940
ccttcatttc	catgacagac	ttaattgtga	gggcatcctc	a		8981

<210> 21

<211> 20284

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<222> (1)...(20284)

<223> n = a, t, c, or g

<400> 21

actgtgtag	caaggatggt	ctcgatctcc	tgacctcgtg	atccgcctgt	atcggcctcc	60
caaagtgtg	ggattacagg	cgtgaaccac	tgcgcctgt	tgagaatttt	ttttttttt	120
tttgggagaa	agagtttcgc	tcttgttgcc	cgggctagag	tgcaagtaca	caatctcggc	180
tcaactgcaac	ctctgcctcc	tgggttcaag	caattctcct	gcctcagcct	catgcgtcac	240
cacgcccagc	taattttgta	tttttagtag	agacaggggt	tctccatggt	ggtcaggctg	300
gtctcgaaat	cccaacctca	ggtgggtcgc	ccgccttggc	ctcccaaagt	gctgggattg	360
caggcatgag	ccactgcgcc	cagccccaaa	ttttgtttt	tgcttgaaaa	ctgaggctct	420
aattcagcct	tctgggtgoc	cctcaagagt	cagtttaaat	gttggtcatg	ttagttgtca	480
gtgaaaacaa	tgttgaggct	ggcatgagag	tgtgaatctg	gatgggagg	cttgtgcttc	540
atgaaaacat	ttttccagat	cagctcagtc	gtgagttatc	cgtcattgac	gttataataa	600
gctctgatta	tttatcaagc	atcattcttt	atagatatct	cagtttaatc	tgagataatc	660
ttctccacat	ctctccacat	agatgttatg	aattttactt	ttacagagga	gccaaactgag	720
gctcagataa	gttacttatt	atatgactag	tagtggtaga	gctgggggtt	caactaagaa	780
ctctctggct	ccaaagccct	tgtaagtttc	tatcagtata	tgacctgca	tatgagcatt	840
tgtctctcct	cttcttcata	gctccttact	gcaatgattt	gatgaagaat	ttggagtcta	900
gtcctctttc	cgcattatc	tggaaagctc	tgaagccgct	gctcgttggg	aagatcctgt	960
atacacctga	cactccagcc	acaaggcagg	tcatggctga	ggtaagctgc	ccccagccca	1020
agactccctc	cccagaatct	ccccagaact	gggggcaaaa	aactcaaggt	agcttcagag	1080
gtgtgcgcta	agtatactca	cggctcttct	ggaattccca	gagtgaatac	ctcaagctctg	1140
atgcagacca	gagctggggc	agctccccag	tctgtgggtat	agaatcatag	ttacaagcag	1200
gcatttcttg	gggatgggga	ggactggcac	agggtctgtg	tgatggggta	tcttttcagg	1260
gaggagccaa	acgctcattg	tctgtgcttc	tcctcctttt	tctgcggtcc	ctggctcccc	1320
acctgactcc	aggatgaaca	gacottccag	gaactggctg	tgttccatga	tctggaaggc	1380
atgtgggagg	aactcagccc	caagatctgg	accttcattg	agaacagcca	agaaatggac	1440
cttgtccggg	tgagtgtccc	tcccattatt	accatgtgcc	tgcttgatac	tggagagggtg	1500
agtttctggg	cactttccca	ggtgtgagt	aggtgagaat	tctttcagtt	tatctagctg	1560
ggggaatgta	gtgagcatag	ctaaagtcac	agggcaccac	ctctccagaa	gtacaggcca	1620
tgggtgcagag	ataacgctgt	gcataatcagc	atccatgcca	ctcacggtca	aatagcagtt	1680
ttctgcaaaa	cttagtgagg	gctgggtgtt	ggaagtggag	ttgagtaatt	gcagtaacct	1740

atcttccttt	ttgctgcagc	ctctcagcca	gccacagcat	ctccctgtgt	cttggttaggt	1800
tttggaaaga	agtgtgggag	caaaagcatg	atgttacatg	tagactggcc	tgagatactc	1860
attctcaggg	cactgtgtga	atgatgagct	gctgttactg	tgtggagggg	aaatgcactt	1920
agtgtctcag	agccacttga	aagggataag	tgctctagag	acaattgggt	tcaaatgtgg	1980
agcagggtga	gcaagaacag	aatgtctcct	ttgcctgagc	ctgagtgtcg	ttaatcacat	2040
cttcctgctc	tgggctgagt	tagagaatca	ttagactatt	tcctgtttcc	atgggtgaggg	2100
aggcctcttc	cttttgtctc	tgctcccttt	aagaagcagg	tgaggatttt	gccaggtttc	2160
ttgttttgaa	ccttattgac	tttaaggcg	gctgggtttt	agagactgta	cctacctagg	2220
gggaacactt	ccgaagttta	ggactattcc	ctgatccgct	gggaggcagg	ttactgagga	2280
agtcccttta	aaaacaaagg	agttttatact	gagaaaagca	taaacagtga	tttgtatgga	2340
ttcacactga	ctaatatagc	tcatgccatt	aaagtgggt	ctcttctcta	aaggagggtt	2400
atatgatcta	gccccgtaga	cctaagtgtg	gtttcagacc	tgttcttctc	ggtcctctcc	2460
ttggaatcca	tatttctact	agttggactt	tttctgtttg	tctggctctc	agaggattat	2520
aggaggccct	gtgaagtgc	tcagtgaatt	ttgatttgtg	ggcaagtaga	tggttccta	2580
gtctgaaatt	gaotttgctt	taggtgcttc	aattcttcat	aagctcccag	ttcttaaagg	2640
acaagatcct	tgtaaacatg	gcaatggcat	tcattaggaa	tctagctggg	aaaatccagt	2700
gtgtatgctt	ggaaatgagg	gatctggggc	tggagagaaa	ggcatgggca	tgcttgggag	2760
ggacttgtgt	gtcaagctga	ggacctttac	tttaagctct	aggggaccag	gcaaggggag	2820
atgtagatac	gttactctga	tgggggtggat	gaattgaaga	aggatgaggc	aagaatgaag	2880
gcagagacca	gggaggaggc	tctccaagtg	gccaaaggcat	aaagcaagaa	atgaggcctg	2940
gtgactgctt	agtggcagag	cagtgaagaa	gagggaggca	tcaaagttag	tctcgatttc	3000
tagctgggtg	ggtggttagcg	atgtccagta	ggccagtggc	tactgaggtc	tgcaagtggag	3060
gaggggtggt	gggctggaga	cagatgatga	gggagtcctc	agcctgtggg	tggaagaaaa	3120
gggaacctct	tccaactgtt	ttcttgtgct	cttccctctc	tttctctttt	tttttttttt	3180
tggacagagt	cttgctctgt	cacccaggct	gaaatgcagt	ggcatgatct	tggtccacca	3240
cagcctccgc	ctcctgggtt	caagcaattc	tcctgtctca	gcctccagag	tagctgggat	3300
tacaggccaca	tatcactgtg	cccggttaat	ttttgtattt	tcagtggaga	tggtatttca	3360
ccatgttggg	cgggctggaa	tgaactcctg	acctcaagtg	atccacctgc	ctcagcctcc	3420
caaagtgttg	ggattacagg	catgagccac	cgcgcctggc	ctttcttccc	tctcttaaa	3480
agtgtttatt	taattccaca	aacatgagct	tgtcaccccc	tgtagcctgg	catctcctac	3540
acgaggtgat	ggctgaggct	tctgcttctg	ctggggtagc	tctgatcttt	ctgctttctc	3600
tggcactgtc	tacccatggt	gcctcacccc	acaggtccca	gggcacctct	ctcgggcaag	3660
tcttggaacc	ctctgacact	gatttgcctc	ctttcttgag	ctgcttttag	ccacctacc	3720
tcgggacctg	tttctctctc	gcctccaccc	ctgcccggag	tcttaggtct	cctgcccctc	3780
acgagcaccc	cagagaggcc	acgtgctcag	tgtatctcag	gggcgcctct	ttctagtctt	3840
gctattcttt	ttggccatgt	tgttcagaaa	ccatactggg	cagggcgcag	ttcacccctaa	3900
aggctgcgtc	tcttcactct	gcttttgttt	gttccaaata	aagtggcttc	agaattgcta	3960
accctagcct	ctgtgaactt	gtgaggtaca	attttgtgtc	tggtatgtta	acaaaaatc	4020
atacatacct	tcctgggtgat	ggtataaatt	gctattctct	attggaaagc	aatttgggat	4080
gaaaatttaa	agaaccattt	taaaatatgc	tatcctgcgt	acctccattc	caccaccccc	4140
cagggatgta	gcctactgaa	ataattttta	agaagtcacc	atatgagaga	aatgtgtatt	4200
gctatatatt	tattgtgaga	aattggaaat	agactaaaatg	ttcagcacta	taggaataat	4260
taatgaaatt	acatatactc	tatacaatca	ttagtctgcc	attgaaataa	taaatacaaa	4320
ggcgcaaggg	gggaaaagct	tataatgtta	gtgaaactaa	gactgatttt	tttataaagc	4380
agcagttttc	agacccttgg	agactccaat	tcggtagaac	cagagcttca	tcttctctgt	4440
cgaagctgtg	acaggagtgt	caaatgcctc	tcctttttgc	tgagtttgca	gctgctgttt	4500
ttccggcagc	acatctgtgc	aggcctctgc	ctcggccctc	ctggatctgc	tgattgagca	4560
gcggattgat	ctgtcctctc	ctttcgtgtt	gacccatgtg	aggaaccaac	tggaagggga	4620
acaagaaatg	gaaataggcc	tccttttgcat	catgacctgt	acatcctgca	attggaaaag	4680
attgtacttt	agttgggtta	accagcagca	ttatttttct	aaactaagca	gtaagaagga	4740
attagggtttt	atgtggggtc	aacagactgg	gtctcaaaag	aggaaggtga	tagaacacag	4800
tggggagggg	gaggtgcact	agaaacagag	ggcctatgct	ttcattctgg	ctttgtctact	4860
taatatgtgt	gtgacccaat	cttagagact	taacctctct	gaacttccat	tttctcatgt	4920
ataaaaatgg	aaatattaaa	ggatactcac	tgggctgggt	gcttgtgctc	gtaatcccag	4980
cacttgggga	ggttgaggtg	ggaggatcac	ttgagccag	gtgttcaaga	ccagcccagg	5040

caacatggca	agactctgtc	tctatgaaaa	aattaaaaat	tagccagggtg	tgggtgggtg	5100
caactgtagt	cttagctact	tggtaggctg	agatggggagg	atcacttggg	cttggggagg	5160
caaggctgcg	gtgagctgtg	attccatcac	tgcaactccag	cccggggcg	agagcgagac	5220
actgaatcca	aacgacaaca	acaacaaaag	gcaaaaaaat	aaaagtgccc	tctttatgga	5280
gttgtgttaag	gtgaagcata	tacactattc	aacatagtaa	ctatataaag	gaagtattgt	5340
tgttgttact	gtagttaata	ccattaaagt	agatgtttcg	tatagtggaa	agcacatgga	5400
ctctgaattc	agactgggtc	gactttgagt	ctcagctcca	catctagtaa	tactatgacc	5460
aagccctggt	taaaatcatg	tttttttttc	ttcagcctca	gtcttctcac	atataaaaata	5520
gggacactgt	catttacctc	agttttctgt	gaggataaaa	caacgacagt	gtatatgcaa	5580
gtattttgta	aatttttag	tgctctcaa	gatttagttg	gtgtttacta	cttgactctt	5640
ctcactggaa	tggcagatgc	tggtggacag	cagggacaat	gaccactttt	gggaacagca	5700
gttggatggc	ttagattgga	cagcccaaga	catcgtggcg	tttttggcca	agcaccagga	5760
ggatgtccag	tccagtaatg	gttctgtgta	cacctggaga	gaagctttca	acgagactaa	5820
ccaggcaatc	cggaccatat	ccgcttcac	ggaggtgaat	ctgttgctgg	gatcatttag	5880
aaaagactta	acggcttctt	tctctgagac	gttacaataa	ggttcaggca	ggaggcaagt	5940
ttagaaataa	tgtatagtct	catttcaaaa	actatccctc	aagcctaaca	caggatttga	6000
taacaaaagg	cacttaataa	atgttagttg	agtgggtgaa	tgagtaaata	aactctagct	6060
ttagttaatt	aactctagct	tattctatat	aggctcaaga	gaatatttct	acctatttct	6120
ttctaggttt	tcctatctca	gtgactaatg	gtagcaaaag	attcccttaa	aaaggcatta	6180
tttgtgaaac	ttayctaaaa	togaattcgg	gtccaattaa	atttttgaaa	ttttatatta	6240
aaaattatat	tagtagggat	gggtaagagg	tgttttggct	tggttgggtg	gttagttgct	6300
atgctacaga	attgctaaga	aaacagaaaa	gtaagataag	atcattgttt	taacctcttt	6360
tcctccacaa	aatcaataaa	taacatattc	ctaaattact	cttagaattt	ctcttaaat	6420
gcagtgaaaa	acccaaatcc	ttcattcttg	gttgaagggt	ggaaaactac	gttagagagg	6480
attagagaga	gaggatgagc	aatcgtgtag	tcagcccttg	cctcctagt	taggatttgt	6540
ctcagccact	gcttgtgtg	ctggctgcca	acgttctcat	gaaggctgtt	cttctatcag	6600
tgtgtcaacc	tgaacaagct	agaacccata	gcaacagaag	tctggctcat	caacaagtcc	6660
atggagctgc	tggatgagag	gaagttctgg	gctgggtatt	tgttcaactg	aattactccm	6720
rgcagcattg	agctgcccc	tcattgtcaa	tacaagatcc	gaatggacat	tgacaattgt	6780
gagaggacaa	ataaaatcaa	ggatgggtaa	gtggaatccc	atcacaccag	cctgggtctt	6840
gggagggtcca	gagcacctat	tattattagga	caagaggtag	tttattttta	ctaaaaattt	6900
ggtagaattt	tcaacaacaa	caaaaaaact	caacttgggt	tcattgattt	ggtgaaattg	6960
gtacatgact	tgctggaagg	tttttcatag	gtcataaaat	aacagtatct	tttgatttag	7020
catttctact	caagggaatt	aattccagga	attttggtgg	caggcacctg	taatcccagc	7080
tactcgggag	gctgaggcag	gagaattgct	tgaacccagg	aggcagagg	tgcaagtggc	7140
taagatcgca	tcattgcact	cccgcctggg	caataagagt	gaaactccat	ctcaaaaaaa	7200
aaaaagatac	aaaaatagaa	aaaggggctt	ggtaagggtg	gtagggtttt	gggcaatttt	7260
tttttttttt	ttttttttta	ttgtatgggt	ctaaagggaat	ggttgattac	ctgtgggttt	7320
gttttaggta	ctgggaccct	ggctctcgag	ctgacccctt	tgaggacatg	cggtacgtct	7380
ggggggggctt	cgctactctg	caggatgtgg	tggagcaggc	aatcatcagg	gtgctgacgg	7440
gcaccgagaa	gaaaactggt	gtctatatgc	aacagatgcc	ctatccctgt	tacgttgatg	7500
acatgtaagt	tacctgcaag	ccactgtttt	taaccagttt	atactgtgcc	agatgggggt	7560
gtatatatgt	gtgtgcatgt	gcatgcatgt	gtgaatgatc	tggaaataag	atgccagatg	7620
taagttgtca	acagttgcag	ccacatgaca	gacatagata	tatgtgcaca	cactagtaaa	7680
tcctcttctc	tcctatccat	gggtgccact	tttatctttt	tatttttatt	tttttttttg	7740
agatggagtc	tcgctctgac	gccagggtg	gagtgcatg	gctcgatctc	ggctcactgc	7800
aacctttgct	tccccgggtc	aagctattct	cctgcctcag	cctccacagt	agctgggact	7860
acaggctcat	gctgccacgc	ccgctgact	ttttgtattt	tagtagagac	gaggtttcac	7920
catgttcccc	aggctagact	tcaactcctg	agctcaggca	atccacccct	cttggcctcc	7980
caaagtgtct	ggattacagg	tgtgagccac	tgacccacgc	ccaccacttt	aattttttac	8040
actctaccct	tttgggtcaaa	atttgctcaa	tctgcaagct	taaaatgtgt	catgacaaac	8100
acatgcaagc	acatactcac	acatagatgc	agaaacagcg	tctaaactta	taaaagcaca	8160
gtttatgtaa	atgtgtgcac	ttctctctcc	taggtggtaa	accacatttc	aaaacaaccc	8220
aaataaaact	gaacaaagct	tcttctctct	agacttttta	gaaaatcttt	cagtgctgag	8280
tcactaagct	gccaagttct	cattgtggga	actatgcctt	tggatgtaat	gatttcttct	8340

aagacaatgg	gcgagggtgt	agttattgca	gacatctgaa	atatgtaatg	tttcttccag	8400
attctggaaa	ttctcttatt	ctctgtggtt	ggtgggtggtg	gtgggatgtg	tgtgtgtgtg	8460
tgtgtgtgtg	tgtgtgtgtg	tgtgtaggga	tcaggatgcg	ggaggagctg	ggttctgctt	8520
gtattgggtt	tctgttttgc	attgaatagt	gtgtttcctt	gtatggctat	ctatagcttt	8580
tcaaggtcac	cagaaattat	cctgtttttc	accttctaaa	caattagctg	gaatttttca	8640
aagggaagact	tttacaaaaga	cccctaagct	aagggtttact	ctagaaaagga	tgtcttaaga	8700
cagggcacag	gagttcagag	gcattaagag	ctgggtgcctg	ttgtcatgta	gtgagtatgt	8760
gcctacatgg	taaagctttg	acgtgaacct	caagttcagg	gtccaaaatc	tgtgtgcctt	8820
tttactttgc	acatctgcat	tttctattct	agcttggaat	ctgaaacatt	gacaagagct	8880
gcctgaaatg	tatgtctgtg	gtgtgattag	agttacgata	agcaagtcac	tagtgagatg	8940
accttgaggga	tgttgaactt	ttgtgagaga	atgagttgtt	tttttgtttt	ggttttttagt	9000
actttaacat	aatctacctt	tagtttaagt	atcgctcaca	gttacctagt	tactgaagca	9060
agcccccaaa	gaaatttgggt	ttggcaacac	tttgttagcc	tcgtttttct	ctctacattg	9120
cattgctcgt	gaagcattgg	atcatacgta	catttcagag	cttagagggc	ctgtccttct	9180
gtggcccaga	tgtggtgctc	cctctagcat	gcaggctcag	aggccttggc	ccatcacctt	9240
ggctcacgtg	tgtctttctt	tctcccttgc	tccttccctg	gggctccag	ctttctgagg	9300
gtgatgagcc	ggccaatgcc	cctcttcatg	acgctggcct	ggatttactc	agtggctgtg	9360
atcatcaagg	gcctcgtgta	tgagaaggag	gcacggctga	aagagacctc	gcggatcatg	9420
ggcctggaca	acagcatcct	ctggtttagc	tggttcatta	gtagcctcat	tcctcttctt	9480
ggctcacgtg	gcctgctagt	ggctcatcct	aaggttaagg	agcctcactc	gctcttccct	9540
gccaggaaac	tcgaaatag	ctcaacacgg	gctaagggag	gagaagaaga	aaaaaaatcc	9600
aagcctctgg	tagagaaggg	gtcatacctg	tcatttccctg	caatttcctc	cattttatagt	9660
tggggaaaagt	gaggccacga	gaggggcagt	gacttgccca	aggtcaacct	agccgggtag	9720
cagctaagta	ggatgagagt	gcagggttca	tgctttccag	ataaccacat	gctcaactgt	9780
gccatgctgt	ctcattggta	gtggttcatg	gcagcatctg	aaagctatct	attttcttag	9840
atatattggg	tggcgattct	tcctaagttt	ctaagaacaa	taatcagaag	gatataatatt	9900
gttgaggtt	agactgtctg	gaagcagagg	ctgaaataga	gtttgatgta	tgggtattta	9960
tgagggctca	atacctatgg	aagagatatg	gaagatgcag	gattggggcag	aggaggaggt	10020
tgaaatgtga	tatagggccca	accccggtgg	gcactctaga	gaatatgcag	ctgtgtggag	10080
ttgtttctca	tcgagctgaa	acatccagcc	ctttgtgctc	ccccaaaggc	tcctctctga	10140
caccacctac	ctcagccctc	tcaatcaatc	actggatgtg	ggctgcccctg	ggaaggtcgt	10200
gccccagggc	ctacatggct	ctctgctgct	gtgacaaacc	cagagttgct	gatgcctgag	10260
gccgtctact	gacagctggg	caacaaggct	tccttgaatg	gggaactctgg	gcagtgcagt	10320
tttgtgtctg	aaccatacat	taatatattt	atatccgaat	tttctttctc	tgcagcatt	10380
tcataaaaag	acacatcagg	taaaaataaa	tgtttttgaa	gcaaaaggag	tacaaagaga	10440
taagaactaa	ctaatttaat	actagttacc	atctgttaca	aatagttcct	actgattgcc	10500
aaggactgtt	taaaacacatc	acatgggctt	cttcttctat	cctcactaac	ccttttaaca	10560
gacaaggaaa	tgaggctcag	gaaggtcaag	gactttattg	aggttccaca	gtaggataca	10620
gttcttgcta	aaagcaacct	ctccctcatg	ctctgttatc	taactgcaag	gggaagggtca	10680
gtggcagagg	tagtgggtccc	atgggtgggtg	cataagagct	gctctgagac	aactgcattg	10740
tgggtgggtcc	tgcagacatg	tacccatcag	ccggagatag	gctcaaaata	tcacaaagag	10800
tttggatgat	tgtgggaatg	cagaatccat	ggtgatcaag	agggaaagtc	aagttgcctg	10860
gccattttcc	ttggctttta	gacagaaaag	ttacgtggga	tattatctcc	cacagctctt	10920
ctgtggtgcc	accagtcata	gtccttatat	aaggagaaac	cagttgaaat	tacctattga	10980
agaaacaaaag	agcaaaactcg	cccactgaaa	tgcttagaaa	gccctggact	ctgttgtatt	11040
cataactctg	ccattatttt	tctgcgtagt	tttgggttaag	tcacttatct	tccttaggat	11100
ggtaatgata	agttgcctca	tcagaaagat	gaacagcatt	acgcctctgc	attgtctcta	11160
acatgagtag	gaataaaccc	tgtctttttt	ctgtagatca	tacaagttag	tgcttgggat	11220
tgttgaggca	gcacatttga	tgtgtctctt	ccttcccagt	taggaaacct	gctgccttac	11280
agtgatccca	gcgtgggtgtt	tgtcttctctg	tcctgtgttg	ctgtgggtgac	aatcctgacg	11340
tgtctctctga	ttagcacact	cttctccaga	gccaaacctg	cagcagcctg	tgggggcata	11400
atctacttca	cgctgtacct	gccctacgtc	ctgtgtgtgg	catggcagga	ctacgtgggc	11460
ttcacactca	agatctctgc	tgtgagtagc	tctggccttt	cttcagtggc	tgtaggcatt	11520
tgaccttctt	ttggagtccc	tgaataaaaag	cagcaagttg	agaacagaag	atgattgtct	11580
tttccaatgg	gacatgaacc	ttagctctag	attctaaagt	ctttaagggt	aagggcaagc	11640

attgtgtttt	attaaattgt	ttacctttag	tcttctcagt	gaatcctggg	tgaattgaat	11700
tgaatgggaat	ttttccgaga	gccagactgc	atcttgaact	gggctgggga	taaatggcat	11760
tgagggaatgg	cttcaggcaa	cagatgccat	ctctgccctt	tatctcccag	ctctgttggc	11820
tatgttaagc	tcatgacaaa	ccaaggccac	aaatagaact	gaaaactcct	gatgtcagag	11880
atgacctctc	ttgtcttctt	tgtgtccagt	atgggtgttt	gcttgagtaa	tgttttctga	11940
actaagcaca	actgaggagc	aggtgcctca	tcccacaaat	tcctgacttg	gacacttcct	12000
tcctcgttac	agagcagggg	gatattcttg	agagtgtgtg	agcccttaca	agtgaagtt	12060
gtcagatgtc	cccagggtcac	ttatcaggaa	agctaagagt	gactcatagg	atgctcctgt	12120
tgcctcagtc	tgggcttcat	aggcatcagc	agccccaac	aggcacctct	gatcctgagc	12180
catccttggc	tgagcaggga	gcctcagaag	actgtgggta	tgcgcatgtg	tgtgggggaa	12240
caggattgct	gagccttggg	gcattcttgg	aaacataaag	ttttaaaagt	tttatgcttc	12300
actgtatatg	catttctgaa	atgtttgtat	ataatgagtg	gttacaaatg	gaatcatttt	12360
atatgttact	tggtagccca	ccactcccta	aagggaactc	ataggtaaat	actacttctg	12420
caccttatga	ttgatccatt	ttgcaaatcc	aaatttctcc	aggataaatt	tacactagaa	12480
gagatagaaa	aatgagactg	accaggaaat	ggatagtgta	ctttgcctgt	ttctcacaga	12540
gcctgctgtc	tcctgtggct	tttgggtttg	gctgtgagta	ctttgccctt	tttgaggagc	12600
agggcattgg	agtgcagtgg	gacaacctgt	ttgagagtcc	tgtggaggaa	gatggcttca	12660
atctcaccac	ttcgggtctcc	atgatgctgt	ttgacacctt	cctctatggg	gtgatgacct	12720
gggtacattga	ggctgtcttt	ccagggtacac	tgtcttgggc	atctgtttgg	aaaatatgac	12780
ttctagctga	tgtcctttct	ttgtgctaga	atctctgcag	tgcattgggt	tccttgggaa	12840
gtgtgttggg	ctatagatct	atagtaaaaca	gatagtccaa	ggacaggcag	ctgatgctga	12900
aagtacaatt	gtcactactt	gtacagcact	tgtttcttga	aaactgtgtg	ccaggcagca	12960
tgcaaaatgt	tttatacaca	ttgcttcatt	taattctcac	aaggctactc	tgaagttagtt	13020
actataataa	ccagcaattt	tcaaatgaga	gaactgtgac	tcaaagacgt	taagtaacca	13080
gcttgggtca	cacaactgtt	aaatgttggg	acgtggagggt	gaatccactt	cgggtacact	13140
gggtcaataa	gcccaggcga	atcctcccaa	tgtccaccca	attctgtatt	tctgtgtcct	13200
cagaggggggt	acaactagga	gaggtttctgt	ttcctgagta	caggttgtta	ataattaaat	13260
atactagctc	taaggcctgc	ctgtgattta	attagcattc	aataaaaatt	catgttgaat	13320
ttttctttag	tacttctttc	ttaatataat	acatcttctt	gaccaagtcc	aagagggaacc	13380
tgcgttggac	agttttcata	tgagatcaaa	ttctgagaga	gcaagattta	accctttttg	13440
gttccaccttc	tgatcctccc	ctaaggagggt	atacatgaaa	tatttattac	tcctgcctga	13500
acttctttca	ttgaatatgc	aattttgcag	catgcagatt	ctggatttaa	attctgagtc	13560
tttaacttact	ggctgaggga	ccttggtatg	gtccttcttc	cctcagtttc	ctcatctcta	13620
aaatggggat	ggcacttgcc	ccgtgggttg	ttggaaggac	ttacagagggt	gcagaatgta	13680
cgtttgtacat	agcagggttc	agcaaatggt	agctccctct	ttcccacat	ccattcaaat	13740
ctgttctcttc	tccaaaggat	gtgtcaaggga	ggaatgggac	ctggctggga	aacctcaga	13800
atactgggat	gatgctgagc	ttggctcata	cctgtgcttt	gctttcaggc	cagtacggaa	13860
ttcccaggcc	ctggtatttt	ccttgcacca	agtcctactg	gtttggcgag	gaaagtgatg	13920
agaagagcca	ccctgggtcc	aaccagaaga	gaatgtcaga	aagtaagtgc	tgttgacctc	13980
ctgctctttc	tttaacctag	tgtgctgccc	tctgctaact	gttgggggca	agcgatgtct	14040
cctgcctttc	taaaagactg	tgaaccactc	ccaggggcag	agaaatcaca	tgcagtgtcc	14100
ctttccaaat	cctcccatgc	catttatgtc	caatgctgtt	gacctattgg	gagttcacgg	14160
tctcgatccc	tgagggacat	tttctttggt	gtcttggtct	ctagaagagt	atcttttact	14220
tgccccctcc	caaacacaca	tttcatggct	tcttaacaag	ctagaagaaa	gaggtaaaaga	14280
caagcgtgat	tgtggaacca	tagcctcgct	gcctgcctgt	gacatgggtga	cctgtgtatc	14340
agcctgtgtg	ggctgagacc	aagtgggtac	cacagagctc	agcctatgct	tcataatgta	14400
atcattaccc	agatccctaa	tcctctcttg	gctcttaact	gcagacagag	atgtccacag	14460
ctcatcaaaag	gctctgcttc	tgggttcttt	gtgcttagag	tggcttcccta	aatattttaa	14520
aggtcccttt	tctgcoagtc	tcttctgtgc	ccatcccttg	attgcccctg	gtaaaagtat	14580
gatgcccctt	agtgtagcac	gcttgccctg	tgttcttaat	catcttctcc	tacctcctct	14640
ttacacctag	ctcctgtttc	agtcacctag	aaatgctcac	agtcgctgga	atatgtcatg	14700
ttcttccaca	cctccatgcc	ttttaggtga	ctgtttgtct	tcacaggaga	actttctctc	14760
taacttgctt	atcttctcaa	ctcctccttt	ctctccaaag	tctagtcccg	gatccccctc	14820
cctgagcatc	cctccttggg	tctcaggtag	tcagtcactc	tctgccttga	acttccatgg	14880
cacgtgaaaag	aaaatctttt	tatttttaaa	caattacaga	ctcacaagaa	gtaatacaaa	14940

ttacatgagg	gggttccctt	aaacctttca	tccagtttcc	ccaatggtag	cagcatgtgt	15000
aactgtagaa	tagtatcaaa	accatgaaat	tgacataggt	acaattcaca	aaccttcttc	15060
agatttcact	agctttatgt	gcgctcattt	gtgtgtgtgt	gtgcgtattt	agttctatgc	15120
aattttatca	tgtgtgaatt	catgtaatta	ctagctcagt	caagctgcag	aaatatctca	15180
ttgtcacaaa	gctccttcat	gctacccctt	aatggccaca	gccacctccc	ttcttctcca	15240
gttcttgaca	cctgtcaacc	actaatgcgt	tcctcgtttt	tacagtttta	ttatttctag	15300
aatgttacat	aaatggaacc	atacagtagg	tatccttttg	atactggctt	tttttttttt	15360
ttcactcagc	agtattccct	tagatctatc	caagttgtgt	gtgtcaacag	ttcattcctc	15420
ttcactgctg	agtagtggtc	cctgggaggg	gtgtatcaca	gttccatggc	atttttttag	15480
gtatttttta	aacagctttc	agcatcctct	attttaattg	ttcatcaagt	cctttttccc	15540
aatagactct	gaatgctcct	ttatcatcgt	attcccatca	ccaacatcag	tacccaaata	15600
ggccctaaat	aaacattttat	agcctcctgc	ctgcctgaga	aaccagggtg	gacatggaga	15660
gaaggcactt	ctgaaagtcc	aagcgcagtg	csctgtgtcc	ttacactcca	ctcctcagtg	15720
ctttctgtgg	gttcattttc	gtcttctctc	ctgtcacagt	ctgcattggg	gaggaaccca	15780
cccacttgaa	gctgggctgt	tccattcaga	acctggtaaa	agtctaccga	gatgggatga	15840
aggtggtctg	cgatggcctg	gcactgaatt	tttatgaggg	ccagatcacc	tccttctctg	15900
gccacaatgg	agcggggaag	acgaccacca	tgtaagaaga	gggtgtgggt	cccgcagaat	15960
cagccacagg	aggggtctgc	agtagagtta	gaaattttata	ccttaggaaa	ccatgctgat	16020
ccctgggcca	aggggaaggag	cacatgagga	gttgccgaat	gtgaacatgt	tatctaata	16080
tgagtgtctt	tccacgtgct	agtttgctag	atgttatctc	ttcagcctaa	aacaagctgg	16140
ggcctcagat	gacctttccc	atgtagtcca	cagaattctg	cagtgggtct	ggaacctgca	16200
gccacgaaaa	gatagattac	atatgttgga	gggagttggg	aattcccagg	aactctgtct	16260
ctaagcagat	gtgagaagca	cctgtgagac	gcaatcaagc	tgggcagctg	gcttgattgc	16320
cttccctgct	acctcaagga	ccttacagtg	ggtagtatca	ggaggggtca	ggggctgtaa	16380
agcaccagcg	ttagcctcag	tggcctccag	cacgattcct	caaccattct	aaccattcca	16440
aagggatata	ctttgggggg	tgacattctt	ttcctgtttt	ctttttaatc	tttttttaaa	16500
acatagaatt	aatatattat	gagcttttca	gaagattttt	aaaaggcagt	cagaaatcct	16560
actacctaac	acaaaaattg	tttttatctt	tgaataatat	gttcttgttt	gtccattttc	16620
catgcatgct	atgttaggca	tacaaaatac	attttttaaa	gaatactttc	attgcataat	16680
ggaaactctg	tttaaaaaat	gctcatacta	aaattggcat	ttctaaccga	tagggccact	16740
tgtagttatt	taccgaagca	aaaggacagc	tttgctttgt	gtgggtctgg	taggggtcat	16800
tagaaaaggaa	tgggggctgt	gggagggttg	gtgttctgtt	ctctctgcag	actgaatgga	16860
gcactctagag	ttaagggtag	gtcaaccctg	acttctgtac	ttctaatttt	ttgtcctcag	16920
gtcaatcctg	accgggttgt	tccccccgac	ctcgggcacc	gcctacatcc	tgggaaaaga	16980
cattcgcctc	gagatgagca	ccatccggca	gaacctgggg	gtctgtcccc	agcataacgt	17040
gctgtttgac	atgtgagtag	cagcagcacg	ttaagaatag	gccttttctg	gatgtgtgtg	17100
tgctcatgcca	tcatgggagg	agtgggactt	aagcatttta	ctttgctgtg	ttttgttttt	17160
ttcttttttt	cttttttatt	tttttgagat	ggagtctcgc	tctgtagcca	ggctggactg	17220
tagtggcgct	atctcggctc	actgcaacct	tggcctccca	ggttcaagcg	attctcctgc	17280
ctcagcctcc	cgagttagctg	ggactctagg	cacacaccac	catgcccagc	taatttttgt	17340
gttttttagta	gagacggggg	ttcaccatgt	tggccaggat	gggtccaatg	tcttgacctc	17400
gtgatccgcc	cacctcggct	tcccaaagtg	ctgggaacac	aggcatgagc	cactgtgtct	17460
ggccacattt	tactttcttt	gaatatggca	ggctcacctc	cgtgaacacc	ttgagacctc	17520
ggtgtttctt	gatttttagga	gaagtgggag	gtgaatgggt	gagctgtaga	ggtgacatca	17580
gccagccag	tggatggggg	cttgggaaac	attgtctccc	attattgtca	tgctggaggg	17640
cccttttagcc	catcctctcc	ccccgccacc	ctccttattg	aggcctggag	cagacttccc	17700
agacctggta	gtgcttcagg	gccctgggat	gatggacctc	tatttgcctg	ttaagacatt	17760
tgctcccact	cagggttgtcc	catcagccat	aaggccccc	gggagcccg	gtgatggagc	17820
agagagagac	ctgagctctg	caatcttggg	caaggctttt	cccttatgtt	tcttcttatt	17880
taaagtgaac	agctggggct	catgtgctcc	ctcctcatct	aaagtgaaca	catggggctc	17940
atgtgcaggg	tcctccccgc	tttcagagcc	tgaggctccc	tgaggctcag	gaaggctgct	18000
ccaggtgag	gocgagctga	cttcttggtg	gacgtgctgt	ggggacagcc	cattaaagac	18060
ccatcttgg	ggccctgaaa	ttgaaagtgt	taactgcctg	gtgcatgggt	gccaggcctg	18120
ctggaaacag	gttggaagcg	atctgtcacc	tttcactttg	atttctctag	cagctcatgt	18180
ggttgctcac	tgttggtcta	ccttgaatct	tgaagattat	ttttcagaaa	ttgataaagt	18240

tatttttaaaa	agcacgggga	gagaaaaata	tgccattct	catctgttct	ggggcagggg	18300
acactgtatt	ctggggatc	cagtagggcc	cagagctgac	ctgcctccct	gtccccaggg	18360
tgactgtcga	agaacacatc	tggttctatg	cccgttgaa	agggctctct	gagaagcacg	18420
tgaaggcgga	gatggagcag	atggccctgg	atgttggttt	gccatcaagc	aagctgaaaa	18480
gcaaaacaag	ccagctgtca	ggtggggccc	agagctacct	tccctatccc	tctccctccc	18540
tcctccggct	acacacatgc	ggaggaaaat	cagcactgcc	ccagggtccc	aggctgggtg	18600
cggttggtta	cagaaacttg	tccttggtg	tgccctagg	tcctctgct	tcactcactg	18660
tctggggctg	gtcctggagt	ttgtcttgc	ctgtttttt	gtaggtggaa	tgagagaaa	18720
gctatctgtg	gccttggcct	ttgtggggg	atctaagggt	gtcattctgg	atgaaccac	18780
agctgggtgtg	gaccttact	cccgcagggg	aatatgggag	ctgctgtga	aataccgaca	18840
agggtgcctga	tgtgtattta	ttctgagtaa	atggactgag	agagagcggg	gggcttttga	18900
gaagtgtggc	tgtatctcat	ggctaggctt	ctgtgaagcc	atgggatact	cttctgttak	18960
cacagaagag	ataaagggca	ttgagactga	gattcctgag	aggagatgct	gtgtctttat	19020
tcctcttttt	gtccccaaca	tgggtgacta	aatttatggt	tagttgaaag	gtgtggatgct	19080
taaatgaatg	gaagcggaga	ggggcaggaa	gacgattggg	ctctctggtt	agagatctga	19140
tgtgttacag	tatgaggagc	acaggcaggc	ttggagccaa	ctctggcttg	gccctgagac	19200
attgggaaaag	tcacaacttg	cctcaccttc	ttgcccga	ataatagtgg	tgctgtacct	19260
catagaggat	taaattaaat	gagaatgcac	acaaaccacc	tagcacaatg	cctggcatat	19320
agcaagttcc	caataaaaat	gcgtactgtt	cttacctctg	tgaggatgtg	gtacctatat	19380
atacaaaagt	ttggcattct	aggggtcata	gccatacagg	gtgaaagggtg	gcttccagggt	19440
ctcttccagt	gcttaccctc	gctaataatc	ctctagtccc	tgctactgtg	acaaatcaga	19500
actgagaggc	ctcacctgtc	ccacatcctt	gtgtttgtgc	ctggcaggcc	gcaccattat	19560
tctctctaca	caccacatgg	atgaagcggg	cgtcctgggg	gacaggattg	ccatcatctc	19620
ccatgggaag	ctgtgctgtg	tgggctcctc	cctgtttctg	aagaaccagc	tgggaacagg	19680
ctactacctg	accttgggtc	agaaagatgt	ggaatcctcc	ctcagttcct	gcagaaacag	19740
tagtagcact	gtgtcatacc	tgaaaaaggt	gagctgcagt	cttggagctg	ggctgggtgtt	19800
gggtctgggc	agccaggact	tgctggctgt	gaatgatttc	tcacatctcca	ccccttttgc	19860
catgttgaaa	ccaccatctc	cctgctctgt	tgcccctttg	aaatcatatc	atacttaagg	19920
catggaaaagc	taaggggccc	tctgctccca	ttgtgctagt	tctgttgaa	cccgttttcc	19980
ttttcttatg	aggcacanag	agtgtgggag	aaggtcctta	gaggacatta	ttatgtcaaa	20040
gaaaaagagac	ttgtcaagag	gtaagagcct	tggtacaaa	tgacctgggc	gttctgtctc	20100
attacttttc	aatctcattg	accttaactt	ttaaactata	aaacagccaa	tattttatag	20160
gcactgattt	catgccagag	acactctggg	cattgaaaga	aagtaatgat	aatagttaat	20220
tttatatagc	gttggtacca	tttcaacctt	tttttttttt	taacctctat	catctcaatt	20280
aaag						20284

<210> 22

<211> 7052

<212> DNA

<213> Homo sapiens

<400> 22

gtgaacacac	attaaagcat	gagaagcatg	aactagacat	gtagccaggt	aaaggccttg	60
ctgagatggt	tggcaaaggc	ctcattgcag	cattcattgg	caggccacag	ttcttttggc	120
agctctgctt	cctgaccttt	cacctcagg	aagcgaggct	gttcacacgg	cacacacatg	180
ccagacaggg	tcctctgaag	ccacggctgc	cagtgcattg	gtcccaggga	aagctttttc	240
cttttagttct	cacacaacag	agcttctctg	aagccctccc	cggcgaaggt	gctgggtggct	300
ctgccttgct	ccgtccctga	cccgttctca	cctccttctt	tgccatcagg	aggacagtgt	360
ttctcagagc	agttctgatg	ctggcctggg	cagcgaccat	gagagtga	cgctgaccat	420
cggtaaaggac	totgggggttt	cttattcagg	tggtgcctga	gcttccccca	gctgggcaga	480
gtggaggcag	aggaggagag	gtgcagaggc	tggtggcgct	gactcaaggt	ttgctgctgg	540
gctggggctg	ggtggctgctg	gggggtgggag	cagcttggtg	gcgggttggc	ctaattgcttg	600
ctgggggtgct	tggggctcgg	tttgggagct	agcagggcag	tgcccagag	agctgagatg	660

attgggggttt	ggggaatccc	ttaggggagt	ggacactgaa	taccagggat	gaggagctga	720
ggggccaagcc	aggagggtgg	gatttgagct	tagtacataa	gaagagtgag	agcccaggag	780
atgaggaaca	gccttccaga	ttttctctgg	gtagcgtgtg	taggaggcca	gtgtcaccag	840
tagcatatgt	ggaacagaag	tcttgaccct	tgctatctct	gcctagtcct	aatggctggc	900
ttttccagg	aaggcttctg	cttccatgga	ctgttagatt	aaccctttat	ttaggtaaat	960
gagggaaacct	actttataag	cataggaaa	ggggaagaat	cttttaagat	tcctttactc	1020
aagttttctt	ttgaagaatc	ccagagctta	ggcaatagac	accagacttt	gagcctcagt	1080
tatccattca	cccattccacc	caccacccca	cccattcctc	catcctccca	tcctccctatt	1140
caccatccca	cccattccagc	tgccacccca	ttctacactg	agtaacctata	atgtgcctgg	1200
cttttggtgat	acaaagggtga	ataagacata	gtcctttcct	ttgcccccaa	ccctcagacc	1260
agagatgaac	atgtggaatg	acctaaccac	ctggaacagg	tggtggtgat	gagcggcagg	1320
cctctgatga	gaggggtggg	gatggccagc	cctcactccg	aagccccctc	gagttgattg	1380
agccatcttt	gcattctggt	ctgcagatg	tctctgctat	ctccaacctc	atcaggaagc	1440
atgtgtctga	agcccggtcg	gtggaagaca	tagggcatga	gctgacctat	gtgctgccat	1500
atgaagctgc	taaggaggga	gcctttgtgg	aactctttca	tgagattgat	gaccggctct	1560
cagacctggg	catttctagt	tatggcatct	cagagacgac	cctggaagaa	gtaagttaag	1620
tggtctgactg	tcggaatata	tagcaaggcc	aaatgtccta	agggcagacc	agtagcctgc	1680
attgggagca	ggattatcat	ggagttagtc	attgagtttt	taggtcatcg	acatctgatt	1740
aatgttgccc	ccagttagcc	atttaagatg	gtagtgggag	atagcaggaa	agaagtgttt	1800
tcctctgtac	cacagtacat	gcctgagatt	tgtgtgttga	aaccagtggg	acctaacaca	1860
tttaccatccc	aaccttaaac	tcctatgcac	ttatttaacc	tttaatgagc	ctctttactt	1920
aagtacagtg	kgaggaaacag	cggcatcagg	atcacttggg	aacttgtag	aaattcagca	1980
acttggggccc	agctcagacc	tactgaatca	gaatcaggag	caattctctg	gtgtgactgt	2040
gtcacagcca	ggtatcaact	ggattctcat	acataggaaa	tgacaaacgt	ttatggatgg	2100
atagcttact	tgtgccaggt	gctgagattt	gttttttggt	ttttgatttt	tttttaatca	2160
ctgtgacctc	atttaattct	caaaaaaaga	tgaaaaaatg	aacactcagg	aatgctgaca	2220
tgagattcag	aatcaggggt	ttggggcttc	aaagtccatc	ctctctttat	ccatgtaatt	2280
cctcccccta	gagatacaac	atcacagacc	ttgaaggctg	aaggggata	aaaagctgtc	2340
tgcccaagt	gtctccaagg	ttgacagtgc	agcagaatca	cctggggata	ttattaaaaa	2400
taaacatact	aagggttggc	ttcagggcct	gtgaatcaga	atttctggag	gtgaggcctt	2460
gaagtctgta	tttctattgc	atactttgga	cacagtggtc	tatagactag	agtttgga	2520
tgattgcgct	cattcagatt	ctcttctgat	gtttgaattg	ctgccatcat	atttctagt	2580
ctctatttcc	tcctgctcat	tctgtcttgg	ataacttatc	atagtactag	cctactcaaa	2640
gatttagagc	cacagtcctg	aaagaagcca	cttgactcat	tcctcttagg	ttcagaataa	2700
atthcttctg	cgcagtgtct	gtcatagctt	tttttaaat	tttttttatt	tttgatgaga	2760
ctggagtttt	gctcttattg	cccaagctgg	agtgcagtg	tgcgattttg	gctcactgca	2820
acotccacct	cccagggtta	agcgattctc	ctgcctcagc	ctcccaagta	gctgagatta	2880
caagcatgtg	ctaccacgcc	cagctaattt	tgtattttta	gtagagatgg	gttttatcca	2940
tgttggtcag	gctggtctcg	agctccagac	ctcagggtgat	ctgcccgcct	cggcctccca	3000
aagtgtctgg	attataggcc	tgagccacag	cgctcagcca	taactttaat	ttgaaaatga	3060
ttgtctagct	tgatagctct	caccactgag	gaaatgttct	ctggcaaaaa	cggcttctct	3120
cccaggtaac	tctgagaag	tgattattaag	aaatgtggct	tctactttct	ctgtcttacg	3180
gggctaacat	gccactcagt	aatataataa	tcgtggcagt	gggtgactact	ctcgtaattg	3240
tgggtgcttat	aatgttctca	tctctctcat	tttccagata	ttcctcaagg	tgccgaaga	3300
gagtgggggtg	gatgctgaga	cctcaggtaa	ctgccttgag	ggagaatggc	acacttaaga	3360
tagtgccctc	tgctggcttt	ctcagtgcac	gagttattgt	cctttccctt	tgaattgttc	3420
tattgcattc	tcattttag	agtgtagggt	tgttgagat	ggggaagggt	tgttttgttg	3480
taaaataaat	aaagtatggg	attctttcct	tgtgccttca	gatggtacct	tgccagcaag	3540
acgaacagg	cgggccttcg	gggacaagca	gagctgtctt	cgcccgttca	ctgaagatga	3600
tgctgctgat	ccaaatgatt	ctgacataga	cccaggctct	ttagggcaag	atcaaacagt	3660
gtcctactgt	ttgaatgtga	aattctctct	catgctctca	cctgttttct	ttggatggcc	3720
tttagccaag	gtgatagatc	cctacagagt	ccaaaagagaa	gtgaggaaat	ggtaaaagcc	3780
acttgttctt	tgacagcatg	tgcatgtgat	caaacctgaa	agagcctatc	catatcactt	3840
cctttaaaga	cataaagatg	gtgcctcaat	cctctgaacc	catgtattta	ttatcttttc	3900
tgcgggggtcc	tagtttcttg	tatacattag	gtgtttaatt	gttgaacaaa	tattcattcg	3960

agtagatgag	tgattttgaa	agagtcagaa	aggggaattt	gctgttagag	ttaattgtac	4020
cctaagactt	agatatttga	ggctgggcat	ggtggctcat	gccaagtaac	ccagcgcttt	4080
gagaggctga	ggtgggtaga	tcacctgagg	tcaggagttt	gagaccagtc	tgaccaacaa	4140
ggtgaaaccc	cgtctctact	aaatacaaaa	aattagccga	gtgtgggtggc	acatgcctgt	4200
catocccagct	acttgggagg	ctgaggcagg	agaatcgctt	gaaccacagga	ggcagagggtt	4260
gcagtcagcc	acggttgccg	cattgcactc	cagactgggc	aacaagagtg	aaaactccat	4320
ctcaaaaaag	aaaaaaaaag	aattagatat	tttggatgag	tggtgtctttg	tggtgttaac	4380
tgagatggag	aggagagcta	agacatcaaa	caaataattgt	taagatgtaa	aagcacatca	4440
gttaggtatc	attagtttag	gacaaggatt	tctagaaaat	ttttagggaac	agaaaaacttt	4500
ccagttctct	cacccctgct	caaagagtgt	atggctctta	cattatatat	aactgcctga	4560
cttcatacag	tatcagtact	tagatcattt	gaaatgtgtc	cacgttttac	caaaatataa	4620
taggggtgaga	agctgagatg	ctaattgccca	ttgtgtattc	tcaaatatgt	caagctacgt	4680
acatggcctg	tttcatagag	tagtctataa	gaaattgatg	acttgattca	tccgaatggc	4740
tggtgttaac	acctggttac	gcataaacac	ctcttttcag	ttgtctcaag	acacctttct	4800
tttctgtact	tatcagacaa	ggactgaaag	gcagagactg	ctactgttag	acatttttag	4860
tcaagctttt	ccttggacat	agctttgtca	tgaaagccct	ttacttctga	gaaacttcta	4920
gcttcagaca	catgccttca	agatagtgtt	tgaagacacc	agaagaagga	gcattggcaat	4980
gccgaaaaac	cctaagataa	taggtgacct	tcagtgttgg	cttcttgca	aatccagaga	5040
gacagacttg	ctcagtgagg	tggatggcaa	aggggtccac	caggtgaaag	gctggaaact	5100
tacacagcaa	cagttttgtg	cccttttgtg	gaagagactg	ctaattgccca	gacggagtcg	5160
gaaaggattt	tttgcctcag	tgagacgtgc	tggttttcgcc	agagactctg	gcttcattggg	5220
tggtgctgcag	gctctgtgac	cagtgaaagg	aggatagcat	cctggtcaag	atatggatgc	5280
cggagccaga	tttatctgta	tttcaatccc	agttctattc	cttgccagtt	gtgtatccgc	5340
tggaagttta	cttctctatg	cctcaatctc	ctcatctgta	aaatggggat	aataatatta	5400
cctgcaatac	agggttggtta	cgaaaaataa	aatgaatagg	tgcttagaat	ggggcctgac	5460
attagtaagt	gcttagtttt	gtgtgtgtat	atgttatttt	tattttggag	gagaacataa	5520
aaaggacaaa	gtgtagaaaa	actgggtggg	tgtattcagc	tgctcataaca	tgagagtgtg	5580
tatgcccaga	tgcaactgac	atgtgaattt	attagaacaa	tgatttttct	ctgagttgat	5640
gtttaactca	aactgataga	aaagatagg	cagaatatag	ttggccaaca	gagaagactt	5700
gttagactat	tgtctgcatg	tcagtgtttg	catgctaact	tgcttagtta	gaaagggtta	5760
attttttcac	tctataaaat	caagaaatat	agagaaaagg	tctgcagaga	gtctttcatt	5820
tgatgatgtg	gatattgtta	agagcgggag	tttggagcat	acagagctca	agttgaaatcc	5880
tgactttgct	acttattggc	tatatgacct	tgggcaagct	gcttagtctc	tctgatcctc	5940
agttaccctt	gtttgttgat	gatgaccatt	gataacacaa	ccataaataa	tgacaacata	6000
gagatagttc	tcattatagt	agttgttata	cagaattatt	cactcaatgt	taattttctg	6060
cattgaaatc	ccagaacatt	agaattgggg	gcattatttg	aatcttttaag	gttataagga	6120
atacattttc	cagcaataaa	tggaaggagt	tttgggttaa	cttataaagt	ataccaagt	6180
catttttttt	cagagaagat	atggtagaaa	gtcttaggag	gttgaagaag	gaattggata	6240
tttattcttt	ctgagactat	catgggagat	aatgactatg	gttgtccatg	attggagccg	6300
ttgctgtaga	gttgggttta	ttatagtgtg	ggatttgaat	ggggccatgtg	ttctcagacc	6360
tcagaataaa	aagagaaaac	tgaggccagt	ggggagcgtg	acttcacatg	ggtaacattg	6420
tgctagagac	agaaccagga	ttcaggactt	ctggctcctg	gtcctggggt	catggcccaa	6480
tgtagtcttt	ctcagtcctc	aggaggagga	agggcaggac	ccagtgttct	gagtcaccc	6540
gaatgtgagc	actattttact	tcgtgaactt	cttggcttag	tgctctgccc	aggtggccat	6600
aacctctggc	cttgtgttgc	cagagaaaag	gttttagttt	caggctccat	tgcttcccag	6660
ctgccaaagaa	tgccctgggtg	cagcacagtc	ataggccctg	cattctctcat	tgccgtgctg	6720
gttgggtcggg	gaggtgggct	ggactcgtag	ggatttgccc	cttggccttg	tttctaacac	6780
ttgccgtttc	ctgctgtccc	cctgccccct	ccactgcctg	ggtaaaagatt	gtcttgccag	6840
ctgtgtttgt	ctgcattggc	cttgtgttca	gcttgatcgt	gccacccttt	ggcaagtaac	6900
ccagcctgga	acttcagccc	tggatgtaca	acgaacagta	cacatttgtc	aggtatgttt	6960
gtcttctaca	tcccaggagg	gggtaagatt	cgagcagacc	aaagatgttt	acgagggcca	7020
agggaaatgga	cttcagaatt	acacgggtgga	at			7052

<210> 23
<211> 2534
<212> DNA
<213> Homo sapiens

<400> 23
gggaagcatt taaaaaaaaa aaagtatata tatatatata tatatatata tgtaattgtga 60
attggcctct ttttctctaa gcccacattt tcttcttaca tagttcaggt ttacttttatt 120
ttttcctttc cggctgctga ccctgtattg ccctgtagtg tggaacatag catgtgtttg 180
tgacctgtgc ctgttatatt tgtgctttct agttgtgcat gcaaagagta caaagttttc 240
ttgccccttc ttggaaaatc ctgcttctct gtgccaaagg gataattgtg aaagcacttt 300
tgaaatactt aatgagttga ttttcttcaa attaaaaaaaa atatatataat gtatatgtgt 360
atgtacatgt gtgtacacat acacaccttt atacatacag cccattttaa acaagctcca 420
ctttggagtg ctctacgtca ccttgatgcc gaatacaggg ccagagtctg agatccttct 480
gggtgggttc tgtgttttgt tcattttctg tttaagagcc tgtcacagag aaatgcttcc 540
taaaatgttt aatttataaa aacattttta tctctcgatt actggtttta atgaattact 600
aagctggctg cctctcatgt acccacagca atgatgtccc tgaggacacg ggaacctcgg 660
aactcttaaa cgcctcacc aaagacctg gcttcgggac ccgctgtatg gaaggaaacc 720
caatcccggt agtgccactt tagccataag cagggtctct tgtgcttgtt gctggtttg 780
atttctaata tgcgtcattt atcaactgca tgccacattg tgaccgccag catttgccct 840
ttgaattatt attatgtttt atttacaata agcgaaggta gtaaccgaac taaattatct 900
aggaacaaac gtttgagag tcttctaaca ccgyscaaag cactgcatta cagacatttg 960
tttactgtat tagaacctta atatttaatt taaatacgc ctttacactt actgatgaaa 1020
tgcttttctt tctttctct cccagccctt gtacttaagt gcttcaatag gctctcatta 1080
tatatgattt ttaggttttg cttatcagct tcttcgctt tataatctga aaagatggca 1140
tatgaatttt tataaaaagg gacactttct tcttctcaa ttgtatattt ttattgtact 1200
ttccttcaaa accccctttt aaaaagtaag cagtggataa ataaattcag tgaagcatcc 1260
atatgacctt taagttagtg taggggaagg gaggtcacca gatcactgtg agtgaagatg 1320
gtggagaggt gaggatctta tgaggccgtg ctcaaggctg gtagaggctg gttagtgttt 1380
ccaggtttag gcagaatctc agctgaggtc atgaaacaac agtgatctct gaaaaattat 1440
ggcaagggtg gaaggtgctg gagaattgga gagggggcaa acttgacttt caagtttcaa 1500
tgggaaagata ggtgactctg cacaccacag aacagtgagc atgataacct gtttatacaa 1560
ggttctagag cagatttcta aatggatagc tactgtgtgc ttgtttgttc ttaattagta 1620
ttggatagtt actaaatact tgtagtact tagtacataa tgggtggtaa atcctagcag 1680
ctaataattg ttcccaata accagatgac aaggatagag aaggacacag acacggccta 1740
tctggatttc atgtgacct tgattttcca catgaagggt gtagtagggaa gatagaagca 1800
tgagatgaga tgataatata gttatctgga tcatcactg gccagctgaa ccatatgaac 1860
tcatggattg atgctagctt aggaaggctc tgtaggagcc agaactgggc tgagagccag 1920
cccatagaga caaaagaggg ccggccctga catcagaggg ttcaaacatg atgtctgagc 1980
cccacctaca gtctgcccga ggtggttga aggaagagcc tttatcctta caattcttac 2040
tgaaattcaa atttttaggt ttgcaaaaa aatggtggac ctgaaggaaa tttgacagga 2100
gcatgtctca gctgtattta aatttgtctc agccaatccc cttttgaatg ttcagagtgt 2160
aagcttcagg agggcagcgc gtcttagtgt gacttttctg gtcagttcag gtgctttaag 2220
gagacaatta gagatcaatc tggaaaactt catttgaatt ttttaatacat aagaaaacaa 2280
taagaaatag ttaaaaatat atatttatat aatatatata tgtgtgtgtg tgtgtgtgtg 2340
tgtgtgtgtg tatatatata tatattttat ttattttatt ttttttgaga tggagtctcg 2400
ctctgttgcc caggctggag tgcagtggct caatcttggc tcaactgccac ctctgcctcc 2460
caggttcaag tgattctcct acctcagcct cctgagtagc tgggattaca agcatgtgcc 2520
accacactgg ctaa 2534

<210> 24
<211> 2841
<212> DNA
<213> Homo sapiens

<400> 24

tcttgccagt	ctctactcat	ttttcagcac	atcgagcata	agatccagac	tctttccag	60
gcctctctca	tctgggtcct	ctcctcctcc	tttatcatta	ctcttcttcg	tagcttatcc	120
tactccagcc	atgctgtctt	cctattatcc	ctaaaaarta	gaaatgcatt	tcttccctagg	180
gcctttgtac	ctgcacttgc	catcgctttt	gctcagaatg	ttctttttgc	caagcttttg	240
cccagcttgt	tctccatcat	tgttatgttt	tggtgaaat	gtcttctctt	agtaggttca	300
ttctccccag	tcaactgtct	tttattttgc	tttattttgg	gccatctaag	gttatcttat	360
tagtgtattt	gttggttcgtc	tcctccatgg	gcatacacct	ccatgaaggc	aggtattttc	420
accttaggcc	ctcgaatata	ctggacagca	tctggcacgt	agtagatgct	caacgaatgt	480
ttgttgtgtg	agcaaatggg	tgggttgattg	gattgaaactg	agttcagtat	gtaaatattt	540
agggcctctt	tgcatctctat	tttacttatg	tataaaatga	tacataatga	tgataataat	600
gatgtcacag	tgtacaaggc	tgttgtggga	tcaagcaatc	aaatgagatc	atgcttgtct	660
tttccaaatg	gtgaggggaat	agatgcattg	ttgtgtgtgt	tacgggaatga	tcctgtgtct	720
ctgaggcaac	agaaaggcca	ggccatctct	ggtaatccta	ctcttgcctg	cttccctttg	780
cagagacacg	ccctgccagg	caggggagga	agagtggacc	actgccccag	ttccccagac	840
catcatggac	ctcttccaga	atgggaactg	gacaatgcag	aaccttcac	ctgcattgcca	900
gtgtagcagc	gacaaaatca	agaagatgct	gcctgtgtgt	ccccaggggg	caggggggct	960
gcctcctcca	caagtgcagc	actttcaggg	ggtgattggg	cagaaggggt	gcaggatggg	1020
ctggtagctt	ccgcttgga	gcagggaatga	gtgagatata	atggtgggag	ggtctgtttc	1080
agtctttttt	gttttttgtt	tttttttctg	aggcggagtc	ttgctctgtc	gccaggctg	1140
gagtgtgtgt	gcattgatctt	gcctcactgc	aacctccacc	tcccagggtt	aagcgattct	1200
cctgcctcag	cctcctgagt	agctgggatt	acaggcacgc	accaccatgt	ctggctaatt	1260
tttgtgtttt	tagtagagat	aggttttctg	cgtgttggtc	aggctggtct	ggattctctg	1320
acctcagggt	atccaccgcg	ctcggcctcc	caaagtgtct	ggattacagg	cgtgagccac	1380
tacgcccagc	cctgtttcag	tctttaactc	gcttctgttc	ataagaaaaa	gcattgtgag	1440
tttgagggga	gaagggtttg	accacactgt	gcccatgcct	gtcccacagc	agtaaagtc	1500
caggacagac	tgtggcaggc	ctggcttcca	atcttggtct	tgcaacaaat	gagctggtag	1560
cctttgacag	gcctgggcct	gtttcttcac	ctctgaatta	gggaggtctg	accagaaaac	1620
tcctgtggat	cttgtcaact	ctgggtattct	tagagactct	gtttgggaag	gagtcctgag	1680
ccattttttt	tttcttgaga	atttcaggaa	gaggagtgtc	tatgatagct	ctctgctgct	1740
tttatcagca	accaaattgc	aggatgagga	caagcaatc	taaatgagta	cagggaactaa	1800
aagaaggcct	ggttaccact	cttgaaaata	atagctagtc	cagggtgcggg	gtggctcaca	1860
cctgtaactc	cagtattttg	ggatgcccag	gtggactgat	cacctaaagt	caggagttcg	1920
aaaccagctt	ggccaatgtg	gcgaaacctt	gtctctacta	aaaattcaaa	aattagccag	1980
gcattgtggc	acatgcctgt	aatcccagtt	acttgggagg	ctgaagcagg	agaattgctt	2040
gaacctggga	gggtggaggc	gcaggggagc	aaaattgcgc	cactgtactc	cagcctgagc	2100
aacacagcaa	aactccatat	caaaaaataa	aatgaataaa	ataacagcta	atctagtcat	2160
cagtataact	ccagtgaaca	gaagatttat	taggcatagt	gaatgatggg	gcttcctaaa	2220
aatctcttga	ctacaaagaa	tctcatattc	atgtttattg	tttagatgtt	cagaataaat	2280
tcttgggaaa	gaccttgggt	tgggtgaagt	gaattaccag	tggcgggggc	aggggtgaacc	2340
aagtctcagt	gctgggtgac	tgagggcagt	gtctgggacc	tgtagtcagg	tttccgggtc	2400
cactgtggac	atgggtcactg	ttgtccttga	ttgtttttct	gtttcaattc	ttgtctataa	2460
agaccctgat	gcttgggtttt	catgtgatga	cagagaaaac	aaaacactgc	agatattcct	2520
caggacctga	cagggaagaaa	catttcggat	tatctgggtg	agacgtatgt	gcagatcata	2580
gccaaaaggt	gacttttttac	taaaacttgg	ccctgcctta	ttattactaa	ttagaggaat	2640
taaagacctc	caaataacag	actgaaacag	tgggggaaat	gccagattat	ggcctgattc	2700
tgtctatttg	aagttagga	tattatccca	aactagaaaa	gatgacgaga	gggactgtga	2760
acattcagtt	gtcagcttca	aggctgaggc	agcctggtct	agaatgaaa	tagaaatgga	2820
ttcaacgtca	aattttgcca	c				2841

<210> 25

<211> 852

<212> DNA

<213> Homo sapiens

<400> 25

gcatgctgga	gtgatagtga	ccatgagttt	ctaagaaaga	agcataat	ctccatatgt	60
catccacaat	tgaaatatta	ttgttaattg	aaaaagcttc	taggccaggc	acgggtggctc	120
atgcctgtaa	tcccagcact	ttaggagcca	aggcgggtgg	atcacttgag	gtcaggagtt	180
tgagaccagc	ctggccaaca	tggggaaacc	ctgtctctac	taaaaataca	aaataagctg	240
ggcgtgggtg	tgcgtgcctg	taatcccagc	tacttgggag	gctgaggcag	gagaactgct	300
tgaatctggg	aggcggaggt	tgcaagtgagc	tgagttcatg	ccattgcatt	ccagcctggg	360
caacaagagc	gaaaccatct	cccaaaaaga	aaaaaaaaga	aagaaaaagc	ttctagtgtg	420
gttacatctt	gggtctataag	gtggttttgta	aattggttta	acccaaggcc	tggttctcat	480
ataagtaata	gggtattttat	gatggagaga	aggctggaag	aggcctgaac	acaggcttct	540
tttctctagc	acaaccctac	aaggccagct	gattctaggg	ttatttctgt	ccgttccctta	600
tatcctcagg	tggtatattta	ctccttttgc	atcattagga	ataggctcag	tgctttcttt	660
gaactgattt	tttgtttctt	tgtctctgca	gcttaaagaa	caagatctgg	gtgaatgagt	720
ttaggtaagt	tgctgtcttt	ctggcacgtt	tagctcaggg	ggaggatggt	gttgtaggtg	780
tgcttgggatt	gaagaaagcc	ttggggattg	ttgtcactc	acacacttgt	gggtgccatc	840
tcactgtgag	ga					852

<210> 26

<211> 6289

<212> DNA

<213> Homo sapiens

<400> 26

gctttataga	gtttctgcct	agagcatcat	ggctcagtc	ccagcagccc	ctccagaggc	60
ctctgaatat	ttgatatact	gatttccctt	aggagaatca	gaaatctcct	gcagggtgtct	120
agggatttca	agtaagtagt	gttgtgaggg	gaatacctac	ttgtactttc	ccccaaaacc	180
agattccoga	ggcttcttaa	ggactcaagg	acaatttcta	ggcatttagc	acgggactaa	240
aaaggcttta	gaggaaataa	gaagcgccaa	aacctctctc	ttgcaactga	tttcaaccga	300
tttgtccttc	tgggttttga	aggaacaggt	gggactgggg	acagaagagt	tcttgaagcc	360
agttttgtoca	tcattggaaaa	tgagataggt	gatgtggcta	cgtcaggggg	ccgaaggct	420
ccttggtact	gatttccgtc	ttttctctct	gccttttccc	caaggggccag	gacccctgga	480
tctctgggca	gagcagacgc	aggcccttat	aatagccctc	atgctagaaa	ggagccggag	540
cctgtgtata	aggccagcgc	agcctactct	ggacagtgc	gggttcccac	tctcccaact	600
cccactctgc	ttgcctccag	acccacattc	acacacgagc	cactgggttg	gaggagcatc	660
tgtagatga	aacaccattc	tttctcfaat	gtctcagcta	tctaactgtg	tgtgtaatca	720
ggccagggtcc	tccctgtctg	gcagaaacca	tgggagttaa	gagattgcca	acatttatta	780
gaggaaagctg	acgtgtaact	tctgaggcaa	aatttagccc	tcctttgaac	aggaatttga	840
ctcagtgaac	cttgtaacaca	ctcgactga	gtctgctgct	gatgatactg	tgacccccac	900
tgtctggggt	ttaatgtcag	gctgttcttt	taggtatggc	ggcttttccc	tgggtgtcag	960
taatactcaa	gcacttctct	cgagtcaaga	agttaatgat	gccatcaaac	aaatgaagaa	1020
acacctaaag	ctggccaagg	taaaatatct	atcgtaagat	gtatcagaaa	aatgggcatg	1080
tagctgctgg	gatataggag	tagttggcag	gttaaacgga	tcacctggca	gctcattgtt	1140
ctgaatatgt	tggcatacag	agccgtcttt	ggcatttagc	gatttgagcc	agacaaaact	1200
gaattactta	gttgtaacgtt	taaaagtgt	ggcctcaaac	aaatccagag	gccaggaggt	1260
gtggctcatg	cctgtaatcc	tagcactttg	ggaggctgaa	gcgggtggat	cacttgaggt	1320
caggaggttcg	agaccagcct	ggcctacatg	acaaaacccc	gtatctacta	aaaatacaaa	1380
aaaattagct	gggcttggtg	gcacacacct	gtaatcccag	ctacttggga	ggctgaggca	1440
ggagaattgc	ttgaaccctg	taggaagagg	ttgtagttag	ccaagatcgc	accgttgca	1500
tccagccttg	gcaacaagag	caaaaactcca	tctcaaaaaa	caaatataat	ccagagattt	1560
aaaagctctc	agaggctggg	cgcggtggct	tacacctgtt	atcccagcat	tttgggatgc	1620
cgaggcgggc	aaagcacaag	gtcaggagtt	tgagaccagc	ctggccaaca	tagtgaaacc	1680
ctgtctctgc	taaaaacata	gaaaaattag	ccgggcatgg	tggcgtgcgc	ctgtaatccc	1740
agcttactcg	gaggctgagg	tgagagaatt	rtttgaaccc	gggaggcgga	gggtgcagt	1800
agcccagatt	gcaccactgc	actccagcct	gggcgacaga	gcaagactcc	atctcaaaaa	1860
aagctctcag	aacaaccagg	tttacaatt	tgggtcagttg	gtaataaac	tgggtttcaa	1920

acatactttg	ctgaaayaat	cactgactaa	ataggaaatg	aatctttttt	tttttttttt	1980
taagctggca	agctggctcg	taggacctga	taagtactca	cttcatttct	ctgtgtctca	2040
ggtttcccat	ttttagggtga	gaattaaggg	gctctgataa	aacagaccct	aggattgtgg	2100
acagcagtga	tagtcctaga	gtccacaagt	ctgcttttga	gtgatgggcc	catgtatctg	2160
gcacatctgc	aggcagagcg	tggttctggc	tcttcagatg	atgccggtgg	agcactttga	2220
ggagtcctca	ccccaccgtg	ataaccagac	attaaaatct	tggggctttg	catcccagga	2280
tttctctgtg	attcctttcta	gacttgtggc	atcatggcag	catcactgct	gtagatttct	2340
agtcacttgg	ttctcaggag	cogtttattt	aatggcttca	catttaattt	cagtgaacaa	2400
ggtagtggca	ttgtctcttca	caggggccgtc	ctgttgtcca	cagggtccag	attgactgtt	2460
gccccttctc	tatgtgaaca	gtccacaactg	aggcagggtt	ctgttgttta	caggacagtt	2520
ctgcagatcg	atttctcaac	agcttgggaa	gatttatgac	aggactggac	accagaaata	2580
atgtcaaggt	aaaccgctgt	ctttgttcta	gtagcttttt	gatgaacaat	aatccttatg	2640
tttctctggag	tactttcaac	tcatgggtaaa	gttggcaggg	gcattcaca	cagaaaaagag	2700
caaactatta	actttaccag	tgaggcagta	cgggtgtagt	tagtgattca	gagaatttgc	2760
tttgcacca	gacataccag	gtaaccttga	ctaagtact	taacctatct	aaacctcagt	2820
tycctcatct	gtgaaatgga	gacagtaatc	atagctattt	ccaaactgtt	gtgagaattc	2880
aatgagttaa	aggtataagg	tcctcaccac	agcgcctgcc	cacatagtca	gtgatcacta	2940
tgctctgaac	actgtaatta	cttcgccata	ttctctgac	atagtgtttt	gccttgggtat	3000
gtgactagaa	tttctttctg	aggtttatgg	gcattgggttg	tgggtatgca	cctgcctgca	3060
ggagcccggt	ttgggggcat	taccttgtac	ctggtatgtt	ttctttcagg	tgtgggtcaa	3120
taacaagggc	tggcatgcaa	tcagctcttt	cctgaatgtc	atcaacaatg	ccattctccg	3180
ggccaacctg	caaaaggggag	agaaccctag	ccattatgga	attactgctt	tcaatcatcc	3240
cctgaatctc	accaagcagc	agctctcaga	gggtggctctg	taagtgtggc	tgtgtctgta	3300
tagatggagt	gggggcaagg	agaggttat	ggagaagggg	agaaaaatgt	gaatctcatt	3360
gtaggggaac	agctgcagag	accgttatat	tatgataaat	ctggattgat	ccaggctctg	3420
ggcagaagtg	ataagtttac	gaattggctg	gttgggcttc	ttgaactgca	gaagagaaaa	3480
tgacactgat	atgtaaaaat	cgtaacattt	agtgaattca	tataaagtga	gttcaaaaaat	3540
tgttaattaa	attataattt	aattataagt	gtttaatcag	tttgatttgt	ttaaaaacca	3600
ctgttttaaa	tttgggtggaa	tatgttttta	ttagcttgta	tctttaattc	ctaaattaaag	3660
ctgtgtgtgt	gtgtgtgtgt	gtgtgtgtgt	gtgtgtgtgt	gtgtgtgtgt	gaagtttaaa	3720
gccaggatga	gctagttaa	agtatgcagc	ctttggagtc	atacagatct	gggtttgaat	3780
ctgggtctcta	aactttatag	atgtatgata	ttaaatgagg	cagttcatgt	aaattgcca	3840
gcccagcact	cagcacagag	ttgatatttc	acacacatta	gatacctttc	ctgtatgtgg	3900
agcatggcag	tcctgttttc	tgctttactc	ctacaggata	ctaatatagg	acactaggat	3960
ctttatacca	agaccccatg	taatgggctt	atgagaccat	tcttcttata	aaaatctgac	4020
agaatttttg	tatgtgttag	atcaataggc	tgcatactgt	tattttcaag	ttgatttaca	4080
gccagaaata	ttaattttatt	tgagtagtta	cagagtaata	tttctgctct	catttagttt	4140
tcaagcccca	ctagtctctt	gtgtgtgaaa	atttacaact	tactgctctt	acaaggctcat	4200
gaacagtggg	ccaaagtga	tgccattaac	cactctgact	tccttcatta	gtttttatgt	4260
gacagtggac	tcttttgacc	tcagtaatac	cagtttggca	tttacattgt	catattttta	4320
gacttaaaaa	tgatcatctt	aaccttgaat	aaaatgtgtc	tgggtgaacag	atgtttttcc	4380
ttggctgtgc	ctcagatata	tctgtgtgtg	tgtacgtgtg	tggttgtctg	tgtgtccatg	4440
tcctcactga	ttgagcccta	actgcatcaa	agacccctca	gattttccaca	cgctttttct	4500
ctccaggatg	accacatcag	tggtgtcctt	tgtgtccatc	tgtgtcatct	ttgcaatgtc	4560
cttcgtccca	gccagctttg	tcgtattcct	gatccaggag	cgggtcagca	aagcaaaaaca	4620
cctgcagttc	atcagtggag	tgaagcctgt	catctactgg	ctctctaatt	ttgtctggga	4680
tatggtaagg	acacaggcct	gctgtatctt	tctgatgtct	gtcaggggcca	tggattgata	4740
tggataagaa	agaaagagct	ctggctatca	tcaggaaatg	ttccagctac	tctaaagatg	4800
tatgaaaaag	aaatagccag	aggcagggtga	tcactttcat	gacacaaaac	acagcattgg	4860
gtaccagagt	tcattgtcaca	ccagaggga	aattctgtac	acaatgatga	aaattaatac	4920
cactaccact	taagttccta	tgtgacaact	ttcccaagaa	tcagagagat	acaagtcaaa	4980
actccaagtc	aatgcctcta	acttctctga	tgggttttaa	cctccagagt	cagaatgttc	5040
tttgccttac	taggaaaagg	atctgtcatt	tagaaaaactc	tgtacatttt	atcagcagct	5100
tatccatcca	ttgcaaatat	tgtttttgtg	ccasccacaa	tatatgtgct	ctatttggac	5160
caatatgggg	gatttgaagg	aattctgaag	ttctaattat	atttcaactc	tactttacaa	5220

tatctccctg	aaatatatct	cactgtaact	tctattaatt	ataagctaca	cagagcaaat	5280
ctaattcttc	tcccaccgaa	caagtccttg	gataatttaa	aataactctc	atactctcat	5340
ttaacctgag	tattacccag	ataagatgat	atatgagaat	acaccttgta	acctccgaag	5400
cactgtacaa	atgtgagcaa	tgatgggtgga	gatgatgatg	agatctttgc	tgtttatacc	5460
aagcccttta	gactgtgtca	ctcttctgat	ccggttggtc	ttgtatggcc	atgctgtata	5520
ttgtgaatgt	cccgttttca	aaagcaaagc	caagaattaa	ccttgtgttc	aggctgtggt	5580
ctgaatgggt	atgggtccag	agggagttga	tctttagctc	acacttctat	tactgcagca	5640
caaagatgtt	gcatttttga	aggagcaccg	tcttactggc	aacttagtgg	taaaccaaaa	5700
cctocatttc	acacaaatga	ttgtgaaatt	cgggtctcct	tcattctata	caaattcatt	5760
tgattttttt	gaaactaaac	tttatattta	tccatattaa	attacatggg	ttttattttt	5820
gtttttatct	gattcagtaa	ttactccttt	cagtaaaccac	agactgagtg	ctgtgtgtct	5880
gacttatgcc	aggcataggt	gattcagaga	tgaaagggtca	agtccttgaa	cccatctctt	5940
gtcttctctg	gtattatctg	tccctccctg	ctttagagct	cctgaaattt	gctagaagca	6000
tgtcttcatc	taagttgttg	ataaacacat	caagtaggat	tggactgagg	cagagccctg	6060
tagtctgaag	ctgcagttct	tctagcggct	gacaagcccc	actatcactt	ccctctctgt	6120
gctttgtctc	gccagctgtg	aattctcata	attgtcctat	cgtcaagtct	ttatttctgc	6180
attttactgc	ttgatacact	gtcaggacag	actttaaaat	tattctcagt	gcatgaaac	6240
aattctgaca	ttcatgttat	gagcagttac	ctcataaata	gattacatg		6289

<210> 27

<211> 4244

<212> DNA

<213> Homo sapiens

<400> 27

aaattactct	gactgggaat	ccatcggtca	gtaagtttac	tgagctgtac	accttggctt	60
gactgttggg	aagacagaaa	gggcatgtag	tttataaaat	cagccaaggg	gaaaatgctt	120
gtcaaaatgt	attgtcgggt	attttgatta	atagtttatg	tggcttcatt	aattcagagt	180
tactctccaa	tatgtttatc	tgccctttct	tgtctgataa	tgggtgaaaac	ttgtgtgatg	240
cattgtatat	ttgatttagg	gggtgaactgg	atgtctttgt	tttcactttt	agtgcattta	300
cgttgtccct	gccacactgg	tcattatcat	cttcactctg	ttccagcaga	agtcctatgt	360
gtcctccacc	aatctgcctg	tgctagccct	tctacttttg	ctgtatgggt	aagtcacctc	420
tgagtggagg	agctgcacag	tggataaggc	atttgggtgc	cagtgtcaga	aggagggcag	480
ggactctcag	tagacactta	tctttttgtg	tctcaacagg	tgggtcaatca	cacctctcat	540
gtaccacgcc	tcctttgtgt	tcaagatccc	cagcacagcc	tatgtgggtg	tcaccagcgt	600
gaacctcttc	attggcatta	atggcagcgt	ggccaccttt	gtgctggagc	tgttcaccca	660
caatgtgagt	catgcagaga	gaacactcct	gctgggatga	gcattctctg	gagccagagg	720
acagtgttta	attgtgatct	tattccactt	gtcagtggta	ttgacactgc	tgactgcctt	780
gtcctgtctt	cagagtctgt	cttccctgag	aaggcaaaag	acctttcttt	cttgcgtgtg	840
cttacatttt	gctgggtcaag	ccctttcagt	tcttttgaca	gtttttttta	cttctttctt	900
ttttcaatgt	tgctcttacc	aagagttagt	cctctgcctt	ccactttaca	catgagagct	960
gggcgacgca	ttcagtccta	aggcttttac	catcacctct	cttgggtgtt	ttattgtcat	1020
ctctaagatc	aatgccttta	gccttgatca	taaccttgaa	ctctaactct	aaattctcac	1080
ttgcctagtg	gattgctcca	tttagatagt	atatagatac	cccaacctgg	atatgtccta	1140
gtttttcttt	cccttgggaa	ttaatgcttt	tcttgccatc	cctgtcacac	tcagtggcac	1200
taccatccac	tgggttgccc	aagctggctc	ttagagttat	cctagatgct	tgccttgcct	1260
ttgcagatgt	cccacattca	actgggttat	ttgtcagttc	ttccaggtat	ggacctctaa	1320
aataaggcct	cctctccatt	ccggttgtca	ttgcctttgt	ccaaacacag	cacacaaggc	1380
ctttttacagt	tgcacaactc	ttcctgtcca	tacccaccac	accttttccc	agctgtaagc	1440
ttcagatgag	ttgcctccaa	ccaccatgct	cctgtaggcc	tggcttgaaa	tgcccttctt	1500
ctgtcacagg	gtctggtagt	atatcccttg	cccttcaaga	tttagctaaa	atgtgaaagt	1560
ttccttacct	gctgggaggt	gttctctctt	ttctctgtgc	tctcagagtc	cttagtccat	1620
gcctccagta	caacgtacat	ccacttacat	ggtaatttcc	tgttttacata	cttttccctac	1680

tcggagtggga	gtctgtttct	taataatttt	gcctctccca	tgccctagca	cagtgcctcc	1740
agcgtatagc	cccttattca	gttggttagat	atctggccac	tggtgccttg	tggtgacata	1800
agttctgatg	tatttgagaa	gaattttctaa	aattctgaca	aaatccctgaa	actcaaatat	1860
tgaccocagac	atgagcaatt	tgcttttcaa	atgctaaggg	atttttaatg	gatttgcttt	1920
aattaaatct	agcctgtttc	taagctttat	tcattatttc	tcataactca	gagcatttct	1980
ccagattttc	taaagaatag	aattttattg	ctacatatca	tcagctatgc	ctgctgctat	2040
tttaattggta	tctgaattaa	aaggctcggg	ttgtccctag	agaatcaaat	tttttcttca	2100
ctcccatatt	tcagaacttg	atacattttt	aggataaaac	atgaatgaca	ccgtttcttt	2160
ctccctcacc	ctcccttccc	tcccattttt	tttttttttt	tttttttagaa	gctgaataat	2220
atcaatgata	tcctgaagtc	cgtgttcttg	atcttcccac	atttttgctt	gggacgaggg	2280
ctcatcgaca	tggtgaaaaa	ccaggcaatg	gctgatgccc	tggaagggtt	tggtgagtga	2340
agcagtggtc	gtaggatgct	tttaattggaga	tggtcactctg	cataggcctt	ggtaccctga	2400
actttgtttt	ggaaagaagc	aggtgactaa	gcacaggatg	ttccccacc	cccatgccc	2460
gtgacagggc	tcctgccaac	acagctgggt	gtggcatggg	ttttgtgaca	caaccatttg	2520
tctgtgtctc	tgatagcatt	gagaaaagtg	aaagggcagt	tttgaaggta	aggaaaatag	2580
tgttattttg	ttggatccac	tggtcctatg	cactgtcttg	gttgggttaga	agcactggaa	2640
aagtcaaac	ataactttga	gaattaggtg	atcaggggat	cagaaggaaa	gatgcaaac	2700
ttggctcttt	taggcgaatc	atgtgcctgc	agatgaggtc	atttattatc	ttttacacag	2760
tcctataaaat	tataatgtat	tacatctttt	tctaccttta	gaatggttta	aaatatttct	2820
cggtagccca	tatgattatt	attcatccat	tagataatat	agtcaaaatg	gcatgttat	2880
ttactgttca	tagaagaggg	gctttttgca	acttgggcta	caaaggagat	atgtaaggaa	2940
tttaagggaat	ggttacatgg	aactagatgt	aattgaatct	agtggtttta	ttgattcact	3000
aggatatatg	ctactgaaag	gggaactctg	ttaaagtgtc	ttctgatatt	tattattact	3060
aaaacttaga	atttattaaa	aatactgact	gtgaaaatta	cttgggtcgt	ttgctttttt	3120
aaaaggatgt	ttggcatgtc	tcattaaaaa	aagaaatact	agatatcttc	agtgaagtta	3180
caaatcgaat	acacattggc	tctgaaatct	tgattgatac	tggttcataa	aaagttttcc	3240
caaatcagac	ttggaagtgt	atcactctct	tgttactctt	ttttccttgt	catgggtgat	3300
agccatttgt	gtttatttga	agatcgggtg	attttaagg	acataggccc	aaatttgagg	3360
aagggccatg	gtttttgatc	cctccattct	gaccggatct	ctgcatttg	tctactaggg	3420
gagaatogct	ttgtgtcacc	attatcttgg	gacttggtgg	gacgaaacct	cttcgccatg	3480
gccgtggaag	gggtgggtgt	cttccctcatt	actgttctga	tccagtacag	attcttcac	3540
aggccaggt	gagctttttc	ttagaacctg	tggagcacct	gggtgaggg	cacagaggag	3600
gcgcacaggg	aaadactaac	caatgggggt	tgcatggaac	tgaactcaaa	atatgtgata	3660
aaactgattt	tcctgatgtg	ggcatccctc	agcccccctc	ctgcccctcc	tgagactgt	3720
ggcaagttagg	ttttataata	ctacgttaga	gactgaatct	ttgtcctgaa	aaatagtgtg	3780
aaagggtcat	ttttcttgtt	ttttccccc	agacctgtta	atgcaaagct	atctcctctg	3840
aatgatgaag	atgaagatgt	gaggcgggaa	agacagagaa	ttcttgatgg	tgagggccag	3900
aatgacatct	tagaaatcaa	ggagtgtacg	aagggtgag	agtacaggtt	acaatagctc	3960
atcttcagtt	tttttcagct	ttatgtgctg	taaccagca	gtttgctgac	ttgcttaata	4020
aaagggcatg	tgttcccaaa	atgtacatct	ataccaaggt	tctgtcaatt	ttattttaaa	4080
aacaccatgg	agacttctta	aagaattctt	actgagaatt	cttttgatg	atgaattccc	4140
attctcgaat	actttgggtt	tatatgctta	catttatgtg	ttagtattta	aaacatacta	4200
atattgtata	tctagtcaaa	ctgagtagag	agataatggt	gatt		4244

<210> 28

<211> 5023

<212> DNA

<213> Homo sapiens

<400> 28

ttttaaaata	cctgcaatac	atatatatgt	tgaatagatg	aaaaattatg	tagatgataa	60
tgaatgatac	ggttctaaaa	agacagggtta	aaaagtaagt	tcactttttat	tttgagcttc	120
agaatcattc	agaagccagt	cgccacaaac	gcagaccaag	gctcttgcca	catcaaatat	180
gcctatggct	taggggtatt	gacaagtctt	atggtgcagt	gtatgtgggt	tatagtcctg	240
ccttcacacg	ttgcttggga	gagctgtgag	tcactgagge	ttatgaatgt	ttacattttg	300

tttgttgag	atatatagaa	ggaagcggaa	gcctgctgtt	gacaggattt	gcgtgggcat	360
tcctcctgg	gaggtaaaga	cactttgtct	atattgcgtt	tgccctatt	agttcagact	420
atctctacc	aatcaagcaa	cgatgctcgt	taagaggtaa	aagtggattt	taaaggcttc	480
tgtattttat	ccaggatgga	gcaatttagtc	atcgagaaga	gagggaccct	gtatgtcaag	540
agaatgattt	cagagaatgc	aatacaattt	aagaaaaagc	atggggctgg	gcgcagtgat	600
tcactcctgt	aatcccagca	ctttggggag	ccgagggtgg	cggaactcac	aggtcaggag	660
attgagacca	tcctggccaa	catggtgaaa	ccccatctct	actataaata	caaaaatttag	720
ctggggcatag	tagtgcatte	ctgtagtcct	agctactcgg	gaggctgagg	caggagaatt	780
gcttgaacct	aggaggggga	gggtgcccag	attgcctgc	tgcaactccag	cctgggtgaca	840
gagtgagact	catgtcaaca	acaaaaacag	aaaaagcacg	cacatctaaa	acatgctttt	900
gtgatccatt	tgggatgggt	atgacattca	aatagttttt	taaaaataga	ttttctcctt	960
tctgtgttcc	gtttgtgttc	ttttatgccc	ttttgccaga	gtagggtggg	caatttgggt	1020
agctggcttt	cattactggt	tttcacacat	taactttggc	ctcaacttga	caactcaaat	1080
aatattttata	aatacagcca	cacttaaaat	gggtccatta	tgaataacat	atttaaatat	1140
ctatacgtat	tggttaaaacc	aagaaaatat	ttgattcttc	tctgataatt	aagaattgaa	1200
ggtttcgagt	agttacgtgt	taggggcatt	tatatctatg	tttttagagt	ttgctttatc	1260
aacttaactct	ttccttttca	gtgctttggg	ctcctgggag	ttaatggggc	tggaaaatca	1320
tcaactttca	agatgttaac	aggagatacc	actgttacca	gaggagatgc	tttccttaac	1380
aaaaataggt	gagaaaagaa	gtggcttgta	ttttgctgca	aagactttgt	ttttaattta	1440
tttaaaagaaa	taggttggtta	tttttgatta	cagtggtatt	tttagagttc	ataaaaatgt	1500
tgaaatatag	taaagggttaa	agaagcacat	aaaatcatcc	atgatttcaa	tatctagaga	1560
taatcacaat	ttacattttcc	tttcagtctc	attctcttct	tttaacagct	ttattcaggt	1620
ataatttaca	tacaatataa	tttgcttggt	ttttaagagt	ataatttagt	gatttttggg	1680
aaattgagag	ttttgcaacc	atcaccacaa	tccagtttta	gaacttttcc	atcaccaccac	1740
atctgtctta	tatacacata	taaatgtgcc	atacaattga	gatcatactg	tatgtagaat	1800
ttaaaattag	tttttattgt	taatgagttg	attatgaata	tttcccagtg	ggttacattt	1860
cctaagatgt	ggaattttac	attgctacat	aaaatccccc	tatgtacatg	tacctataat	1920
ttattttaata	aattccttat	aaatgttga	cacattagtt	tccatttttc	actatgtaaa	1980
tatgtccctg	tatacatctt	ttattatttc	ctcagggaaca	attcctacaa	agtaaatgtc	2040
cctctctaaa	gagcatacaa	attgactgag	ccaccgttag	gccattttct	gagactgcac	2100
agggtcacaaa	gcaatctgat	ctttgggaat	acagctacat	tttataggct	tcttagataa	2160
tgttactcta	agtactttaa	atatgtgggg	cttctctggg	cttttttttt	tttgagacgg	2220
agttttcactc	ttactgcccc	ggctggagag	caatggcgcg	accttggctc	actgcaacct	2280
ccgcctccca	ggttcaagcg	attctcctgc	ctcagcctcc	tgagtagctg	agattacagg	2340
tgcccgccac	aatgcctgcc	taattttttt	gtattttcag	tagagatggg	gtttcaccat	2400
gttggccaga	ctggtctcga	gctcctgacc	tcagggtgatc	cacctgcctc	agcctcccaa	2460
agttctggga	ttacaggcat	gagccactgc	gcccggcttc	tctggactta	ttatgtggag	2520
agatagtaca	aggcagtggc	tttcagagtt	ttttgaccat	gaccgttggt	ggaaatacat	2580
tttatatctc	aacctagtat	gtacacacag	acatgtagac	acatgtataa	cctaaagtgt	2640
cataaagcag	tacctactgt	tactaattgt	agtgcactct	gctattttct	attctacctt	2700
atactgcgtc	attaaaaaag	tgtgtgtcat	gaccactaa	atttatttcc	caaaccacta	2760
atgaacaatg	actcacaatt	tgaacacact	ggacaggggg	atagccaata	aaattgaaaa	2820
gagcaaggaa	attaatgtat	tcattgatctc	ctctcctgtc	tcttacattt	ttgcagtagc	2880
aatgtaaaag	aatcctaaga	gaacagacat	tctgggaata	gcaggcctag	cgtgcacaaa	2940
ctgcttttct	aggttgcctc	ctagtaccaa	gctcctgacg	catatagcag	tggcagtaat	3000
aaccagccca	tagtaagggt	tgtcacaggg	actggttgta	agaactgatt	tgrttgggtat	3060
agctgtgagg	gcctggcacg	gtgtccacgt	gtgcctcaat	cctaattctg	aaaaaggctg	3120
accctggggg	tgctaattag	atacacagag	aggaatgaat	gctgccagaa	ggccaagtcc	3180
atggcaatgc	cgctgtggct	gaggtgcagt	catcagtcct	gaacgtgaac	actgaacttc	3240
tctcacatgt	gattctttcac	ttgactggct	tcatagaacc	ccaaagccac	cccaccacca	3300
cataaattgt	gtctctaggt	tctgtgttgc	tcacactcaa	aattttctggg	cctttctcatt	3360
tgggtgcatgt	gaatggtgca	tatgagttaa	gtctagtagt	gggccttagc	gttaaaagccc	3420
tggggtagtg	tgactgagat	tgttggtaaa	gaatgtgcag	tgggtggcat	gacctcagaa	3480
attctgaaat	gggactgcac	ctgcagactg	aagtgttcag	agagccaggg	aggtgcaagg	3540
actggggagg	gtagaggcag	gaaccctgcc	tgccagggaag	agctagcatc	ctgggggag	3600

aaaggctgtg	ctttcaagta	gcagcagatg	tattggtatc	tttgtaatgg	agaagcatac	3660
tttacaggaa	cattaggcca	gattgtctaa	ccagagtatc	tctacctgct	taaaatctaa	3720
gtagttttct	tgtcctttgc	agtatcttat	caaacatcca	tgaagtacat	cagaacatgg	3780
gctaactgcc	tcagtttgat	gccatcacag	agctgttgac	tgggagagaa	cacgtggagt	3840
tctttgccct	tttgagagga	gtcccagaga	aagaagttgg	caaggctactg	tgggcacctg	3900
aaagccagcc	tgtctccttt	ggcatcctga	caatatatac	cttatggctt	ttccacacgc	3960
attgacttca	ggctgttttt	cctcatgaat	gcagcagcac	aaaatgctgg	ttctttgtat	4020
ctgctttcag	gggtgaaacc	tgtaacgggtg	gtggggcagg	gctgggtggg	cagagagggga	4080
gtgcttgctcc	caccacacga	gtcccttctc	cctgcttttg	ctcctcacca	gttgtcaggt	4140
tatgattata	gaatctagtc	ctactcagtg	aaagaacttt	catacatgta	tgtgtaggac	4200
agcatgataa	aattcccaag	ccagaccaaa	gtcaagggtgc	tttttatcac	tgtaggttgg	4260
tgagtggggc	attcggaaac	tgggctctgt	gaagtatgga	gaaaaatatg	ctggtaacta	4320
tagtggggc	aacaaacgca	agctctctac	agccatggct	ttgatcggcg	ggcctcctgt	4380
gggtgtttctg	gtgagtataa	ctgtggatgg	aaaactgttg	ttctggcctg	agtggaaaac	4440
atgactgttc	aaaagtccta	tatgtccagg	gctgttgtat	gattggcttg	tcttccccca	4500
gggacagcag	agcaaccttg	gaaaagcaga	gggaagcttc	tcccttggca	cacactgggg	4560
tggctgtacc	atgcctgcag	atgtcccaa	atagaggcac	tccaagcact	ttgtttctta	4620
gcgtgattga	ggctggatat	gtgatttgat	cttctctctg	aacattcttt	ctaatactct	4680
ttgtgttcat	tccctgaaaa	tgaagagtgt	ggacacagct	ttaaaatccc	caaggtagca	4740
actaggtcat	agttccttac	acacggatag	atgaaaaaca	gatcagactg	ggaagtggcc	4800
cttgaccttt	tttctctctg	agataagagc	attgatgtta	ttacgggaag	aagcctttga	4860
ggcttttatg	tattccacct	cgtctctgaa	tttgtttctg	taaggctaac	agttgcaata	4920
tactagggtg	atctgagtga	gctggaatta	aaaaaaaaaa	ggaatttcac	cccaatctta	4980
tactgacttc	aatagaggtt	tcagacaaaa	agttgttttg	tat		5023

<210> 29

<211> 5138

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<222> (1)...(5138)

<223> n = a, t, c, or g

<400> 29

ngccnngttt	aaaangaaaa	tttnnnnmaa	attnaanntt	annngngnnn	tttccccaga	60
aaaaacnaaa	angatttccn	cccnnggggg	ncccccnant	cnaaaaggcc	ccncttnttt	120
gnngngaggg	aaagnttttt	ttggaatttt	taattttttg	tcccccaaaa	cctattattg	180
agaattttaat	tacataaaaa	agtactcaga	atattttgagt	ttcctgcac	aataagacat	240
ttataataat	gaccttgttt	acaaatgaat	ttgaaagtta	ctctaattct	ttgattcatc	300
aagaaataac	tagaatggca	agttaaaaat	taagctgttt	caaagatgct	tctgcattta	360
aaaacaaatt	tatctttgat	tttttttccc	cccagcaaat	aagacttatt	ttattctaat	420
tacaggatga	acccaccaca	ggcatggatc	ccaaagcccg	gcggttcttg	tggaaattgtg	480
ccctaagtgt	tgtcaaggag	gggagatcag	tagtgcttac	atctcatagg	tccgtagtaa	540
agtcttgggt	tcctcactgt	gggatgtttt	aactttccaa	gtagaatatg	cgatcatttt	600
gtaaaaatta	gaaaaatacag	aaaagcaaa	agtaaaacaa	ttattacctg	aaattatata	660
tgcataattct	tacaaaaatg	caagcccagt	ataaatactg	ctctttttca	cttaatatat	720
tgtaaacatt	attccaagtc	agtgcattta	gggtgcattt	cttatagctg	gatagtattc	780
cattaggata	tactcttatt	taactattcc	cccttttgta	gacatttgga	ttatttccaa	840
cttggttcaca	attgtaaaca	ccactacact	gaacagcatc	atccctatat	cccatgtac	900
ttgtaacaga	atacaattcc	ctaggaagct	ggaatgctgg	aagtcattgg	gatgttctca	960
tggttacaga	gaatctctct	aaaactaaaa	cctctttctg	ttttaccgca	gtatggaaga	1020

atgtgaagct	ctttgcaacta	ggatggcaat	catgggtcaat	ggaagggttca	ggtgccttgg	1080
cagtggtccag	catctaaaaa	ataggtaata	aagataattt	ctttgggata	gtgcctagtgt	1140
agaaggcttg	atattttatc	ttttgtgagt	atataaatgg	tgccctctaaa	ataaaggga	1200
ataaaactga	gcaaaacagt	atagtggaaa	gaatgagggc	tttgaagtcc	gaactgcatt	1260
caaattctgt	ctttaccatt	tactgggtct	gtgactcttg	ggcaagttac	ttactactgt	1320
taagagttag	tttccctgga	agatctacct	cctagctttg	tgctatagat	gaaatgaaaa	1380
aaattttacat	gtgccagtac	tggtgagagc	gcaagctttg	gagtcacaca	caaattgggtt	1440
tgcatccctgg	ccctaccaat	tatgagctct	gagccatggg	caagtgcacta	actccctggg	1500
cctcagtttc	tctgtaacat	ctgtcagact	tcattgggtcc	agggtaggat	taaaggagat	1560
catgtattta	cagcacatgg	catgggtgctt	cacataaaat	aagtatttag	taaatgataa	1620
ctgggttccct	ctctcagaaa	cttattttctg	ggcctgcccag	gggcccgcctt	ttttcattggc	1680
acaagtgtggg	ttcccagggt	tcagtattct	tttaaatagt	tttctggaga	tcctccattt	1740
gggtattttt	tcctgcttct	agggttggag	atgggttatac	aatagtgtga	cgaatagcag	1800
ggtcccaacc	ggacctgaag	cctgtccagg	atttcttttg	acttgcattt	cctggaagtgt	1860
ttcyaaaaga	gaaacaccgg	aacatgctac	aataccagct	tccatcttca	ttatcttctc	1920
ttggccaggat	attcagcatc	ctctccaga	gcaaaaagcg	actccacata	gaagactact	1980
ctgttttctca	gacaacactt	gaccaagttaa	gctttgagtg	tcaaaacaga	tttacttctc	2040
agggtgtgga	ttcctgcccc	gacactcccg	cccataggtc	caagagcagt	ttgtatcttg	2100
aattgggtgct	tgaattcctg	atctactatt	cctagctatg	ctttttacta	aacctctctg	2160
aacctgaaaa	gggagatgat	gcctatgtac	tctataggat	tattgtgaga	atttactgta	2220
ataataacca	taaaaactac	catttagtga	gcacctacca	tgggccaggc	attttacttg	2280
gtgcctaata	ctattttaat	tagataaaaa	agtaccaa	agggtcctgac	acttaagaag	2340
tactccagtaa	atattttctt	ccctcttccc	tttaatacaag	accgtatgtg	ccaaagttaa	2400
tggtatgactg	agcagttggg	gatgtagggg	tgggggggcga	tatagaaagt	cagtttttgg	2460
ccgggctggtg	tggtctcatgc	ctgtaatccc	agcacttttg	gagggtgagg	agcaggcaga	2520
tcattgaggtc	aggagatcca	gataatcctg	gccaacaggg	tgaaaccccg	tctctactaa	2580
aaatacaaaa	attagctggg	catgggtggg	cgcacttgta	gtcccagcta	cttgcgaggc	2640
tgaggcagga	gaattgctcg	aacccaggag	gtggagggtta	cagtgcagcca	agggtctcgcc	2700
actgcactcc	agcctgggga	cagagcaaga	ccccatttca	aggggggaaa	aaaagtctat	2760
ttttaagttg	ttattgcttt	tttcaagta	tcttccctcc	ttcacacaca	gttttctagt	2820
taattccattt	atgtaattct	gtatgctcct	acttgacctt	atttcaacat	ctgggaaaaat	2880
agaactagaa	taaaagaatga	gcaagttgag	tggtatttat	aaagggtccat	cttaattcttt	2940
taacagggtat	ttgtgaactt	tgccaaggac	caaagtgatg	atgaccactt	aaaagacctc	3000
tcattacaca	aaaaccagac	agtagtggac	gttgcagttc	tcacatcttt	tctacaggat	3060
ggagaaagtga	aagaaagcta	tgtatgaaga	atcctgttca	tacgggggtg	ctgaaagtaa	3120
agagggaacta	gacttttctt	tgccaccatgt	gaagtgttgt	ggagaaaaga	gccagaagtt	3180
gatgtgggaa	gaagtaaaact	ggatactgta	ctgatactat	tcaatgcaat	gcaattcaat	3240
gcaatgaaaa	caaaaattcca	ttacaggggc	agtgcccttg	tagcctatgt	cttggtatggc	3300
tctcaagtga	aagacttgaa	tttagttttt	tacctatacc	tatgtgaaac	tctattatgg	3360
aacccaatgg	acatatgggt	ttgaactcac	actttttttt	ttttttttgt	tcctgtgtat	3420
tctcattggg	gttgcaacaa	taattcatca	agtaatcatg	gccagcgatt	attgatcaaa	3480
atcaaaaggt	aatgcacatc	ctcatttact	aagccatgcc	atgcccaggga	gactgggtttc	3540
ccggtgacac	atccattgct	ggcaatgagt	gtgccagagt	tattagtgtcc	aagtttttca	3600
gaaagtttga	agcaccatgg	tgtgtcatgc	tcactttttg	gaaagctgct	ctgctcagag	3660
tctatcaaca	ttgaatatca	gttgacagaa	tggtgccatg	cgtgggctaac	atcctgcttt	3720
gattccctct	gataagctgt	tctgggtggc	gtaacatgca	acaaaaatgt	gggtgtctcc	3780
aggcacggga	aacttgggtc	cattgttata	ttgtcctatg	cttcgagcca	tggtgtctaca	3840
gggtcatcct	tatgagactc	ttaaatatac	ttagatcctg	gtaagaggca	aagaatcaac	3900
agccaaactg	ctggggctgc	aactgctgaa	gccagggcac	gggattaaag	agattgtgcg	3960
ttcaaaccta	gggaagcctg	tgcccatattg	tcctgactgt	ctgctaactg	ggtacactgc	4020
atctcaagat	gtttatctga	cacaagtgtg	ttattttctg	ctttttgaa	taattctagaa	4080
aatgaaaaga	tggtgtgtga	ttttgacaaa	aatgtttgtg	cttttttaag	ttatttggaa	4140
ttttaagttc	tatcagtgac	ttctgaatcc	ttagaatggc	ctctttgtag	aacctgtgtg	4200
tatagaggag	tatggccact	gcccactatt	tttattttct	tatgtaagtt	tgcatatcag	4260
tcattgactag	tgccctagaaa	gcaatgtgat	gggtcaggatc	tcattgacatt	atatttgagt	4320

ttctttcaga	tcatttagga	tactcttaat	ctcacttcat	caatcaaata	ttttttgagt	4380
gtatgctgta	gctgaaagag	tatgtaogta	ogtataagac	tagagagata	ttaagtctca	4440
gtacacttcc	tgtgccatgt	tattcagctc	actggtttac	aaatataggt	tgtcttgagg	4500
ttgtaggagc	ccactgtaac	aatactgggc	agcctttttt	tttttttttt	taattgcaac	4560
aatgcaaaag	ccaagaaagt	ttaaggggtca	caagtctaaa	caatgaattc	ttcaacaggg	4620
aaaacagcta	gcttgaaaac	ttgctgaaaa	acacaacttg	tgtttatggc	atttagtacc	4680
ttcaaataat	tggtcttgca	gatattggat	acccatttaa	atctgacagt	ctcaaatttt	4740
tcactctctc	aatcactagt	caagaaaaaa	tataaaaaca	acaaatactt	ccatatggag	4800
cattttttcag	agttttctaa	cccagtcctta	tttttctagt	cagtaaacat	ttgtaaaaat	4860
actgtttcac	taatacttac	tggttaactgt	cttgagagaa	aagaaaaata	tgagagaact	4920
attgtttggg	gaagttcaag	tgatctttca	atatcattac	taacttcttc	cactttttcc	4980
agaatttgaa	tattaacgct	aaaggtgtaa	gacttcagat	ttcaaattaa	tctttctata	5040
ttttttaaat	ttacagaata	ttatataacc	cactgctgaa	aaagaaacaa	atgattgttt	5100
tagaagttaa	aggtcaatat	tgatttttaa	atattaag			5138

<210> 30

<211> 20

<212> DNA

<213> Homo sapiens

<400> 30

gtgttcctgc agagggcatg

20

<210> 31

<211> 20

<212> DNA

<213> Homo sapiens

<400> 31

cacttccagt aacagctgac

20

<210> 32

<211> 21

<212> DNA

<213> Homo sapiens

<400> 32

ctttgcgcat gtccttcacg c

21

<210> 33

<211> 21

<212> DNA

<213> Homo sapiens

<400> 33

gacatcagcc ctcagcatct t

21

<210> 34

<211> 19

<212> DNA

<213> Homo sapiens

<400> 34

caacaagcca tgttcctc 19

<210> 35
<211> 18
<212> DNA
<213> Homo sapiens

<400> 35
catgttcct cagccagc 18

<210> 36
<211> 19
<212> DNA
<213> Homo sapiens

<400> 36
cagagctcac agcaggac 19

<210> 37
<211> 21
<212> PRT
<213> Homo sapiens

<400> 37
Cys Ser Val Arg Leu Ser Tyr Pro Pro Tyr Glu Gln His Glu Cys His
1 5 10 15
Phe Pro Asn Lys Ala
20

<210> 38
<211> 14
<212> DNA
<213> Homo sapiens

<400> 38
gcctgtgtgt cccc 14

<210> 39
<211> 14
<212> DNA
<213> Homo sapiens

<220>
<221> misc_feature
<222> (1)...(14)
<223> n = t or c

<400> 39
gcctgtgngt cccc 14

<210> 40
<211> 45
<212> DNA
<213> Homo sapiens

<400> 40
aagaagatgc tgctgtgtg tccccaggg gcaggggggc tgcct 45

<210> 41
<211> 15
<212> PRT
<213> Homo sapiens

<400> 41
Lys Lys Met Leu Pro Val Cys Pro Pro Gly Ala Gly Gly Leu Pro
1 5 10 15

<210> 42
<211> 15
<212> PRT
<213> Mus musculus

<400> 42
Lys Lys Met Leu Pro Val Cys Pro Pro Gly Ala Gly Gly Leu Pro
1 5 10 15

<210> 43
<211> 15
<212> PRT
<213> Homo sapiens

<400> 43
Lys Lys Met Leu Pro Val Arg Pro Pro Gly Ala Gly Gly Leu Pro
1 5 10 15

<210> 44
<211> 5
<212> PRT
<213> Caenorhabditis elegans

<400> 44
Leu Leu Gly Gly Ser
1 5

<210> 45
<211> 45
<212> DNA
<213> Homo sapiens

<400> 45
aagaagatgc tgctgtgcg tccccaggg gcaggggggc tgcct 45

<210> 46
<211> 14
<212> DNA
<213> Homo sapiens

<400> 46
gcctacttgc agga 14

<210> 47
<211> 14
<212> DNA
<213> Homo sapiens

<400> 47
gcctacttgc ggga

14

<210> 48
<211> 45
<212> DNA
<213> Homo sapiens

<400> 48
tgggggggct tcgcctactt gcaggatgtg gtggagcagg caatc

45

<210> 49
<211> 15
<212> PRT
<213> Homo sapiens

<400> 49
Trp Gly Gly Phe Ala Tyr Leu Gln Asp Val Val Glu Gln Ala Ile
1 5 10 15

<210> 50
<211> 15
<212> PRT
<213> Mus musculus

<400> 50
Trp Gly Gly Phe Ala Tyr Leu Gln Asp Val Val Glu Gln Ala Ile
1 5 10 15

<210> 51
<211> 15
<212> PRT
<213> Homo sapiens

<400> 51
Trp Gly Gly Phe Ala Tyr Leu Arg Asp Val Val Glu Gln Ala Ile
1 5 10 15

<210> 52
<211> 12
<212> PRT
<213> Caenorhabditis elegans

<400> 52
Phe Met Thr Val Gln Arg Ala Val Asp Val Ala Ile
1 5 10

<210> 53
<211> 45
<212> DNA

<213> Homo sapiens

<400> 53

tgggggggct tgcctactt ggggatgtg gtggagcagg caatc

45

<210> 54

<211> 25

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<222> (1)...(25)

<223> n is a, t, c, or g.

<400> 54

tcattcctct tgnngcncn gnncn

25

<210> 55

<211> 45

<212> DNA

<213> Homo sapiens

<400> 55

agtagcctca ttctcttct tgtgagcgt ggctgctag tggtc

45

<210> 56

<211> 15

<212> PRT

<213> Homo sapiens

<400> 56

Ser Ser Leu Ile Pro Leu Leu Val Ser Ala Gly Leu Leu Val Val
1 5 10 15

<210> 57

<211> 15

<212> PRT

<213> Mus musculus

<400> 57

Ser Ser Leu Ile Pro Leu Leu Val Ser Ala Gly Leu Leu Val Val
1 5 10 15

<210> 58

<211> 14

<212> PRT

<213> Homo sapiens

<400> 58

Ser Ser Leu Ile Pro Leu Val Ser Ala Gly Leu Leu Val Val
1 5 10

<210> 59

<211> 15

<212> PRT
<213> Caenorhabditis elegans

<400> 59
Ile Asn Tyr Ala Lys Leu Thr Phe Ala Val Ile Val Leu Thr Ile
1 5 10 15

<210> 60
<211> 42
<212> DNA
<213> Homo sapiens

<400> 60
agtagcctca ttcctcttgt gagcgctggc ctgctagtgg tc 42

<210> 61
<211> 25
<212> DNA
<213> Homo sapiens

<220>
<221> misc_feature
<222> (1)...(25)
<223> n is a, t, c, or g.

<400> 61
tgatgaagat gananncn gn ngcga 25

<210> 62
<211> 36
<212> DNA
<213> Homo sapiens

<400> 62
aatgatgaag atgaagatgt gaggcgggaa agacag 36

<210> 63
<211> 12
<212> PRT
<213> Homo sapiens

<400> 63
Asn Asp Glu Asp Glu Asp Val Arg Arg Glu Arg Gln
1 5 10

<210> 64
<211> 12
<212> PRT
<213> Mus musculus

<400> 64
Asn Asp Glu Asp Glu Asp Val Arg Arg Glu Arg Gln
1 5 10

<210> 65

<211> 10
<212> PRT
<213> Homo sapiens

<400> 65
Asn Asp Glu Asp Val Arg Arg Glu Arg Gln
1 5 10

<210> 66
<211> 15
<212> PRT
<213> Caenorhabditis elegans

<400> 66
Asp Glu Arg Asp Val Glu Asp Ser Asp Val Ile Ala Glu Lys Ser
1 5 10 15

<210> 67
<211> 30
<212> DNA
<213> Homo sapiens

<400> 67
aatgatgaag atgtgaggcg ggaaagacag

30

<210> 68
<211> 14
<212> DNA
<213> Homo sapiens

<400> 68
agttgtacga atag

14

<210> 69
<211> 14
<212> DNA
<213> Homo sapiens

<220>
<221> misc_feature
<222> (1)...(14)
<223> n is t or c.

<400> 69
agttgtanga atag

14

<210> 70
<211> 20
<212> DNA
<213> Homo sapiens

<400> 70
ggctggatta gcagtcctca

20

<210> 71

<211> 20
<212> DNA
<213> Homo sapiens

<400> 71
ggatttccca gatcccagtg

20

<210> 72
<211> 20
<212> DNA
<213> Homo sapiens

<400> 72
gacagacttg gcatgaagca

20

<210> 73
<211> 20
<212> DNA
<213> Homo sapiens

<400> 73
gcacttggca gtcacttctg

20

<210> 74
<211> 20
<212> DNA
<213> Homo sapiens

<400> 74
cgtttctcca ctgtccatt

20

<210> 75
<211> 20
<212> DNA
<213> Homo sapiens

<400> 75
acttcaagga cccagcttcc

20

<210> 76
<211> 24
<212> DNA
<213> Homo sapiens

<400> 76
tcggtttctt gtttggttaa ctca

24

<210> 77
<211> 20
<212> DNA
<213> Homo sapiens

<400> 77
tcccaaggct ttgagatgac

20

<210> 78
<211> 19
<212> DNA
<213> Homo sapiens

<400> 78
ggctccaaag cccttgtaa 19

<210> 79
<211> 20
<212> DNA
<213> Homo sapiens

<400> 79
gctgctgtga tggggtatct 20

<210> 80
<211> 25
<212> DNA
<213> Homo sapiens

<400> 80
tttgtaaatt ttgtagtgct cctca 25

<210> 81
<211> 20
<212> DNA
<213> Homo sapiens

<400> 81
tagtcagccc ttgcctccta 20

<210> 82
<211> 20
<212> DNA
<213> Homo sapiens

<400> 82
aaaggggctt ggtaagggtta 20

<210> 83
<211> 20
<212> DNA
<213> Homo sapiens

<400> 83
gatgtggtgc tcctcttagc 20

<210> 84
<211> 20
<212> DNA
<213> Homo sapiens

<400> 84
caagtgagtg cttgggattg 20

<210> 85
<211> 21
<212> DNA
<213> Homo sapiens

<400> 85
gcaaattcaa atttctccag g

21

<210> 86
<211> 20
<212> DNA
<213> Homo sapiens

<400> 86
tcaaggagga aatggacctg

20

<210> 87
<211> 20
<212> DNA
<213> Homo sapiens

<400> 87
ctgaaagttc aagcgagtg

20

<210> 88
<211> 20
<212> DNA
<213> Homo sapiens

<400> 88
tgcagactga atggagcatc

20

<210> 89
<211> 20
<212> DNA
<213> Homo sapiens

<400> 89
gccaggggac actgtattct

20

<210> 90
<211> 20
<212> DNA
<213> Homo sapiens

<400> 90
aggtcctctg ccttcactca

20

<210> 91
<211> 20
<212> DNA
<213> Homo sapiens

<400> 91
ccagtgtta cccctgctaa

20

<210> 92
<211> 21
<212> DNA
<213> Homo sapiens

<400> 92
cacacaacag agcttcttgg a 21

<210> 93
<211> 20
<212> DNA
<213> Homo sapiens

<400> 93
acctggaaca ggtgtggtgt 20

<210> 94
<211> 21
<212> DNA
<213> Homo sapiens

<400> 94
gggctaacat gccactcagt a 21

<210> 95
<211> 20
<212> DNA
<213> Homo sapiens

<400> 95
gtttgttgca gatggggaag 20

<210> 96
<211> 20
<212> DNA
<213> Homo sapiens

<400> 96
caccagaaga aggagcatgg 20

<210> 97
<211> 20
<212> DNA
<213> Homo sapiens

<400> 97
ctggactcgt agggatttgc 20

<210> 98
<211> 21
<212> DNA
<213> Homo sapiens

<400> 98
gcctgtcaca gagaaatgct t 21

<210> 99
<211> 21
<212> DNA
<213> Homo sapiens

<400> 99
ttacggaatg atcctgtgct c 21

<210> 100
<211> 20
<212> DNA
<213> Homo sapiens

<400> 100
agtcagggtt cgggtcacac 20

<210> 101
<211> 22
<212> DNA
<213> Homo sapiens

<400> 101
ccgttcctta taccctcagg tg 22

<210> 102
<211> 21
<212> DNA
<213> Homo sapiens

<400> 102
ccttgtagac actgcactg a 21

<210> 103
<211> 20
<212> DNA
<213> Homo sapiens

<400> 103
tggtgtccac aggttccaga 20

<210> 104
<211> 20
<212> DNA
<213> Homo sapiens

<400> 104
tgagggttat gggcatggtt 20

<210> 105
<211> 20
<212> DNA
<213> Homo sapiens

<400> 105
atgtttttcc ttggctgtgc 20

<210> 106
<211> 20
<212> DNA
<213> Homo sapiens

<400> 106
atctgccctt tcttgctga 20

<210> 107
<211> 20
<212> DNA
<213> Homo sapiens

<400> 107
agggagctgc acagtggata 20

<210> 108
<211> 24
<212> DNA
<213> Homo sapiens

<400> 108
tcactcccat atttcagaac ttga 24

<210> 109
<211> 22
<212> DNA
<213> Homo sapiens

<400> 109
tgtttattgg aagatcggtg aa 22

<210> 110
<211> 25
<212> DNA
<213> Homo sapiens

<400> 110
cgtttagagac tgaatctttg tcctg 25

<210> 111
<211> 20
<212> DNA
<213> Homo sapiens

<400> 111
agtcttgctt tccacagttg 20

<210> 112
<211> 21
<212> DNA
<213> Homo sapiens

<400> 112
ggtagttacg tgtaggggc a 21

<210> 113
<211> 21
<212> DNA
<213> Homo sapiens

<400> 113
caggaacatt aggccagatt g 21

<210> 114
<211> 23
<212> DNA
<213> Homo sapiens

<400> 114
catgtatgtg taggacagca tga 23

<210> 115
<211> 21
<212> DNA
<213> Homo sapiens

<400> 115
ctgtttcaaa gatgcttctg c 21

<210> 116
<211> 20
<212> DNA
<213> Homo sapiens

<400> 116
cctaggaagc tggaatgctg 20

<210> 117
<211> 20
<212> DNA
<213> Homo sapiens

<400> 117
gggttcccag gggttcagtat 20

<210> 118
<211> 23
<212> DNA
<213> Homo sapiens

<400> 118
cttgacctaa tttcaacatc tgg 23

<210> 119
<211> 20
<212> DNA
<213> Homo sapiens

<400> 119
atcccccaact caaaaccaca 20

<210> 120
<211> 21
<212> DNA
<213> Homo sapiens

<400> 120
aagtccaatt tagcccacgt t 21

<210> 121
<211> 20
<212> DNA
<213> Homo sapiens

<400> 121
ccagccattc aaaattctcc 20

<210> 122
<211> 20
<212> DNA
<213> Homo sapiens

<400> 122
ggtgcaggtc aatttccaat 20

<210> 123
<211> 20
<212> DNA
<213> Homo sapiens

<400> 123
ccccttcacc accattacaa 20

<210> 124
<211> 20
<212> DNA
<213> Homo sapiens

<400> 124
tgtccaagga aaagcctcac 20

<210> 125
<211> 20
<212> DNA
<213> Homo sapiens

<400> 125
aggacctctt gccagactca 20

<210> 126
<211> 20
<212> DNA
<213> Homo sapiens

<400> 126
aggagatgac acaggccaag 20

<210> 127
<211> 20
<212> DNA
<213> Homo sapiens

<400> 127
cgcacacctc tgaagctacc 20

<210> 128
<211> 20
<212> DNA
<213> Homo sapiens

<400> 128
acctcactca cacctgggaa 20

<210> 129
<211> 20
<212> DNA
<213> Homo sapiens

<400> 129
gcctcctgcc tgaaccttat 20

<210> 130
<211> 23
<212> DNA
<213> Homo sapiens

<400> 130
caaaatcatg acaccaagtt gag 23

<210> 131
<211> 20
<212> DNA
<213> Homo sapiens

<400> 131
catgcacatg cacacacata 20

<210> 132
<211> 20
<212> DNA
<213> Homo sapiens

<400> 132
ccttagcccg tgttgagcta 20

<210> 133
<211> 21
<212> DNA
<213> Homo sapiens

<400> 133
tgcttttatt cagggactcc a 21

<210> 134
<211> 20
<212> DNA
<213> Homo sapiens

<400> 134
cccatgcact gcagagattc 20

<210> 135
<211> 19
<212> DNA
<213> Homo sapiens

<400> 135
aaggcaggag acatcgctt 19

<210> 136
<211> 20
<212> DNA
<213> Homo sapiens

<400> 136
gggatcagca tggtttccta 20

<210> 137
<211> 20
<212> DNA
<213> Homo sapiens

<400> 137
gcttaagtcc cactcctccc 20

<210> 138
<211> 20
<212> DNA
<213> Homo sapiens

<400> 138
attttcctcc gcattgtgtg 20

<210> 139
<211> 20
<212> DNA
<213> Homo sapiens

<400> 139
tcacagaagc ctagccatga 20

<210> 140
<211> 20
<212> DNA
<213> Homo sapiens

<400> 140
aacagagcag ggagatggtg 20

<210> 141
<211> 20
<212> DNA
<213> Homo sapiens

<400> 141
tctgcacctc tcttcctctg 20

<210> 142
<211> 20
<212> DNA
<213> Homo sapiens

<400> 142
actggggcca acattaatca 20

<210> 143
<211> 20
<212> DNA
<213> Homo sapiens

<400> 143
cttccccatc tgcaacaaac 20

<210> 144
<211> 20
<212> DNA
<213> Homo sapiens

<400> 144
gctaaaaggcc atccaaagaa 20

<210> 145
<211> 20
<212> DNA
<213> Homo sapiens

<400> 145
tcaagtgcac ctgggcataa 20

<210> 146
<211> 20
<212> DNA
<213> Homo sapiens

<400> 146
tctgaagtcc attcccttgg 20

<210> 147
<211> 20
<212> DNA
<213> Homo sapiens

<400> 147
caatgtggca tgcagttgat 20

<210> 148
<211> 19
<212> DNA
<213> Homo sapiens

<400> 148
gaagctacca gcccatcct 19

<210> 149
<211> 20
<212> DNA
<213> Homo sapiens

<400> 149
catttcccc actgtttcag 20

<210> 150
<211> 20
<212> DNA
<213> Homo sapiens

<400> 150
ccaaggcttt cttcaatcca 20

<210> 151
<211> 20
<212> DNA
<213> Homo sapiens

<400> 151
gatccgttta acctgccaac 20

<210> 152
<211> 19
<212> DNA
<213> Homo sapiens

<400> 152
atgcccctgc caactttac 19

<210> 153
<211> 20
<212> DNA
<213> Homo sapiens

<400> 153
ctctgcagct gttccctac 20

<210> 154
<211> 20
<212> DNA
<213> Homo sapiens

<400> 154
tatcaatcca tggccctgac 20

<210> 155
<211> 20
<212> DNA
<213> Homo sapiens

<400> 155
agagtcctg ccctccttct 20

<210> 156
<211> 20
<212> DNA
<213> Homo sapiens

<400> 156
aaggcagtca gcagtgtcaa 20

<210> 157
<211> 20
<212> DNA
<213> Homo sapiens

<400> 157
ggggaacatc ctgtgcttag 20

<210> 158
<211> 20
<212> DNA
<213> Homo sapiens

<400> 158
ccattggtga gtgtttccct 20

<210> 159
<211> 20
<212> DNA
<213> Homo sapiens

<400> 159
agtcagcaaa ctgctgggtt 20

<210> 160
<211> 20
<212> DNA
<213> Homo sapiens

<400> 160
attgctccat cctggcataa 20

<210> 161
<211> 23
<212> DNA
<213> Homo sapiens

<400> 161
tcatggatga ttttatgtgc ttc 23

<210> 162
<211> 20
<212> DNA
<213> Homo sapiens

<400> 162
gcgtgtggaa aagccataag 20

<210> 163
<211> 20
<212> DNA
<213> Homo sapiens

<400> 163
gccaatcata caacagccct 20

<210> 164
<211> 23
<212> DNA
<213> Homo sapiens

<400> 164
tgatcgcata ttctacttgg aaa 23

<210> 165
<211> 22
<212> DNA
<213> Homo sapiens

<400> 165
tccctttatt ttagaggcac ca 22

<210> 166
<211> 21
<212> DNA
<213> Homo sapiens

<400> 166
gatcaggaat tcaagcacca a 21

<210> 167
<211> 24
<212> DNA
<213> Homo sapiens

<400> 167
tgggttccat aatagagttt caca 24

<210> 168
<211> 22
<212> DNA
<213> Homo sapiens

<400> 168
tgtcagctgt tactggaagt gg 22

<210> 169
<211> 22
<212> DNA
<213> Homo sapiens

<400> 169
tgtcagctgc tgctggaagt gg 22

<210> 170
<211> 21
<212> DNA
<213> Homo sapiens

<400> 170
aggagctggc cgaagccaca a 21

<210> 171
<211> 21
<212> DNA
<213> Homo sapiens

<400> 171
aggagctggc tgaagccaca a 21

<210> 172
<211> 21
<212> DNA
<213> Homo sapiens

<400> 172
aatgatgccca ccaaacaaat g 21

<210> 173
<211> 21
<212> DNA
<213> Homo sapiens

<400> 173
aatgatgccca tcaaacaaat g 21

<210> 174
<211> 21
<212> DNA
<213> Homo sapiens

<400> 174
gaggtggctc cgatgaccac a 21

<210> 175
<211> 21
<212> DNA
<213> Homo sapiens

<400> 175
gaggtggctc tgatgaccac a 21

<210> 176
<211> 21
<212> DNA
<213> Homo sapiens

<400> 176
ttccttaaca gaaatagtat c 21

<210> 177
<211> 21
<212> DNA
<213> Homo sapiens

<400> 177
ttccttaaca aaaatagtat c 21

<210> 178
<211> 21
<212> DNA
<213> Homo sapiens

<400> 178
ggaagtgttc caaaagagaa a 21

<210> 179
<211> 21
<212> DNA
<213> Homo sapiens

<400> 179
ggaagtgttc taaaagagaa a 21

<210> 180
<211> 21
<212> DNA
<213> Homo sapiens

<400> 180
agtaaagagg gactagactt t 21

<210> 181
<211> 21
<212> DNA
<213> Homo sapiens

<400> 181
agtaaagagg aactagactt t 21

<210> 182
<211> 21
<212> DNA
<213> Homo sapiens

<400> 182
gcctacttgc aggatgtggt g 21

<210> 183
<211> 21
<212> DNA
<213> Homo sapiens

<400> 183
gcctacttgc gggatgtggt g

21

<210> 184
<211> 23
<212> DNA
<213> Homo sapiens

<400> 184
cctcattcct cttcttgtga gcg

23

<210> 185
<211> 20
<212> DNA
<213> Homo sapiens

<400> 185
cctcattcct cttgtgagcg

20

<210> 186
<211> 21
<212> DNA
<213> Homo sapiens

<400> 186
gcaggactac gtgggcttca c

21

<210> 187
<211> 21
<212> DNA
<213> Homo sapiens

<400> 187
gcaggactac atgggcttca c

21

<210> 188
<211> 21
<212> DNA
<213> Homo sapiens

<400> 188
aaaagtctac cgagatggga t

21

<210> 189
<211> 21
<212> DNA
<213> Homo sapiens

<400> 189
aaaagtctac tgagatggga t

21

<210> 190
<211> 21
<212> DNA
<213> Homo sapiens

<400> 190
ggccagatca cctccttcct g

21

<210> 191
<211> 21
<212> DNA
<213> Homo sapiens

<400> 191
ggccagatca tctccttcct g

21

<210> 192
<211> 21
<212> DNA
<213> Homo sapiens

<400> 192
acacaccaca tggatgaagc g

21

<210> 193
<211> 21
<212> DNA
<213> Homo sapiens

<400> 193
acacaccaca cggatgaagc g

21

<210> 194
<211> 21
<212> DNA
<213> Homo sapiens

<400> 194
cctggaagaa gtaagttaag t

21

<210> 195
<211> 21
<212> DNA
<213> Homo sapiens

<400> 195
cctggaagaa ctaagttaag t

21

<210> 196
<211> 21
<212> DNA
<213> Homo sapiens

<400> 196
gctgctgtg tgtccccag g

21

<210> 197
<211> 21
<212> DNA
<213> Homo sapiens

<400> 197
gctgcctgtg cgtccccag g 21

<210> 198
<211> 22
<212> DNA
<213> Homo sapiens

<400> 198
tagccattat ggaattactg ct 22

<210> 199
<211> 21
<212> DNA
<213> Homo sapiens

<400> 199
tagccattat caattactgc t 21

<210> 200
<211> 26
<212> DNA
<213> Homo sapiens

<400> 200
gatgaagatg aagatgtgag gcggga 26

<210> 201
<211> 20
<212> DNA
<213> Homo sapiens

<400> 201
gatgaagatg tgaggcggga 20

<210> 202
<211> 21
<212> DNA
<213> Homo sapiens

<400> 202
aatagttgta cgaatagcag g 21

<210> 203
<211> 21
<212> DNA
<213> Homo sapiens

<400> 203
aatagttgta tgaatagcag g 21

<210> 204
<211> 21
<212> DNA
<213> Homo sapiens

<400> 204
acacgctggg ggtgctggct g 21

<210> 205
<211> 21
<212> DNA
<213> Homo sapiens

<400> 205
acacgctggg cgtgctggct g 21

<210> 206
<211> 20
<212> DNA
<213> Homo sapiens

<400> 206
gaccagccac ggcgccctg 20

<210> 207
<211> 21
<212> DNA
<213> Homo sapiens

<400> 207
gaccagccac gggcgccct g 21

<210> 208
<211> 22
<212> DNA
<213> Homo sapiens

<400> 208
cattttctta gaaaagagag gt 22

<210> 209
<211> 22
<212> DNA
<213> Homo sapiens

<400> 209
cattttctta gagaagagag gt 22

<210> 210
<211> 21
<212> DNA
<213> Homo sapiens

<400> 210
gaaaattagt atgtaaggaa g 21

<210> 211
<211> 21
<212> DNA
<213> Homo sapiens

<400> 211
gaaaattagt ctgtaaggaa g 21

<210> 212
<211> 25
<212> DNA
<213> Homo sapiens

<400> 212
cctccgcctg ccaggttcag cgatt 25

<210> 213
<211> 25
<212> DNA
<213> Homo sapiens

<400> 213
cctccgcctg ccgggttcag cgatt 25

<210> 214
<211> 25
<212> DNA
<213> Homo sapiens

<400> 214
tatgtgctga ccatgggagc ttggt 25

<210> 215
<211> 25
<212> DNA
<213> Homo sapiens

<400> 215
tatgtgctga ccgtgggagc ttggt 25

<210> 216
<211> 21
<212> DNA
<213> Homo sapiens

<400> 216
gtgacaccca acggagtagg g 21

<210> 217
<211> 21
<212> DNA
<213> Homo sapiens

<400> 217
gtgacaccca gcggagtagg g 21

<210> 218
<211> 21
<212> DNA
<213> Homo sapiens

<400> 218
agtatccctt gttcacgaga a 21

<210> 219
<211> 25
<212> DNA
<213> Homo sapiens

<400> 219
agtatccctc ccttggtcac gagaa 25

<210> 220
<211> 21
<212> DNA
<213> Homo sapiens

<400> 220
ctgggttcct gtatcacaac c 21

<210> 221
<211> 21
<212> DNA
<213> Homo sapiens

<400> 221
ctgggttcct atatcacaac c 21

<210> 222
<211> 21
<212> DNA
<213> Homo sapiens

<400> 222
ggcctaccaa gggagaaact g 21

<210> 223
<211> 21
<212> DNA
<213> Homo sapiens

<400> 223
ggcctaccaa aggagaaact g 21

<210> 224
<211> 20
<212> DNA
<213> Homo sapiens

<400> 224
tttaaagggg gtgattagga 20

<210> 225
<211> 20
<212> DNA
<213> Homo sapiens

<400> 225
tttaaagggtt ttgattagga 20

<210> 226
<211> 22
<212> DNA
<213> Homo sapiens

<400> 226
gaagaaattt gtttttttga tt 22

<210> 227
<211> 22
<212> DNA
<213> Homo sapiens

<400> 227
gaagaaattt ttttttttga tt 22

<210> 228
<211> 21
<212> DNA
<213> Homo sapiens

<400> 228
gcgggcatcc cgaggagggt g 21

<210> 229
<211> 21
<212> DNA
<213> Homo sapiens

<400> 229
gcgggcatcc tgaggagggt g 21

<210> 230
<211> 21
<212> DNA
<213> Homo sapiens

<400> 230
agggaggggt gctgaagatc a 21

<210> 231
<211> 21
<212> DNA
<213> Homo sapiens

<400> 231
agggaggggt actgaagatc a 21

<210> 232
<211> 20
<212> DNA
<213> Homo sapiens

<400> 232
aggagccaaa cgctcattgt

20

<210> 233
<211> 21
<212> DNA
<213> Homo sapiens

<400> 233
aggagccaaa gcgctcattg t

21

<210> 234
<211> 21
<212> DNA
<213> Homo sapiens

<400> 234
aagccactgt ttttaaccag t

21

<210> 235
<211> 21
<212> DNA
<213> Homo sapiens

<400> 235
aagccactgt atttaaccag t

21

<210> 236
<211> 21
<212> DNA
<213> Homo sapiens

<400> 236
cgtgggcttc acactcaaga t

21

<210> 237
<211> 21
<212> DNA
<213> Homo sapiens

<400> 237
cgtgggcttc ccactcaaga t

21

<210> 238
<211> 21
<212> DNA
<213> Homo sapiens

<400> 238
tcacactcaa gatcttcgct g

21

<210> 239
<211> 21
<212> DNA
<213> Homo sapiens

<400> 239
tcacactcaa catcttcgct g

21

<210> 240
<211> 21
<212> DNA
<213> Homo sapiens

<400> 240
gcagcctcac ccgctcttcc c

21

<210> 241
<211> 21
<212> DNA
<213> Homo sapiens

<400> 241
gcagcctcac tcgctcttcc c

21

<210> 242
<211> 21
<212> DNA
<213> Homo sapiens

<400> 242
agaagagaat atcagaaatc t

21

<210> 243
<211> 21
<212> DNA
<213> Homo sapiens

<400> 243
agaagagaat gtcagaaatc t

21

<210> 244
<211> 21
<212> DNA
<213> Homo sapiens

<400> 244
gcgcagtgcc ctgtgtcctt a

21

<210> 245
<211> 21
<212> DNA
<213> Homo sapiens

<400> 245
gcgcagtgcc ctgtgtcctt a

21

<210> 246
<211> 21
<212> DNA
<213> Homo sapiens

<400> 246
gatctaaggt tgtcattctg g 21

<210> 247
<211> 21
<212> DNA
<213> Homo sapiens

<400> 247
gatctaaggt ggtcattctg g 21

<210> 248
<211> 23
<212> DNA
<213> Homo sapiens

<400> 248
ctcttctggt agcacagaag aga 23

<210> 249
<211> 23
<212> DNA
<213> Homo sapiens

<400> 249
ctcttctggt atcacagaag aga 23

<210> 250
<211> 21
<212> DNA
<213> Homo sapiens

<400> 250
cattctaggg atcatagcca t 21

<210> 251
<211> 21
<212> DNA
<213> Homo sapiens

<400> 251
cattctaggg gtcataagcca t 21

<210> 252
<211> 22
<212> DNA
<213> Homo sapiens

<400> 252
aagtacagtg ggaggaacag cg 22

<210> 253
<211> 22
<212> DNA
<213> Homo sapiens

<400> 253
aagtacagtg tgaggaacag cg 22

<210> 254
<211> 22
<212> DNA
<213> Homo sapiens

<400> 254
attcctaaaa aatagaaatg ca 22

<210> 255
<211> 22
<212> DNA
<213> Homo sapiens

<400> 255
attcctaaaa agtagaaatg ca 22

<210> 256
<211> 21
<212> DNA
<213> Homo sapiens

<400> 256
ggccctgcc ttattattac t 21

<210> 257
<211> 21
<212> DNA
<213> Homo sapiens

<400> 257
ggccctgcc gtattattac t 21

<210> 258
<211> 22
<212> DNA
<213> Homo sapiens

<400> 258
tgagagaatt acttgaaccc gg 22

<210> 259
<211> 22
<212> DNA
<213> Homo sapiens

<400> 259
tgagagaatt gcttgaaccc gg 22

<210> 260
<211> 21
<212> DNA
<213> Homo sapiens

<400> 260
tttgctgaaa caatcactga c 21

<210> 261
<211> 21
<212> DNA
<213> Homo sapiens

<400> 261
tttgctgaaa taatcactga c 21

<210> 262
<211> 22
<212> DNA
<213> Homo sapiens

<400> 262
aacctcagtt cctcatctg tg 22

<210> 263
<211> 22
<212> DNA
<213> Homo sapiens

<400> 263
aacctcagtt tctcatctg tg 22

<210> 264
<211> 21
<212> DNA
<213> Homo sapiens

<400> 264
ctggacacca gaaataatgt c 21

<210> 265
<211> 21
<212> DNA
<213> Homo sapiens

<400> 265
ctggacacca aaaataatgt c 21

<210> 266
<211> 21
<212> DNA
<213> Homo sapiens

<400> 266
tcctatgtgt cctccaccaa t 21

<210> 267
<211> 21
<212> DNA
<213> Homo sapiens

<400> 267
tcctatgtgt gctccaccaa t

21

<210> 268
<211> 21
<212> DNA
<213> Homo sapiens

<400> 268
aagaagtggc ttgtattttg c

21

<210> 269
<211> 21
<212> DNA
<213> Homo sapiens

<400> 269
aagaagtggc ctgtattttg c

21

<210> 270
<211> 23
<212> DNA
<213> Homo sapiens

<400> 270
aactgatttg attggtatag ctg

23

<210> 271
<211> 23
<212> DNA
<213> Homo sapiens

<400> 271
aactgatttg gttggtatag ctg

23

<210> 272
<211> 21
<212> DNA
<213> Homo sapiens

<400> 272
caggggtccaa cccggacctg a

21

<210> 273
<211> 21
<212> DNA
<213> Homo sapiens

<400> 273
caggggtccaa tccggacctg a

21

<210> 274
<211> 22
<212> DNA
<213> Homo sapiens

<400> 274
ttgggaggct aaggcaggag aa 22

<210> 275
<211> 22
<212> DNA
<213> Homo sapiens

<400> 275
ttgggaggct gaggcaggag aa 22

<210> 276
<211> 15
<212> DNA
<213> Gallus gallus

<400> 276
accaggggaa tctcc 15

<210> 277
<211> 15
<212> DNA
<213> Gallus gallus

<400> 277
accagggaaa tctcc 15

<210> 278
<211> 45
<212> DNA
<213> Gallus gallus

<400> 278
cgctacccaa caccagggga atctcctggt attgttgga acttc 45

<210> 279
<211> 15
<212> PRT
<213> Homo sapiens

<400> 279
Arg Tyr Pro Thr Pro Gly Glu Ala Pro Gly Val Val Gly Asn Phe
1 5 10 15

<210> 280
<211> 15
<212> PRT
<213> Mus musculus

<400> 280

Arg Tyr Pro Thr Pro Gly Glu Ala Pro Gly Val Val Gly Asn Phe
1 5 10 15

<210> 281
<211> 15
<212> PRT
<213> Gallus gallus

<400> 281
Arg Tyr Pro Thr Pro Gly Glu Ser Pro Gly Ile Val Gly Asn Phe
1 5 10 15

<210> 282
<211> 15
<212> PRT
<213> Gallus gallus

<400> 282
Arg Tyr Pro Thr Pro Gly Lys Ser Pro Gly Ile Val Gly Asn Phe
1 5 10 15

<210> 283
<211> 45
<212> DNA
<213> Gallus gallus

<400> 283
cgctacccaa caccagggaa atctcctggg attgttgga acttc

45

<210> 284
<211> 19
<212> DNA
<213> Homo sapiens

<400> 284
gcgtcagggg tggggacag

19

<210> 285
<211> 20
<212> DNA
<213> Homo sapiens

<400> 285
gcgtcagggg tggggacag

20

<210> 286
<211> 17
<212> DNA
<213> Homo sapiens

<400> 286
ccacttcggg ctccatg

17

<210> 287
<211> 17

WO 00/55318

PCT/IB00/00532

78

<212> DNA
<213> Homo sapiens

<400> 287
ccacttcgat ctccatg

17